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CPRIT-CURE Summer Undergraduate Program
Abstract Number: 1

Role of ATM in Regulating Meiotic Crossovers in Sex Chromosomes and Autosomes
Lindsey Ran, Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center
Parijat Chakraborty, Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center
Lakshmi Paniker, Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center
Maria Sandoval, Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center,
Francesca Cole, Epigenetics and Molecular Carcinogenesis, MD Anderson Cancer Center
Background: ATM is a kinase that plays crucial roles in the DNA repair pathway homologous
recombination (HR). While multiple pathways for DNA repair exist in somatic cells, meiotic spermatocytes
primarily use HR, making spermatocytes an excellent system to study roles of ATM in HR. ATM is
essential in limiting the programmed self-inflicted double stranded breaks during meiosis that are required
for proper chromosome segregation. Spermatocytes rely on crossovers, products of HR, to connect and
segregate homologous chromosomes to generate haploids. Therefore, failure to form crossovers results
in aneuploidy, and regulating these DSBs is crucial to maintain genome integrity. Aged mouse
spermatocytes have defective crossover formation and thus have higher levels of aneuploidy.
Considering that ATM deficiency in spermatocytes result in increased in DSBs, I hypothesize that ATM+/spermatocytes will have increased DSB levels, which will rescue the age-associated loss of crossovers
and increase in aneuploidy in spermatocytes.
Methods: I used B6xDBA F1 hybrid ATM+/- mice and wildtype littermate controls. The testes of adult (26m) and aged (18-24m) mice were dissected to generate chromosome spreads. These spreads were
either stained with a DNA stain to assess aneuploidy level or stained with antibodies and visualized using
immunofluorescence to assess HR repair intermediates.
Results: Contrary to our expectations, both adult and aged ATM+/- spermatocytes showed similar levels
of aneuploidy to that of corresponding WT spermatocyte controls. Sex chromosome aneuploidy
decreased while autosome aneuploidy increased in ATM+/- as compared to WT spermatocytes. This
indicates that decrease in ATM allelic content may rescue age-associated crossover defects specifically
in sex chromosomes. To identify the role of ATM in crossover formation, we then analyzed the upstream
HR repair intermediate coated with single stranded DNA binding protein RPA. I observed that the number
of RPA foci per nucleus in ATM+/- aged spermatocytes was reduced as compared to ATM+/- adult
spermatocytes. This result suggests that the crossover role of ATM may act earlier in the HR repair
pathway during the first few steps of the DSB repair.
Conclusion: Together, these results provide novel insights on the role of ATM in regulating meiotic
crossovers.
Keywords: ATM, Aneuploidy, Crossover Regulation, Meiosis
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Abstract Number: 2

Tumor Microbiome in Murine 4T1 Triple Negative Breast Cancer
Pranathi Pilla, Cancer System Imaging, University of Texas MD Anderson Cancer Center
Caleb Gonzalez, Cancer System Imaging, University of Texas MD Anderson Cancer Center
David Piwnica-Worms, Cancer System Imaging, University of Texas MD Anderson Cancer Center
Background: The presence of certain microorganisms has been known to have a strong association with
the prognosis and development of human cancers. Recent findings show that the gut microbiome can
have a significant role in activating antitumor innate immune responses. In addition, the microbiome in the
tumor and its compartment has been found to impact progression and immunotherapy outcomes in
patients.
Methods: Herein, we utilized 16S deep sequencing platform to profiled 4T1 tumor microbiome of mice
treated with immune checkpoint therapy (anti-PD-1 + anti-CTLA4) and found that: 1) 4T1 tumors are
mostly colonized by aerobic bacteria, 2) tumor progression may be affected by gut microbiota
composition, and 3) immune checkpoint therapy may affects microbiome profile and the biodiversity.
Results: Furthermore, preliminary qPCR evidence indicates that 4T1 tumors may feature a low microbial
load, compared with pancreatic, liver, and lung tumors.
Conclusion: Future applications of probiotics as an anti-tumor drug vectors remain open for future
exploration.
Keywords: Tumor microbiome, ICT, 4T1
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Abstract Number: 3

Radiation Treatment Reduces Histone Deacetylase Inhibitor Immune Response
Nithin Poreddy, Radiation Oncology, Carleton College
Chen Braun, Radiation Oncology, University of Texas MD Anderson Cancer Center
Steven Lin, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: Evidence has shown that the efficacy of radiation therapy is reliant on type 1 interferon
signaling and expression promoting an immune response against tumors. This study explored whether
HDAC inhibitors could enhance type 1 interferon expression induced by radiation and stimulate the
cascade of the cGAS-STING immune pathway to indirectly induce tumor cell death.
Methods: Wild-type HEK293 cells and HEK293 LKB1 mutated cells transfected with IFNb1 and A549 lung
cancer cells were used in testing the drugs Vorinostat and Belinostat. Luciferase assays were done to
measure and image interferon expression in the wild-type HEK293 and HEK293 LKB1 mutated cell types.
RT-qPCR was done to measure IFNb1 expression in A549 cells in response to 1 uM Vorinostat. A
clonogenic survival assay was also done with 1 uM Vorinostat to test drug and radiation effects on A549
cell survival.
Results: The luciferase assays indicated that radiation had a suppressive effect on immune response by
HDAC inhibitors. RT-qPCR indicated a suppression in immune response with the combined Vorinostat
and radiation treatment. The survival assay indicated that Vorinostat did not lead to a statistically
significant reduction in cell colonies with increasing radiation.
Conclusion: Further experimentation can be done to see if other drugs undergo the same effect. Efforts
could first be focused on other HDAC inhibitors and seeing if their immune response is also suppressed
by radiation. From there, more research would need to be done to figure out the biological mechanism
that causes this effect and whether this is reflected in different drug families. In addition, these results
could possibly serve as a caution against using certain HDAC inhibitors with radiation to treat cancers
such as lung cancer.
Keywords: HDAC inhibitor, radiation, immune response, suppression
CPRIT-CURE Summer Undergraduate Program

5

Abstract Number: 4

Impact of OxPho inhibition on pancreatic cancer metabolism and antitumor immunity
Sayan Alekseev, Department of Immunology, The University of Texas at Sun Antonio, San Antonio, TX
Madeline Stiner, Department of Immunology, The University of Texas MD Anderson Cancer Center,
Houston, TX
Michael Curran, Department of Immunology, The University of Texas MD Anderson Cancer Center,
Houston, TX
Background: Cancers must shift their metabolic state to support the energy demands of tumorigenesis
(1). Cancer cell reliance on upregulated glycolytic and oxidative metabolism depletes oxygen and
essential nutrients from the tumor microenvironment, creating a hypoxic, immunosuppressive landscape
which limits cytotoxic T cell infiltration (2). In order to offset tumor metabolic advantage, studies have
been done utilizing complex I inhibitors of tumor oxidative metabolism to reduce tumor oxygen
consumption and combat tumor hypoxia. However, the impacts of inhibition of downstream components
of the electron transport chain (ETC) remain poorly understood.
Methods: C57BL/6 mice transplanted with MT4-2D pancreatic cells. At day 15 the mice were treated with
either IM-156 orally (complex I inhibitor), Atovaquone i.p. (complex II inhibitor) or aTOS i.p. (complex II
inhibitor), or Atovaquone orally (complex III inhibitor) for seven days. At the end of the treatment cycle,
TILs (tumor infiltrating lymphocytes) and spleen cells were analyzed by high parameter flow using the
BDX30. The Seahorse XF Cell Mito Stress Test was used to measure mitochondrial function, oxygen
consumption rate (OCR) of MT4-2D tumor cells treated in vitro. Ovalbumin-specific CD8+ T cells were
activated in vitro using peptide and cocultured with increased concentrations of Napyradiomycin (complex
I and II inhibitor), aTOS or Atovaquone for 24 hours. T cells were then analyzed by flow cytometry.
Results: In this study we found that complex II and complex III inhibition of the ETC reduced the basal
respiration of MT4-2D in a dose dependent manner. Inhibition of complex I and II with Napyradiomycin
showed a significant decrease in basal respiration and ATP production of MT4-2D. Additionally we saw
trends of a possible shift in metabolism from respiration to glycolysis in response to OxPhos inhibitor
treatment. Ovalbumin-specific CD8+ T cells treated with complex II/III inhibitors post activation in vitro
showed no significant reduction in viability or activation as seen by Ki67, CD44, and PD-1 staining.
MT4-2D tumor bearing mice treated with complex II and complex III inhibitors, respectively, also showed
increased CD8+ T cell function and reduced levels of arginase positive MDSCs and TAMs within the
tumor microenvironment.
We show that inhibition of the complex II/III components of the mitochondrial oxidative phosphorylation
chain has the potential to offset the tumor metabolic advantage while minimally limiting the activation
state of cytotoxic T cells.
Keywords: Pancreatic cancer, cancer metabolism, mitochondrial complex inhibitors, cytotoxic T cells
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Abstract Number: 5

COPD-like Inflammation Induces Neutrophil Invasion and NETosis via the C5a Pathway
Emily Lu, Pulmonary Medicine, University of Texas MD Anderson Cancer Center
Michael J Clowers, Pulmonary Medicine, University of Texas MD Anderson Cancer Center
Atul Sharma, Critical Care, University of Texas MD Anderson Cancer Center
Ashwin Kumar Ramesh, Critical Care, University of Texas MD Anderson Cancer Center,
Samantha Rose Garcia, Critical Care,
Jyotika Sharma, Critical Care, University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam, Pulmonary Medicine, University of Texas MD Anderson Cancer Center
Background: Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are a subset of
pathologically activated, protumorigenic neutrophils with immunosuppressive activity ranging from
enhancing angiogenesis to protecting circulating tumor cells. Recent studies have shown that the ability
of PMN-MDSCs to promote tumor cell invasion and metastases may be enhanced by the formation of
neutrophil extracellular traps (NETs): weblike structures composed of DNA-histone complexes and other
neutrophilic proteins extruded by activated neutrophils. NETs may interact with the tumor
microenvironment (TME) to promote tumor cell invasion, proliferation, and metastases through capture of
circulating tumor cells and release of regulatory proteins. Stimulatory factors released from the TME –
such as neutrophil chemoattractant C5a produced during complement activation – are readily being
characterized as major triggers of NET formation (NETosis). However, relatively little is known about the
effect of TME-associated inflammation in activating NETosis. In this preliminary study, we predict that
COPD-like inflammation promotes NETosis in the lung tissue via a C5a-dependent mechanism.
Methods: We generated COPD-like inflammatory conditions in C57BL/6 mice through once weekly
administration of aerosolized Nontypeable Haemophilus influenzae (NTHi) lysate from 6 to 14 weeks of
age. Frozen tissue, bronchoalveolar lavage fluid (BALF), and whole lung samples were collected from
wild type and NTHi-exposed mice. We performed qPCR to measure expression of the C5a/C5aR1 axis
and downstream receptors, Sytox staining to quantify NETosis, Wright-Giemsa staining for immune cell
lineages, and H&E for visualization of immune cell infiltration.
Results: NTHi exposure promotes immune cell invasion, neutrophilic influx, and a higher percentage of
NETotic neutrophils. NTHi exposure also upregulates the transcription of C5aR1, Tlr4, and Ager (RAGE)
receptors involved in NETosis.
Conclusion: Our results indicate that NTHi may activate NETosis through upregulation of the C5a/C5aR1
axis and other PMN-MDSC surface receptors. Future steps include validating our results on the protein
level and expanding the number of treatment groups to examine NTHi exposure and NETosis inhibition
with DNase in a lung cancer mouse model (CC-LR). We hypothesize that NTHi exposure promotes
NETosis, tumor cell invasion, and metastases in lung cancer through the upregulation of downstream
C5a signaling present on tumor-associated PMN-MDSCs, and that treatment with NETosis inhibitor
DNase will significantly reduce these protumorigenic effects. Confirmation of these results may reveal the
potential of NETosis inhibition by DNase as a targeted therapy in the treatment of lung cancer.
Keywords: NETosis, NTHi, C5a, lung cancer
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Abstract Number: 6

Multimodal Analysis of the Interaction Between CD70-Directed Chimeric Antigen Receptor Natural
Killer Cells and Target Tumors
Dawei Liu, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Pinaki Banerjee, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson
Cancer Center
Hind Rafei, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Paul Lin, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center,
Rafet Basar, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Sunil Acharya, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Nadima Uprety, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson
Cancer Center
Sanjida Islam, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Yan Cui, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Katy Rezvani, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Background: Chimeric antigen receptor natural killer (CAR NK) cells have emerged as an attractive form
of cancer immunotherapy. In addition to a promising safety profile—little or no evidence of cytokine
release syndrome (CRS), graft-versus-host disease (GvHD) in HLA-mismatched patients, or neurotoxicity
in multiple clinical trials—CAR NK cells offer several logistical advantages compared to the current FDAapproved autologous CAR T cell therapies. CD70 is a surface antigen that is highly expressed on
multiple tumor types, ranging from solid cancers to hematologic malignancies. Thus, targeting CD70
holds promising therapeutic potential. As such, NK cells transduced to express a CD27-CAR can be used
to target CD70-expressing tumor cells. CD27 is a tumor necrosis factor receptor (TNFR) family member
and the ligand of CD70. However, the interaction between CD27-CAR NK cells and CD70+ targets has
not been thoroughly investigated. This study aims to compare the conjugate formation between CD27CAR NK cells and nontransduced (NT) NK cells, as well as their cytotoxic capacity and metabolic fitness.
Methods: CAR NK cells were obtained by retroviral transduction with a vector encoding a CD27 receptor
and containing a CD3ζ endodomain. The CAR NK cells were armored with IL-15 to support survival,
stimulated with IL-2 for proliferation, and expanded with feeder cells. Cell lines—MM.1S (multiple
myeloma), Raji (Burkitt lymphoma), Karpas (non-Hodgkin’s lymphoma), K562 (leukemia), UMRC-3 (renal
cell carcinoma)—were employed to assess killing function of the CAR NK and NT NK cells. Standard
51Cr release assay was conducted at various effector-to-target ratios to assess antitumor effect and
sibling CAR NK killing. Samples were stained and ran through Amnis imaging flow cytometer (Luminex)
and LSRFortessa X-20 Cell Analyzer (BD Biosciences). Flow cytometry analysis was performed using
Kaluza Software (Beckman Coulter). The Cell Mito Stress Test and Glycolysis Stress Test were run on
96-well Seahorse XF Extracellular Flux Analyzer (Agilent Technologies) to measure oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR), respectively, of NT and CAR NK cells. Liquid
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chromatography-mass spectrometry (LC-MS) was conducted in the MD Anderson Cancer Center
Metabolomics Core. Quantification was done within TraceFinder software (ThermoFisher Scientific). The
data were analyzed in GraphPad Prism and a normalized heat map was generated in Morpheus (Broad
Institute).
Results: CD27 on the CAR NK cell was able to engage CD70 on the tumor cell at the cell-cell interface,
also known as the immunological synapse (IS). Upon conjugate formation, CD3ζ in the CAR NK—but not
the NT NK cell—accumulated at the IS. This passed the activating signal, resulting in greater CAR NK
cell-mediated cytotoxicity of CD70-expressing cancer cells. This greater cytotoxic capacity was due to
the enhanced metabolic fitness of the CAR NK cells, as evidenced by increased glycolytic and TCA cycle
activity. We also found that the CD27-CAR NK cells exhibited minimal CAR NK sibling killing and limited
off-tumor on-target toxicity, despite HLA mismatch.
Conclusion: CD27-CAR NK cells exhibit increased metabolic fitness, more immunological synapse
formation, and greater cytotoxicity compared to their NT counterparts. The CAR-transduced cells also
avoid sibling fratricide, likely due to pre-existing receptor-ligand binding on cis CAR NK cell (also known
as masking), or downregulation of CD70.
Keywords: Natural killer (NK) cell, chimeric antigen receptor (CAR), CD27, CD70, conjugate
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Abstract Number: 7

Network analysis of gut microbiome throughout a whole foods based high fiber dietary
intervention reveals complex community dynamics in melanoma survivors
Daniel Mousavi, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer
Center
Aditya Mishra, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center
Yan Jiang, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center
Tessa Kus, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer
Center,
Erma Levy, Department of Epidemiology, University of Texas MD Anderson Cancer Center
Marco Montalvo, Department of Epidemiology, University of Texas MD Anderson Cancer Center
Nadim Ajami, Department of Genomic Medicine, University of Texas MD Anderson Cancer Center
Jennifer Wargo, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center
Jennifer McQuade, Department of Melanoma Medical Oncology, University of Texas MD Anderson
Cancer Center
Background: Recent evidence has demonstrated that the gut microbiome modulates response to immune
checkpoint blockade (ICB) treatment in melanoma patients. Microbiome modulation via a habitual highfiber diet was associated with significantly improved progression-free survival (PFS) in melanoma patients
on ICB. Previous findings have suggested that this pro-response is associated with known fiberresponsive taxa and Short Chain Fatty Acid (SCFA) producing taxa. However, little is known about the
communications responsible for stimulating the aforementioned taxa. To explore community dynamics
and identify potential keystone communicating taxa, we conducted microbial association network analysis
throughout a high-fiber dietary intervention (HFDI) in melanoma survivors.
Methods: Ten patients were enrolled to the HFDI study and were provided with whole-food-based fiberenriched meals for the duration of six weeks. Fecal samples were collected longitudinally, and whole
genome sequencing (WGS) of the fecal microbiome was used to calculate microbiome composition
profiles. OTU abundance data was then used to construct, analyze, and compare association networks
across timepoints via the R package NetCoMi. Overall changes in community dynamics were assessed
via changes in global network properties, and significant taxa were identified quantitatively via differences
in calculated centrality measures as well as visually by NetCoMi’s selection of hubs, or specific keystone
taxa.
Results: Network analysis across timepoints demonstrated a general increase in connectivity by both
quantitative and visual comparison throughout the HFDI. Analysis via multiple association statistics
revealed a general rise in several measures of centrality of many known fiber-responsive and SCFAproducing taxa, with many consistently becoming hub taxa. Consensus networks generated by
overlapping several networks generated from different association statistics revealed a consistent
increase in centrality in two particular species: Ruminococcus bromii and Dorea longicatena. Analysis of
networks constructed from only differentially associated taxa revealed similar results, with R. bromii and
D. longicatena having numerous changes in associations with fiber-responsive taxa.
Conclusion: Increases in general connectivity measures indicate that a HFDI prompts the gut microbiome
to become a more interconnected and dynamic community over time. This, in conjunction with an overall
increase in centrality in known fiber-responsive and SCFA-producing taxa, reflects an overall proresponse to the HFDI. Networks constructed via different association statistics yield varied results, with
many identifying different taxa as hubs. Despite this heterogeneity, network analysis consistently
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identified D. longicatena and R. bromii as potential keystone species with an important role in
communicating with fiber-responsive taxa. Further analyses are needed to characterize communications
between keystone species and SCFA-producing taxa.
Keywords: microbiome, fiber, networks, melanoma, immunotherapy
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Abstract Number: 8

Defective Homologous Recombination in Aged Mice
Vindhya Kilaru, Department of Epigenetics and Molecular Carcinogenesis, 1. University of Texas MD
Anderson Cancer Center 2. University of California, Berkeley
Lakshmi Paniker, Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD
Anderson Cancer Center
Francesca Cole, Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD
Anderson Cancer Center
Age is one of the biggest risk factors for cancer, a disease which is often characterized by an
accumulation of DNA damage. We wanted to test if DNA repair machinery responsible for mitigating DNA
damage degrades with age. Homologous recombination (HR) is one of the least error-prone DNA repair
pathways and is the primary pathway utilized during meiosis. Thus, we used meiotic homologous
recombination as a paradigm for studying age-related degradation of HR machinery. Meiotic cell division
requires the formation of crossovers, specific products of HR, to connect homologous chromosomes for
accurate segregation. To initiate HR, intentional double-strand breaks (DSBs) are introduced into the
chromosomes by an enzyme called SPO11. Meiotic cells lacking enough crossovers fail to form viable
embryos in most scenarios. Therefore, the cell works to maintain the required number of crossovers
despite fluctuations in DSB numbers in a process termed “Crossover Homeostasis.” We tested if
crossover homeostasis was disrupted in aged mice.
Male mice heterozygous for the Spo11 null allele were naturally aged for a period of 18-23 months.
Testes from aged mice were dissected, spermatocytes were isolated, and utilized for chromosome
spreads. Spreads were stained with Giemsa to analyze nuclei in Metaphase. Immunofluorescence
staining was performed to count DSBs.
Consistent with earlier reports, decreasing an allelic copy of Spo11 leads to a reduction in DSB formation
in both Adult and Old mice. Removing a copy of Spo11 causes crossover loss only in Old mice and not in
Adult mice, demonstrating a defect in crossover homeostasis in Old mice. Further a proportional level of
aneuploid secondary spermatocytes was observed after the first chromosome segregation, indicating that
Metaphase I cells with unconnected chromosomes make it past the first meiotic checkpoint and could
produce aneuploid gametes.
We demonstrated that Homologous Recombination is defective during meiosis in old mice. Specifically,
we saw that crossover homeostasis is affected. Discounting mutants that directly perturb the crossover
repair pathway, this is the first ever observation of a defect in crossover homeostasis in any organism.
The mouse model was aged naturally, and the genetic perturbation doesn’t affect the DNA repair
machinery, thus allowing our observations to become transferrable to old somatic cells and
correspondingly old humans (70-90 years old). Considering that this is typically the age when DNA
mutational load causes diseases such as cancer, this research becomes relevant for the development of
therapeutic interventions to tackle the root causes of such age-related dysfunction.
Keywords: DNA repair; Meiosis; Crossover Homeostasis; Homologous Recombination; SPO11
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Abstract Number: 9

Dissecting the role of Muc5ac in K-ras Mutant Lung Cancer Progression
Melvin Zarghooni, Department of Pulmonary Medicine, UT MD Anderson Cancer Center; Rice University
Walter Velasco Torrez, Department of Pulmonary Medicine, UT MD Anderson Cancer Center
Michael Clowers, Department of Pulmonary Medicine, UT MD Anderson Cancer Center; The University
of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Linda Phan, Department of Pulmonary Medicine, UT MD Anderson Cancer Center,
Seyed Javad Moghaddam, Department of Pulmonary Medicine, UT MD Anderson Cancer Center; The
University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
Background: Of all cancer types, lung cancer accounts for the most deaths per year and K-ras mutations
are a leading mutational driver. There are limited pharmacological treatment options for K-ras mutant lung
cancer due to the resilient nature of the mutation, raising the need to find and target downstream or
cooperating effectors of K-ras. The mucosal lining of the airways is integral for airway homeostasis and
functions to clear pathogens and debris. In healthy tissue, lung epithelial cells secrete two main mucins:
moderate levels of muc5b and low levels of muc5ac. Notably, patients with K-ras mutant lung
adenocarcinoma (KM-LUAD) have been shown to commonly overexpress muc5ac. Overexpression of
muc5ac can promote respiratory illnesses through its promotion of an inflammatory lung environment,
which can lead to promotion of KM-LUAD. Through a genetic approach, we previously observed that
knocking out the gene that encodes for MUC5AC (Muc5ac) in a K-ras mutated lung adenocarcinoma
mouse model (CC-LR) leads to significantly decreased tumor burden. Therefore, Muc5ac might be a
potential druggable target in KM-LUAD which we explored in this study.
Methods: To translate our genetic targeting approach and dissect the potential mechanism of tumor
promotion by muc5ac, we utilized CC-LR mice and a pharmacologic approach for inhibiting Muc5ac
expression: RNA interference (RNAi). CC-LR mice had muc5ac RNAi treatment started at 6 weeks for a
treatment duration of 8 weeks. Treatment, both of drug and vehicle, are administered through
intratracheal injections. Mice are anesthetized using Isoflurane and a pipette is inserted into the trachea
to administer 50 microliters of treatment. MUC5AC RNAi treatment were given twice a week (5mg/kg
biweekly).
Results: There was a significant reduction of surface tumor numbers with inhibition of Muc5ac by RNAi.
Bronchoalveolar lavage fluid (BALF) analysis revealed a trend for increased total white blood cell (WBC)
count and number of macrophages after RNAi treatment. Muc5ac knockdown decreased expression of
Il6, a cytokine with known pro-tumor function. Muc5ac RNAi also reduced the expression of
immunosuppressive macrophage markers including Fizz1 indicating a possible phenotypic switch in
macrophages from M2 (pro-tumor) to M1 (anti-tumor). There was a reduction in expression of Siglec-e, a
cell surface protein primarily expressed on macrophages, elucidating its potential immunomodulatory role
through its interaction with muc5ac.
Conclusion: We conclude that targeting Muc5ac using RNAi is a potential alternative approach for
prevention and treatment of KM-LUAD via tumor cell intrinsic and immunomodulatory paracrine
mechanisms.
Keywords: Muc5ac, Lung Adenocarcinoma, K-ras, Siglec-e
CPRIT-CURE Summer Undergraduate Program
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Abstract Number: 11

The Genomic and Transcriptomic Landscape of Ultra-Conserved miR-142 in Hematological
Malignancies
Wilson Huang, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Recep Bayraktar, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
George A. Calin, Translational Molecular Pathology, Experimental Therapeutics, Center for RNA
Interference and Non-Coding RNAs, Leukemia, University of Texas MD Anderson Cancer Center
Background: MicroRNAs (miRNAs) are noncoding RNAs that regulate gene expression by targeting the
3’UTR of mRNAs. Dysregulation of miRNAs are often linked to cancer. Our lab demonstrated that among
various miRNAs and cancer types, a high frequency of mutations is concentrated in miR-142 and
hematological malignancies, particularly chronic lymphocytic leukemia (CLL).
Methods: Targeted deep sequencing of ultra-conserved elements (UCEs) of 348 clinically well-annotated
cancers was performed by MD Anderson and collaborating institutions. Sanger sequencing was
conducted in the UCE_5578 region containing miR-142 of 400 CLL (200 indolent; 200 aggressive) patient
genomic samples. HEK293 cell lines were transfected with retroviral plasmids expressing UCE_5578 with
miR-142 scrambled, wild-type, or mutated at the 6th nucleotide downstream. This was followed by RNA
extraction, reverse transcription, and RT-qPCR to compare expression levels of pre-miR-142, miR-1423p, and miR-142-5p.
Results: We identified 5 mutations within UCE_5578, a region found to contain miR-142: two in the miR142-5p seed and one in miR-142-3p. One notable C to T mutation occurred in the 6th nucleotide
downstream of the miR-142 sequence at the CNNC motif known for SRSF3 binding and recruitment of
DROSHA. Expression of UCE_5578 with this mutation in HEK293 cells resulted in a downregulation of
miR-142-3p levels compared to wild-type expression levels.
Conclusion: Our findings suggest that the C to T mutation 6 nucleotides downstream of miR-142 at the
CNNC motif impaired miR-142-3p processing in CLL. This could potentially upregulate miR-142-3p
targets with links to leukemogenesis. The effect of other mutations identified in CLL will be further
investigated.
Keywords: Chronic Lymphocytic Leukemia, Ultra-conserved elements, miR-142
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Abstract Number: 12

Automated Ligand Identification System (ALIS): A Novel Small Molecule Screening System in
Cancer Drug Development
Priya Tirumala, Therapeutics Discovery, University of Texas MD Anderson Cancer Center Institute of
Applied Cancer Science
Small molecule drugs are crucial blockbusters in cancer treatment for their wide availability and simple
dosing; however, discovering them using traditional high-throughput systems(HTS) can be extremely
costly. The Automated Ligand Identification System(ALIS) is a novel affinity-based binding system that
identifies small molecule binders for cancer target Protein X more efficiently than HTS. ALIS's accurate
mass analysis and direct protein-ligand binding, as opposed to HTS’s protein coupling, results in lower
false positive hit rates and experiment trials.
First, buffer conditions for the ALIS screen were determined with a Differential Scanning Fluorimetry(DSF)
experiment. DSF monitors thermally induced protein denaturation via use of a dye (Sypro Orange) which
binds preferentially to unfolded protein. Dependence on NaCl in buffer was tested by determination of the
protein's melting temperature (TM) as it was increased in assay buffer. Concentrations of 11, 50, 100,
200, and 400 mM of NaCl were tested with Protein X. Once optimal NaCl concentrations were
determined, the assay buffer was created with ammonium acetate, HEPES, phosphate, and NaCl.
Protein X and assay buffer were incubated with compound pools in a 384 well plate for a 16-hour ALIS
screen. An experimentally determined switch valve diverted the initial ~80% of protein, along with bound
compounds(named “hits”), from the size-exclusion-chromatography column to reverse-phase column,
where heat and acid denatured the protein and released bound molecules. These molecules eluted to the
mass spectrometer to be ionized and detected.
Protein X showed the greatest stability with >200mM NaCl due to its right shifted melt curve and height of
>10,000 fluorescence units. Data is collated from Apex software to determine the frequency of every ion
identified. Ions whose frequency is >7 times are contaminants and discarded. Ions that occur one time
are "unique" hits and kept. Ions that occur 2-6 times are further examined. For further examination, the
total-ion-chromatogram is scanned at each ion’s retention time to determine whether the hit is reported in
neighboring wells. If so, the hit is most likely a contaminant. The mass ion cluster chromatogram indicates
a true hit if its abundance is 100,000<x<1,000,000 and has a correlation of >0.950.
Using these analyses, the initial 2000 hits were filtered to 50 hits, eliminating false positives and
contaminants. Next, ALIS screens between the 50 hits and Protein X will be conducted to verify proteinligand interactions, measure association and dissociation rates, and binding affinities.
Keywords: drug development, therapeutics, high throughput screening, in-vitro pharmacology
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Abstract Number: 13

Gut Microbiome Signatures Associated with Liver Tumorigenesis in HepPten- Mice
Lorenzo R. Cruz, Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center
Kristyn Gonzalez, Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center
Suet-Ying Kwan, Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center
Laura Beretta, Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center,
Background: The number of patients with non-alcoholic fatty liver disease (NAFLD) and hepatocellular
carcinoma (HCC) continues to increase globally in tandem with the obesity epidemic. Individuals with
NAFLD-related HCC are typically diagnosed at a late stage and have poor odds of survival. As such,
highly sensitive biomarkers and preventative measures are needed to identify individuals at high risk of
HCC.
Methods: We aimed to characterize the gut microbiome and find taxa associated with the development of
HCC in 23 female mice with hepatocyte-deletion of Pten- (HepPten-). Stool samples of 23 female
HepPten- mice were collected and analyzed using 16s sequencing. Mice were necropsied at different
stages of tumor development. Among all histology parameters analyzed, tumor burden, number of tumors
and inflammation, showed significant differences between Partitioning Around Medoid (PAM) clusters. To
identify the specific taxa associated with high tumor burden, number of tumors or inflammation scores,
LEfSe analyses were performed from kingdom to species.
Results: A total of 33 significant taxa were identified associated with high tumor burden (>89 mm^3).
Similarly, 38 taxa were identified to be significantly associated with high number of tumors (>2). The gut
microbiome of mice with high tumor burden and number was enriched with Gordonibacter,
Senegalimassilia, Lachnospiraceae_UCG-006, Monoglobus, and depleted of Prevotellaceae and
Bacteroides_vulgatus. Thirty exclusive taxa were identified to be significantly associated with higher liver
inflammation scores (>0.5) by LEfSe analysis. The gut microbiome of mice with high liver inflammation
scores was enriched with Butyricicoccus, Oscillibacter, Family_XIII_UCG-001, and depleted of
Olsenella_uli, Muribaculaceae_ge_unclass, and Faecalibaculum_rodentium.
Conclusion: These results therefore suggest that specific microbiome components are significantly
associated with liver carcinogenesis.
Keywords: NAFLD, gut microbiome, HCC, HepPten
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Abstract Number: 14

The Role of hnRNPC::RARG in Acute Promyelocytic Leukemia-like Acute Myeloid Leukemia
Matthew Ye, Hematopathology, University of Texas MD Anderson Cancer Center
Yun You, Hematopathology, University of Texas MD Anderson Cancer Center
Yaling Yang, Hematopathology, University of Texas MD Anderson Cancer Center
Andres E. Quesada, Hematopathology, University of Texas MD Anderson Cancer Center,
M. James You, Hematopathology, University of Texas MD Anderson Cancer Center
Background: Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is
distinguished by t(15;17)(q24.1;q21.2)/PML::RARA, characteristic morphologic features, and a propensity
for disseminated intravascular coagulopathy. The fusion of PML with retinoic acid receptor α (RARA)
gene accounts for response to all-trans retinoic acid (ATRA), allowing APL patients to have a favorable
prognosis. However, there have emerged certain cases in which patients who, despite morphologically
and clinically resembling APL, were resistant to ATRA. Rather than the PML::RARA, these patients
presented with an atypical fusion of retinoic acid receptor γ (RARG) gene, with a myriad of fusion
partners. One of these fusion genes involves exon 3 of hnRNPC fused with exons 4-10 of RARG. We aim
to create a retroviral vector containing an hnRNPC::RARG insert in order to study the role of
hnRNPC::RARG fusion protein in leukemogenesis and develop targeted therapy.
Methods: Recombinant cloning was performed to create a retroviral vector (MSCVI) containing an
hnRNPC::RARG insert using overlapping PCR, purification, digestion by restriction enzymes, ligation,
transformation of DH5-alpha E. Coli, and miniprep. The sequences of the resulting miniprep plasmids
were confirmed using Sanger sequencing.
Results: A plasmid consisting of an MSCVI backbone, the whole coding sequence (CDS) of hnRNPC,
and an HA tag was first constructed. A similar plasmid was constructed separately, except with the CDS
of RARG. Sanger sequencing of the plasmids confirmed the correct hnRNPC and RARG sequences,
respectively. These two were then used as the templates for creating the hnRNPC::RARG fusion gene,
using primers designed to create overhangs at the 3’ end of exon 3 of hnRNPC and 5’ end of exons 4-10
of RARG that would facilitate fusion during PCR. Sanger sequencing performed over the hnRNPC::RARG
fusion confirmed the correct fusion sequence without mutation.
Conclusion: We created the hnRNPC::RARG fusion which is one of an unknown myriad of translocations
that may drive the transformation of an “APL-like AML”. We will produce an hnRNPC::RARG retrovirus via
co-transfection of 293T cells using the retroviral vector crafted in this study, along with the packaging
genes gag, env, and pol. Further study of this fusion protein may provide great insight into the
pathogenesis of APL-like AML and mechanisms of resistance to ATRA, as well as reveal new therapeutic
targets.
Keywords: APL, RARG, hnRNPC::RARG, recombinant cloning
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CPRTP Summer Research Experience
Abstract Number: 15
Cigarette smoking and its impact on the survival outcomes and molecular features of metastatic
colorectal cancer patients
Ri Chen, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of
Texas MD Anderson Cancer Center
Kristin Alfaro, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University
of Texas MD Anderson Cancer Center
Catherine Luo, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University
of Texas MD Anderson Cancer Center
Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University
of Texas MD Anderson Cancer Center,
Background: Tobacco use is the most preventable cause of cancer. Smoking itself accounts for
approximately 30% of all cancer-related deaths in the United States. Furthermore, colorectal cancer
(CRC) is the second most common cause of cancer death in the United States. In 2020, approximately
147,950 individuals were diagnosed with CRC and 53,200 died from the disease. 11%-22% of these new
CRC cases were attributable to tobacco use. Although studies have demonstrated a significant
association of cigarette smoking with CRC incidence and mortality, there is very little existing literature
that has shown that cigarette smoking may be a risk factor for metastatic colorectal cancer (CRC). The
impact of smoking on the survival of metastatic CRC patients remains unclear.
Methods: With an initial metastatic CRC diagnosis on or after January 1st, 2012, we reviewed 2,324
patients whose clinicopathological background included a smoking history and 3,826 patients whose
background did not from the University of Texas MD Anderson Cancer Center medical records. Univariate
and multivariate analyses using Kaplan Meier survival curves and the Cox proportional hazard model
were performed to determine the impact of independent prognostic variables on the survival of smokers
and non-smokers.
Results: The aims of this research study were to associate cigarette smoking with survival outcomes and
molecular features of metastatic colorectal cancer patients by analyzing an institutional database.
Preliminary data suggests that smoking history has a modest effect on overall survival in metastatic
patients compared to a never smoker. It also suggests that there may be a correlation between smoking
and KRAS/BRAF mutations.
Conclusion: Smoking is linked to survival outcomes and molecular features of metastatic colorectal
cancer. The association of smoking with colorectal cancer and its clinical, pathological, epidemiological,
and molecular features still needs to be better understood. Future research findings will help point to risk
factors involved with smoking in colorectal cancer patients and at-risk patients. Further findings may help
to identify markers and patterns that will lead to a faster metastatic CRC diagnosis and an overall better
prognosis (improved survival rate and increased survival time). Ultimately, the findings should aim to push
forward the agenda of smoking cessation in metastatic CRC patients, at-risk patients, and the general
population.
Keywords: Smoking, metastatic colorectal cancer, survival analysis, survival outcomes, molecular
features
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Abstract Number: 16

Sun protection awareness, habits, and recommendations of USA Swimming coaches
Madisyn Cox, Health Services Research, University of Texas MD Anderson Cancer Center
Yao Li, Health Services Research, University of Texas MD Anderson Cancer Center
Sanjna Tripathy, Health Services Research, University of Texas MD Anderson Cancer Center
Candice Hinkston, Health Services Research, University of Texas MD Anderson Cancer Center,
Mackenzie Wehner, Health Services Research, University of Texas MD Anderson Cancer Center
Background: Swimming is the most popular recreational activity for children and teens (7-17) in the
United States. The governing body for the sport, USA Swimming has more than 400,000 members and
continues to grow rapidly. Despite the sport's growth, there has not been a paralleled growth in skin
cancer awareness or prevention strategies. Current recommendations for preventing skin cancer include
wearing sun protective clothing, applying sunscreen, and avoiding direct sun exposure. Individuals in the
sport of swimming face unique barriers to following these prevention strategies that have yet to be
addressed.
Methods: This study is a cross-sectional, survey-based study of swimming coaches’ personal attitudes
and practices of sun protection, what recommendations they make to their athletes and their choice of
practice times. The RedCap survey was disseminated via email to 67,000 coaches registered with USA
Swimming. Responses were recorded, and the results were analyzed using the statistical software SAS.
Results: Preliminarily data show that Coaches who have former athlete(s) with a skin cancer diagnosis
are more likely to use sun protection than those with personal or family skin cancer histories.
Furthermore, coaches with increased sun protection habits are more likely to recommend sunscreen use
to their athletes. Finally, our results have shown that coaches who make sun protection recommendations
to their athletes observe higher rates of sunscreen use amongst their athletes.
Conclusion: The associations identified between skin cancer history, sun protection habits, and the sun
protection recommendations USA swimming coaches make to their athletes suggests a need for the
development of sun protection strategies unique to the sport of swimming. These strategies should aim to
educate coaches on proper sun protection habits and effective, persuasive communication of those habits
to their athletes.
Keywords: sun protection, sunscreen, swimming, coaches, skin cancer
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Abstract Number: 17

Disparities in Health-Related Quality of Life among Adolescent and Young Adult (AYA) Cancer
Survivors
Midhat Jafry, Lymphoma – Myeloma, and Pediatrics, University of Texas MD Anderson Cancer Center
Goldy George, Symptoms Research, University of Texas MD Anderson Cancer Center
J. Andrew Livingston, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center
Michelle Hildebrandt, Lymphoma – Myeloma, University of Texas MD Anderson Cancer Center,
Michael Roth, Pediatrics, University of Texas MD Anderson Cancer Center
Background: Adolescent and young adult (AYA; individuals diagnosed between the ages of 15–39 years)
cancer survivors represent an understudied population. While extant studies highlight the correlation
between poor health-related quality of life (HRQoL) and low survival rates in adults, there is limited
research on factors that mediate HRQoL in AYAs with cancer. Moreover, a recent study suggests that the
burden of poor HRQoL differs by race/ethnicity.
Methods: This study consists of a large retrospective analysis of 2,572 AYA cancer survivors (1,737
White, 241 Black, 466 Hispanic, and 128 Asian) from MD Anderson. Patient reported quality of life at
diagnosis (+/- 6 months) was assessed using the SF-12 questionnaire with generation of physical
component summary (PSC) and mental component summary (MSC) scores. ANOVA was used to assess
differences across race/ethnicity for tumor type, age at diagnosis category, and gender. Logistic
regression was conducted to determine odds ratios and corresponding 95% confidence intervals for
sarcoma tumors, age at diagnosis, and gender for each racial/ethnic group.
Results: In older AYAs, there were significant differences in PCS across racial/ethnic groups (p=0.02),
with older AYAs displaying favorable PCS scores compared to younger AYAs. The risk of a poor PCS
was elevated for all younger AYA racial/ethnic populations and reached statistical significance in White
AYA cancer survivors (OR:1.27, 95% CI:1.00-1.61). Compared to White sarcoma patients, minority
sarcoma AYA patients report poorer PCS scores. Risk of poor PCS was found to be significantly higher
for Hispanic survivors (OR:3.06, 95% CI: 1.36-6.87). Generally, while male AYA patients were found to
have a higher risk of poor PCS, they also had a lower risk of poor MCS relative to female AYA patients of
the same race/ethnicity.
Conclusion: Results highlight sarcoma tumors, gender, and age at diagnosis as significant mediators of
poor HRQoL by race/ethnicity among 2+ year survivors of AYA cancer. Findings may inform future health
promotion efforts to reduce racial and ethnic disparities in health-related quality of life among AYA cancer
survivors.
Keywords: Health-related quality of life, Short Form-12, Adolescent and Young Adult
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Abstract Number: 18

An Analysis of Post-Radiation Therapy and Clinical Disease Predictors in the Development of
Xerostomia and Dysphagia in Head and Neck Cancer Patients
Christine Okoro, Department of Head and Neck Radiation Oncology, University of Texas MD Anderson
Cancer Center
Moamen Abobakr, M.D., Department of Head and Neck Radiation Oncology, University of Texas MD
Anderson Cancer Center
Abdallah Sherif Radwan Mohamed, Ph.D., Department of Head and Neck Radiation Oncology, University
of Texas MD Anderson Cancer Center
Clifton David Fuller, M.D., Ph.D., Department of Head and Neck Radiation Oncology, University of Texas
MD Anderson Cancer Center,
Head and neck cancers (HNC) are the sixth most common types of cancers in the world. Current studies
suggest that head and neck cancers are highly treatable and preventable, since most HNCs are
squamous cell carcinomas. The standard treatment of care involves surgery, chemotherapy, and/or
radiation therapy (RT). While surgery alone has been proven effective in targeting and eliminating
oropharyngeal carcinomas, surgery induces metabolic stressors, which heighten the incidence of
recurrences. So, cancer management through radiotherapy is a core mechanism for minimizing
tumorigenesis. A major concern with the use of RT is the unintended targeting of normal soft tissues. RT
often produces toxicities, or side effects, which undermine the effectiveness of head and neck cancer
treatments, and current research related to radiation-induced toxicities is mainly focused on patient
experiences during radiation therapy. This study aims to analyze post-RT toxicity trends in working to
identify social and clinical-based predictors of xerostomia and dysphagia development in HNC patient
populations.
Forty-four head and neck cancer patients, who had undergone radiation therapy, were analyzed in this
study. All study participants were over the age of eighteen and presented evidence of dysphagia and
xerostomia at some point prior or during treatment. The patients were assessed for xerostomia and
dysphagia at the following time points: pre-RT (baseline), mid-radiotherapy, end-radiotherapy, three
months post-RT, six-months post-RT, and twelve-months post-RT. The patients’ objective and subjective
outcomes were scored at each time point to reveal predictors in toxicity development.
Trends in dysphagia and xerostomia revealed that men over the age of fifty (50) were more likely to
develop post-RT toxicities than other gender- or age-based demographics. For patients, who were current
or former smokers, the incidence rate was greatly amplified due to the potential for disease recurrences.
The study also revealed that HPV positive patients were less likely to develop long-term dysphagia and
xerostomia, while therapeutic combinations involving surgery with chemotherapy and/or radiation therapy
presented greater concerns overall.
The presentation of this study will serve as a model for understanding the progression of radiationinduced toxicities–dysphagia and xerostomia–in HNC patients. Through identifying and addressing these
predictors, future studies can be directed towards creating more target-based mechanisms for enhancing
cancer survivorship and maintaining a patient’s overall quality of life. With more funding, research
support, and patient participation, a greater number of toxicity trends can be evaluated in working to
create a more robust secondary analysis.
Keywords: Xerostomia, Dysphagia, Toxicity, RT, Development
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Abstract Number: 19

Analyzing Body Fat in Participants from Project TONE: An Exercise and Diet Intervention to
Improve Body Composition in Postmenopausal Women with Normal BMI but Higher Body Fat
Anne Gao, Kinesiology, Rice University
Karen Basen-Engquist, Behavioral Science, University of Texas MD Anderson Cancer Center
Miranda Baum, Behavioral Science, University of Texas MD Anderson Cancer Center
Background: Obesity as indicated by a high BMI is associated with an increased risk of breast cancer in
postmenopausal women. However, BMI is not necessarily a precise indicator of breast cancer risk
because it does not measure body composition. Iyengar et al. conducted an analysis of body fat levels in
a subset of 3460 postmenopausal women with normal BMI ages 50-79 from the Women’s Health Initiative
(WHI) conducted 1993-1998. This analysis demonstrated that in postmenopausal women with a normal
BMI, higher body fat is associated with an elevated risk of breast cancer. Higher body fat promotes breast
cancer risk through both local changes–including inflamed adipose tissue and an altered
microenvironment–and systemic changes–including circulating metabolic and inflammatory factors.
Therefore, the goal of our ongoing study Project TONE is to determine whether a 16-week exercise and
diet intervention can reduce body fat and thus cancer risk in postmenopausal women with normal BMI but
higher body fat, a population under targeted in traditional interventions. For Project TONE, we are
recruiting postmenopausal women ages 50-69 from the employee pool at MD Anderson. Interested
women with a normal BMI will undergo a DXA scan to measure their body fat levels and determine
whether they have a high enough body fat mass to participate (trunk fat mass ≥ 9.4 kg). I aimed to
compare body fat distributions between postmenopausal women with normal BMI screened for Project
TONE and those analyzed using data from the WHI.
Methods: For postmenopausal women with normal BMI screened for Project TONE, I calculated the
quartiles of trunk fat mass, age, and BMI. I then compared these values to the same values in women
analyzed using data from the WHI.
Results: I found that the first and second quartiles of trunk fat mass were higher in postmenopausal
women with normal BMI screened for Project TONE than in women analyzed using data from the WHI.
Additionally, the ages of women screened for Project TONE were lower and BMI values higher on
average than women analyzed using data from the WHI.
Conclusion: Body fat levels are potentially higher now (2020s) than before (90s), which implies that
lifestyle strategies are needed to promote favorable body composition phenotypes (e.g., lower body fat,
adequate muscle mass). In the future, we hope to assess the efficacy and feasibility of Project TONE, as
well as continue to analyze body fat variables in screened participants.
Keywords: postmenopausal women, intervention study, breast cancer, BMI, body fat
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Abstract Number: 20

Using Novel Carbon Monoxide Devices in Remote Smoking Cessation Treatment: A Utilization and
Reliability Analysis
Joshua Ayala, Behavioral Science, University of Texas MD Anderson Cancer Center
Yong Cui, Behavioral Science, University of Texas MD Anderson Cancer Center
Jason D. Robinson, Behavioral Science, University of Texas MD Anderson Cancer Center
Charles E. Green, Behavioral Science, University of Texas MD Anderson Cancer Center
Jennifer A. Minnix, Behavioral Science, University of Texas MD Anderson Cancer Center
Maher Karam-Hage, Behavioral Science, University of Texas MD Anderson Cancer Center
Paul M. Cinciripini, Behavioral Science, University of Texas MD Anderson Cancer Center
Background:Smoking is the leading cause of preventable death in the world and accounts for a third of
cancer-related deaths. Since 13% of the adult population are smokers, many researchers of smoking
cessation have aimed at conducting smoking cessation research remotely, without the need of in-person
visits. This method of remote intervention has much potential for reducing smoking prevalence,
particularly by treating smokers who lack access to a smoking cessation clinic. For remote interventions,
the standard measurement of verifying smoking abstinence is breath derived carbon monoxide (CO), a
biochemical indicator of smoking/abstinence status. In conventional in-person smoking research,
measuring CO requires special laboratory equipment, which is not accessible to average smokers. The
recent development of portable devices has enabled smartphone-based CO equipment with an affordable
cost. Researchers have been adopting smartphone-based CO measurement equipment for smoking
cessation research. Though, little is known about the utilization and reliability of these novel mobile CO
devices in smoking cessation research. This project will seek to discover if these smartphone-enabled CO
devices are utilized and produce reliable measures among community smokers enrolled in a remote
smoking cessation trial.
Methods:In a remote trial for smoking cessation, participants were recruited from across the entire state of
Texas. Each participant was assigned with a smartphone-based CO device and instructed to use the CO
device at specific time points during the treatment course. The obtained CO readings were uploaded
automatically to our database hosted at MD Anderson Cancer Center. We conducted a secondary
analysis to evaluate the utilization and reliability of smartphone-based CO measurements. We
approached the procedure with participant assignment, data collection, and lastly the processing and data
analysis utilizing Python-based tools.
Results:We examined the frequency of using the smartphone-based CO devices for utilization analysis
and the correlation between CO levels and self-reported daily cigarette consumption for reliability
analysis. We found that participants used the mobile CO devices more than required and CO levels were
significantly correlated with the self-reported daily cigarette consumption. Additionally, a CO level of <6
ppm was the best discriminating cutoff to differentiate smoking from abstinent status.
Conclusion:Participants were able to utilize the smartphone enabled CO devices in a real-world trial more
than required and showed interest in tracking their CO records. Smartphone-based CO devices provided
reliable measures to identify smoking abstinence and serve as the future basis in remote smoking
cessation intervention
Keywords: smarphone-based CO devices,Carbon Monoxide Devices,Novel CO
devices,remotesmokingcessation
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Abstract Number: 21

Risk Assessment Model for Breast Cancer in Women Using MERIT Cohort Study
Sruthi Sridhar B.S.,, Department of Clinical Cancer Prevention, The University of Texas MD Anderson
Cancer Center
Jennifer Dennison PhD, Department of Clinical Cancer Prevention, The University of Texas MD Anderson
Cancer Center
Samir Hanash M.D., PhD, Department of Clinical Cancer Prevention, The University of Texas MD
Anderson Cancer Center
Background: Breast cancer is the most common cancer among women and is the leading cause of
cancer mortality. This stipulates screening mechanisms to promote early detection of breast cancer. The
MERIT cohort study is intended to improve breast cancer detection for all women. It is based on women
who are at risk and have been receiving annual screening. They are between ages 25-80, having not had
breast cancer or breast feeding within the last six months. The study incorporates a questionnaire to the
participants for additional data collection. Cases were identified during the study. This work applies the
Gail Model [1,2] and a variant to identify risk factors using the MERIT cohort. The Breast Cancer Risk
Assessment Tool (BCRAT) [3] developed by the NCI for the Gail Model is widely used to assess
individual breast cancer average risk [4,5]. We develop a novel approach called the MERIT Cohort Risk
Model (MCRM), a variant that includes additional risk factors and compares it against the Gail Model
performance.
Methods: MERIT cohort study consists of 6298 women who have been participating from 2017. The age
range is between 25-81 having not had breast cancer. These participants regularly take part in diagnostic
screening. Additional risk factors gathered include breast density, BMI, menopause status, and
race/ethnicity. 101 of the 6298 were reported as cases through early detection. Using SAS, the BCRAT
tool was applied to build the Gail Model and understand relative risks. Subsequently, we build MCRM
model using GLM to identify individual risks.
Results: The Gail Model showed significant risk factors. Using relative risks, the number of relatives  2
was significant (RR: (1.0006, 1.0031), 95% CI (1.0005, 1.00031). MCRM model showed better results
with additional risk factors like breast density, BMI, and menstrual status. The interaction between breast
density and age significance for women less than 50 (RR: 1.0052, 1.0066). No other measures showed
significant risk after adjusting for loss to follow-up.
Conclusion: In conclusion, MCRM model provides better risk prediction by using additional risk factors in
the MERIT cohort. MCRM is the first model that is based entirely on data specific to the MERIT cohort.
Further studies with respect to race and number of second-degree relatives having breast cancer are
warranted to evaluate the validity of interactions that may be established.
Keywords: MERIT cohort, Gail Model, Relative Risk, GLM
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Abstract Number: 22

Evaluating patient engagement with a digital intervention for adolescent and young adult (AYA)
stem cell transplant survivors
Kellie Krohn, Behavioral Science, University of Texas MD Anderson Cancer Center; Saint Mary's College
Maria Camero, Behavioral Science, University of Texas MD Anderson Cancer Center
Andrea K. Galvan, Behavioral Science, University of Texas MD Anderson Cancer Center
Martha A. Askins, Pediatrics, University of Texas MD Anderson Cancer Center,
Jeffery McLaughlin, N/A, Radiant Digital
Demetrios Petropoulos, Pediatrics, University of Texas MD Anderson Cancer Center
Partow Kebriaei, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson
Cancer Center
Susan K. Peterson, Behavioral Science, University of Texas MD Anderson Cancer Center
Background: Over time, advances in stem cell selection techniques have increased the viability of
hematopoietic stem cell transplantation (HSCT) as a treatment option for leukemia and lymphomas
including in adolescents and young adults (AYAs). AYAs face specific psychosocial and medical
challenges in their HSCT treatment and prolonged recovery, which requires rigorous self-care and
management following hospital discharge. These challenges in recovery can delay important milestones
in education, employment, and relationships. Interventions to alleviate these barriers during their
treatment have been introduced, yet evidence-based interventions focusing on promoting psychosocial
and physical health after treatment and during recovery have yet to be established. Stempowerment is an
online, interactive intervention developed to reduce barriers and increase motivation for self-care
behaviors in AYA HSCT survivors, with the goals of optimizing medication adherence, hydration, physical
activity, and psychological well-being post-discharge. As part of a mixed-methods process evaluation, we
evaluated study enrollment plus engagement with and completion of the intervention in order to identify
potential problems, barriers, and strategies for improvement.
Methods: To address current difficulties with patient recruitment and retention, process evaluation
assessed study recruitment and refusal rates, participants’ website access and social interactions,
completion of intervention components (i.e., “Quests”) and surveys, and end-of-study interview.
Demographic and clinical data were obtained from medical and study records. A literature review was
performed to evaluate published interventions for AYAs HSCT survivors and relative burden.
Results: Most participants recruited to the study completed the baseline survey and completed at least
one quest, however, only 4 (17.4%) completed all quests. Additionally, most online social interactions
were limited to sharing quest completions. Consistent with other studies, common reasons for refusal or
withdrawal include illness severity and feeling overwhelmed. Univariate analyses comparing those who
enrolled, refused, or withdrew revealed no differences in demographic or clinical variables.
Conclusion: To address these findings, our participant communication plan was revised to increase text
messaging reminders and include varied messages reinforcing participation. Preliminary qualitative
evidence suggests increased completion of individual quests and social interactions appear to be more
frequent and may reflect greater engagement with the intervention and other users. Strategies to improve
participation and engagement along with implementing frequent process evaluations with digital
interventions are needed, particularly for patients coping with serious illness and difficult treatments.
Keywords: psychosocial, intervention, cancer, Hematopoietic stem cell transplant, AYA
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Abstract Number: 23

The Effects of COVID-19 Restrictions and Community-Based Participatory Research, Delays in
Project Self Recruitment
Lauryn Allen, B.S., Department of Health Disparities Research, Michigan State University College of
Human Medicine
Surendranath Shastri, MBBS, MD, PhD, Department of Health Disparities Research, University of Texas
MD Anderson Cancer Center
Loren Bryant, MS,MBA, Department of Health Disparities Research, University of Texas MD Anderson
Cancer Center
Edna Parades, MBA, CHES, Department of Health Disparities Research, University of Texas MD
Anderson Cancer Center,
Background: The COVID-19 pandemic has had an overwhelming effect on Community-Based
Participatory Research (CBPR), which ultimately relies on partnerships between community members,
scientists and researchers to improve health. Project Self is a CBPR study with the overall goal to
improve the cervical screening uptake rates among Hispanic and African American women living in
Houston, Texas. This study proposed to complete all recruitment/enrollment and data collection efforts inperson at participating Houston Housing Association (HHA) housing sites (Fulton and Irvinton Village);
which became a barrier with the onset of COVID-19 and the institutional and housing site restrictions.
Methods: This research study utilized literature reviews and in-depth interviews to learn about barriers
faced by MD Anderson faculty/staff related to the COVID-19 pandemic and mandates put in place
regarding community-based participatory research procedures.
Results: Findings provided during the in-depth interviews discussed challenges of community basedparticipatory research during the COVID-19 pandemic. Data collection strategies included literature
reviews (n=5) and in-depths interviews with MD Anderson faculty/staff (n=2).
Conclusion: In an effort to make up for the time the study staff were unable to complete study procedures
in the community, the main focus is to enhance Project Self community engagement strategies pertaining
to recruitment/enrollment procedures at Fulton and Irvinton Village. We plan to stay engaged with the
Houston Housing Authority (HHA) staff, Resident Council members, housing staff and residents by
participating and contributing to upcoming community events and facilitating in-person meetings in the
community centers to also assist with study implemention.
Keywords: Cervical Cancer, HPV, Community Based Participatory Research, Community Engagement
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Abstract Number: 24

PARPis As Immune Modulating Agents in Preventing Ovarian Cancer Recurrence
Melayshia McFadden, Microbiology, Biochemistry & Immunology, Morehouse School of Medicine
Natalie Ngoi, Clinical Cancer Prevention, The University of Texas, MD Anderson Cancer Center
Xueqian Cheng, Clinical Cancer Prevention, The University of Texas, MD Anderson Cancer Center
Guang Peng, Clinical Cancer Prevention, The University of Texas, MD Anderson Cancer Center,
Background: According to the American Cancer Society, in 2022 about 21,000 women will receive an
ovarian cancer diagnosis this year and about 13,000 women will die from ovarian cancer. And
unfortunately, up to 85% of the women who undergo aggressive treatment – surgery, chemotherapy,
and/or radiation – for advanced ovarian cancer face the risk of recurrence after initial treatment. However,
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently approved for the treatment of
advanced breast cancers, ovarian cancers, and pancreatic tumors harboring BRCA1 or BRCA2
(BRCA1/2) mutations [1-6]. So, right now these drugs only help about 50% of patients with ovarian
cancer; specifically, those who have completed initial treatment with surgery and chemotherapy and have
homologous recombination deficiency (HRD) or BRCA mutations. So, it is important to find more
biomarkers and targetable PARPs for patients with other forms of ovarian cancer to benefit from the
cancer preventive effects of PARPis. Interestingly, recent published studies from Dr. Guang Peng’s
laboratory and other groups have revealed a previously unknown function of PARPis as
immunomodulating agents through activation of the DNA sensing cyclic GMP-AMP Synthase (cGAS)stimulator of interferon genes (STING) pathway [7-10] The activation of this immune response in turn
enhances T cell proliferation and trafficking to the tumor microenvironment [11,12]. Thus, PARPis can
indirectly stimulate antitumor immunity by enhancing the recruitment of cytotoxic T-cells in both BRCA
wildtype and mutant cancer cells [10]. Based on preliminary studies, we hypothesize that PARPis will
induce a transcriptional program of immune responses through the cGAS-STING-TBK1-IRF3 pathway
and active anti-tumor immunity in BRCA wildtype ovarian tumors as a preventive agent for recurrence.
Methods: (1) Ovarian Cancer cell cultures will be used as a model to test molecular effects. BRCA1
knockdown cells will be used as a control and compared to BRCA wild type cells. These cells will be
treated with different dosages of PARPis. (2) We will use cell models to test whether PARPis may lead to
an enhanced innate immune signaling in ovarian cancer cells by using RT-PCR to detect CCL5 and
CXCL10. (3) We will use cell models to test whether PARPis may lead to an enhanced innate immune
signaling in ovarian cancer cells by using Western blot to detect p-TBK1/TBK1 and p-IRF3/IRF3.
Results/Conclusion: Results from this project will provide novel mechanistic insights into the therapeutic
efficacy of PARPis as immunomodulating agents. This concept of the underlying mechanism of PARPis
will provide strong rationale to develop predictive biomarkers and preventive effects of PARPis for
patients with other forms of ovarian cancer beyond BRCA deficiencies.
Results/Conclusion: Results from this project will provide novel mechanistic insights into the therapeutic
efficacy of PARPis as immunomodulating agents. This concept of the underlying mechanism of PARPis
will provide strong rationale to develop predictive biomarkers and preventive effects of PARPis for
patients with other forms of ovarian cancer beyond BRCA deficiencies.
Keywords: PARP Inhibitors, Ovarian Cancer, Recurrence, Immune Response, Prevention
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Abstract Number: 25

Racial and Ethnic Disparities in Breast Cancer Patients: A Literature Review of Time to Treatment
(TTT)
Zhabian Gonzalez, Epidemiology, The University of Texas at Austin, The University of Texas MD
Anderson Cancer Center
Kristie Primm, Epidemiology, University of Texas MD Anderson Cancer Center
Shine Chang, Epidemiology, University of Texas MD Anderson Cancer Center
Background: Advances in the diagnosis and treatment of breast cancer (BC) have resulted in a shift
towards earlier detection and increased survival over the past several decades. Despite these advances,
disparities in BC outcomes by race/ethnicity persist. Delays in TTT have emerged as factors that explain
in part disparities between racial and ethnic groups. We performed a literature review to summarize
research on racial and ethnic disparities in time to BC treatment to identify opportunities for intervention.
Methods: The literature search was conducted on June 23, 2022, and utilized five online databases:
Medline, Embase, PubMed, Web of Science, and Scopus. The following criteria for inclusion of original
research articles were used in the search: Focus on delays in BC TTT & disparities by race/ethnicity;
Peer-reviewed & published within the last 15 years (2011-2022); Published in English & conducted in the
United States. Of 120 articles found from the search, 37 articles met the criteria for review. Data extracted
from these articles were compiled into a spreadsheet in order to reveal similarities and patterns across
studies. Data extracted included: purpose, sample size, sex, age, race/ethnicity, the outcome of interest,
findings, etc.
Results: Of the 37 studies, the majority (19) focused primarily on TTT disparities among White and Black
women only. Most other studies examined outcomes across broadly defined racial and ethnic groups,
most commonly Black, Hispanic, and Asian/Pacific Islander (API). Minimal research on disaggregated
racial and ethnic groups was identified. Notably, only 4 studies compared outcomes within API and
Hispanic subgroups. Across studies, findings suggest that people of color are more likely to experience
delays in time to treatment than their White counterparts. Nearly all identified studies (30) showed that
Black patients were more likely to experience longer time from diagnosis to BC treatment compared to
other groups.
Conclusion: Studies in this literature review strongly show that Black BC patients consistently have longer
TTT, which may contribute to their poorer BC outcomes and worse overall survival. Most articles reviewed
used broadly defined racial and ethnic groups such as Asians and Hispanics, however, these are
considered umbrella terms that consist of subgroups just as Asians include Chinese and Japanese.
Future investigations should disaggregate these groups into subgroups to identify disparities.
Undoubtedly, timely treatment is a human right, and receiving it should not be delayed. Implementing
interventions to reduce TTT for Black women with BC should be a priority.
Keywords: Breast cancer, Time to treatment, Race/ethnicity, Disparities
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Abstract Number: 26

Colorectal Cancer Risk: What Does an Existing Tool Reveal About Modifiable Risk Factors in
Young Patients?
Allison Janak, Department of Epidemiology, Division of Cancer Prevention and Population Sciences,
University of Texas MD Anderson Cancer Center
Yi-Qian Nancy You, MD, MHSc, Department of Colon & Rectal Surgery, Division of Surgery, University of
Texas MD Anderson Cancer Center
Background: The National Cancer Institute’s Colorectal Cancer Risk Assessment Tool was developed to
estimate 5-year and lifetime colorectal cancer risk in individuals between the ages of 45 and 85. Despite a
significant increase in colorectal cancer incidence among individuals aged 50 and younger, the existing
tool does not feature validated cancer risk estimations based on age for this population. Risk prediction of
CRC for young adults based on behavioral inputs using an existing tool has not been investigated.
Methods: 563 adult patients aged 18-90 at University of Texas, MD Anderson Cancer Center diagnosed
with colorectal cancer completed a health behavior questionnaire at the time of recruitment. Each
participant’s 5-year and lifetime risks were calculated by entering questionnaire data into the CCRAT.
Health behaviors and characteristics were compared by three age groups, 18-<45, 45-50, and >50. The
prevalence of 5-year and lifetime elevated risk was compared among each group.
Results: The age groups significantly differed in the number of 5-year (<0.001) and lifetime (<.05) risk
estimates that exceeded the population average risk for colorectal cancer. Significant differences were
observed among age groups in cancer type (colon, rectal, or colon and rectal concurrently), body mass
index, race/ethnicity, yearly time spent engaged in moderate and vigorous activity, aspirin use, having a
first degree relative diagnosed with colorectal cancer, number of cigarettes per day (among smokers),
and age at time of smoking cessation (among smokers). Of note, sex, weekly vegetable intake, and
smoking were not significantly different among age groups.
Conclusion: Based on the tool’s ability to predict high risk in this population of early- and late-onset
colorectal cancer patients, the risk factors contributing to early-onset colorectal cancer likely differ from
those of late-onset colorectal cancer. Additionally, differences between early-onset patients and lateonset patients in physical activity, body mass index, and having a first degree relative diagnosed with
colorectal cancer demonstrate several clinical implications and require further investigation.
Keywords: colorectal cancer, young-onset colorectal cancer, risk factors, risk assessment, early-onset
colorectal cancer
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Abstract Number: 27

Early pancreatic cancer detection with hyperpolarized magnetic resonance
Kasen R. Hutchings, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
José S. Enriquez, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Shivanand Pudakalakatti, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Prasanta Dutta, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center,
Florencia McAllister, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer
Center
Pratip Bhattacharya, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer is among the most aggressive forms of cancer with a 5-year survival rate
of 11%. There is an unmet need for diagnostic markers to detect premalignant/early stages of pancreatic
cancer. Recent hyperpolarized magnetic resonance studies at the University of Texas MD Anderson
Cancer Center have shown promise in early detection of pancreatic cancer in animal models. In these
studies, it has been demonstrated that injected hyperpolarized pyruvate was converted to lactate at a
heightened rate during the early stages of pancreatic cancer in mice. However, these studies were limited
by the spontaneous nature of the mouse models, which led us to alter this study by using an inducible
mouse model.
Methods: Hyperpolarization experiments were performed with 1-13C-labeled pyruvate containing 15 mM
trityl radical (OX63) using a commercial DNP polarizer (HyperSense, Oxford Instruments, UK) at 3.35T
magnetic field and a temperature of 1.4 Kelvin. 13C-spectra were obtained using a Bruker BioSpec 7T
imaging scanner, which utilized a dual tuned (1H) volume coil and (13C) surface coil (Doty Scientific, SC).
Area under the curve values were collected for each metabolite, and lactate-to-pyruvate ratios were
compared. Three different inducible mice models were used for these studies: P48CreERT2 (control),
P48CreERT2:LSLKras (KCi), and P48CreERT2:LSLKras:LSLP53 (KPCi). Mice were imaged at three time
points: preinduction, 10 weeks postinduction, and 20 weeks postinduction. A tamoxifen induction system
was implemented to induce mutation and allow for better regulation of the cancer.
Results: There was a significant increase in the 20-week lactate-to-pyruvate found within the KPCi mice
model (preinduction: 0.22; 10 weeks: 0.24; 20 weeks: 0.33). There was also a significant difference in
lactate-to-pyruvate between KPCi mice (0.33) and the KCi (0.25) and control mice (0.26) at 20 weeks. No
significant differences were found at the preinduction or 10-week timepoints in any of the three models.
Conclusion: Hyperpolarized lactate-to-pyruvate ratios in these mice models correlate with the
aggressiveness of pancreatic cancer. Future directions include collecting data from one more timepoint
(30 weeks). We also hope to understand the specificity of this technique to perform hyperpolarized
imaging in a chronic pancreatitis GEM model, a known confounder of pancreatic cancer. Clinical
translation of this technique could enable physicians to detect pancreatic cancer at premalignant stages,
thus improving patient outcomes and survival. We are initiating a clinical trial for early detection of
pancreatic cancer at the MD Anderson high-risk pancreatic cancer clinic by utilizing a recently installed
clinical DNP polarizer
Keywords: Hyperpolarization, Pancreatic Cancer, Pyruvate, Lactate
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Abstract Number: 28

Determination of Clinical and Environmental Risk Factors in Early-Onset Colorectal Cancer
Catherine Luo, Gastrointestinal Medical Oncology, Johns Hopkins University
Jumanah Alshenaifi, Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center
Ri Chen, Gastrointestinal Medical Oncology, University of Central Florida College of Medicine
Yi-Qian Nancy You, Colon & Rectal Surgery, University of Texas MD Anderson Cancer Center,
Background: Colorectal cancer (CRC) is the third most common and deadliest cancer. With the advent of
CRC screenings in 1996, overall colorectal cancer incidence and mortality rates have markedly declined.
Late-onset CRC (LOCRC) cases have also continued to steadily decline due to recommended screening
particularly in patients 50 years and older. However, early-onset CRC (EOCRC) – defined as CRC in
adults younger than 50 – incidences have increased, with 71% of EOCRC cases being diagnosed at
stage III or IV, according to the Colorectal Cancer Alliance. EOCRC differs from LOCRC across various
genomic, clinical, and molecular characterizations, with EOCRC exhibiting later presentation stages and a
greater likelihood for metastatic onset at presentation. The increasing prevalence and mortality rates of
EOCRC along with the scarce existing research into EOCRC highlights the need for further research into
EOCRC risk factors and clinical characterizations. Studying patients’ general and specific external
environment (exposome) along with internal environment factors contributing to heightened EOCRC
incidence enables us to identify key risk factors. Findings from patient clinical and demographic data,
exposures to carcinogens, lifestyle habits, and gene mutations can be used to better inform younger
individuals on lifestyle changes or prevention strategies that could reduce the risk of EOCRC. In addition,
identifying molecular markers and characteristics of EOCRC can assist in early clinical evaluation,
reducing the chances of progression to advanced-stage CRC.
Methods: Analysis of clinical patient information contained in Epic charts will help uncover potential
genetic and biological predispositions, lifestyle risk factors, demographic backgrounds, symptoms, and
screening details that can better reveal links between risk factors and heightened susceptibility to earlyonset colorectal cancer (EOCRC). This information will be drawn from EOCRC patients either currently or
formerly enrolled in CRC clinical studies. Pairing clinical data with results from immune infiltrates,
microbiomes, RNA seq data, and other molecular or biochemical assays could be key in further
differentiating EOCRC from late-onset colorectal cancer (LOCRC) risk factors. CRC patients enrolled in
the MD Anderson Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) study have
completed comprehensive surveys assessing patient habits (smoking, alcohol consumption, diet) and
exposures to various industrial and chemical carcinogens. Investigating these data and comparing
between EOCRC and LOCRC environmental exposures in patients could uncover factors more strongly
correlated with EOCRC cases.
Results: This research project will combine analysis of clinical patient information, biochemical and
genomic assays, and environmental survey assessments to identify key risk factors for early-onset
colorectal cancer (EOCRC). Data will be analyzed through Excel pivot tables and R to yield results that
could help further characterize EOCRC and its profile. Results show significant difference (p<0.5) in
gasoline exposures, with late-onset colorectal cancer patients (LOCRC) exhibiting higher years of
gasoline exposure than compared to those with EOCRC. Smoking duration was also significant between
LOCRC and EOCRC, with LOCRC patients smoking cigarettes for more years than compared to EOCRC
patients’ smoking habits.
Conclusion: Results may be subject to recall bias, as data were obtained through a retrospective patient
survey and patient recall of exposure duration and frequency may not be accurate. Furthermore, LOCRC
patients are expected to have a positive association with greater carcinogen exposure, as they tend to be
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older and therefore have had more chances to be exposed to or use carcinogens. Our study suggests
that exposome results alone are not sufficient to reveal differences between early and late-onset CRC.
Further research needs to be conducted on other risk factors or clinical and molecular characterizations
to uncover the main drivers of early-onset CRC.
Keywords: colorectal cancer, early onset, carcinogen, environment, clinical
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Abstract Number: 29
Identification of cardiovascular disparities among Black and Hispanic survivors of adolescent and
young adult (AYA) lymphoma
Tori Tonn, Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center
Elizabeth Rodriguez, Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center
Midhat Jafry, Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center
Branko Cuglievan, Pediatrics, University of Texas MD Anderson Cancer Center,
Sairah Ahmed, Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center
J. Andrew Livingston, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center
Michael Roth, Pediatrics, University of Texas MD Anderson Cancer Center
Michelle Hildebrandt, Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center
Background: Survival rates for adolescent and young adult (AYA) cancer patients have improved in
recent decades. However, treatments such as anthracyclines and chest radiation therapy carry adverse
cardiotoxic risks, predisposing this survivor population to early-onset cardiovascular dysfunction. To date,
research on treatment-related cardiovascular dysfunction has primarily focused on survivors of pediatric
and adult cancers, particularly of European ancestry. Importantly, Black and Hispanic individuals exhibit
higher cardiovascular disease risk factors within the general population, potentially augmenting the risk
for adverse cardiac outcomes after cancer treatment. Therefore, it is critical to determine the
cardiovascular burden among diverse AYA cancer survivors. Here, we assess the prevalence of
cardiovascular endpoints in a diverse cohort of AYA lymphoma survivors, addressing a crucial knowledge
gap in cancer survivorship.
Methods: Medical records of Hispanic, non-Hispanic Black, and non-Hispanic White AYA lymphoma
survivors (diagnosed between age 15-39, ≥2 years from diagnosis) were systematically abstracted.
Cardiovascular outcomes were analyzed by self-reported race/ethnicity. To account for genetic diversity,
stratification into groups based on proportions of continental genetic ancestry (European, African,
Amerindian) using existing genotyping data and the ADMIXTURE analytical program was performed. The
mean proportion of each ancestry group across the three self-identified race/ethnicity populations was
used as a cut-point for preliminary stratification.
Results: The study population included 322 AYA survivors (12.8% Black, 18.6% Hispanic, 68.6% White)
diagnosed with Hodgkin lymphoma (56.5%), non-Hodgkin lymphoma (41.6%), or other hematologic
cancer (1.9%). Self-identified Black survivors exhibited higher prevalence of hypertension (P=0.005),
pericardial effusion (P=0.026), cardiomyopathy (P=0.002), and congestive heart failure (P=0.017), while
self-identified Hispanic survivors had higher prevalence of hyperlipidemia (P=0.025). The average BMI
change (mean±SD) from initial cancer diagnosis to last follow-up decreased for Black survivors (–0.4±4.5
kg/m2) and increased in Hispanic (2.0±4.8 kg/m2) and White (2.3±3.9 kg/m2) survivors (P=0.036).
Individuals with <4% European genetic ancestry (95.2% self-identified as non-White) showed higher
prevalence of hypertension (P=0.026), pericardial effusion (P=0.010), cardiomyopathy (P=0.002), and
congestive heart failure (P=0.027), compared to those with ≥4% European genetic ancestry (98.6% selfidentified as White).
Conclusion: Despite improvements in AYA cancer survival, adverse effects on cardiovascular health
remain prevalent after treatment. With research largely limited to pediatric and adult patients of European
ancestry, assessment of cardiovascular outcomes in Black and Hispanic AYA survivors is critical to inform
clinical follow-up procedures. This analysis helps to delineate the cardiovascular burden in a diverse AYA
lymphoma cohort, with further variation based on genetic ancestry.
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Abstract Number: 30

The Association Between Persistent Poverty and Melanoma Mortality in Texas: A Retrospective
Study Using Texas Cancer Registry Data
Lillian K. Morris and Karla Madrigal (Co-First Authors), Dermatology, McGovern Medical School, The
University of Texas Health Science Center at Houston; University of Texas MD Anderson Cancer Center
Emelie E. Nelson, Dermatology, McGovern Medical School, The University of Texas Health Science
Center at Houston; University of Texas MD Anderson Cancer Center
Adewole Adamson, Dermatology, Dell Medical School, The University of Texas at Austin
Zhigang Duan, Health Services Research, University of Texas MD Anderson Cancer Center,
Hui Zhao, Health Services Research, University of Texas MD Anderson Cancer Center
Julie M. Simon, Surgical Oncology, University of Texas MD Anderson Cancer Center
Chloe N. Dorsey, Surgical Oncology, University of Texas MD Anderson Cancer Center
Marcita S. Galindez, Office of Health Policy, University of Texas MD Anderson Cancer Center
Hung Q. Doan, Dermatology, University of Texas MD Anderson Cancer Center
Cici X. Bauer, Biostatistics, University of Texas Health Science Center at Houston School of Public Health
Kelly Nelson; Dermatology; University of Texas MD Anderson Cancer Center
Background: Patients in United States counties with persistent poverty (PP, ≥20% of residents in poverty
since 1980) experience significantly higher cancer associated mortality than individuals living in non-PP
counties. While markers of lower socioeconomic status have been correlated to higher melanoma
mortality, the relationship of persistent poverty and melanoma mortality has not been explored.
Methods: We obtained data from 87,713 patients diagnosed with melanoma between 2000-2018 from
the Texas Cancer Registry. We used 2021 US Economic Development Administration data to identify PP
counties. Mixed effect models were used to assess incidence-based melanoma-specific mortality (IMM)
rates by PP, age, sex and race/ethnicity.
Results: In 2021, 56 of 254 Texas counties met PP criteria. Of those diagnosed with melanoma, 5,431
patients in PP counties experienced higher IMM (17.14%) than those in non-PP counties (11.34%,
adjusted odds ratio (AOR) = 1.10, 95% CI: 0.94-1.28). Compared to Non-Hispanic (NH) Whites, NH
Blacks experienced the highest IMM at 25.67% (AOR = 2.97, 95% CI: 2.45-3.62), followed by Hispanics
(19.71%, AOR = 1.98, 95% CI: 1.82-2.16). The disparity in IMM increased with age, with the 80 years +
age group having the highest mortality AOR of 2.53 (95% CI: 2.16-2.96). When exploring sex, more men
(13.43%) than women (9.09%) died from melanoma in PP counties (AOR = 1.48, 95% CI: 1.42-1.55).
Conclusion: Age, race/ethnicity, sex, and PP are associated with significant disparities in melanoma
mortality outcomes within our patient cohort. To address these disparities and develop targeted
melanoma secondary prevention interventions, we will continue to explore how place-based social
determinants of health correlate with melanoma outcomes.
Keywords: Melanoma, Mortality, Texas, Persistent, Poverty
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Abstract Number: 31

The Relationships of Childhood Trauma and Post Traumatic Stress Disorder to Smoking
Outcomes in Cancer Patients
Alina Mahmood, Behavioral Sciences, College of Natural Science, University of Texas at Austin
Janice Blalock, Behavioral Science, University of Texas MD Anderson Cancer Center
George Kypriotakis, Behavioral Science, University of Texas MD Anderson Cancer Center
Maher Karam-Hage, Behavioral Science, University of Texas MD Anderson Cancer Center,
Background: Childhood trauma and post-traumatic stress disorder (PTSD) have been found to be related
to higher levels of nicotine dependence and poorer tobacco cessation outcomes compared to smokers in
the general population without these comorbid factors. To our knowledge, the relationship of these factors
to nicotine dependence and cessation outcomes has not been evaluated in cancer patients.The aims of
the current study are to assess the relationship of PTSD and childhood trauma to nicotine dependence
and tobacco cessation outcomes in cancer patients participating in the MD Anderson Tobacco Treatment
Program (TTP). We also hope to determine whether the effects of PTSD and trauma on abstinence will
be mediated by negative affect.
Methods: We will use data which includes diagnoses of cancer patients seen for psychiatric care in the
TTP. Within a sample of 687 patients, 57 have a diagnosis of PTSD and 183 have a history of childhood
trauma. Generalized linear models will be used to evaluate relationships between PTSD and childhood
trauma with nicotine dependence and abstinence. Analyses will adjust for psychiatric comorbidity as well
as smoking and demographic characteristics. We used mediational analysis to identify the indirect effects
of PTSD and Trauma that is attributed to changes in negative affect.
Results: Overall, the results confirm the hypotheses that PTSD and trauma adversely affect smoking
outcomes. For abstinence, both PTSD and trauma were significant predictors, controlling for
demographics and other psychiatric comorbidities. We found trauma to significantly predict nicotine
dependence, for both negative and positive affect, whereas PTSD significantly predicted negative affect.
Levels of negative affect accounted for a small but significant proportion of the effect of PTSD and trauma
on abstinence.
Conclusion: The 2014 Surgeon General’s Report on the Health Consequences of Smoking highlighted
the negative impact of continued tobacco use in cancer patients, following diagnosis, on cancer treatment
outcomes and survival. It is important to understand whether comorbid PTSD and the experience of
childhood trauma presents additional barriers to tobacco cessation in this population. This additional
knowledge may also aid in the development of targeted tobacco treatments that address these factors in
cancer patients, which may improve tobacco cessation outcomes in cancer patients with these
comorbidities.
Keywords: PTSD, Trauma, Affect, Smoking, Quitting
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Abstract Number: 32

A population-based study comparing comorbid conditions and mental distress among Hispanic
Adolescent and Young Adult cancer survivors to propensity score matched controls
Ashna Shah, Health Disparities, University of Texas MD Anderson Cancer Center
Eunju Choi, PhD, Department of Nursing, University of Texas MD Anderson Cancer Center
Michael Roth, MD, Pediatric Patient Care, University of Texas MD Anderson Cancer Center
Background: The adolescent and young adult (AYA) age range is key for psychosocial growth and
development: therefore, the addition of a cancer diagnosis may cause AYA cancer survivors to face
higher levels of psychosocial distress. Furthermore, AYAs in minority populations, such as Hispanics,
may face even higher psychosocial distress and poorer health-related quality of life (HRQoL). Research
has indicated that risky health practices and chronic health conditions may lead to poorer mental health.
Few studies assess the impact of a cancer diagnosis and risky health practices on Hispanic AYA’s mental
health and HRQoL. Therefore, the aim of this study is to investigate the health practices and mental
distress among Hispanic AYA cancer survivors in comparison with Hispanic AYAs without a history of
cancer in order to develop targeted psychosocial interventions.
Methods: The study was conducted using a cross-sectional, matched case-control design using
population data from the National Health Interview Survey (NHIS). The Kessler nonspecific psychological
distress scale (K6) was used to identify mental distress. The 6-item K6 scale asks respondents how
frequently within the past 30 days they felt nervous, hopeless, restless, worthless, sad, and that
everything was an effort. The total score can range between 6 to 30, with lower scores indicating worse
mental health. Propensity score matching was utilized to match Hispanic AYA non-cancer controls to
Hispanic AYA cancer survivors. Chi-squared test was utilized to examine the distributions of
sociodemographic and health practices variables between the two groups, multiple logistic regression
was used to examine differences in psychosocial distress between matched Hispanic AYAs with cancer
and without cancer.
Results: Hispanic AYA cancer survivors and controls were matched on survey year, age at diagnosis,
sex, education, income level, insurant status, and marital status. After matching, the final study sample
included 295 Hispanic AYA cancer survivors and 295 controls. Sociodemographic and health practices,
such as alcohol status, were comparable between two groups. Hispanic AYA cancer survivors reported
more comorbid conditions than their healthy controls. After matching and adjusting for comorbid
conditions, Hispanic AYA cancer survivors reported poorer psychosocial health than matched controls (b=
-0.898, t= -2.236, p = 0.026).
Conclusion: Overall, these results displayed a higher prevalence of comorbid conditions and worse
mental health outcomes for Hispanic AYA cancer survivors compared to their matched healthy controls.
These results provide a rationale for how Hispanic AYA cancer survivors may benefit from tailored
surveillance and the creation of targeted intervention programs to improve their mental health outcomes.
Keywords: Hispanic, adolescent and young adult cancer, mental distress, kessler distress scale,
psychosocial distress
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Abstract Number: 33

NPRL2: A New Target In Breast Cancer Treatment
Ana-Sofia Ruiz, Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Siqi Wu, Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Guang Peng, Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Background: It has been well established that genomic instability and mutation is a major hallmark of
cancer development (Hanahan & Weinberg, 2011). However, due to deficiencies in mismatch repair,
most breast tumors do not display high rates of mutational burdens compared to other cancers (Li &
Chen, 2018; Marra et al., 2019). This suggests there are alternative pathways better for evaluating risk for
breast tumor progression. Notably, studies from our team and others have revealed that cytosol DNA
fragmentation activates DNA sensing pathways which in turn activate the innate immune response
(Schrock et al., 2019; Shen et al., 2015). Our group decided to investigate molecular determinants of the
c-GAS/STING pathways to see if defects in the S-DDR may reveal biomarkers responsible for the
development of intermediate breast tumors. After running a genetic screen, we selected NPRL2 as a top
candidate in regulating the S-DDR. NPRL2 is a primary component of the GATOR1 complex which has
been linked to tumor suppression through its inhibitory interaction with mTORC1 (Bar-Peled et al., 2013).
Although it has been established that loss of NPRL2/GATOR1 function leads to activation of mTOR
signaling, the definitive role of NPRL2 in regulating the S-DDR warrants further research.
Methods: We utilized immunohistochemistry (IHC) to compare molecular differences in tissue microarray
slides with breast lesions at various stages of breast cancer. Additionally, we used bioinformatic analysis
of breast cancer samples in The Cancer Genome Atlas (TCGA) and generated knockdown of NPRL2 cell
lines using lentivirus. Finally, we ran q-PCR to see if NPRL2-/- or defects in the S-DDR promote innate
immune signaling in breast cancer cells.
Results: Through our research, we found a positive correlation between NPRL2 and CHK1 expression in
Triple Negative Breast Cancer (TNBC). Additionally, we discovered that reduced NPRL2 expression in
breast cancer induced innate immunity and also correlated with a worse prognosis in breast cancer
patients.
Conclusion: From these results, we identified NPRL2 as a mediator of the innate immune response and a
contributor to cancer development. It is important to note that low levels of NPRL2 are associated with
higher risk of breast cancer. Consequently, it is important that we identify these high-risk patients early so
that treatment can be started before the cancer becomes advanced. Although more research needs to be
done to evaluate NPRL2 as a possible target in pharmacological therapies for breast cancer, the
association between the gene and tumor progression has been investigated through these experiments.
Keywords: NPRL2, breast cancer, innate immunity, DDR, CHK1
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Abstract Number: 34

Evaluating Donor PBMC's expression of HLA-A, B, and Cs
Spirit Martin, Department of Thoracic-Head & Neck Med Oncology, University of Texas MD Anderson
Cancer Center
Background: Cervical cancer is the fourth most common cancer seen in women. Nearly all cervical
cancers are attributed to the Human Papillomavirus (HPV). HPV is divided into two groups, high-risk
types, and low-risk types. HPV-16 is a high-risk type of the virus because it can result in cancer.
Currently, cellular therapy is being developed and researched to improve the immune system’s ability to
fight off cancerous tumors. Once malignancies caused by HPV reach the metastatic stage they become
incurable and resistant to standard therapies, such as chemotherapy and radiation. This occurs because
the malignancies uniformly express the HPV E7 antigen, which contributes to cancer cell survival.
Epitopes, also known as antigenic determinants, are protein domains that can elicit a cellular
immunological response from T or B cells. T-cell epitopes are peptides produced from protein antigens
that are presented by MHC molecules on antigen-presenting cells and recognized by T-cell receptors,
which then elicit an immune response to invading pathogens. The Human Leukocyte Antigen (HLA) plays
a huge role in the immune response to viruses/tumor cells by presenting self and non-self epitopes to the
immune system. This may lead to the killing of the cell presented to the epitope on the HLA. T cells are
unable to recognize tumor cells that do not express HLA, which allows the cells to escape the immune
response through downregulation, resulting in malignancies. I will test a sample of Human peripheral
blood mononuclear cells (PBMCs) HLA expression to see if I can then follow the same steps to test the
HLA expression of tumor cells
Methods: PBMCs were obtained from a donor infected with HPV16 and battling cancer as a result. Cells
were then stored in the nitrogen box until ready for use. Cells were collected from the nitrogen box and
soaked in a warm 35-celsius bath until a small ice chunk was present. 10 ML of the prewarmed medium
was added to the cells. The cells were then placed in the centrifuge and spun at 350 rcf, for 5 minutes, at
room temperature. Using the drop-by-drop method when adding the medium to the cells will prevent
osmotic shock. Next, the cells were placed into a flask and incubated in order for the cells to attach to the
flask.Passaging the cells came next after the cells were successfully attached to the flask. The cells were
then rinsed and a dissociation reagent (TRYPLE) was added. The cells appeared round when released
from the substrate. Cells were then placed in the centrifuge and a newly formed pallet formed. The pallet
was then resuspended with a growth medium. A small amount of medium was removed for a cell count.
The cell count was performed by using Trypan blue, which gave the dead to alive cell ratio. I then stained
the cells and used flow cytometry to measure the expression of HLA within my cells. I measured surface
expression of HLA molecules using fluorochrome conjugated antibodies..Flow cytometry told me the
intensity of HLA expression, rather than just yes/no if an expression is present. As the flow cytometry
results were converted into a graph, a variety of T cells were tagged with different color probes so that
they could be separately identified.
Results: The cells went through the staining process and were successfully run through the flow
cytometry machine. The cells were stained for the expression of HLA-A, B, and C. Staining tested for the
positive and negative controls of HLA expression within my cells. I proposed that not all of the cells would
express HLA and that the levels of different HLA molecules are different. I said this because cells are
very sensitive, when growing the cells they are under a great amount of stress and this could alter
whether or not they will express HLA. After staining my cells and running them through Flow Cytometry I
found that all of my cells from donor 1 expressed HLA A, B, AND C. I compared them against Isotypes A,
B, and C to see if the expression of HLA was present.
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Conclusion: I used healthy donor PBMCs to undergo the process of thawing cells, staining, and running
the cells through flow cytometry. This experiment was important because it allowed me to understand the
process that I later use with tumor cells. Flow cytometry allowed me to see the intensity of HLA
expression within my cells, which is very important because HLA acts as the immune response to
pathogens. When HLA is decreased/down-regulated mutations occur and pathogens are able to evade
being presented to epitopes by HLA, which allows them to not be killed and form tumors.
Keywords: PBMCs, HLA expression, epitopes, cellular therapy
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Abstract Number: 35

Elucidating the Role of Microbiome in Low- and High-Grade Glioma
Aditi Manjrekar, Neurosurgery, University of Texas MD Anderson Cancer Center
Golnaz Morad, Surgical Oncology, University of Texas MD Anderson Cancer Center
Matthew Wong, Surgical Oncology, University of Texas MD Anderson Cancer Center
Ashish Damania, Surgical Oncology, University of Texas MD Anderson Cancer Center,
Pranoti Sahasrabhojane, Surgical Oncology, University of Texas MD Anderson Cancer Center
Sarah Johnson, Surgical Oncology, University of Texas MD Anderson Cancer Center
Sherise D. Ferguson, Neurosurgery, University of Texas MD Anderson Cancer Center
Nadim J. Ajami, Surgical Oncology, University of Texas MD Anderson Cancer Center
Jennifer A. Wargo, Surgical Oncology, University of Texas MD Anderson Cancer Center
Background: Glioma is a type of CNS tumor, originating from glial cells and further classified into grades IIV. Low-grade gliomas are often characterized by mutant IDH while high-grade gliomas tend to express
the wild-type. Glioblastoma (grade IV) is the most prevalent malignant adult brain tumor, characterized
with a poor prognosis despite maximal therapy. While immunotherapy, specifically immune checkpoint
blockade, has been effective in other solid malignancies, it has demonstrated limited success against
glioblastoma, likely due to its immunosuppressive tumor microenvironment and intrinsic immune evasion.
The gut microbiome has been demonstrated to be involved in the immune system and tumor immunity in
various tumors. However, the role of the microbiome and microbiota-driven immune modulation in glioma
is still largely unknown, presenting the opportunity to investigate the glioma development through the
modulation of systemic and local immune responses.
Methods: Gut microbiome samples collected from 30 patients with low- and high-grade glioma at the time
of surgical resection and sequenced via metagenomic shotgun sequencing were analyzed in order to
determine the association of microbial signatures with tumor grade and tumor progression metrics. To
determine the mechanistic role of the gut microbiome in shaping the immune microenvironment in the
brain, we used a mouse model of gut microbiome depletion. This model consisted of mice treated with a
cocktail of non-absorbable broad-spectrum antibiotics to deplete the gut microbiome and control mice
treated with vehicle alone. Three weeks after the initiation of treatment, the animals were euthanized,
brain tissue was analyzed for the local and systemic immune profiles using flow cytometry, and gut
microbiome profiles were analyzed using sequencing.
Results: Clinical studies demonstrated patients with high-grade glioma and IDH-wild-type glioma had
higher bacterial taxa diversity within the gut microbiota than low-grade glioma and IDH-mutant glioma,
respectively, with enrichment of distinct taxa in low- vs high-grade and mutant vs wild-type IDH glioma.
The pre-clinical studies demonstrated a decrease in gut microbiome diversity with antibiotic treatment
administration. Evaluation of the local and systemic immune profiles suggested gut microbiome depletion
in non-tumor-bearing mice induced an immunosuppressive environment in the brain.
Conclusion: Enrichment of distinct microbial communities is associated with glioma grade and IDH type.
The absence of gut microbiota can modulate T cell and microglia activity regulation, inducing an
immunosuppressive microenvironment in the brain. Future studies will investigate the distribution of cells
and microbes in the tumor microenvironment using spatial transcriptomics to further elucidate the role of
these microbial signatures in glioma growth.
Keywords: Glioma, glioblastoma, microbiome, immunotherapy
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Abstract Number: 36

Lipocalin 2 protects from lung tumorigenesis associated with gut microbiota alterations
Elizabeth Tang, Translational Molecular Pathology, University of Illinois at Urbana-Champaign
Zahraa Rahal, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Humam Kadara, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Background: Lung adenocarcinoma (LUAD), the most common cancer diagnosed in smokers, frequently
exhibits somatic mutations in the KRAS oncogene. KRAS-mutant LUAD (KM-LUAD) displays dismal
prognosis, warranting better understanding of its pathogenesis and new strategies for early prevention
and/or interception. Growing evidence shows that the gut microbiome is a key player in modulating host
immune response, tumorigenesis, and response to therapy. Yet, our knowledge of the gut-lung axis is still
in its infancy. Our lab previously showed genetic deletion of Gprc5a leads to lung tumors harboring driver
KrasG12D mutations, the same variant found in human KM-LUAD, and that are accelerated by exposure to
tobacco carcinogens such as nicotine-specific nitrosamine ketone (NNK). Tumor burden after NNK
exposure was associated with progressive and distinct changes in the gut microbiome taxonomical
composition. Notably, we found that loss of the antimicrobial immunomodulatory Lcn2 in NNK-exposed
Gprc5a-/- mice (Gprc5a-/-/Lcn2-/-) led to increased tumor development, inflammation, as well as distinct
microbial profiles with markedly reduced bacterial diversity. This suggested that LCN2 perhaps
counteracts microbial dysbiosis and ensuing LUAD development.
Methods: We thus compared and contrasted tumor development in syngeneic lung cancer mouse models
with that received fecal microbiota transfer (FMT) from Gprc5a-/-/ Lcn2-/- (GL) and Gprc5a-/- (G) mice.
Results: We found that FMT from GL animals led to markedly increased growth of transplanted LUADs
relative to animals that received feces from G animals with intact LCN2. This observation was consistent
across different recipient syngeneic animals, both in Gprc5a-/- and 129-Elite wild-type mice. Increased
tumor growth in animals receiving GL FMT was associated with pronounced mesenteric lymph nodes and
presence of erythematous Peyer’s patches suggestive of perhaps systemic immune and inflammatory
cues linking gut microbial dysbiosis to LUAD growth.
Conclusion: Specifically, we show that LCN2 plays critical roles in maintaining gut microbiome
homeostasis against bacteria that perpetuate LUAD development. Our study highlights functional roles for
the gut microbiome in LUAD development. Our preliminary findings warrant further efforts to identify
specific tumor-promoting bacteria that can potentially be targeted for the prevention and intervention of
LUAD.
Keywords: lung adenocarcinoma, microbiome, lipocalin 2, smoking, carcinogenesis
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Abstract Number: 37

Mindfulness-base Intervention for Latino Patients and their Caregivers
Jazmin Zuniga, Health Disparities, University of Texas MD Anderson Cancer Center
Background: Latinos with cancer are more likely to suffer from psychological morbidities compared to
non-Latino white patients. Similarly, Latino caregivers also suffer from increased distress. However,
Latino cancer patients report less use of psychosocial interventions compared to their non-Latino white
patients. Latinos are severely underrepresented in psychosocial intervention research, resulting in limited
knowledge on the feasibility, acceptability, and efficacy of mindfulness-based interventions in this
population.
Methods: As part of a larger study to adapt a mindfulness-based intervention for Latino cancer patients
and their family caregivers, this project evaluated aspects of feasibility of conducting a mindfulness
intervention and explored strategies for coping with cancer in this population. Latino patient-caregiver
dyads were recruited from MD Anderson’s Oncology Program at Lyndon B. Johnson Hospital (LBJ).
Where LBJ serves low-income and medically underserved patients. During Phase 1, rigorous formative
research was conducted with 20 different Latino cancer patient-caregiver dyads. The dyads participated
in a brief survey over the phone and a 1.5-hour formative research session that included a semi structed
interview to explore cancer related experiences and two brief mindfulness exercises. ATLAS.ti was used
to identify preliminary themes related to how patients and caregivers cope with cancer.
Results: The two main goal for this project include evaluating the feasibility of a mindfulness intervention
for Latinos and to better understand how this population copes with cancer. Participants were primarily of
Mexican origin (70%) and with low levels of education (30% reporting 8th grade or less). Although men
and women were represented similarly among cancer patients, caregivers were predominantly women
(60%). According to ATLAS.ti, religion and the support of family/friends were the two predominantly
preliminary themes seen to cope with cancer between the dyads. Where some have even said that “The
faith we have has helped us; we’re a catholic family. I think that mutual support and faith in God, I think
that’s what has helped us stand on our feet.”
Conclusion: The data collected suggests that mindfulness-based practice may be a feasible approach to
decrease stress in Latino patients/caregivers, as well as give a understand on the effect of mindfulnessbased practice in the Latino community. Findings will then be used in a later state to adapt to a larger
study of Latino patient caregiver dyads in Phase 2.n:
Keywords: Psychosocial, Mindfulness, Latino, Morbidities, Mindfulness-Based Practice
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Abstract Number: 38

Analysis of Primary and Secondary Ewing Sarcoma Outcomes
Andrew Kolodziej, Orthopedic Oncology, University of Texas Rio Grande Valley School of Medicine
Dr. Patrick Lin, Orthopedic Oncology, University of Texas MD Anderson Cancer Center
Background: Ewing Sarcoma (EWS) is a rare cancer of bone and soft tissue that predominately occurs in
adolescents and young adults. EWS is often associated with a second malignancy, which can occur
before or after the EWS diagnosis. EWS occurring after a prior malignancy is less common and
understudied. We aimed to determine whether clinical presentations and long-term survival were different
between primary and secondary EWS.
Methods: Patients diagnosed with EWS and confirmed by the EWSR-FLI1 fusion transcript by pathology
reports at MD Anderson were analyzed by a retrospective chart review. Patients with a Peripheral NeuroEctodermal Tumor (PNET) diagnosis were not included in our cohort. Overall survival was determined by
Kaplan-Meier methods and calculated using the log-rank test. Differences in average survival were
calculated with two-sample t tests.
Results: Twenty-two cases of secondary EWS were reported, accounting for 47.8% of all EWS cases.
Patients with secondary EWS were diagnosed with EWS at an older age than patients with primary EWS
(47.9 years vs 30.6 years, p = 0.004). Patients with secondary EWS had a significantly lower five-year
survival rate (16.7% vs 62.2%, p < 0.001). However, patients with secondary EWS had a longer time gap
between malignancies than patients with primary EWS, (109.7 months vs 39.5 months, p = 0.001).
Secondary EWS patients had a significantly worse response to radiation therapy than primary EWS
patients (22.6 months vs 113.5 months, p = 0.001). Average survival was significantly longer in secondary
EWS patients without metastasis compared to secondary EWS patients with metastasis (36.4 months vs
15.4 months, p = 0.023).
Conclusion: Conclusion: Secondary EWS patients are diagnosed with EWS at an older age, have poorer
long-term survival, take more time to develop a future malignancy, and respond worse to radiation
therapy than primary EWS patients. These findings indicate that secondary EWS patients are distinct
from primary EWS patients and possibly have a unique germline mutation predisposing them to EWS.
Keywords: Ewing, Sarcoma, malignancies, survival
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Abstract Number: 39
Psychosocial mediators of the association between distress related to COVID-19 and physical
activity among rural cancer survivors
Seth M. Rinehart, Health and Human Performance, University of Houston
Scherezade K. Mama, Health Disparities Research, The University of Texas MD Anderson Cancer Center
Background: The COVID-19 pandemic notably impacted cancer survivors and those living in rural areas
more severely than those without a history of cancer and those living in urban settings. Cancer survivors
and rural adults reported lower quality of life and higher psychosocial distress during the pandemic.
Furthermore, higher distress is associated with physical inactivity, which can further worsen overall
health. Previous studies have looked at the association between COVID-19 distress and physical activity.
However, few have examined this association in rural cancer survivors. This study explored associations
between COVID-19 distress and physical activity among rural cancer survivors and explored psychosocial
mediators of this association. We hypothesized that higher distress related to COVID-19 and poorer
psychosocial wellbeing were associated with lower physical activity in rural cancer survivors and that
psychosocial wellbeing partially mediated the association between COVID-19 related distress and
physical activity.
Methods: This was a secondary data analysis from the Partnering to Prevent and Control Cancer (PPCC)
study. Rural cancer survivors (n=219) residing in central Pennsylvania completed a mailed questionnaire
to assess health behaviors and ecologic determinants in 2017-2018. Participants who provided a working
email address (n=195) were re-contacted in April 2020 and completed an online questionnaire assessing
changes in health behaviors, psychosocial wellbeing and psychosocial distress related to COVID-19.
Those who completed this questionnaire (n=104) were included in this study. Linear regression models
were used to assess associations between COVID-19 distress and physical activity, and psychosocial
wellbeing and physical activity, controlling for age, gender, BMI and education. Meditation analyses
included four single-mediator models to assess the indirect effects of COVID-19 distress on physical
activity through psychosocial wellbeing (anxiety, depressive symptoms, perceived stress, and negative
affect).
Results: Participants were an average age of 61.9±13.9 years, mostly women (65.4%), and 63.4% having
a bachelors or higher education. Most participants were breast (26%) or prostate (20.2%) cancer
survivors. After controlling for covariates, greater COVID-19 distress was associated with higher (walking)
physical activity (B=80.8, SE=39.4, p=.043). Anxiety (B=-38.9, SE=17.6, p=.030), depressive symptoms
(B=-33.0, SE=14.7, p=.028), and negative affect (B=-139.6, SE=67.9, p=.043) were all negatively
associated with (moderate/vigorous) physical activity. Single-mediator models showed anxiety (Indirect
Effect=-71.6, SE=20.7, 95% CI=-122.8, -30.5), depressive symptoms (Indirect Effect=-46.6, SE=16.4,
95% CI= -79.2, -14.0), and negative affect (Indirect Effect=-187.9, SE=77.3, 95% CI=-341.5, -34.3)
significantly mediated associations between COVID-19 distress and physical activity.
Conclusion: Rural cancer survivors who reported greater COVID-19 related distress reported higher
anxiety and depressive symptoms, which was associated with lower levels of physical activity. Findings
point to the need for psychosocial interventions that address pandemic-related distress to improve
physical activity in rural cancer survivors. Additional studies are needed to better understand how to
improve psychosocial wellbeing to reduce distress and increase physical activity to reduce cancer health
disparities in rural communities.
Keywords: Psychosocial Distress, Physical Activity, COVID-19, Mediation
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Abstract Number: 40

Multiple levels of influence on Asian American colorectal cancer screening
Daniel Ghaly, Health Disparities Research, University of Texas at Austin
Dalnim Cho, Health Disparities Research, University of Texas MD Anderson Cancer Center
Background: Although the United States has seen its Asian population nearly double to approximately 19
million over the past 20 years, Asians remain severely underrepresented in colorectal cancer screening
when compared to other racial groups. This is especially concerning given Asians are the only United
States racial group where cancer is the leading cause of death in both males and females. To effectively
improve colorectal cancer screening among Asian Americans, it is important to understand factors,
beyond knowledge, associated with their colorectal cancer screening across multiple levels of influence.
Thus, the aim of this study is to review what factors across individual, physician, cultural, and healthcare
levels are associated with colorectal cancer screening.
Methods: The electronic database PubMed was searched. Eligible studies were coded across 4 levels of
influence: (a) individual demographic psychological, such as perceived risk of colorectal cancer and
embarrassment (b) physician (e.g., physician recommendation, physician trustworthiness), (c) cultural
(e.g., acculturation), and (d) healthcare (e.g., insurance status, having a primary care physician).
Results: Of the initial 47 studies identified in the PubMed search, 13 studies, all of which were crosssectional, were deemed eligible for review. Most eligible studies collected data on a single race/ethnicity
(n=9/13), while the remaining studies (n=4/13) included multiple racial/ethnic groups. Both papers
analyzing perceived colorectal cancer risk showed a positive association with colorectal cancer
screening, while both papers analyzing knowledge score found no significant association. Physician
recommendation was shown to have a positive association with colorectal cancer screening in all five
papers analyzing the impact of recommendation, while having routine check-ups was also shown to have
a positive association in all three papers analyzing check-ups. Acculturation, which encompasses English
fluency and duration in the United States, was shown to have a positive association with colorectal cancer
screening.
Conclusion: All four levels of influence (Individual demographic psychological, physician, cultural, and
healthcare) were shown to be associated with Asian American colorectal cancer screening. However,
because the acculturation paradox suggests increased duration in the United States is associated with
decreased health, contrary to the positive association found with colorectal cancer screening, more
research is needed to show how acculturation impacts Asian American cancer related health.
Keywords: Asian American, colorectal cancer, screening rates, multiple levels of influence, health
disparities
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Abstract Number: 41

Personalized Lung Cancer Screening - Acceptability among Primary Care Providers
Paul Resong, Health Services Research, University of Texas MD Anderson Cancer Center
Jiangong Niu, Health Services Research, University of Texas MD Anderson Cancer Center
Iakovos Toumazis, Health Services Research, University of Texas MD Anderson Cancer Center
Background: Lung cancer screening via LDCT (low dose computed tomography) has been shown to
significantly decrease lung cancer-specific mortality. Current LCS (lung cancer screening) guidelines are
reliant solely on a patient’s age and smoking history. Despite its proven benefit, only 5-15% of eligible
patients receive LCS, with Texas having one of the lowest rates in the United States. Recent
advancements in screening methodologies suggest that personalized approaches can increase
screening’s effectiveness, reduce false positives, and reduce the net screening examinations required per
life-year obtained. This study assesses the current practice of and acceptability of a personalized
approach for LCS among primary care providers in Texas.
Methods: We developed and distributed a survey to 32983 Texas-based primary care providers on an
existing network (Protocol 2019-1257; PI: Dr. Sanjay Shete) including primary physicians, physician
assistants, and nurse practitioners. Deidentified demographics, information regarding current LCS
practices, and acceptability of a personalized approach were obtained. Responses were broken down
and analyzed in sub-categories using comparative statistics and a 10x bootstrapped logistic regression to
further understand respondent tendencies by subgroup. Thirty willing respondents will be randomly
selected and interviewed to investigate survey responses, opinions of LCS, and feedback on a decision
tool that delivers personalized screening decisions.
Results: There were 91 (0.3%) respondents. The demographic data included: female 74%. 72% White,
14% Black, 12% other, with 11% being Hispanic. There were relatively even numbers of physicians
(32%), PAs (23%), and NPs (44%). We found that 70% of respondents provided LCS services into their
practice and 48% were interested in adopting a personalized approach to LCS screening, with 40%
unsure about the personalized approach. Majority (62%) of respondents expressed concern about the
increased time of the personalized approach. Comparison of each age group among providers (40-49,
50-59, 60-69) to providers under 40 using the logistic regression found positive correlation between
provider young age and interest in personalized LCS (p<0.05. OR 0.259, 0.594, and 0.081 respectively).
Conclusion: Of the primary care providers who responded, the majority included some elements of
screening into their practice. Nearly half of the respondents were open to adopt a personalized approach
to LCS screening. Time limitation was the main concern, and if addressed, acceptability of personalized
LCS may potentially reach 70-90%.
Keywords: Lung cancer screening, risk based approach, acceptability, current practice
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Abstract Number: 42

Barriers with Implementing the Federal Smoke-Free Public Housing Rule at Cuney Homes,
Houston’s Largest Public Housing Site
Antara Gupta, Health Disparities Research, University of Texas MD Anderson Cancer Center
Surendranath Shastri, Health Disparities Research, University of Texas MD Anderson Cancer Center
Loren Bryant, Health Disparities Research, University of Texas MD Anderson Cancer Center
Edna Paredes, Health Disparities Research, University of Texas MD Anderson Cancer Center,
Background: Second-hand smoke exposure (SHSe) in non-smokers increases the chances of developing
lung cancer by 20-30%. Since even brief smoke exposure is carcinogenic, there is no risk-free level of
SHSe. To address the higher rates of SHSe in public housing communities, the U.S. Department of
Housing and Urban Development (HUD) implemented the Smoke-Free Public Housing Rule (HUDSFPHr) in 2018, which mandated that all public housing sites prohibit smoking inside residential and
communal buildings, as well as within 25 feet of these properties. Previous research indicates that HUDSFPHr has not been entirely effective, so this study aims to identify barriers interfering with the
implementation of HUD-SFPHr at Cuney Homes, Houston’s largest public housing site with an 89.5%
African American/Black residential population.
Methods: Property observations at Cuney Homes were performed and the number of cigarette litter,
HUD-SFPHr signage, and active smokers were recorded. Furthermore, in-depth staff interviews (n=2)
were conducted to learn about the implementation of HUD-SFPHr at Cuney Homes.
Results: During the property observations, 2,311 pieces of cigarette litter, 15 active smokers, and 0 HUDSFPHr signage were found. The in-depth interviews revealed that residents are not aware of HUD-SFPHr
due to a lack of education provided about the rule, staff are hesitant to have conversations with residents
about tobacco use, and there are currently no tobacco treatment services or resources available to
residents. Furthermore, due to the COVID-19 pandemic there have been no property health inspections
since 2019, which has led to a lack of violations being given out for breaking HUD-SFPHr. Many residents
also fear retaliation from their neighbors, so they do not complain about SHSe.
Conclusion: The property observations revealed that residents at Cuney Homes are not adhering to HUDSFPHr. Based on the barriers identified from the interviews, staff need to be trained to educate residents
about HUD-SFPHr, SHSe, & the risks associated with tobacco use during New Resident Orientation.
There also needs to be a bigger emphasis on encouraging tobacco treatment. This can be done by
promoting community-based cessation programs and offering culturally tailored resources which talk
about menthol cigarette use and big tobacco marketing, both of which have disproportionately affected
African American/Black communities. Through Project Smoke-Free, we will be evaluating how
implementing these recommendations will improve resident adherence of HUD-SFPHr. Overall,
addressing the barriers in implementing HUD-SFPHr may reduce the disproportionate amount of lung
cancer and other tobacco-related health conditions in African American/Black and lowincome/underserved communities.
Keywords: smoke free public housing rule, public housing, intervention, lung cancer, African American
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Abstract Number: 43

Understanding the Impact of COVID-19 on Psychosocial Distress and Quality of Life Among Rural
Cancer Survivors
Megha Bhatia, Health Disparities Research, The University of Texas at Austin; The University of Texas
MD Anderson Cancer Center
Ian M. Leavitt, Health Disparities Research, The University of Texas MD Anderson Cancer Center
Scherezade K. Mama, DrPH, Health Disparities Research, The University of Texas MD Anderson Cancer
Center
Background: COVID-19 has impacted millions of people globally, and cancer survivors and underserved
populations face increased risk of infection and death. Rural adults and cancer survivors, who are at
greater risk of COVID-19, experience greater psychosocial distress. However, COVID-19’s impact on
psychosocial distress and quality of life (QOL) among rural cancer survivors has gone unexplored. This
study examined (1) changes in psychosocial distress and QOL in rural cancer survivors during COVID-19
and (2) associations between changes in psychosocial distress and QOL and health behaviors among
rural cancer survivors in central Pennsylvania.
Methods: This study is a secondary data analysis from the Partnering to Prevent and Control Cancer
(PPCC) study (2017-2018) and the follow-up COVID-19 Impact Study (April-May 2020). Rural cancer
survivors (n=219) in PPCC completed questionnaires assessing individual, social, and environmental
factors that affect health behaviors. A subsample of PPCC participants (n=104) completed the follow-up
questionnaire, which assessed the impact of COVID-19 on health behaviors and psychosocial distress.
Changes in psychosocial distress and QOL from pre- to post-pandemic were evaluated using paired
samples t-tests. Multiple regression models were used to explore the association between changes in
psychosocial distress and QOL and health behaviors (physical activity, sleep quality, fruit and vegetable
intake, and alcohol use) during the pandemic, adjusting for age, gender, BMI, and education.
Results: Rural cancer survivors were in their early 60s (M=61.86±13.9) and mostly women (65.4%). The
majority were breast (26%) or prostate (20%) cancer survivors, not currently receiving cancer treatment
(92.2%), and at least 3 months post treatment (95.1%). Participants reported decreased perceived stress
(Δ=0.3) and positive affect (Δ=0.4) but increased depressive symptoms (Δ=1.4), anxiety (Δ=0.5), negative
affect (Δ=0.3), and general health (Δ=0.8). However, changes were not statistically significant (ps>0.05).
Changes in perceived stress (b=-0.180, p=.004) and negative affect (b=-0.139, p=.030) were negatively
associated with post-COVID alcohol use, and anxiety (b=0.164, p=0.047) was positively associated with
post-COVID sleep quality.
Conclusion: Rural cancer survivors did not report statistically significant changes in psychosocial distress
or QOL, and the minimal changes reported were associated with healthful behaviors, including reduced
alcohol use and better sleep quality. Cancer survivors residing in rural areas may have experienced less
drastic lifestyle changes due to lockdowns early during the pandemic, contributing to healthful behaviors.
Additional research is needed to explore the impact of COVID-19 on psychosocial wellbeing and health
behaviors further into the pandemic to determine the long-term effects.
Keywords: Rural Health Disparities, Cancer Prevention, Psychosocial Distress, Quality of Life, Health
Behaviors
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Abstract Number: 44

Skin cancer surveillance patterns of actinic keratoses patients in US Medicare population: a
cohort study
Sanjna Tripathy, Health Services Research, McGovern Medical School at UTHealth
Yao Li, Health Services Research, University of Texas MD Anderson Cancer Center
Madisyn L Cox, Health Services Research, McGovern Medical School at UTHealth
Mackenzie R Wehner, Health Services Research, University of Texas MD Anderson Cancer Center,
Background: Actinic Keratoses are precancerous skin lesions that are very common. Patients with actinic
keratoses (AKs) are at higher risk for developing skin cancer. However, the follow up patterns and skin
cancer surveillance for AK patients are relatively unknown in the US.
Methods: This retrospective cohort study used de-identified United States Medicare claims data from
4,999,999 beneficiaries aged ≥65 from 2009 to 2018. Participants had to have been in the dataset for one
year prior to an AK diagnosis and had to be in the dataset for at least one year after that AK diagnosis.
Participants were identified using outpatient AK diagnosis codes. Number and percentage of patients who
had total body skin checks/skin cancer screenings identified by: outpatient derm visits, visits with skin
cancer screening diagnosis codes, or visit with one or more of the commonly used derm codes, within 12
months after principal AK diagnosis.
Results: 64.14 % of patients with at least one actinic keratoses diagnosis were seen back for a skin
cancer surveillance exam within 12 months.
Conclusion: AK follow up skin exam frequencies are lower than what we expected for 12 months.
Understanding the current patterns in skin cancer surveillance for AK patients is important to guide the
creation of evidence-based recommendations for this high-risk population.
Keywords: Skin cancer prevention, Actinic Keratoses,
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Abstract 44-A
Association Between Rare TP53 variants and Cancer Predisposition in Colorecta, Melanoma,
Ovarian, Pancreatic, and Prostate Cancer
Tatyana Childs Jolivette, Epidemiology, The University of Texas MD Anderson Cancer Center
Yao Yu, Epidemiology, The University of Texas MD Anderson Cancer Center
Michael Cao, Epidemiology, The University of Texas MD Anderson Cancer Center
Ryan J. Bohlender, Epidemiology, The University of Texas MD Anderson Cancer Center
Chad D. Huff, Epidemiology, The University of Texas MD Anderson Cancer Center
Background: Pathogenic variants in the TP53 gene lead to Li-Fraumeni syndrome (LFS). TP53 codes for
tumor suppressor proteins that control cell division, DNA repair, and apoptosis. When variants of this
gene occur, the proteins can be prevented from performing their function. Individuals with LFS have a
very high risk of developing multiple cancers, including breast cancer, bone cancer, leukemia, lung, and
sarcomas. However, TP53 carriers can be at risk for developing other cancers which are not typically
linked with this syndrome. This study took a closer look at rare TP53 variants through a sequencing casecontrol studies in colorectal, melanoma, ovarian, pancreatic, and prostate cancer to evaluate potential
association between variants and cancer predisposition.
Methods: DNA from a total of 13,396 cases and up to 7,788 controls from the University of Texas MD
Anderson Cancer Center (MDA), H. Lee Moffitt Cancer Center & Research Institute, The University of
Utah School of Medicine, Duke University, and UK Biobank were sequenced. All controls had no prior
history of cancer and cases reported that the tumor they were categorized under was their primary tumor.
We conducted gene-based p-values to evaluate associations with rare, protein-coding TP53 variation and
each cancer using VAAST. We also calculated effect size estimates for three categories of variants in
each cancer as classified by ClinVar: pathogenic (including novel truncating variants), variants of
uncertain significance (VUS), and benign. For pathogenic variants, we also derived more precise risk
estimates through a meta-analysis incorporating 1-2 additional studies for each cancer type.
Results: We report gene-based association results for rare protein-coding variants in TP53 for each of the
five cancer types. We also report OR point estimates and confidence intervals for pathogenic, VUS, and
benign variants in each cancer. For pathogenic variants, we conducted a meta-analysis incorporating 1-2
additional studies for each cancer type.
Conclusion: Our results provide evidence that rare TP53 protein-coding variants confer an increased risk
of colorectal, melanoma, ovarian, pancreatic, and prostate cancer, in part due to missense variation
which is not currently classified as pathogenic. Our meta-analysis results provide precise estimates of the
risk conferred by pathogenic TP53 variants for each cancer type. Future studies will expand this analysis
to other cohorts and integrate this dataset with additional controls from other sources, such as UK
Biobank, to improve risk estimate precision.
Keywords: Rare, TP53, Case-control, Whole-exome, meta-analysis
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Abstract 44-B
The Community Scientist Program: Utilizing a multi-site rapid feedback approach to facilitate community
engagement in research
Chiamaka Chukwu, Department of Health Disparities Research Tufts University
Sophia Russell, Department of Health Disparities Research, The University of Texas MD Anderson
Cancer Center
Leonetta Thompson, Department of Health Disparities Research, The University of Texas MD Anderson
Cancer Center
Background: Patient and community engagement is increasingly recognized as critical for enhancing the
relevance, quality, and benefits of research. Nevertheless, factors related to time, competing priorities,
and skills in interacting with communities may interfere with researchers’ ability and/or willingness to take
part in meaningful engagement. First established in 2018, the Community Scientist Program (CSP) aims
to facilitate engagement, and improve the implementation and application of research by providing
researchers with rapid feedback from trained patients and community members in order to improve the
implementation and application of research within communities. This project evaluated the CSs and
Researchers’ satisfaction, CSP’s impact on the implementation and application of research, and its
effects on the Community Scientists’ overall perception of research.
Methods: CSP has expanded to include four research institutions across geographic regions of Texas
(Houston, Northeast Texas, Rio Grande Valley), encompassing both urban and rural settings. The CSP
offers researchers one-hour facilitated online sessions where researchers present topics for feedback,
ranging from conceptions of a research question to study implementation and dissemination to
Community Scientists (CSs). Feedback forms are then sent to the researcher and the CS to gauge their
satisfaction with each of the feedback sessions. REDCap was utilized to analyze saved information and
analyze the effectiveness of the CSP on the benefit of research for the researchers, and its overall effect
on community engagement.
Results: In total, the CSP has hosted 79 feedback sessions with CS across the three regions. The
evaluation results revealed high researcher satisfaction with 76% of researchers feeling very prepared to
engage with community members and patients following the session compared to 26% beforehand.
Furthermore, 99% of Community Scientists agreed that their feedback was valued, with 100% of
researchers’ indicating that they would recommend the Community Scientist Program to a colleague.
Furthermore, 98% of the Community Scientist agreed that the feedback they provided will help improve
the research project.
Conclusion: Programs such as the CSP that connect researchers with the community and patient
stakeholders offer a vital and scalable resource to efficiently incorporate community input and values into
the research process. CSP offers a vital and scalable resource to incorporate community input and values
into the research process. CSP creates a safe space where researchers and community members and
patients are able to learn from one another while ensuring that the individuals who are most impacted by
the research being conducted are at the forefront.
Keywords: Community Scientist, community engagement, patient engagement, translational research.
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First Year Medical Student Program
Abstract Number: 45

HXR9 Inhibits the HOX-PBX Cluster, Inducing Glioma Apoptosis and Cell-Cycle Arrest
Ramy Safwat Tawfik Gadalla, Translational Molecular Pathology, Georgetown University School of
Medicine, University of Texas MD Anderson Cancer Center
Prit Malgulwar, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Jason Huse, Translational Molecular Pathology, Pathology, University of Texas MD Anderson Cancer
Center

Background: Gliomas are the most common malignant primary brain tumors in humans,
representing over 80% of all brain cancers. Among the various molecular alterations reported in
gliomas, deficiency in alpha-thalassemia/mental retardation, X-linked (ATRX), a member of the
SWI/SNF family of chromatin regulators, is found in 86% of IDH-mutant low-grade gliomas
(LGGs). ATRX is associated with alternative lengthening of telomeres and an aggressive
phenotype. Our integrated chromatin analysis has identified HOXA cluster genes to be
overexpressed in ATRX-deficient gliomas. HOXA is a developmentally essential gene, and its
overexpression has been associated with an oncogenic phenotype in various types of cancers.
The clinically applicable peptide HXR9 inhibits heterodimerization of HOX with PBX; therefore,
we sought to determine whether HXR9 had anti-glioma effects.
Methods: Methods: The TCGA database was mined to identify the HOXA gene cluster

expression level in LGGs and the respective survivability. Patient-derived glioma stem-cells
(GSCs), GS522 (IDH1-mutant, ATRX-loss) and TS603 (IDH1-wild type, ATRX intact) were
treated with HXR9 and flow cytometry was run after 48 hours of incubation to detect apoptosis
(annexin V), necrosis (PI), and cell proliferation (DAPI).

Results: The TCGA data showed an increased HOXA expression in ATRX deficient gliomas
with its role in poor prognosis. We found a dose-dependent increase in apoptosis upon HXR9
treatment, preferentially in ATRX deficient cells. Notably, our cell proliferation study suggested a
decrease in S-phase of cell cycle.
Conclusion: With this background, we aim to further characterize the functional role of HXR9 as
a therapeutic peptide for ATRX-deficient gliomas and to translate our study in preclinical in vivo
models.
Keywords: HXR9, Glioma, ATRX, HOX
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Abstract Number: 46

Ephrin mimics may reduce metastasis and angiogenesis in breast and ovarian cancers
Shandis Fancher, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Haiyan Chen, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Chiyi Xiong, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Chun Li, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center,
Background: Breast cancer is the second most common cause of cancer-related death in women, and
ovarian cancer, while less common, is associated with very poor prognosis due to late-stage detection.
Both cancers exhibit upregulation of Eph receptor tyrosine kinases, which are involved in cell migration,
adhesion, and proliferation, and angiogenesis. This phenomenon results in aggressive cancers with high
degrees of vascularization. The ligand-receptor association occurs between adjacent cells and results in
“forward signaling” in the Eph-expressing cell and “reverse-signaling” in the ligand, or ephrin, expressing
cell. Competitive inhibition with non-cell bound, high affinity ephrin mimics should decrease reverse
signaling and cause a shift away from metastasis and angiogenesis. Because cells which undergo
pathologic epithelial to mesenchymal transition (EMT) have increased metastatic capacity, the reversal of
these expression levels would be an indication of decreased metastatic potential.
Methods: Peptide B and T are ephrin mimics, and peptide Y is a natural ligand for Eph. Novel peptides
based on peptide Y were synthesized and underwent purification and analysis via prep-HPLC and LCMS. 4T1 (breast cancer) cells were incubated with peptides B and T before Western blotting and
collection of qualitative and semi-quantitative results. Synthesis of modified peptide Y primarily resulted in
peptides with equal MW, as well as a peptide (peptide D) with decreased MW resulting from truncation.
Eph knockout SK-OV-3 (ovarian cancer) cells and SK-OV-3 control cells were incubated with
fluorescently-conjugated peptide Y. Cell lines A2780 (ovarian cancer) and control SK-OV-3 were
incubated with unconjugated peptide Y (an ephrin-mimic peptide), “blocked” peptide Y, and the
fluorescently-conjugated peptide D.
Results: Eph knockout in SK-OV-3 caused lack of peptide Y internalization as compared to the control
SK-OV-3. This was enough to eliminate peptide Y binding, demonstrating the significance of Eph RTKs
on ephrin binding capacity. In A2780 and control SK-OV-3, cells treated with peptide Y had high
intracellular uptake, while those blocked or treated with peptide D had minimal to no uptake.
Conclusion: Immunochemistry analysis results were significant for increased E-cadherin and decreased
Twist following incubation with peptide D, demonstrating potential for reduction of reverse signaling by
inhibiting natural ligand binding. Confocal microscopy results indicating effective binding of peptide Y but
decreased binding after blocking and a similar decrease for cells treated with peptide D demonstrate the
impact of slight changes on peptide Y AA sequence on its binding capacity. Therefore, ephrin mimic
peptides provide potential for decreased angiogenic and metastatic capacity in breast and ovarian
cancers.
Keywords: breast cancer, ovarian cancer, peptide synthesis, bi-directional signaling
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Abstract Number: 47
Role of PARP inhibitors, SGLT2 inhibitors and Colchicine in Regulating Post-Chemotherapeutic
Cardiotoxicity
Michelle Lu, The University of Texas MD Anderson Cancer Center, John A. Burns School of Medicine
Sivareddy Kotla, Cardiology, The University of Texas MD Anderson Cancer Center
Kyung Ae Ko, Cardiology, The University of Texas MD Anderson Cancer Center
Venkatasubrahman K Samanthapudi, Cardiology, The University of Texas MD Anderson Cancer Center
Jun-ichi Abe, Cardiology, The University of Texas MD Anderson Cancer Center
Background: As evidenced by previous work, the Persistent Senescence-Induced Phenotype caused by
mitochondrial DNA damage is implicated in post-irradiation ad chemotherapeutic cardiotoxicity in cancer
patients. We are investigating whether certain inhibitors (Olaparib, SGLT2 inhibitors, and colchicine) can
inhibit mitochondrial DNA/telomere damage.
Methods: Hela cells were cultivated until 80~100% confluency from frozen stocks in DMEM, penicillinstreptomycin, and 10% FBS. The cells were then passaged into 6-cm plates equally, and cultured until
90~100% confluence. The cells were pre-treated with Olaparib (10μM). 1 hour after pre-treatment, the
cells were treated with Doxorubicin at 1 μM for either 10 minutes, 30 minutes or 24 hours, and were then
lysed with RIPA+ buffer with phosphatase inhibitors to collect protein. The protein lysates were spun
down at 7000 RPM for 10 minutes at 4°C to isolate the protein lysate. The lysates were then transferred
to a different Eppendorf tube and stored at -80°C until quantification.
Western Blotting: Protein quantified using the BCA Assay and BSA standards. The samples were loaded
at 30ug/well and then run on a 10% SDS-PAGE gel. The blot was then transferred at 90V for 1 hour to a
nitrocellulose membrane, blocked in 5% powdered milk in TBST, and then probed with antibodies to pp90RSK, p-PKCζ, and p-ERK4-S496 at a concentration of 1:1000, 1:3000, and 1:1000 respectively. The
blots were then washed with TBST, incubated in goat-produced anti-mouse or rabbit IgH, at a
concentration of 1:3000 and then imaged.
Results: We are looking at the role of p-PKCζ in cancer cells. We wanted to see whether Olaparib (PARP
inhibitor) would inhibit phosphorylation of PKCζ or increase it. After 24 hours of treatment with
Doxorubicin after 1 hour of inhibitor treatment, we observed an increase PKCζ phosphorylation in Hela
cells, indicating the presence of chemotherapeutic mtDNA damage. The band of Hela cells treated with
doxorubicin for 10 and 30 minutes shows slightly more phosphorylation at 30 min vs 10 min. The same
trend is true in Hela cells treated with Doxorubicin for 10 and 30 minutes. However, Olaparib induction for
1 hour and doxorubicin treatment for 24 hours shows significant reduction in P-PKCζ, indicating that
Olaparib inhibits phosphorylation of PKCζ. These results indicate that by Olaparib may be able to act
prophylactically against chemotherapy-induced cardiotoxicity.
Conclusion: Seen inhibition of phosphorylation of PKCζ in HeLa cells treated with doxorubicin after 1 hour
of stimulation with Olaparib. This indicates that Olaparib has therapeutic potential in reducing postchemotherapeutic atherosclerosis.
Keywords: cardiotoxicity, chemotherapy, colchicine, SGLT2 inhibtior, olaparib, premature senescenceinduced phenotype
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Abstract Number: 48

A preliminary study of potential variations in toxicities from RT in early stage breast Cancer
patients treated pre and post-COVID with attention to ultrahypofractionation
Revathi Gnanasekaran MBA, Radiation Oncology, Texas Tech Foster School of Medicine
Melissa Mitchell MD, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: During the weeks and months after COVID, when healthcare resources were scarce, then
recently published UK-FAST-forward data and the 26 Gy in 5 fraction regimen became a frequent option
for early stage patients. This regimen balanced tumor control that is non-inferior to hypofractionation with
decreased time in the hospital at a time when resources were short due to the COVID pandemic.
Anecdotally, patients appeared to have more breast toxicity during COVID, and there was uncertainty
whether this was related to COVID exposure among treated patients versus increasing use of
ultrahypofractionation. This project sought to explore differences in toxicity for early stage breast cancer
patients treated pre and post COVID, with attention to fractionation. The weeklong FAST-forward (ultrahypofractionation) is being rapidly been adopted in countries like UK and SWEDEN. However, in USA
standard hypofractionation over 3-4 weeks remains the most frequent treatment. Hesitation to utilize the
FAST-forward regimen more frequently includes the short follow-up (5 years), as well as concerns
regarding toxicity. This is a preliminary report on differences seen in toxicity for ultra-hypofractionation
versus hypofractionation in the pre and post the COVID era to further understand the impact of
fractionation schedule and COVID exposure on breast radiation toxicity.
Methods: We sought to assess the impact of COVID and implementation of ultrahypofractionation on
acute and 6 month toxicity radiation therapy in patients undergoing treatment for early stage breast
cancer. We reviewed 299 charts from patients treated from January 2019 date to September 2021 treated
with whole breast radiation with or without treatment to the low axilla. We excluded patients receiving
treatment to the partial breast and patients receiving comprehensive nodal radiation. Demographic and
treatment characteristics were extracted from the electronic medical record. We extracted the following
characteristics: age, race, histology, T and N stage, modality, dermatitis, edema, fibrosis, breast
shrinkage, breast discoloration, breast pain, ECOG, chemotherapy, hormone therapy, smoking history,
cardiovascular diseases, COVID exposure, and COVID immunizations. We tabulated baseline patient
and pathologic characteristics for all patients stratified by time and fractionation, hypofractionation prior to
the pandemic, hypofractionation during the pandemic and ultrahypofractionation during the pandemic.
57 patients received up to 10 fractions of whole breast radiation, 243 patients received 11-28 fractions of
radiation. 17 patients tested covid positive prior to radiation. 36 patients tested positive following
radiation. 36 patients received COVID vaccination. Patients treated in the pre-COVID era with
hypofractionation (107 patients), post-COVID with hypofractionation (141 patients), and post-COVID with
ultrahypofraction (52 patients) were compared. Acute toxicity measured at the end of radiation included
pain and dermatitis. Toxicity measured at the 6 month time point and later included breast edema, breast
shrinkage, breast discoloration, breast pain, fibrosis. Oncora was used to identify patients with early
stage breast cancer treated with lumpectomy and radiation over the designated time defined in an IRB
approved protocol. Patient and tumor characteristics, as well as systemic therapy detail and dosimetric
data were gathered from the EPIC EMR. We used RedCap to record and verify the data. Statistical
analysis was performed in SPSS
Results: Using Fischer Exact test, the only toxicity endpoint with a difference between groups was acute
dermatitis at the end of treatment. Comparison of patients treated with hypofractionation verus
ultrahypofractionation showed a marked decrease in acute dermatitis with ultrahypofractionation
(p<0.001). There was a trend towards increased acute dermatitis in patients treated with
hypofractionation post-COVID as compared to pre-COVID (p=0.06). There was no difference in breast
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shrinkage, breast discoloration, breast edema, or breast pain at 6 months between pre-COVID and postCOVID hypofractionation or between hypofractionation and ultrahypofractionation.
Conclusion: As expected hypofractionation was associated with increased acute dermatitis as compared
to ultrahypofractionation, which is consistent with the current literature. The finding of increased
dermatitis in the post-COVID era is novel, though the lack of increased toxicity at the 6 month mark does
not suggest that any COVID related changes in acute breast radiation toxicity will impact long term
toxicity outcomes. A lack of difference in 6 month toxicity outcomes counters the anecdotal observation
of ultrahypofractionated patients experiencing increased toxicity and supports the continued routine use
of this new regimen in appropriately selected patients.
Keywords: Ultra-hypofractionation, Hypofractionation, Radiation, Adverse, Effect
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Abstract Number: 49

A preliminary study of potential variations in toxicities from RT in early stage breast Cancer
patients treated pre and post-COVID with attention to ultra-hypofractionation
Revathi Gnanasekaran MBA, Radiation Oncology, Texas Tech Foster School of Medicine
Melissa Mitchell MD, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: During the weeks and months after COVID, when healthcare resources were scarce, then
recently published UK-FAST-forward data and the 26 Gy in 5 fraction regimen became a frequent option
for early stage patients. This regimen balanced tumor control that is non-inferior to hypofractionation with
decreased time in the hospital at a time when resources were short due to the COVID pandemic.
Anecdotally, patients appeared to have more breast toxicity during COVID, and there was uncertainty
whether this was related to COVID exposure among treated patients versus increasing use of
ultrahypofractionation. This project sought to explore differences in toxicity for early stage breast cancer
patients treated pre and post COVID, with attention to fractionation. The weeklong FAST-forward (ultrahypofractionation) is being rapidly been adopted in countries like UK and SWEDEN. However, in USA
standard hypofractionation over 3-4 weeks remains the most frequent treatment. Hesitation to utilize the
FAST-forward regimen more frequently includes the short follow-up (5 years), as well as concerns
regarding toxicity. This is a preliminary report on differences seen in toxicity for ultra-hypofractionation
versus hypofractionation in the pre and post the COVID era to further understand the impact of
fractionation schedule and COVID exposure on breast radiation toxicity.
Methods: Oncora was used to identify patients with early stage breast cancer treated with lumpectomy
and radiation over the designated time defined in an IRB approved protocol. Patient and tumor
characteristics, as well as systemic therapy detail and dosimetric data were gathered from the EPIC EMR.
We used RedCap to record and verify the data. Statistical analysis was performed in SPSS
Results: Using Fischer Exact test, the only toxicity endpoint with a difference between groups was acute
dermatitis at the end of treatment. Comparison of patients treated with hypofractionation verus
ultrahypofractionation showed a marked decrease in acute dermatitis with ultrahypofractionation
(p<0.001). There was a trend towards increased acute dermatitis in patients treated with
hypofractionation post-COVID as compared to pre-COVID (p=0.06). There was no difference in breast
shrinkage, breast discoloration, breast edema, or breast pain at 6 months between pre-COVID and postCOVID hypofractionation or between hypofractionation and ultrahypofractionation.
Conclusion: As expected hypofractionation was associated with increased acute dermatitis as compared
to ultrahypofractionation, which is consistent with the current literature. The finding of increased
dermatitis in the post-COVID era is novel, though the lack of increased toxicity at the 6 month mark does
not suggest that any COVID related changes in acute breast radiation toxicity will impact long term
toxicity outcomes. A lack of difference in 6 month toxicity outcomes counters the anecdotal observation
of ultrahypofractionated patients experiencing increased toxicity and supports the continued routine use
of this new regimen in appropriately selected patients.
Keywords: Ultra-hypofractionation, Hypofractionation, Radiation, Adverse, Effect
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Abstract Number: 50

Longitudinal Analysis of Lymphedema-Related Quality of Life Among Locally Advanced Breast
Cancer Patients
Peter Youssef, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center
Alison Yoder, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center
Tianlin Xu, Department of Biostatistics, UT Graduate School of Biological Sciences
Lynn Isales, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center,
Melissa B. Aldrich, Center for Molecular Imaging, UT Health Science Center
Simona F. Shaitelman, Department of Radiation Oncology, University of Texas MD Anderson Cancer
Center
Breast cancer-related lymphedema (BCRL) is a chronic and progressive, debilitating side effect of breast
cancer treatment that typically occurs after axillary lymph node dissection (ALND) and/or regional node
irradiation. Lymphedema is typically diagnosed at a stage where reversal of symptoms is not possible.
This study aimed to find early predictors of lymphedema, with the ultimate goal of identifying an early
timepoint for preventative intervention.
Women undergoing definitive treatment for locally advanced breast cancer that were treated with surgery
followed by adjuvant radiation were included in this study. Patients were evaluated prior to surgery, prior
to radiation, and at 6 months, 12 months, and 18 months after radiation. To measure lymphedema
several objective lymphedema assessment measures were utilized. These include perometry
measurements, which are volumetric measurements of the patient’s arm compared to baseline, and nearinfrared fluorescence Imaging of lymphatics, which enable one to visualize fluid backflow in arm
lymphatics using extravascular dye. We also measured several patient-reported outcomes (PROs), as
patient-reported lymphedema has shown to be strongly associated with development of lymphedema
related symptoms. These included EQ-5D-5L, Quick DASH, Lymphedema Symptom Intensity and
Distress Survey Arm v2.0, Patient Lymphedema Symptom Survey Instrument, and Work Productivity and
Impairment Survey. To evaluate the correlation between radiation dose to lymphatic structures and the
development of lymphedema, we contoured the regional lymph nodes, supraclavicular, internal
mammary, and axillary levels I-III since these regions drain breast cancers and are typically targeted in
radiation treatment. The maximum dose, minimum dose, dose covering 95% of the structure, and percent
of the volume covered by 90% of the target dose were recorded.
Analyses are ongoing to assess the baseline distribution of characteristics of patients on the study, as
well as the distribution of objective and patient reported outcome measures, in addition to radiationspecific predictors of lymphedema. Our goal is to assess whether any dosimetric variables or PROs can
predict for the development of lymphedema.
Conclusion:
Keywords: Breast Cancer-Related Lymphedema, Patient-Reported Outcome Measures, Axillary lymph
node dissection, Near-Infrared Fluorescence Imaging
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Abstract Number: 51

Segmental Tracheal Resection in Advanced Thyroid Cancer Patients
Emily K. Hyde, BS, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Anastasios Maniakas, MD, PhD, Head and Neck Surgery, University of Texas MD Anderson Cancer
Center
Li Xu, PhD, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Mark E. Zafereo, MD, Head and Neck Surgery, University of Texas MD Anderson Cancer Center,
Background: Less than 1% of advanced thyroid cancer (TC) patients require segmental tracheal
resection. This procedure is amongst the most technically challenging and high risk in thyroid and neck
surgery. Ishihara and colleagues provided the first significant experience with segmental tracheal
resection for 60 advanced TC patients from 1973-1988, and this remains the largest experience in the
published literature to date. Herein, we describe a contemporary high-volume experience with segmental
tracheal resection for advanced TC, evaluating perioperative outcomes and survival.
Methods: We retrospectively reviewed consecutive patients undergoing TC surgery at MD Anderson
Cancer Center from 2016-2022. Patients who underwent segmental or window tracheal resection were
included, while patients with shave excisions were excluded. Primary endpoints were overall and
progression free survival.
Results: Fifty-three patients underwent tracheal resection for intraluminally-invasive TC over a 6-year
period (51 segmental; 2 window). Pathology included 37 (70%) patients with papillary TC, 7 (13%)
Hurthle cell cancer, 1 (2%) medullary cancer, and 8 (15%) poorly differentiated or anaplastic thyroid
cancer (ATC). Eighteen (34%) patients had a preoperative unilateral vocal cord paralysis. Median number
of tracheal rings resected was 5 (range 1-12). Median hospitalization was 5 days (range 2-36). Seven
(13%) patients had a new tracheostomy placed intra/postoperatively (11% temporary; 2% permanent), 4
(8%) had concomitant laryngectomy, and 24 (45%) had concomitant esophageal muscularis resection.
Postoperative complications included hypoparathyroidism (40% temporary; 6% permanent), obstructive
airway event requiring intervention (9%), air leak (9%), tracheoesophageal fistula (6%), wound infection
(4%), hematoma (4%), pneumothorax/pneumoperitoneum (4%), and partial dehiscence of tracheal
anastomosis (2%), with 11 (21%) requiring return to the operating room for management. One (2%) died
within 30 days of surgery due to respiratory distress. One-year, 3-year, and 5-year overall survivals were
94%, 88%, and 88%, respectively. Median follow-up was 2.3 years (range 11 days-6 years), with 5
patients having died, 3 of which had ATC. Five (9%) patients developed locoregionally recurrent disease,
all in the central neck. One-year, 3-year, and 5-year local recurrence free survivals were 92%, 80%, and
74% respectively. One-year, 3-year, and 5-year local/distant recurrence and/or progression free survivals
were 68%, 44%, and 24%, respectively.
Conclusion: In the largest contemporary experience with segmental tracheal resection for advanced TC,
we highlight the complexity and significant perioperative risks associated with these surgeries, with few
patients requiring return to the operating room, and rare perioperative death. Almost all patients remain
alive and locoregionally disease-free several years following surgery.
Keywords: segmental tracheal resection, thyroid cancer, survival complications
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Abstract Number: 52

Mechanism-rooted therapeutic strategies for inflammatory arthritis induced by checkpoint
inhibitors
Lulu Peng, Immunology, The University of Texas MD Anderson Cancer Center, NYU Grossman School of
Medicine
William Padron, Immunology, The University of Texas MD Anderson Cancer Center
Naimah Turner, Immunology, The University of Texas MD Anderson Cancer Center
Sang T. Kim, General Internal Medicine, The University of Texas MD Anderson Cancer Center,
Roza Nurieva, Immunology, The University of Texas MD Anderson Cancer Center
Background: Immune checkpoint inhibitor (ICI) therapy is a revolutionary cancer treatment that
reinvigorates T cells to eradicate tumors. However, inflammatory toxicities called immune-related adverse
events (irAEs) frequently occur and can affect nearly every organ system. Arthritis is the most common
rheumatologic irAE and is treated with steroids but occasionally requires the cessation of ICI therapy.
Given the chronicity of arthritis, balancing autoimmunity and antitumor immunity is critical in clinical
management. Our lab recently analyzed synovial fluid from cancer patients with arthritis-irAE and found
that T helper (Th)1, Th1-17, and Th17 cells are involved in the inflammatory process (Nat. Com. (2022)).
Notably, combination ICI therapy (anti-CTLA-4 and anti-PD-1) is associated with greater steroid
resistance and increased Th1-17 and Th17 cell population compared to monotherapy (anti-PD-1 alone).
Currently, we lack further understanding of pathophysiology due to the lack of a preclinical murine model.
Methods: C57BL/6 mice were immunized with chicken collagen II emulsified with complete Freund’s
adjuvant (CII/CFA) along with injection PBS, anti-PD-1 antibody, or combined ICIs, and arthritis severity
was later assessed. In some experiments, mice were treated with blocking antibodies against Th-17related cytokines. At the endpoint of the experiment, we harvested spleen and bone from euthanized
mice to perform flow cytometry (spleen) and histology (bone) analyses.
Results: Mice receiving CII/CFA developed inflammatory arthritis only after they were challenged with
ICIs, recapitulating human clinical setting. Furthermore, similarly to arthritis-irAE patients, combined ICI
treatment resulted in greater arthritis severity and enhancement of IL-17-producing T cells when
compared to monotherapy. Importantly, blockade of Th17-related factors improved arthritis severity.
Conclusion: We have successfully developed the murine model of arthritis-irAE supported by clinical
settings and immune landscapes similar to humans. Along with findings in patients, our mouse model
lends evidence to the theory that Th17 cells may play an essential role in the pathogenesis of arthritisirAE and that targeting factors related to these cells may treat arthritis while preserving anti-tumor
immunity.
Keywords: Inflammation, arthritis, immune-related adverse events, checkpoint inhibitor, Th17 cells
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Abstract Number: 53

Golgi Apparatus in Airway Secretory Cells
Colin Chan, Pulmonary Medicine, University of Texas MD Anderson Cancer Center
Oanh Hoang, Pulmonary Medicine, University of Texas MD Anderson Cancer Center
Michael Tuvim, Pulmonary Medicine, University of Texas MD Anderson Cancer Center
Burton Dickey, Pulmonary Medicine, University of Texas MD Anderson Cancer Center,
Background: Mucus plays an important role in trapping foreign pathogens in the respiratory system.
Mucus is formed through hydration of large, heavily glycosylated proteins called mucins, such as
MUC5AC and MUC5B, along with other solutes such as salts. Mucin overproduction plays a key role in
muco-obstructive diseases such as COPD. Preliminary data show that Golgi in airway epithelial cells
appear dispersed. The Golgi stacks which appears separate from the classical perinuclear ribbon are
called outposts. We sought to elucidate how mucin is trafficked within the cell and packaged in the Golgi
apparatus using immunofluorescence (IF) and electron microscopy (EM). Understanding mucin trafficking
could offer therapeutic targets in the future to halt deleterious mucus production.
Methods: Naïve and IL-13 treated mouse lungs were studied using IF and EM. IL-13 was used to
increase mucin production. For IF, mice and human lungs were fixed in 4% paraformaldehyde and
subsequently paraffin embedded. Tissue samples were cut perpendicular to major airways in 5 µm
sections and stained with Golgi antibodies. Images were taken with the Deltavision Deconvolution
microscope. For EM, mice lungs were harvested and fixed in 2.5% glutaraldehyde with a post-fixation in
OsO4. The lung was then sectioned with a transverse cut and embedded in epoxy resin. Sections of
100nm were viewed on a Tecnai 12 transmission EM.
Results: Within airway secretory cells, the Golgi apparatus show a different organization compared to the
classical perinuclear Golgi. For one, the perinuclear Golgi ribbon in secretory cells is extremely long, and
secondly, the Golgi appears to stretch farther out towards the apex of the cell and along the lateral cell
walls as shown by the NtO/NtA and CtO/CtL values in both naïve and metaplastic datasets. In addition,
evidence of small individual cisternae stacks in EM along with distinct punctate in IF imply the presence of
several Golgi outposts throughout the cell.
Conclusion: These observations of an unusual Golgi apparatus architecture can suggest many

possible things. One of which could be that the need for a high volume of glycosylated protein in
the form of mucin would dictate the need for a larger and more robust Golgi machinery. Another
possibility is that the large size of the mucin protein (greater than 10 MDa) would mean
trafficking mucin throughout the cell is impractical, thus requiring the need to synthesize and
glycosylate the mucins in place before exocytosis.
Keywords: mucin, Golgi, Golgi outposts
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Abstract Number: 54

The mTOR Pathway Independent Function of NPRL2 in the Regulation of S-Phase DNA Damage
Response
Clemens An, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Yang Peng, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Lulu Wang, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Jianfeng Shen, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer
Center,
Hui-Ju Hsieh, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer
Center
Guang Peng, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Background: Mismatch repair (MMR) was one of the first pan-cancer biomarkers for immune checkpoint
blockade. However, not all tumors exhibit high mutation load due to MMR deficiency. Therefore we
sought to identify if other defects in genome maintenance mechanisms could predict immune
responsiveness in tumors. The GATOR1 complex functions as a negative regulator of the mammalian
target of rapamycin complex 1 (mTORC1). NPRL2 is a subunit of GATOR1, and its function in the
regulation of S-DDR has not yet been reported.
Methods: We initially conducted a genetic screen to systematically identify molecular determinants of Sphase DNA damage response (S-DDR). Once we identified that NPRL2 was a strong candidate, we used
a reverse phase protein array to identify which proteins might be regulated by NPRL2. Then we used
immunoprecipitation and mass spectrometry analysis to systematically identify NPRL2 interacting
proteins. Then we analyzed orthotopic tumors to confirm the activation of the STING pathway and
immune response to verify the therapeutic efficacy of anti-PDL1 treatment in NPRL2-deficient tumors.
Results: The data suggests that NPRL2 binds to an E3-ligase UHRF1 and controls UHRF1-mediated
ubiquitination of CHK1 which is a key DNA damage checkpoint kinase. Loss of NPRL2 increases CHK1
protein instability which results in defective S-DDR. DNA replication, recombination, and repair and cell
cycle were among the top networks of proteins interacting with NPRL2, consistent with its role in S-DDR.
The findings demonstrate that NPRL2 deficiency promotes an innate immune response by the activation
of the DNA sensor STING-mediated pathway.
Conclusion: This project identifies NPRL2 as a key regulator of genome maintenance and anti-tumor
immunity. NPRL2 regulates S-DDR in an mTOR pathway-independent manner. We found that NPRL2 is
required for S-DDR through its ability to regulate CHK1 degradation mediated by the UHRF1 E3-ligase.
We also demonstrated that defective S-DDR in NPRL2-deficient tumors links accumulation of
endogenous DNA damage to the promotion of innate immune response and tumor infiltrating
lymphocytes through the activation of the STING pathway. The data provides an example for a future
pathway-based biomarker to identify tumors with enhanced innate immunity, and thus predict therapeutic
response to immune checkpoint blockade, particularly for tumors with low mutation load.
Keywords: DNA Damage Response, Innate Immunity, Biomarker, Immune Checkpoint Blockade,
Genome Maintenance
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Abstract 54-A
Characterization of Glioblastoma Tumor Microenvironment in Humanized Mice
Christiana Agbo, Neurosurgery, The University of Texas MD Anderson Cancer Center
Kristin Huntoon, Neurosurgery, The University of Texas MD Anderson Cancer Center
DaeYong Lee, Neurosurgery, The University of Texas MD Anderson Cancer Center
Yifei Lu, Neurosurgery, The University of Texas MD Anderson Cancer Center
Thomas Gallup, Neurosurgery, The University of Texas MD Anderson Cancer Center
Betty Kim, Neurosurgery, The University of Texas MD Anderson Cancer Center
Background: Humanized mice are immunodeficient mice engrafted with hematopoietic stem cells (HSCs)
which equips them with a reconstituted functional immune system capable of producing T and B celldependent immune responses, antibodies, and antiviral responses. The humanized mice model provides
us with the best translational research model for investigating certain immunotherapies as treatment for
glioblastomas. We want to use humanized mice as a form of targeted therapy for glioblastoma treatment
by using the humanized mice model to simulate glioblastoma tumor biology, determine the efficacy of
different combinations of immunotherapies on a patient’s tumor, and determine the human immune
response expected based on these therapies. To begin utilizing humanized mice as a form of targeted
therapy in glioblastoma treatment, we have documented the tumor microenvironment of glioblastoma in
humanized mice after engraftment with patient-derived xenografts (PDXs) of glioblastoma.
Methods: Through immunofluorescence, we were able to visualize immune cells in the tumor
microenvironment by using anti-human and anti-mouse antibodies to document the humanization process
using confocal fluorescence microscopy. We generated fluorescent microscopic images of immune cells
in the humanized mice.
Results: We expect to see strong florescent signal for the human immune cells in the fluorescent images
which would confirm the humanization of the mice. We used 4′,6-diamidino-2-phenylindole (DAPI) to
identify the nucleus of the cells in the brain tissue and different fluorophore spectra to detect human and
animal immune cells. We observed a greater fluorescent signal for the human immune cells in
comparison to the mouse immune cells.
Conclusion: We observed a greater signal for the human immune cells in comparison to the mouse
immune cells indicating that the engraftment worked.
Humanized mice, glioblastoma, immunofluorescence, patient-derived xenografts, immunotherapy
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Delineating Structure-Function Relationships in FANCA Using Chaperones
Nikitha Kota, Department of Genetics, The University of Texas MD Anderson Cancer Center
Brant Gracia, Department of Genetics, The University of Texas MD Anderson Cancer Center
Natalia Condic, Department of Genetics, The University of Texas MD Anderson Cancer Center
Georgios Karras, Department of Genetics, The University of Texas MD Anderson Cancer Center,
Background: The FANCA protein is essential to the tumor suppressive Fanconi Anemia (FA) pathway that
protects the human genome from DNA damage. Heat shock chaperone proteins, HSP70 and HSP90, are
endogenous cellular systems that reveal the severity of FANCA missense mutations. Specifically, FANCA
mutants with severe cellular phenotypes have greater chaperone binding compared to other mutants.
However, the exact mechanism for this enriched binding and whether these chaperone-engaging mutants
have other structural or functional consequences is still poorly understood.
Methods: The LUMIER assay is a high throughput co-immunoprecipitation experiment that was used to
quantify the interaction of mutant FANCA proteins with HSP70, HSP90, and other FA partner proteins.
The ChaperISM program was used to measure the effect of FANCA mutations on HSP70 binding motifs.
FANCA mutants were classified into three groups based on their predicted effects on HSP70 binding
motifs: increases, decreases, or no change. Furthermore, to understand structural effects, the FoldX
Protein Design Algorithm was used to predict the ddG values of FANCA mutants, with positive values
representing a destabilization. Lastly, a mixed methods pipeline was developed to predict the location of
FANCA interfaces with partner proteins.
Results: There was a poor correlation between predicted HSP70 binding groups and experimental HSP70
binding for FANCA missense mutations. However, examining the spatial distribution of HSP70 engaging
mutants showed mutations that disrupt the FANCA core have more HSP70 binding than those at the
surface. Moreover, many FANCA structural mutations had enriched chaperone binding. Switching focus,
mutations that disrupt partner protein binding were distributed throughout the FANCA structure and not
localized to interface regions. Expectedly, HSP70 engaging FANCA mutations tended to suffer the most
significant partner protein binding loss.
Conclusion: Chaperone binding reflects the severity of FANCA missense mutations, with severe
mutations having the most substantial binding. Changes in the number, quality or size of predicted
HSP70 binding sites was not found to explain the chaperone binding pattern of FANCA mutants.
However, predicted structural FANCA mutants showed enriched HSP70 binding and may have loss of
partner protein binding.
Keywords: Fanconi Anemia, HSP70, Cancer, Missense Mutations
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Abstract Number: 56

Primary Breast Sarcoma: A Retrospective Single Institution Study of Clinicopathologic Features,
Treatment and Prognosis
Abdulkader Almosa, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center
Hannah Wingate, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center
Min Yi, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center
Qingqing Ding, Pathology, The University of Texas MD Anderson Cancer Center,
Kelly K. Hunt, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center
Background: Primary breast sarcomas (PBS) are a rare and heterogeneous group of cancers with limited
research, publications and treatment algorithms. Previous PBS studies showed that the median overall
survival (OS, time from surgery to death from any cause) for patients was 108 months. Reports using
SEER data cannot report on many of the clinicopathologic features of the tumor that may affect outcome,
such as surgical margins, and treatment specifics. Single institution studies have been performed;
however, these have been small due to the rarity of these malignancies. In this study we aim to determine
factors associated with the survival of primary breast sarcoma patients and to develop a database of
primary breast sarcoma cases from a single institution.
Methods: We retrospectively reviewed data on 62 patients who underwent surgical treatment for breast
sarcoma at MD Anderson Cancer Center from 2000-2020 that were identified from a previous institutional
study. This study was approved by the MDACC Institutional Review Board (IRB). Clinicopathologic factors
examined included but were not limited to patient demographics, clinical features, and pathological
features. Of the patients studied, 34 had PBS, and 28 had radiation-induced sarcoma from a previously
treated breast carcinoma. Prognostic factors were determined using univariable and multivariable Cox
hazard ratio modeling.
Results: Final tumor size was the only factor significantly associated with poor prognoses for PBS
patients (HR: 1.1, p: 0.03). Excisional/incisional biopsy was found to be a significant factor associated
with decreased overall survival (p: 0.003), and positive margins were found to be significantly associated
with increased local regional recurrence (LRR, time from surgery to first local or regional recurrence; p:
0.02); however, the data is unreliable as the confidence interval is too wide in range as a result of minimal
data. No clinicopathological factors were found to be significantly associated with outcomes for breast
sarcomas that were radiation-induced. There was no significant difference in OS, disease-specific survival
(DSS, time from surgery to death due to breast sarcoma), or LRR based on different treatment strategies
(type of surgery, neoadjuvant or adjuvant treatment). Preliminary data suggested that neoadjuvant
chemotherapy was not effective in patients with PBS, except possibly in the cases of angiosarcoma.
Conclusion: Our data confirm that increased tumor size is associated with decreased survival for patients
with PBS. Interestingly, our data also suggests that different treatment strategies were not associated
with outcomes. However, more patients are needed in the database to make the data more significant
due to the inherent heterogeneity of breast sarcomas.
Keywords: breast, sarcoma, tumor, database, retrospective
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Abstract Number: 57

Development of Novel ATC PDX Models in Vivo
Vincent Nguyen, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Ying Henderson, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Yunyun Chen, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Nikhil Chari, Head and Neck Surgery, University of Texas MD Anderson Cancer Center,
Stephen Lai, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Background: Anaplastic thyroid cancer (ATC) is an extremely dangerous variation of tumors that inflicts
humans with very low survival rates after a year. Although ATC makes up for a minority of thyroid
cancers, it contributes to almost half of the annual mortality. In addition, ATC is usually resistant to
standard chemotherapy, so patient derived xenograft (PDX) models are often used to explore possibilities
with various therapeutic agents. With the close similarities in gene expression patterns and genetic
differences. PDX models allow for a more accessible and effective assessment of drug responses.
Methods: Thyroid tumors from patients who were diagnosed with ATC prior to operations were collected
and divided to develop cell lines and PDX models 1. In vivo mice models, the previously stated thyroid
tumors were prepared into 4 x 4 x 4 mm sections and implanted into immunodeficient mice. These mice
were then measured for the following weeks in order to record tumor growth volume (height x length x
width). When tumors reached 1000 mm ^3 1 volume, the mice were euthanized and the resulting tumor
was divided into pieces to be used for PDX model expansion 1. PDX models are established when the
mice have gone through four generations (F0 to F3).
Results: One ATC PDX model has been developed and suggests the possibility of many others. Two
other tumors have had success growing tumors, although the volumes of said tumor have decreased
since their initial growth. Many of the remaining tumors have not yet had success with growing a tumor,
possibly due to their early development.
Conclusion: As the experiment is still ongoing, more time is needed to further expand upon developing
PDX models. For the ATC PDX model that has been developed, it will undergo though profiling methods,
such as hematoxylin-eosin staining, immunohistochemistry stains, and short tandem repeats DNA
fingerprinting analysis, to determine the resulting model’s resemblance to the original tumor.
Keywords: anaplastic thyroid cancer, patient-derived xenografts, short tandem repeats, hematoxylin-eosin
staining
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Abstract Number: 58

ApoA-I binding protein (AIBP) decreases mechanical hypersensitivity after plantar incision in a rat
model of post-operative pain
Jessica K. Lin, Anesthesia and Pain Medicine, University of Texas MD Anderson Cancer Center
Yan Li, Anesthesia and Pain Medicine, University of Texas MD Anderson Cancer Center
Megan L. Uhelski, Anesthesia and Pain Medicine, University of Texas MD Anderson Cancer Center
Juliana M. Navia-Pelaez, Medicine, University of California San Diego,
Claudio Esteves Tatsui, Neurosurgery, University of Texas MD Anderson Cancer Center
Robert Y. North, Neurosurgery, University of Texas MD Anderson Cancer Center
Christopher B. Bankston, University of Texas Health Science Center
German Corrales, Anesthesiology & Perioperative Medicine, University of Texas MD Anderson Cancer
Center
Juan P. Cata, Anesthesiology & Perioperative Medicine, University of Texas MD Anderson Cancer Center
Luke B. Farson, University of Texas Health Science Center
Graham Beaton; Raft Pharmaceuticals, LLC
Kathleen McDonough; Anesthesia and Pain Medicine; University of Texas MD Anderson Cancer Center
Tony L. Yaksh; Anesthesiology; University of California San Diego
Yury I. Miller; Medicine; University of California San Diego
Patrick M. Dougherty; Anesthesia and Pain Medicine; University of Texas MD Anderson Cancer Center
Background: Post-operative pain is common in surgical patients, with many reporting inadequate pain
relief. This can lead to cardiopulmonary complications, delayed mobilization, longer hospitalization, sleep
disturbances, and psychological stress. Pro-inflammatory cascades triggered by toll-like receptor 4
(TLR4) activation contribute to chronic pain. Specifically, TLR4 localizes to lipid rafts and dimerizes,
initiating inflammatory signaling. Apolipoprotein A-I binding protein (AIBP), a secreted protein that has
been shown to bind ApoA-I and high-density lipoprotein, can reduce lipid rafts by removing excess
cholesterol from the plasma membrane. Because lipid rafts play a key organizational role in neuronal
membranes, changes in lipid rafts can produce pro- or anti-nociceptive effects. Modified AIBP that binds
to TLR4 has been shown to reduce hypersensitivity in preclinical models of inflammatory and neuropathic
pain. In this study, we aim to investigate the impact of AIBP on mechanical hypersensitivity and wound
healing in a post-operative pain model.
Methods: In this study, adult male and female Wistar rats from Harlan were used. To model postoperative pain, all rats received a 15 mm incision through the skin and fascia of the plantar hind paw. The
plantaris muscle was stressed, then the wound was closed with two sutures. The rats in the AIBP
treatment group were injected intravenously with 0.3 mg AIBP 30 minutes before the surgery. Von Frey
filaments (0.4, 0.6, 1, 2, 4, 8, 10, and 15 g) were used to determine mechanical paw withdrawal threshold
via the up-down method. Rats were tested before surgery and at 2 hr, 4 hr, 24 hr, 48 hr, 72 hr, 7 days,
and 10 days after surgery. Images were taken at 3, 6, 9, and 10 days after surgery to determine wound
size and rate of healing.
Results: Intravenous AIBP pre-treatment significantly attenuated paw incision-induced mechanical
hypersensitivity in the ipsilateral hind paw compared to untreated controls in male rats. In females, there
was no significant difference in mechanical hypersensitivity between the two groups, and the wound size
and rate of healing between the two groups did not differ. However, additional subjects are needed for
sufficient statistical power.
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Conclusion: Targeting TLR4 lipid rafts with AIBP could be an effective method to reduce post-operative
incision pain without compromising wound healing. Ongoing studies are investigating the potential role of
AIBP on wound healing in males and the mechanisms that caused the mechanical hypersensitivity
difference between males and females.
Keywords: Post-operative pain, mechanical hypersensitivity, AIBP, TLR4
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Abstract Number: 59

CCR4 Antagonists in Cutaneous T-Cell Lymphoma (CTCL)
Cheryl Lee, Dermatology, University of Texas MD Anderson Cancer Center
Wei Han, Dermatology, University of Texas MD Anderson Cancer Center
Xiaohong Wang, Dermatology, University of Texas MD Anderson Cancer Center
Loka R Velatooru, Dermatology, University of Texas MD Anderson Cancer Center,
Xiao Ni, Dermatology, University of Texas MD Anderson Cancer Center
CC Chemokine Receptor 4 (CCR4) is highly expressed by type 2 helper T-cells (Th2) and regulatory T
cells (Treg). It orchestrates cell migration and leads to the accumulation of Th2/Tregs in tumors, allowing
tumors to evade immune attacks. Cutaneous T-Cell lymphoma (CTCL) cells have Th2/Treg phenotypes
and highly express CCR4, which serves as a prominent therapeutic target for CTCL. We hypothesize that
treatment with CCR4 antagonists will decrease CTCL cell accumulation and inhibit tumor development
and progression in CTCL.
C021-dihydrochloride, a small molecule CCR4 inhibitor, was investigated in this study. NSG mice were
used for xenograft mouse models by injecting MJ CTCL cells subcutaneously. Arm 1 mice received C021
and MJ cells simultaneously; Arm 2 mice were first injected with MJ cells, then treated with C021 after
tumor formation. Each arm included 3 groups (5 mice/group): Group 1 – vehicle control, Group 2 – low
dose (5 mg/kg), Group 3 – high dose (20 mg/kg). Tumors were removed and weighed for each group at
the end. The proliferation marker Ki67 (monoclonal rabbit antibody D3B5, 1:3000) and CCR4 (polyclonal
human antibody NBP1-86584, 1:500) expression in tumors were analyzed using immunohistochemistry
(IHC). The average of three graders was taken to measure the level of expression for each section. Ki67
stains were graded by the percentage of positive cells. CCR4 stains were graded by the percentage of
cells within 4 intensity classes: negative, weak, moderate, and strong.
Arm 1 mice had a lower average tumor weight in the low dose (56.00±42.20 mg) and high dose groups
(46.60±35.18 mg) compared to the control group (153.80±95.71 mg). Lower average tumor weights were
also observed in Arm 2 low dose group (164.60±101.3 mg) compared to the control group
(220.50±102.50). In Arm 1 mice, the high dose group (17.83±21.43) had a lower average Ki67 score
compared to the control group (28.54±10.68). The low dose group in Arm 2 had a lower average Ki67
score (11.19±11.33) than the control group (20.29±17.73). Arm 1 CCR4 expression did not have major
differences between control (59.17±27.30), low dose (62.22±19.32), and high dose group (67.78±11.82).
Arm 2 also did not have a major difference between control (74.58± 46.77) and low dose group
(69.22±23.84).
Our results suggest that C021 treatment led to decreased tumor volume and decreased tumor
proliferation. However, levels of CCR4 expression did not drastically change. Future studies will assess
Th2/Treg phenotypes, apoptosis, and necrosis to elucidate the anti-tumor effects of C021 in CTCL.
Keywords: CTCL, CCR4, immunohistochemistry, Ki67, tumor proliferation
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Abstract Number: 60

Effect of ZRANB1 on PARP inhibitor resistance in breast cancer cells
Christina Do, Radiation Oncology, University of Texas MD Anderson Cancer Center
Yalan Deng, Radiation Oncology, University of Texas MD Anderson Cancer Center
Marisela Sheldon, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: When DNA is damaged, the repair process is usually activated with Poly (ADP-ribose)
polymerases (PARPs). PARP is an enzyme found in our cells and its function helps damaged cells repair
themselves. PARPS act as DNA damage sensors and bind to those damaged DNA at single strand DNA
breaks site in which signals DNA repair effectors to the breaks sites. PARP inhibitors stop the enzymes
from repairing damaged cells in cancer cells which causes the cells to die. In breast cancer cells
(BRCA1/2 deficient tumor cells) are more sensitive to PARP inhibitors (PARPi) due to synthetic lethality.
Since there are cancer patients who may or may not be resistant to the sensitivity of drugs, the PARP
inhibitor allows us to investigate the mechanism. The aim is to learn about the mechanisms behind PARP
inhibitor resistance, specifically in breast cancer cells, using the protein ZRANB1.
Methods: Immunoblotting of ZRANB1 and GAPDH in parental SUM149 and PARPi-resistant (SUM149PR) cells. SUM149-PR cells stably expressing doxycycline (DOX)-inducible ZRANB1 shRNA were treated
with DOX (100 ng/ml) for 4 days, followed by immunoblotting with antibodies against ZRANB1, NBS1,
RAD50, MRE11, and β-actin. SUM149-PR cells stably expressing 764 doxycycline (DOX)-inducible
ZRANB1 shRNA were treated with different concentrations of talazoparib with or without DOX for 6 days.
Cell viability was measured by a CCK8 assay (left panel). Hereafter, the IC50 value was defined as the
concentration of PARPi resulting in a 50% reduction in the number of drug768 treated cells compared
with the number of control cells (right panel). n = 3 wells per group. Left panel: BT549 cells stably
expressing doxycycline (DOX)-inducible ZRANB1 shRNA were treated with different concentrations of
olaparib with or without DOX for 3 days. Cell viability was measured by a CCK8 assay. Right panel: the
IC50 values. n = 3 wells per group.
Results: Knowing before that the protein ZRANB1 increases the PARP inhibitor. The knockdown of
ZRANB1 shows its mechanism with PARP inhibitor resistance in breast cancer cells.
Conclusion: Based on the results, the knockdown of ZRANB1 resensitizes the resistant cells to the PARP
inhibitor.
Keywords: PARPI, breast cancer, damaged DNA, ZRANB1, resistance
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ITERT Undergraduate Summer Research Training Program
Abstract Number: 61

Prevention of early stage Kras-mutant lung adenocarcinoma via targeted KRASG12D Inhibition
Camille Abaya, Translational Molecular Pathology, Trinity University
Yuejiang Liu, Translational Molecular Pathology, MD Anderson Cancer Center Graduate School of
Biomedical Sciences
Zahraa Rahal, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Ansam Sinjab, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center,
Humam Kadara, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Background: Our group recently identified alveolar intermediary cells (AICs) that arise early on posttobacco carcinogen exposure in vivo and during AT2-mediated repair mechanisms. Notably, and prior to
tumor onset, a subset of AICs harbored driver KrasG12D mutations which were later found in the resultant
LUADs, and which comprise the same variants found in human smoker LUADs. These findings support a
role for AICs as precursors for LUAD pathogenesis. Our ongoing studies are studying AICs at high
resolution to identify targets for early prevention and/or interception of LUAD pathogenesis, including
specifically targeting KrasG12D mutations. While targeted KRASG12D inhibitors (e.g., MRTX 1133, Mirati) are
showing strong pharmacological activity against frank human lung cancer, the effects of these agents on
tumor precursors is not known. Evaluation of MRTX 1133 as a KRASG12D inhibitor in preclinical mouse in
vitro and in vivo models is necessary to assess its effectiveness as an intervention strategy against early
pathogenesis of LUAD.
Methods: Here, we treated mF471 murine lung cancer cells from mice with knockout of Gprc5a (Gprc5a-/-)
with varying concentrations of MRTX 1133. We then utilized an MTT proliferation assay and western
blotting analysis to probe the minimal inhibitory concentration (MIC) of MRTX 1133 on cell growth as well
as the effects of this drug on signaling components downstream of KRAS activation.
Results: We found that increasing concentrations of MRTX 1133 resulted in statistically significant
decreases in cell viability when compared to control-treated cells. In addition, MRTX1133 showed dosedependent inhibition of mitogen-activated protein kinase (MAPK) signaling at various time points tested,
with significant reductions as early as 3 hours post-treatment and concentrations as low as 1 nM.
Conclusion: These results suggest that MRTX 1133 inhibits various malignant phenotypes (growth, protumor cell signaling) of murine Kras mutant lung cancer cells. This study provides new insights into
effectiveness of MRTX 1133 in murine lung cancer cells as a precursor to targeted clinical prevention of
LUAD in vivo. Further experiments are underway to assess the anti-tumoral (including preventive) impact
of MRTX 1133 KrasG12D inhibition using genetically engineered in vivo and ex vivo mouse models.
Keywords: Lung adenocarcinoma, KrasG12D inhibition, MRTX 1133, targeted prevention
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Abstract Number: 63

Tungsten nanoparticle and polymer blends as novel coating for radiopaque resorbable inferior
vena cava filters
Erin San Valentin, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Jossana Damasco, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Marvin Bernardino, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Sarah Honegger, Interventional Radiology, The University of Texas MD Anderson Cancer Center,
Karem Court, Nanomedicine, Houston Methodist Research Institute
Biana Godin, Nanomedicine, Houston Methodist Research Institute
William Norton, Veterinary Medicine and Surgery, University of Texas MD Anderson Cancer Center
Stephen Chen, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Natalie Fowlkes, Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center
Steven Huang, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Marites P. Melancon; Interventional Radiology; The University of Texas MD Anderson Cancer Center
Background: Deep vein thrombosis (DVT) or pulmonary embolism (PE) affects about 900,000 individuals
annually in the United States. Placement of inferior vena cava filters (IVCFs) is used for patients with
contraindications to anticoagulation. However, non-retrieval of IVCFs pose patient safety concerns
including risks of IVCF migration, embolization, and thrombosis. Absorbable IVCFs constructed with polyp-dioxanone (PPDO) eliminate the need for filter retrieval, whilst improving radiolucency of PPDO-IVCFs
through addition of radio-enhancing nanoparticles (NPs) such as gold (Au) and bismuth (Bi). To further
improve the performance of radiopaque absorbable IVCFs, we explored the use of tungsten (W) NPs with
polyhydroxybutyrate (PHB), polyvinylpyrrolidone (PVP) and polycaprolactone (PCL) polymer blends as
coating materials for PPDO.
Methods: WNPs were synthesized by thermal decomposition method. WNPs were characterized in terms
of size using dynamic light scattering and powder X-ray diffraction (XRD) patterns, morphology using
transmission/scanning electron microscopy (TEM/SEM), and radiopacity using computed tomography
(CT). WNPs combined with PHB, PCL, and PVP polymers were coated onto PPDO using a wet-dipping
technique. In vitro biocompatibility was tested against EC-RF24 using alamarBlue assay. Rat blood was
used to screen hemolytic activity upon contact with NP-coated PPDO. W+PHB and W+PHB+PCL+PVP
IVCFs were deployed in separate pig models. Autologous thrombus was deployed 1-2 weeks after filter
implantation. Hematological tests were monitored and images of the chest, abdomen, and pelvis were
taken weekly for 12 weeks via CT imaging.
Results: The additional PCL+PVP coating with WNP+PHB enhanced filter visualization during
fluoroscopy-guided deployment into porcine models. Moreover, initial CT monitoring showed 14-fold
signal enhancement of WNP+PHB+PCL+PVP (1201 HU ± 885 HU) compared to the background (muscle
area, 62 ± 13 HU), while WNP+PHB was only 8-fold higher (468 ± 220 HU) than the background (muscle
area, 62 ± 8 HU). Maximum HU values showed decreasing CT intensities throughout the 12 weeks for
both WNP+PHB only and WNP+PHB+PCL+PVP. Although WNP+PHB+PCL+PVP showed higher
intensity at week 12, gross necropsy images show necrotic lumen, suggesting local toxicity brought about
by the implanted IVCF.
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Conclusion: Bioresorbable IVCFs coated with WNPs and PHB+PCL+PVP reinforcement can be fully
visualized with fluoroscopy and CT for real-time image-guided deployment and monitoring of IVCF in
pigs. However, initial findings suggest possible local toxicity in the luminal wall brought about by
implantation of WNP+PHB+PCL+PVP filter. Further analyses are currently ongoing to assess the in vivo
safety of WNP+polymer-coated IVCFs, as well as the use of other high-Z nanoparticles.
Keywords: IVC filters, nanoparticles, medical device
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Abstract Number: 63-A
Utilizing Patient-Reported Outcome Questionnaires in Standard Practice: A Study from Thoracic
Radiation Oncology
Nicholas Pham, School of Medicine, Louisiana State University Health Sciences Center
Kelsey Corrigan, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Lauren Andring, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Aileen Chen, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Background: Patient-reported outcome (PRO) questionnaires are one approach to improve patientprovider communication, enhance satisfaction, and increase survival. However, there is limited research
on its effectiveness in radiation oncology, and providers are hesitant to implement PROs due to possible
disturbance of clinical flow or lack of utility. So, we examined provider and patient sentiments towards
PRO questionnaires as part of routine clinical care.
Methods: Patients and providers were given a questionnaire to elicit their viewpoints on PRO utilization in
the thoracic radiation oncology (TRO) department before and after PRO implementation. The provider
questionnaire included questions about the benefits and downfalls of implementation. The patient
questionnaire included questions about care management, communication, decision-making, and comfort
level. Questionnaire answers included “always, often, sometimes, rarely, never.” We used summary
statistics to compare surveys before and after PRO implementation.
Results: Overall, 16 providers (6 [37.5%] attendings, 6 [37.5%] midlevels, 4 [12.5%] nurses) and 45
patients completed the pre-surveys, while 16 providers (8 [50%] attendings, 5 [31.3%] midlevels, 3
[18.8%] nurses) and 96 patients completed post-surveys. In the provider pre-surveys, 44% believed that
PRO-CTCAE questionnaires “somewhat improve” clinical flow. In the post-survey, 94% were neutral. In
the pre-survey, “visualizing data” was selected as the main advantage of PROs compared to creating a
high-alert-value system in the post-survey. In the patient pre-surveys, 93% “always” felt comfortable with
providers’ symptom-related questions, compared to 73% in the post-survey. In the pre-survey, 84%
“always” felt their provider communicated well, compared to 73% in the post-survey. 31% in the presurvey agreed that they were taught coping mechanisms “very well,” which decreased to 26% in the postsurvey. 81% in the pre-survey “always” agreed that they understood how to manage symptoms, which
decreased to 51% in the post-survey. When asked how often patients were given information to help
make decisions about managing their symptoms, 47% responded “a great deal” in the pre-survey
compared to 41% in the post-survey.
Conclusion: Pre-implementation, providers were optimistic that PROs could improve clinical flow.
However, most developed a neutral stance post-implementation, suggesting an opportunity for
improvement. Providers wanted PROs for data visualization and creation of a high-alert-value system;
thus, these elements should be considered in PRO implementation. Patients’ perception of patientprovider communication did not improve post-implementation. Patients desired more information on
symptom management and comfort. This suggests that while PRO implementation is an important tool to
determine where communication gaps exist, additional strategies are needed to improve communication.
Keywords: Patient-reported outcomes, Thoracic Radiation Oncology
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Abstract 63-B
Detecting and Intervening on Rare Pre-Existing Resistant Subclones to BRAF/MEK Inhibitors in
Melanoma
Maria Bao-Loc-Trung, School of Medicine, Louisiana State University Health Science Center
Michael Nakazawa, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Lawrence Kwong, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Background: A challenge to cancer treatment is acquired resistance to targeted therapies. Little is known
if drug resistance occurs de novo or how to best counteract them. In melanoma, patients with BRAF
activating mutations are treated with BRAF and MEK inhibitors (BRAFi+MEKi). Although the majority of
these patients respond to therapy, over 80% of patients progress on therapy within one year.
A majority of resistant mutations found are in the MAPK or PI3K pathways and are postulated to be the
resistance mechanism. Unfortunately, targeting these resistant mutations after relapse have not proven
effective, and thus demonstrate clinical unmet need.
Methods: We identified 147 patients with BRAF-mutated cutaneous melanoma from The University of
Texas MD Anderson Cancer Center. 79 FFPE patient tumor samples from 29 patients had their tumor
DNA extracted using the Covaris truXTRAC Automated FFPE Kit according to protocol with UNG
treatment at 50C for 1 hour after reverse crosslinking step. A Zymo Quick-DNA Microprep kit was used to
remove excess melanin to optimize PCR amplification. qBDA technology enriched several different
groups from the MAPK or PI3K pathways via different BDA primer/blocker sets, and then underwent nextgeneration sequencing.
Patient data was obtained from EPIC, including progression-free survival (PFS) while on BRAFi+MEKi
treatment, best response (RECIST), and overall survival (OS). PFS and OS Kaplan-Meir curves were
generated through GraphPad Prism 9. Statistical significance was determined through Log-rank (MantelCox) test using Prism software. Values were determined to be statistically significant if P < 0.05.
Results: Out of the 29 patients, 12 (41.4%) patients were determined to have no mutations, while 17
(58.6%) patients had detectable mutations. The median PFS of patients without any mutation was 8.45,
while with any mutation, the median survival was 5.00. The p-value for the data was .137, indicating that
the data is not significant. Given that this is preliminary data, the increased number of samples once the
project is completed will hopefully yield significant results.
Conclusion: In this interim analysis, patients that did not have a detectable resistance mutation using
qBDA in the MAPK/PI3K pathways had a trend towards overall higher PFS compared to the group with
any mutation. This preliminary data supports the hypothesis that pre-existing mutations may infer
resistance to BRAFi/MEKi therapy that leads to tumor progression. The next steps are to obtain more
patient samples to demonstrate how personalized counter-resistance therapies can increase the longterm outcome of patients harboring pre-existing low-VAF resistance subclones.
Keywords: melanoma, BRAF, MEK, resistance, mutation
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Abstract 63-C
Dose Accumulation with CBCT Conversion in Head and Neck and Prostate
Olubunmi Lebimoyo, Image Guided Cancer Therapy Research Program, Texas Southern University
Androniki Mitrou, Imaging Physics, University of Texas MD Anderson Cancer Center
Emma McCollum, Imaging Physics, University of Texas MD Anderson Cancer Center
Caleb OConnor, Imaging Physics, University of Texas MD Anderson Cancer Center
Guillaume Cazoulat, Imaging Physics, University of Texas MD Anderson Cancer Center
Background: Standard radiotherapy utilizes a single CT study to inform treatment planning, however,
tumor(s) and organs at risk can shift and change size over the course of treatment, thereby rendering
initial planning less effective. These changes can lead to significant dosimetric effects and suboptimal
therapy if not taken into account. While daily imaging using Cone Beam CT (CBCT) can ameliorate such
challenges and improve therapeutic delivery limitations that exist. Compared to CT, CBCT, image quality
is lower, and the field of view is smaller leading to potential errors in the dose calculations.
Methods: To enable daily CBCT-based dose calculations, CBCTs were converted to synthetic CTs via
deformable image registration (DIR) techniques, which resolves the spatial differences between sets of
images. Planning and weekly CTs, and daily CBCTs were imported into a commercial treatment planning
system (TPS) and rigid registrations and DIRs were applied. Next, CBCTs were converted to synthetic
CTs using a clinical algorithm in the TPS. Doses were calculated and dose accumulation was performed
Results: The TPS algorithm deployed facilitated the successful conversion of CBCTs to synthetic CTs
with smooth transitions. Synthetic CTs were then used to accurately determine dose calculations while
taking into account daily shifts and changes in the size of tumor(s) and organs at risk. Accumulated dose
calculations using converted CBCTs were compared to planned doses and yielded up to a ±10%
difference to organs at risk. The clinical impact of these dose differences are currently being investigated.
Lastly, we determined that CBCTs can be converted successfully with either the planning CT or the
weekly CT since minimal dose differences were observed between the two methods.
Conclusion: CBCT conversion shows promise for applications in Head and Neck, and Prostate Cancer
Radiotherapy.
Keywords: CT, CBCT, Radiotherapy, Head and Neck, Prostate
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Immunopathogenesis of Granulibacter bethesdensis, an opportunistic pathogen causing
recurrent infection in immunocompromised Chronic Granulomatous Disease Patients
Atul Sharma, Department of Critical Care, University of Texas MD Anderson Cancer Center
Ashwin Ramesh, Department of Critical Care, University of Texas MD Anderson Cancer Center
Samantha Garcia, Partnership for Careers in Cancer Science and Medicine, Department of Faculty
Diversity, Equity & Inclusion, University of Texas MD Anderson Cancer Center
Jyotika Sharma, Department of Critical Care, University of Texas MD Anderson Cancer Center,
Background: Chronic Granulomatous Disease (CGD) is a X-linked genetic disorder that affects the white
blood cells, specifically phagocytes leading to a delay in the ability to promptly expel any invading
bacterial or fungal pathogen. Bacterial infections caused by Granulibacter bethesdensis (Gb) were first
identified in CGD patients. Healthy individuals are unaffected by Gb infections, but CGD patients require
the aid of antibiotics to clear the chronic infections caused by Gb. Infection manifests in the form of fever
and necrotizing lymphadenitis which may recur or relapse. Very little is known regarding host immune
responses required for efficient clearance of this pathogen in lung microenvironment, the primary site of
recurrent infections in CGD patients. A murine X-CGD model of Gb infection has been developed to allow
us to better understand the roles played by different immune cells during different phases of infection.
Methods: In this study, WT and X-CGD mice (n=13) were infected with Gb and euthanized at Day 1, Day
4, and Day 12. Mice were monitored for clinical signs of infection and upon euthanasia, blood,
bronchioalveolar lavage (BAL), and lungs were collected for bacterial burden and lung tissues for
histology. Cells were isolated from BAL for slide preparation to determine their phenotype and
morphology using Wright-Giemsa stain.
Results: The WT mice displayed a transient increase in clinical score correlating with moderate increase
in local and systemic bacterial burdens characteristic of a mild, resolving infection, XCGD mice exhibited
a marked increase in clinical scores and bacterial burdens which remained high through Day 12 post
infection, the time at which 100% of XCGD mice became moribund. Histology of lungs from WT and
XCGD mice showed significant increase in white blood cell counts within the lung microenvironment.
Microscopy revealed that BAL cells primarily comprised of macrophages and neutrophils with the
numbers mirroring the clinical severity of infection among WT and XCGD mice. We observed high
numbers of macrophages and neutrophils at Day 1 among both groups of mice with the cell numbers
returning to basal levels by Day 4 among WT mice. An increase in neutrophil counts was observed in
XCGD mice at Day 4 and remained high at Day 12 indicating a continued state of inflammation within the
lung microenvironment.
Conclusion: The inability to efficiently clear Gb among XCGD mice causes an alteration to the lung
microenvironment which led to an exacerbated disease condition. With the rise of multi-drug resistant
bacteria, we need to focus on alternative therapeutic strategies capable of boosting the immune system
while minimizing treatment costs.
Keywords: Chronic Granulomatous Disease, Granulibacter bethesdensis, Giemsa Staining, Phagocytes,
Bronchioalveolar Lavage Fluids (BALF)
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Abstract Number: 65

The Effects of a Brief Educational Intervention on COVID-19 Knowledge, Beliefs, and Intention to
Get Vaccinated in Black and Hispanic Populations
Nicole Small, Health Disparities Research, University of Texas MD Anderson Cancer Center
Nga Nguyen, Health Disparities Research, University of Texas MD Anderson Cancer Center
Alba Calzada, Health Disparities Research, University of Texas MD Anderson Cancer Center
Belen Villanueva, Health Disparities Research, University of Texas MD Anderson Cancer Center,
Lorna McNeill, Health Disparities Research, University of Texas MD Anderson Cancer Center
Background: Vaccine hesitancy is prevalent in minority populations, specifically Black and Hispanic
populations in the United States due to medical mistrust stemming from historical events, and/or negative
perceptions vaccines due to misinformation (Momplaisir, et al., 2021; Doherty, et al., 2021; Willis, et al.,
2021; Khubchandani, et al., 2021). The use of media and technology may be crucial in disseminating
pertinent and accurate information to increase vaccine acceptance among these communities.
Understanding strategies to reduce vaccine hesitancy is critical to acquiring herd immunity. This study
seeks to explore the role of a brief educational intervention on an individuals’ knowledge of the COVID-19
vaccine, belief of its effects, and intention to receive the vaccine.
Methods: Data from the Community Engagement Alliance Against COVID-19 Disparities study was used.
English-speaking Black and Hispanic adults were recruited for the study (n = 1606, mean age = 31.9 ±
5.9). Participants were primarily recruited from community-based organizations, and all participants were
unvaccinated against COVID-19. After being screened for eligibility, consented participants completed a
baseline survey, viewed the COVID-19 educational materials, and then completed a follow-up survey.
The educational materials consisted of a frequently asked questions document, an infographic, a social
media guide, and two ethnically appropriate social media flyers. Factor analysis was performed for
vaccine knowledge and belief measures. Knowledge score was created by summing two items (score
range from 0 - 2). Similarly, belief score was calculated by summing two items (score range from 0 - 2).
Intention to get the COVID-19 vaccine in the next 30 days was assessed using 1 item, treated as a
continuous score (score range from 1 – 5). Change in score before and after the educational intervention
was assessed with paired t-tests (or Wilcoxon signed-rank test when appropriate).
Results: The mean scores for COVID-19 knowledge increased from 1.07 ± 0.87 to 1.29 ± 0.85
(p<0.0001), beliefs increased from 1.20 ± 0.88 to 1.36 ± 0.75 (p<0.0001), and intention to get vaccinated
in the next 30 days increased from 3.18 ± 0.92 to 3.45 ± 0.88 (p<0.0001).
Conclusion: The educational intervention led to significant increases in COVID-19 knowledge, positive
beliefs, and intention to get vaccinated in the next 30 days. These findings indicate that one strategy that
may prove effective in decreasing vaccine hesitancy in Black and Hispanic populations is short, ethnically
appropriate educational materials. These materials can be posted in schools, waiting areas, places of
worship, the workplace, or other frequently visited areas to educate the public on the COVID-19 vaccine,
increase vaccine acceptance, and lead us closer to herd immunity.
Keywords: COVID-19, vaccine hesitancy, Black, Hispanic
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Abstract Number: 66

Deciphering the multifaceted roles of a novel ultraconserved noncoding RNA, overexpressed in
Chronic Lymphocytic Leukemia
Paola Rausseo, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Swati Mohapatria, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Background: Chronic Lymphocytic Leukemia (CLL) is a malignancy of CD5+ B cells that primarily occurs
in the blood and bone marrow. It’s one of the most common blood cancers in Western countries and
about 10% of patients diagnosed with CLL develop into Richter Syndrome (RS), an extremely aggressive
transformation into lymphoma. These patients have a poor survival rate with a median survival of 12
months. This death sentence is the reason why we want to better understand the aggressive
transformation of CLL and investigate novel factors contributing to the genetic events behind this
transformation. Ultra-conserved regions (UCRs) are genomic regions that are perfectly (100%) conserved
in between humans, mice and rats. Some of the UCRs get transcribed into long noncoding RNAs often
called as Transcribed Ultraconserved regions. Perfect conservation of T-UCRs makes them interesting
and aberrations in such regions has been correlated to cancer susceptibility. TRUC-16 is found to be
overexpressed in aggressive CLL and Richter patients. Direct interaction of TRUC-16 to p16INK4A leads
to lower levels of p16INK4A and overexpressed conditions of TRUC-16. P16INK4A, a tumor suppressor,
is found to be silenced in 30% of Richter Transformation cases. We hypothesize that forced
overexpression of TRUC-16 in B cells leads to aggressive transformation into CLL and RS-like phenotype
in C57BL6 mice.
Methods: In order to investigate the disease phenotype in the CRISPR-Knockin mice, generated in Dr.
Calin’s lab, we performed flow cytometry to assess lymphocytes in the peripheral blood. The Flow
cytometry analysis was performed using two panels comprising of CLL markers (CD5, B220, CD19, IgK
and Ig) and a Richter panel including CD23, CD20, and Ki-67. Retro-orbital bleedings were performed
on mice to collect peripheral blood that was further subjected to surface and intracellular staining. Data
was acquired using BD LSR Fortessa and further analyzed using FlowJo software.
Results: Our results show that native B cells are potentially migrating to spleen and lymph nodes in old
mice nearing the transformation timepoint.
Conclusion: Further, to characterize the B cell subtype, we would design a new panel utilizing CD80,
CD27, CD138, and other B cell markers to better understand the B cell population in the immune
compartment of these TRUC-16 overexpressing mice. This study will help us in understanding the role of
T-UCRs in CLL and RS and help in identifying the key regulators that drive this aggressive transformation
Keywords: CLL, Richter Syndrome, Ultraconserved
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A Cancer Gene-Drug Connectivity Map for DrBioRight
Varshini Vakulabharanam, University of Houston
Hu Chen, Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer
Center
Yitao Tang, Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer
Center
Jun Li, Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
Han Liang, Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer
Center
Background: The DGIdb provides gene-drug interactions that are curated by experts’ manual curation
and text-mining from public resources, including Drug Target Commons and DrugBank. Such interaction
information can help easily identify potential drug targets or check whether a cancer related gene is
targetable by any drug. By incorporating such information, our users can visualize the associated drugs
for each queried gene and easily find the corresponding publication information for each gene-drug
interaction.
Methods: First, 261 cancer genes were obtained from TCGA highly mutated cancer genes. Second,
interactions (~80,0000) for the 261 cancer genes were filtered from DGIdb. Third, two histograms were
generated to show the gene and drug association. Fourth, high frequency genes and drugs were sorted
to generate the two lists by using cutoff of greater than or equal to 100 for genes and greater than or
equal to 20 for drugs. Then, bar plots were created to show two lists from output of step four. 82
interactions were extracted based on the high frequency genes and drugs from step four. Lastly, data
from the previous step was used to generate connectivity map using Cytoscape.
Results: Figure 1 shows the number of interacted drugs for each gene, in which there is one gene
associated with 770 drugs. Figure 2 shows the number of genes for each interacted drug. Figure 3 and 4
summarize the top genes and drugs ranked by their degrees in the interaction network, in which, the gene
NFR2L2 and the drug CETUXIMAB have the highest number of neighbors. Figure 5 shows a subconnectivity map constructed by the top genes and drugs identified from Figure 3 and 4.
Conclusion: Our results serve as the foundation in building a new module for DrBioRight. It will help users
obtain information of drug-gene interactions conveniently in DrBioRight rather than referencing other
databases. The new module for DrBioRight will consolidate the data generated in this study to further
increase the utility and improve its user experience.
Keywords: DrBioRight, Connectivity Map, DGIdb, Cancer Gene-Drug
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Abstract Number: 69

The Arginine Methylation of p14ARF
Robert Lwanga, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Dr. John R Horton, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Dr. Xiaodong Cheng, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson
Cancer Center
Background: P14ARF is a tumor suppressing protein that inhibits the growth of cancer cells by indirectly
activating p53 which is a key tumor suppressing gene. P14ARF is mostly made up of the following four
amino acids Arginine, Alanine, Glycine, and Leucine. This protein is important to deepen our
understanding of cancer progression.
Methods: (1) express recombinant p14ARF protein via autoinduction in E. Coli expression system, (2)
purify p14ARF via chromatography, and (3) characterize the posttranslational modification via arginine
methylation.
Results: After we expressed the recombinant p14ARF protein via autoinduction we split the protein into 4
separate samples and used a different purification process for each. As it turns out the samples with the
His-SUMO tag show higher methyl activation than the samples that are not His-SUMO tagged.
Conclusion: Sample 3 which went through the nickel column, and was concentrated, and sample 4 which
went through the nickel column, then the SP column, and was concentrated showed both showed high
methylation activity compared to the others. Samples 3 and 4 are His-SUMO tagged. Sample 2 is cleaved
but contains both p14ARF and His-SUMO. Sample 2 has very weak activity. In the future we plan to
optimize the activity of the methylation of p14ARF.
Keywords: P14ARF, Arginine Methylation, His-SUMO
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Abstract Number: 70

Investigation of Acute Hypoxia Effects on a 3D Model of Renal Cell Carcinoma
Jose Araujo, Faculty Diversity, Equity, & Inclusion, University of Texas MD Anderson Cancer Center
Luigi Perelli, Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center
Giannicola Genovese, Genitourinary Medical Oncology, Genomic Medicine, University of Texas MD
Anderson Cancer Center
Background: Genetic alterations of the hypoxia response pathway are common drivers of clear cell Renal
Cell Carcinoma (ccRCC). On the other hand, non-clear cell Renal Cell Carcinoma (nccRCC) usually
displays a genetically intact response-to-hypoxia stress signaling, suggesting a unique response of
nccRCC when subjected to low oxygen levels. Understanding how different genomic driven Renal
Cancers survive under hypoxic stress is of extreme importance for understanding nccRCC progression
Methods: We derived three-dimension tumor culture systems (tumor organoids) from explants obtained
from a Genetically Engineered Mouse Model (GEMM) of nccRCC with somatic mosaic knockouts of key
drivers of nccRCC evolution, already established in our lab. After organoid stabilization, they were
challenged with severe hypoxia (1% hypoxia) or with normoxia conditions (21% oxygen) for 72 hours.
Random fields of tumor organoids were collected at time 0 (immediately before hypoxia or normoxia
treatment) and 72 hours after hypoxia or normoxia treatment. Data from images were analyzed with
ImageJ software FIJI and statistical analysis with GraphPad Prism 9.
Results: A statistically significant (p < 0.05) difference was observed in numbers of organoids that were
challenged with normoxia, while no statistically significant difference was observed tumor organoids
challenged with hypoxia after 72 hours. Likewise, size of organoids in normoxia showed statistical
significance (p<0.01) while no differences in the organoids in hypoxia after 72 hours.
Conclusion: Our data suggests that hypoxia severely impacts tumor organoids proliferation and stemness
capabilities of nccRCC. Further investigation is required to better characterize the effects of hypoxia on
models of nccRCC: 1) prolonged hypoxia challange (i.e 7 days) should be performed with different levels
of hypoxia (i.e. 5%, 2%, 0.5%); 2) different genetic background should be challanged to hypoxia in to
clarify genomic events responsible for sensitivity or resistance to low oxygen levels.
Keywords: Hypoxia, RCC, Tumor organoids, GEM model
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Abstract Number: 71

Determining the Growth Rate of Various Escherichia coli Cell Lines in Different Broths
Sandra Diaz, Structural Chemistry, University of Texas MD Anderson Cancer Center
Background: One of several organisms of choice for producing recombinant proteins is Escherichia coli.
There are a variety of E. coli cell lines that can be used for protein expression. These cell lines are often
cultivated in Luria broth (LB) and Terrific broth (TB). However, there are many broths that E. coli cell lines
can be cultivated in. We wanted to determine the growth rate and expression level of four protein
constructs (1345, 1313, 1208 & 1211) in four E. coli cell lines utilizing various broths. In this study, we
analyzed growth rates in the following cell lines: BL21 (DE3), BL21 Star 905, BL21 Star 906, and BL21
Star 907. The broths that were tested include TB, 2XY, Superior, Hyper, LB, Power, Glucose, and
Autoinduction media.
Methods: Each cell line was cultivated in an overnight culture using LB. The overnight cultures were
diluted with media to have an optical density (OD) of two. The diluted overnight cultures were transferred
into 96 well plates with the appropriate media and construct. Every 30 minutes the absorbance was
measured at a wavelength of 600 nm until it reached the inducible OD. IPTG was then added to the cell
lines. Protein expression was analyzed using the dot blot method.
Results: Our approach demonstrated that the broth that produced the desired OD for each cell line the
fastest was TB. The OD of the BL21 cell line was attained in 2 hours for TB, 2XY, and LB broths. The OD
of the other broths was obtained after two hours and thirty minutes. The optical density of the remaining
cell lines ranged between two and thirty minutes and three hours.BL21 (DE3) and BL21 Star 905 cell
lines expressed the constructs well.
Conclusion: Current evidence suggest that there were significant differences in growth rate between each
E. coli cell line. The most common broth (TB) used supported the growth rate the best and reached
induction OD the fastest.
Keywords: protein expression, Escherichia coli, culture media, E. coli cell lines
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Abstract Number: 72

Microtubule-associated tau in breast cancer
Jennifer Zarate, Radiation Oncology, University of Texas MD Anderson Cancer center
Background: Tau is microtubule associated protein that provides function of stability in cytoskeleton and
shows high expression in breast cancer cells. Reports have demonstrated an abatement of tau is
displayed in radiated cancer cells but it’s still unclear how this loss will affect cellular function. In this study
we will be delineating tau’s role in breast cancer cells with the objective of analyzing tau expression, pre
and post radiation using cancer cell line, MCF-7.
Methods: Tau expression was visualized by performing immunofluorescence on MCF-7 under a
microscope.
Results: Interestingly the cells that have phospho tau (pTau) expression are also undergoing DNA
damage repair and have nuclear localization with total tau and pTau. Additionally, total tau and DNA
damage repair protein (γH2AX) exhibits colocalization in the nucleus, a strong indication that both
proteins are interacting.
Conclusion: Therefore this indicates that tau has a potential nuclear function in radiated breast cancer
cells and DNA damage repair proteins like γH2AX colocalizes with both total and ptau, further indicating
tau’s novel roles in cancer cells exposed to radiation. This finding could bring us one step closer into
understanding tau’s patterns and function in breast cancer cells.
Keywords: Tau protein, MCF-7, Breast cancer, Radiation
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Abstract Number: 73

The Association Between Persistent Poverty and Melanoma Mortality in Texas: A Retrospective
Study Using Texas Cancer Registry Data
Karla Madrigal and Lillian K. Morris (Co-First Authors), Dermatology, McGovern Medical School, The
University of Texas Health Science Center at Houston; University of Texas MD Anderson Cancer Center
Emelie E. Nelson, Dermatology, McGovern Medical School, The University of Texas Health Science
Center at Houston; University of Texas MD Anderson Cancer Center
Adewole Adamson, Dermatology, Dell Medical School, The University of Texas at Austin
Zhigang Duan, Health Services Research, University of Texas MD Anderson Cancer Center,
Hui Zhao, Health Services Research, University of Texas MD Anderson Cancer Center
Julie M. Simon, Surgical Oncology, University of Texas MD Anderson Cancer Center
Chloe N. Dorsey, Surgical Oncology, University of Texas MD Anderson Cancer Center
Marcita S. Galindez, Office of Health Policy, University of Texas MD Anderson Cancer Center
Hung Q. Doan, Dermatology, University of Texas MD Anderson Cancer Center
Cici X. Bauer, Biostatistics, University of Texas Health Science Center at Houston School of Public Health
Kelly C. Nelson; Dermatology; University of Texas MD Anderson Cancer Center
Background: Patients in United States counties with persistent poverty (PP, ≥20% of residents in poverty
since 1980) experience significantly higher cancer associated mortality than individuals living in non-PP
counties. While markers of lower socioeconomic status have been correlated to higher melanoma
mortality, the relationship of persistent poverty and melanoma mortality has not been explored.
Methods: We obtained data from 87,713 patients diagnosed with melanoma between 2000-2018 from the
Texas Cancer Registry. We used 2021 US Economic Development Administration data to identify PP
counties. Mixed effect models were used to assess incidence-based melanoma-specific mortality (IMM)
rates by PP, age, sex and race/ethnicity.
Results: In 2021, 56 of 254 Texas counties met PP criteria. Of those diagnosed with melanoma, 5,431
patients in PP counties experienced higher IMM (17.14%) than those in non-PP counties (11.34%,
adjusted odds ratio (AOR) = 1.10, 95% CI: 0.94-1.28). Compared to Non-Hispanic (NH) Whites, NH
Blacks experienced the highest IMM at 25.67% (AOR = 2.97, 95% CI: 2.45-3.62), followed by Hispanics
(19.71%, AOR = 1.98, 95% CI: 1.82-2.16). The disparity in IMM increased with age, with the 80 years +
age group having the highest mortality AOR of 2.53 (95% CI: 2.16-2.96). When exploring sex, more men
(13.43%) than women (9.09%) died from melanoma in PP counties (AOR = 1.48, 95% CI: 1.42-1.55).
Conclusion: Age, race/ethnicity, sex, and PP are associated with significant disparities in melanoma
mortality outcomes within our patient cohort. To address these disparities and develop targeted
melanoma secondary prevention interventions, we will continue to explore how place-based social
determinants of health correlate with melanoma outcomes.
Keywords: Melanoma, Mortality, Texas, Persistent, Poverty
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Abstract Number: 74

Using CRISPR for gene editing in Caenorhabditis elegans
Keirra Davis, Partnership for Careers in Cancer Science and Medicine Summer Experience, University of
Texas MD Anderson Cancer Center
Jacob Seemann, Department of Genetics, University of Texas MD Anderson Cancer Center
Swathi Arur, Department of Genetics, University of Texas MD Anderson Cancer Center
Background: CRISPR/Cas9 is a system discovered in Escherichia coli and now used as a tool in many
different model organisms to edit specific genes. We used CRISPR in C. elegans to tag the gene lin-53
with mRuby, a fluorescent protein.
Methods: We designed a crRNA to target lin-53 as well as a repair template to facilitate homology
directed repair. We built the repair template using PCR, purified it, and used it in our injection mix. We
injected 25 worms with our repair template and a co-CRISPR to screen for edited animals.
Results: After 72 hours we found 220 potentially edited animals, put them on individual plates, then we
used PCR to genotype them and find which potentially had the mRuby tag. Of these, 31 appeared to
have the desired edit. We picked 8 of these to sequence because they had visible red fluorescence
under the microscope.
Conclusion: We use CRISPR because it’s an extremely efficient, straightforward way to edit a gene. The
use of CRISPR/Cas9 allows us to target specific genes to edit using crRNAs as guide sequences, which
allows us to insert a fluorescent tag on almost a protein of our choosing.
Keywords: CRISPR, lin-53, C. elegans, gene editing
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Abstract Number: 75

Exploring the Use of a Restoration Step to Detect Mosaic Chromosomal Alterations in Prostate
Samples
Ayanna N. Woodberry, MS, MPH, Epidemiology, University of Texas MD Anderson Cancer Center
Justin Wong, PhD, Epidemiology, University of Texas MD Anderson Cancer Center
Paul Scheet, PhD, Epidemiology, University of Texas MD Anderson Cancer Center
Background: Prostate cancer is the most common cancer (besides skin cancer), and the second leading
cause of death among American men. Genetic instability is a hallmark in tumor prevalence, resulting in
mosaic chromosomal alterations (mCAs), including gains and losses. Although prostate cancers exhibit a
lower mutation burden than other malignancies, mCAs are a relatively common mutation type within this
cancer and tend to be prognostic. The purpose of the study was to assess the relationship between
mCAs and cancer outcomes. It is useful to study cohorts with historical biospecimens and long-term
follow-up. However, this means the samples will be stored for a long period in formalin-fixed and paraffinembedded (FFPE), which over time further degrades DNA through cross-linking. Here we assess the
impact on a cost-intensive restoration step in terms of mCA detection.
Methods: This pilot study consisted of an extensive analysis of prostate samples obtained through the
Health Professionals Follow-up Study (HPFS). We studied 24 DNA samples from 10 participants, with
varying concentrations of DNA. Each sample was processed two ways: with and without a restoration
step to address damage from FFPE, resulting in 48 samples. We applied DNA SNP microarrays to these
48 samples and applied a mCA detection software to the data. The methodologies (non-restored vs.
restored) were assessed based on: (1) genotype distribution and call rates, and (2) number of detected
mCAs. A component of our comparisons involved the DNA quantities; some samples had less than the
recommended 200ng. The restoration step itself further consumes DNA, resulting in some samples
having as few as 9ng of DNA present.
Results: Our analysis found that the restoration step generally resulted in a higher genotype call rate.
Consistent with this, we detected one third more mCAs with the restoration step.
Conclusion: Overall, the restoration step seems to be the more powerful method. We found the higher
number of mCAs to be encouraging given the low false positive rate of the detection method. A drawback
of the restored method is that it is three times more costly for the specific array used here, thus
considerations may be made about power vs. sample size. This pilot informs a larger study with 1,000
patients with advanced prostate cancer and 1,000 patients without advanced cancer.
Keywords: chromosomal alterations, SNPs, archival samples, prostate cancer
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Abstract Number: 76

Cytotoxic potential of Mithramycin against DIPG cell lines
Habibatou Diallo, Pediatrics, University of Texas MD Anderson Cancer Center
Sandeep Singh, Pediatrics, University of Texas MD Anderson Cancer Center
Shinji Maegawa, Pediatrics, University of Texas MD Anderson Cancer Center
Donghang Cheng, Pediatrics, University of Texas MD Anderson Cancer Center,
Jyo Swaminathan, Pediatrics, University of Texas MD Anderson Cancer Center
Vidya Gopalakrishnan, Pediatrics, University of Texas MD Anderson Cancer Center
Background: Diffuse Intrinsic Pontine Glioma (DIPG) is a glial tumor of the pons with an extremely poor
prognosis and limited treatment options due to its location in the brain stem. Current treatment involves
radiation, but survival rates remain dismal. Thus, our goal is to identify novel oncogenic targets in order to
develop effective targeted therapeutics. To identify novel targets, we performed integrated analyses of
RNAseq and ATACseq of three different DIPG cell lines. This led to the identification of RE1 Silencing
Transcription Factor (REST) and SET Domain Bifurcated Histone Lysine Methyltransferase (SETDB1)
regulated genes as highly altered in human DIPG cell lines. REST is a repressor of neuronal genes, and
SETDB1 is involved in the silencing of euchromatic genes, in contrast to the SuVAR family of proteins,
which control heterochromatin formation. Expression of REST and SETDB1 is elevated in human DIPG
tumors and cell lines. Co-immunoprecipitation demonstrated a direct physical interaction between REST
and SETDB1 in a subset of DIPG cells. REST has been previously shown to be important for DIPG tumor
growth. More recently, knockdown studies confirmed that SETDB1 is required for DIPG growth as well.
REST and SETDB1 bind the upstream regulatory sequences of a target gene called CAV1, which is
involved in several cellular processes including protein trafficking. Thus, we hypothesize that the RESTSETDB1 complex activity can be therapeutically targeted in DIPG cells. Mithramycin is an anti-cancer
antibiotic produced by the bacterium Streptomyces plicatus. It binds GC-rich regions on DNA and thus,
interferes with the binding of proteins that recognize and bind GC-consensus sites on DNA. Mithramycin
is known to block the binding of Specificity Protein 1 (SP1) to DNA, downregulate the expression of the Xlinked inhibitor of apoptosis protein (XIAP), and induce cancer cell death. SP1 is also required for the
upregulation of SETDB1, and could potentially decrease its expression in DIPG cells. Here, we provide
evidence that Mithramycin potently decreases the growth of DIPG cells in vitro.
Methods: We used DIPG cell lines (IV, IV-REST, VII, VII-REST, XIII, XIII-REST) and performed MTT
cytotoxicity assay and cell cycle assay upon treatment with Mithramycin.
Results: REST and SETDB1 are overexpressed in DIPG tumors and contribute to proliferative potential.
Interaction of REST and SETDB1 may be indicative of cooperative oncogenic behavior in DIPGs.
Mithramycin treatment results in an increase in sub-G1 cell population in the three DIPG cells under
study. Interestingly, REST elevation caused an increase in the sub-G1 population as well as cells
arrested in S-G2/M phases of the cell cycle.
Conclusion: Mithramycin potently blocks the growth of DIPG cell lines in vitro. The underlying
mechanisms remain to be evaluated. The role of REST in modulating DIPG response to Mithramycin also
remains to be understood.
Keywords: DIPG, REST, SETDB1, Mithramycin, MTT
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The Role of Radiation Therapy on Postmastectomy Breast Reconstruction Patients
Megan Rodriguez, Radiation Oncology, University of Texas MD Anderson Cancer Center
Melissa Mitchell, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: Postmastectomy radiation therapy (PMRT) following breast reconstruction is among the
leading choices of treatment in patients with breast cancer. However, various reconstruction
complications have been linked to this approach. While some research has sought to identify covariates,
which influence the rate of complications, there lies a gap in the literature. Our research assesses the
impact of radiation therapy (RT) on complications for patients undergoing implant-based reconstruction
following mastectomy.
Methods: A retrospective cohort study was conducted in patients who underwent mastectomy followed by
breast reconstruction from October 2016 to December 2019. We reviewed charts from 548 patients
undergoing mastectomy in 765 breasts, planned for implant-based breast reconstruction using tissue
expanders (TE). Identified breasts were separated into four groups: mastectomy without RT (n=566),
mastectomy with TE removed before RT (n=20), mastectomy with TE in place during RT (n=156), and TE
implanted in a prior radiated breast (n=23). Categorical variables were compared using the Chi-squared
test. P-values less than 0.05 were considered statistically significant.
Results: The most common complication type was infection (34%), followed by seroma (22%), wound
dehiscence (13%), necrosis (12%), implant exposure (9%), hematoma (4%), deflation/rupture (4%), and
capsular contracture (2%). The complication rate was highest among breasts with TE removed prior to RT
(95%), followed by a complication rate of 45.8% in breasts with prior RT. 38.1% of breasts with TE in
place during RT developed complications. Those breasts without RT developed the least number of
complications (P= .000). In breasts that received RT, half of complications occurred over 10 months
following surgery. Contrastingly, among those that did not receive RT, majority (55.2%) of complications
took place within one month.
Conclusion: Postmastectomy breasts that did not receive RT developed the least number of
reconstruction complications. Breasts that had undergone RT with TE in place had a higher risk for
infection, seroma, and implant exposure (P < .05). Majority of the complications in breasts without RT
took place within one month of the reconstructive procedure while most of the complications in breasts
with RT took place months later.
Keywords: PMRT, implant-based reconstruction, tissue expander
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Creating an Inexpensive Medical Linear Accelerator for Training and Educational Purposes
Gabriela Rodriguez, Faculty Diversity, Equity, and Inclusion, University of Texas MD Anderson Cancer
Center
Noah Court, Radiation Physics, University of Texas MD Anderson Cancer Center
Adriana Torres Li Ning, Radiation Physics, University of Texas MD Anderson Cancer Center
Hannah Kuruvila, Radiation Physics, University of Texas MD Anderson Cancer Center,
Ananya Das, Radiation Physics, University of Texas MD Anderson Cancer Center
Kai Huang, Radiation Physics, University of Texas MD Anderson Cancer Center
Ramon Salazar, Radiation Physics, University of Texas MD Anderson Cancer Center
Laurence Court, Radiation Physics, University of Texas MD Anderson Cancer Center
Background: Medical Linear Accelerators (LINAC) are at the frontline of helping patients battle cancer
through radiotherapy (RT) treatment. LINACs create high-energy X-rays which can kill cancer cells. The
innovation of LINACs has helped save many patients' lives; however, this radiotherapy machine is
extremely expensive—costing up to 4 million dollars. LINACs are constantly in use, making it difficult for
trainees and patients to familiarize themselves with the RT machine. The development of a scale model
of the LINAC would help facilitate patient and trainee education about the RT machine’s functions and
treatment expectations.
Methods: LINAC scale model that could be built using cardboard and other inexpensive materials, with
movement controlled using UNO R3 Controller (Arduino) as the source powering the model. Arduino
Software (IDE) was used to code Arduino.
Results: We designed the LINAC scale model to include four major parts, including the gantry, collimator,
couch, and a platform. Two UNO R3 Controller Boards (Arduino) were used, one located in the gantry’s
stand and another in the platform. The gantry required rotation of 180 degrees clockwise and
counterclockwise from the vertical. The collimator, attached to the gantry, required rotation of 180
degrees clockwise and counterclockwise from neutral. The 28BYJ-48 Stepper Motor (SM) was used to
accomplish these movements since it required no tuning and was the most cost-effective. The couch had
two distinct movements: up and down and 90 degrees from neutral. The SM was implemented in a
scissor lift to produce the up and down movement of the couch and the Servo Motor SG90 (Servo) was
implemented for the rotation of 90 degrees from neutral. To control the movement of each motor,
joysticks were used for the SM and a potentiometer controlled the Servo. The 43.18cm x 20.32cm x
7.62cm platform was made to hold the couch and gantry in one place as well as the Servo needed for the
couch.
Conclusion: We successfully designed and built a low-cost scale LINAC model that could be used for
patient and staff education
Keywords: Medical Linear Accelerator, Scale Model, Training and Patient Education
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Soluble E-Cadherin in regulation of ROS in Inflammatory Breast Cancer
Yair Romero, Breast Medical Oncology, University of Texas MD Anderson Cancer Center
Bisrat Debeb, Breast Medical Oncology, University of Texas MD Anderson Cancer Center
Hu Xiao Ding, Breast Medical Oncology, University of Texas MD Anderson Cancer Center
Background: Breast Cancer is the most common cancer in women and is the second leading cause of
death. Inflammatory Breast Cancer (IBC) is an aggressive variant of breast cancer with a strong
propensity to spread to distant organs. Although only making about 1-4% of all breast cancer patients, it
accounts for 8-10% of all breast cancer-related deaths. The mechanisms underlying the aggressive
biology of IBC are unknown and no specific biomarker for IBC has been identified to date. An increase in
thein the expression of E-cadherin, an epithelial adhesion molecule, has been noticed in tumors from IBC
patients and cell lines. In preliminary work, soluble E-cadherin, an extracellular fragment of Full-length Ecadherin, was shown to promote tumor growth and survival of IBC cells. Also, Reactive Oxygen species
(ROS) signaling is enriched in soluble E-cadherin-expressing IBC cells. The purpose of this study is
determine whether soluble E-cadherin promotes survival of IBC cells by regulating ROS.
Methods: The levels of ROS were compared between two groups, a control and Soluble E-cadherin
overexpression SUM149 IBC cells. To achieve this, we performed culturing of cells, staining the cells with
DCFDA and then quantifying by using a flow cytometer machine. We repeated the experiments twice.
Results: Hallmark pathway analysis showed that ROS signaling is enriched in soluble E-cadherinexpressing IBC cells. We found that the SUM149 IBC cells with soluble E-cadherin overexpression have
significantly lower ROS levels compared to the control group (p<0.05).
Conclusion: We conclude that soluble E-cadherin reduces the levels of ROS in IBC cells. This suggests
that soluble E-cadherin may promote the survival of IBC cells by inhibiting ROS levels, sparing the IBC
cells from ROS-mediated cell death.
Keywords: E-Cadherin, ROS, IBC, Soluble E-Cadherin
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Establishing Optimized Culture Conditions for Human Intestinal Organoids
Richard Garcia, Radiation Oncology Research, University of Texas MD Anderson Cancer Center
Neeraj Kumari, Radiation Oncology Research, University of Texas MD Anderson Cancer Center
Natividad Fuentes, Radiation Oncology Research, University of Texas MD Anderson Cancer Center
Cullen Taniguchi, Radiation Oncology Research, University of Texas MD Anderson Cancer Center
Background: Pancreatic Adenocarcinoma (PDAC) is among the deadliest forms of cancer with a 5-year
survival rate of 11%. A contributing factor of poor prognoses is that PDAC tumors are highly resistant to
radiotherapy. A high radiation dose is difficult to achieve because of the toxicity to nearby healthy tissues
like the intestine. Intestinal organoids, or enteroids, can help study the physiology and diversity behind
PDAC. Organoids are a form of 3D cell culture that provide a tractable method of studying cellular
interactions which are more representative of in vivo conditions than 2D cell cultures because they
replicate nutrition gradients and drug sensitivity like human organs.
Methods: Since they can be cultured by harvesting cells from adult tissues, embryonic, or induced
pluripotent cells, genetic variation across donors is preserved. By adding the proper growth factors, the
pluripotency of these cells can be preserved, and they can organize in 3D spheroid structures in a
basement membrane like material. Among the growth factors necessary are three proteins important to
preserving the stemness and proliferative nature of the cells: Noggin, Wnt 3A, and R-spondin. The lab
utilizes a L-WRN cell line which secretes these three proteins into their cell media. The media is then
collected, filter-sterilized, and supplemented with other growth factors necessary for enteroid growth.
Results: In order to determine that the cultured media from the L-WRN cells had sufficient levels of these
growth factors, we measured their concentration via an ELISA assay. The cultured media was found to
have sufficient levels of the three growth factors. These enteroids could be differentiated by omitting stem
cell inducing factors such as Wnt3a and R-spondin. Such differentiated enteroids had increased villi cell
density.
Conclusion: We found that the conditioned media from L-WRN cells provides sufficient levels of the
growth factors to maintain enteroids without variations between batches. Enteroids ability to be cultured in
a period of 5-7 days, while preserving the cell diversity and genetic alterations make them a good vector
for studying GI toxicity to therapies. Because cancer cases are diverse, this form of sampling provides a
safe way to test the impacts of therapies on a more personal and representative basis.
Keywords: Enteroids, L-WRN cells, Pancreatic Adenocarcinoma
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PDX USE IN CLINICAL TRIALS FOR TREATING COLORECTAL CANCER
Alexandra Deras Diaz, Gastroenterology Oncology, University of Texas MD Anderson Cancer Center
Scott Kopetz MD PHD, Gastroenterology Oncology, University of Texas MD Anderson Cancer Center
Preeti Marie Kanikarla PHD, Gastroenterology Oncology, University of Texas MD Anderson Cancer
Center
Melanie Wood, Gastroenterology Oncology, GSBS, The University of Texas MD Anderson Cancer Center
Maria Perez, Gastroenterology Oncology, The University of Texas MD Anderson Cancer Center
April Vallian, Gastroenterology Oncology, University of Texas MD Anderson Cancer Center
Patricia Jensen loewe, Gastroenterology Oncology, University of Texas MD Anderson Cancer Center
Background: Colorectal Cancer is the third most commonly diagnosed cancer in men and women
combined in the U.S. The second leading cause of cancer death in men and women combined in the U.S.
As the number of younger colorectal patients rises, a colonoscopy is now recommended at 45 instead of
50.
Methods: Clinical trials are a way for researchers to test new drugs or combinations of drugs more
effectively. A PDX model is tumor tissue taken from a patient and implanted into mice for research
purposes, to test Cancer drugs and other types of treatment to see how well they work before they are
given to the patient. Clinical Trial 2019-1016 is researching the best dose of LY3214996 WITH
CETUXIAMB alone or with ABEMACIABLB E for patients with colorectal cancer that cannot be removed
with surgery or has spread to other parts of the body. LY3214996/ AMEMACICILB may stop the growth of
tumor cells by blocking some enzymes needed for cell growth. Cetuximab is a monoclonal antibody that
may infer tumor cells’ ability to grow and spread. Blood and tissue samples with predictive markers
activity for immune effects for the treatments. Surgical implanted the tumor Subcutaneous into
immunocompromised mice, in matched patients with cetuximab refractory metastatic colorectal cancer.
The tumor was removed and expanded the tumor into more immunocompromised mouse. Molecular
profiling can be done on the tumor with PCR or western blots. Afterward, the tumor is expanded into more
mice to test the combination of mice with LY3214996 with CETUXIAMB alone or with ABEMACICLIB in
two different sets of mice to test for biomarker response and resistance in LY3214996 with CETUXIAMB
and LY3214996, CETUXIAMB, and abemaciclib.
Results: After testing on mice and if there is not much progression of the tumor and low toxicity, the trial
can move into patients. Patients are divided into 2 arms, both starting with dose escalation. The 1st arm
is Erk ½ inhibitor LY3214996 orally and cetuximab over 1-2 hrs. The 2nd arm is Erk ½ inhibitor
LY3214996 and cetuximab as in arm a and ABEMACILIB PO twice daily.
Conclusion: The PDX model is an effective way of treating patients with colorectal cancer as it somewhat
predicts the toxicity and its effectiveness. Protocol 2019-1016 is still ongoing therefore there are
currently no results but its primary outcome measure is overall response and best response
Keywords: Colorectal Cancer, PDX Model, Clinical Trials, Cetuxiamb,Abemaciable
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MALT1 Inhibitor as a Therapeutic for Sézary Syndrome
Jeffrey Mayo Jr, Dermatology, University of Texas MD Anderson Cancer Center
Xiaohong Wang, Dermatology, University of Texas MD Anderson Cancer Center
Loka R Velatooru, Dermatology, University of Texas MD Anderson Cancer Center
Madeleine Duvic, Dermatology, University of Texas MD Anderson Cancer Center,
Xiao Ni, Dermatology, University of Texas MD Anderson Cancer Center
Background: Therapeutic options for treating Sèzary Syndrome (SS), an aggressive cutaneous T-cell
lymphoma (CTCL), are currently limited. Thus, there is a critical need to develop enhanced treatment
strategies. Genomic profiling of SS patients has revealed activating mutations in CARD11, a mediator of
NF-κB activation through complex formation with BCL10 and MALT1. Selective inhibition of MALT1, a
proteolytically active component of the CARD11-BCL10-MALT1 (CBM) complex, has proven efficacious
in decreasing cell proliferation and inducing apoptosis in adult T-cell lymphoma and Diffuse Large B-Cell
lymphoma cell lines overexpressing CARD11. Our study aims to demonstrate MALT1 inhibitors as a
potential therapeutic for SS.
Methods: Immunoblotting was performed to assess expression levels of MALT1, BCL10, and/or CARD11
in four CTCL-derived cell lines (MJ, Myla, HH, and Hut78), CD4+ SS cells (n=5), and CD4+ T-cells from
healthy donors (n=3). Three MALT1 inhibitors - Mepazine, Thioridazine and MI-2) were used to treat
CTCL-derived cell lines at a series of concentrations (0.1, 0.5, 1.0, 5.0, and 10.0 µM). RealTime-Glo MT
Cell Viability Assay was used to assess the inhibitory effects by inhibitors on cell proliferation at 6 time
points (3, 6, 18, 24, 48, 72 hours).
Results: We were able to confirm that MALT1 and BCL10 expression was upregulated in CD4+ SS cells
compared to CD4+ T-cells from healthy donors. Of note, the levels of MALT1 and BCL10 proteins in
CD4+ SS cells were parallel to absolute SS cell counts in patients. Three proteins (CARD11, BCL10,
MALT1) in CBM complex were highly expressed in 4 CTCL-derived cell lines. Thioridazine and MI-2 had
more inhibitory effects on cell proliferation than Mepazine. HH cells were more sensitive to inhibitors than
MJ and Myla cells. Overall, the inhibitory effects of Thioridazine and MI-2 on CTCL-derived cell lines
showed a time and dose-dependent manner.
Conclusion: Our results suggest that Thioridazine and MI-2 decrease cell proliferation in CTCL cell lines.
More experiments are ongoing for dosages and mechanisms of action. Since thioridazine is well-tolerated
and FDA-approved for treating anxiety disorders, this project has the potential to be directly and swiftly
translated into the clinical setting.
Keywords: Sèzary Syndrome, CARD11, MALT1, NF-κB
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Exploring the Effects of Oncolytic Viruses on the NK Cell Killing of Solid Tumors
Oluwatosin Banjo, Biochemistry and Biological Sciences, Wellesley College
Xin Ru Jiang, Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer
Center
Katy Rezvani, MD, PhD, Stem Cell Transplantation and Cellular Therapy, University of Texas MD
Anderson Cancer Center
Background: Natural killer (NK) cells are integral components of the innate immune system which
recognize and lyse virally infected cells and tumor cells. However, NK cell therapy is currently mostly
being used to treat liquid tumors. This is because solid tumors exhibit severe tumor hypoxia and maintain
a suppressive tumor microenvironment (TME) through the secretion of NK sensitive-inhibitory cytokines,
for example, TGF-. TGF- is an immunosuppressive cytokine released into the tumor microenvironment
and generally functions to inhibit inflammatory immune cells including NK cells from killing a tumor.
Additionally, these tumors do not express many of the activating ligands that NK cells use to immediately
recognize and kill these malignant cells, allowing them to hide in the body. Ultimately, this presents
challenges for NK cell therapy development for some of the most aggressive cancers in the body,
including glioblastoma (GBM) and pancreatic ductal adenocarcinoma (PDAC). Oncolytic viruses are
genetically-engineered viruses to specifically target and infect tumor cells rather than normal cells. This
includes the ‘oncolytic-Herpes Simplex Virus (oHSV)’ and ‘Delta-24-RGD (Adenovirus).’ Due to NK cells’
ability to recognize virally infected cells, we hypothesize that the infection of solid tumor cells with
oncolytic viruses will increase NK anti-tumor lysis. In addition, the virus is a pathogen that can induce a
local inflammation at the tumor site which can reverse the inhibitory nature of the TME to help NK
infiltration and killing of the tumor.
Methods: In this study, we use xCelligence and Incucyte to monitor GBM and PDAC viability over time
after the infection of the tumor cells with oHSV/delta24RGD and the addition of NK cells. Next, we explore
the mechanism behind the virus-induced enhancement in NK killing through a preexposure assay. We
use magnetic bead isolation to purify NK cells from coincubation with infected tumor cells and expose
them to fresh tumors to observe the effects on NK cytotoxicity. Finally, we investigate the mechanism
behind the enhanced cytotoxicity of dual knockout NK cells (knockout TGF- and glucocorticoid receptor),
in combination with virally pretreated tumor cells. We pretreat NK cells with TGF- prior to tumor exposure
and perform a TGF- titer assay in order to optimize this experiment.
Results: Overall, we find that oncolytic viruses enhance the NK cell killing response of solid tumors.
Additionally, NK cell preexposure to infected tumors elicits a hyperactivation or memory-like behavior of
these immune cells. Finally, we find that the dual knockout receptor of TGF- increases the probability of
survival in vivo.
Conclusion: N/A
Keywords: NK Cell, Oncolytic virus, TGF-, Glioblastoma, Pancreatic Ductal Adenocarcinoma
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Epigenetic Regulator, KDM4C, is Overexpressed in Pancreatic Cancer
Ernesto Flores, Pathology, University of Texas MD Anderson Cancer Center
MennatAllah Shaheen, Pathology, University of Texas MD Anderson Cancer Center
Sarah Dhebat, Pathology, University of Texas MD Anderson Cancer Center
Bidyut Ghosh, Pathology, University of Texas MD Anderson Cancer Center,
Anirban Maitra, Pathology, University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer is one of the deadliest types of cancer as it has no early signs and
spreads rapidly to surrounding organs. Pancreatic cancer begins as a non-invasive ductal lesion and
progresses into an invasive pancreatic ductal adenocarcinoma (PDAC) which accounts for 95% of
pancreatic cancer cases. KDM4C is an epigenetic regulator that removes methyl groups from methylated
lysines in heterochromatin which leads to an open chromatin structure that allows gene expression to
occur. KDM4C is overexpressed in brain, lung, and breast cancers. However, KDM4C has not been
previously studied in pancreatic cancer. Therefore, we are investigating the role that KDM4C expression
plays in PDAC progression.
Methods: Normal and pancreatic cancer tissue samples were collected from mice and stained using
immunohistochemistry. Using immunohistochemistry aid in comparing the presence of KDM4C in normal
versus pancreatic cancer samples. A cell proliferation assay and colony formation assay were performed
using PDAC cell lines and two different KDM4C knockout clones. Finally, normal and pancreatic cancer
mice samples were collected and western blotted to assess the presence of KDM4C
Results: Immunohistochemistry staining showed that the pancreatic cancer tissue samples had higher
levels of KDM4C than the normal pancreas tissue samples. The western blots showed that KDM4C was
present in the pancreatic cancer cell lines but not in the knockout cell lines. The cell proliferation and
colony formation assays showed that in the presence of KDM4C, cells reproduced at a higher rate than in
the knockout cell lines.
Conclusion: KDM4C was found to be overexpressed in pancreatic cancer in mice and human samples.
KDM4C also played a role in cell proliferation. As a result, the connection between histone demethylases
and tumorigenesis is further strengthened. There is potential for histone demethylases to be used as
therapeutic agents and in cancer therapies.
Keywords: pancreatic cancer, KDM4C, over expression, PDAC
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Creation and Characterization of Patient Derived Xenograft Animal Model of Chromophobe Renal
Cell Carcinoma
Oscar Ochoa, PCCSM: Urology, The University of Texas MD Anderson Cancer Center
Carolyn De La Cerda, Urology, The University of Texas MD Anderson Cancer Center
Tapati Maity, Urology, The University of Texas MD Anderson Cancer Center
Priya Rao, Translational molecular pathology, The University of Texas MD Anderson Cancer Center,
Jose Karam, Urology, The University of Texas MD Anderson Cancer Center
Paylos Msaouel, genitourinary medical oncology, The University of Texas MD Anderson Cancer Center
Niki Zacharias Millward, Urology, The University of Texas MD Anderson Cancer Center
Background: Chromophobe renal cell carcinoma is a rare type of cancer that arises from the intercalated
cells of the kidney’s collecting duct and makes up 5% of all total RCCs. Due to the infrequent incidences,
treatment usually comes from other types of RCC, such as the clear-cell subset. CHRCC is unique due to
its association with aneuploidy and elevated mitochondrial pathways. While studies are still in very early
stages, exploitation of this unique metabolic nature could lead to new treatments of CHRCC.
Methods: Chromophobe Renal Cell Carcinoma PDX Animal model:
Resected CHRCC tumors were
implanted subcutaneously into Fox Chase mice. Two tumors were each placed into 5 different mice.
Once the tumors reached an approximate size of 1500 mm3, they were harvested. The tumors were
collected for analysis and passaged onto the next group of mice.
Results: Short tandem repeat fingerprinting was used to compare the original CHRCC patient tissue to
the PDX tissue. The results indicated below demonstrate very similar morphological and genetic
composition of the original tissue and two passages.
Conclusion: A CHRCC PDX animal model was generated. As of June 2022, the animal model is on
passage 4. STR fingerprinting was used to determine that the PDX tumors and original patient tumors
were still morphologically and genetically similar after multiple passages. The creation of the animal
model is a substantial development in the process of creating a unique treatment for CHRCC. While still
in early stages, the animal model could potentially be used to test any new treatments and their safety on
a continuous supply of tissue before moving on to human testing.
Keywords: Chromophobe Renal Cell Carcinoma, OXPHOS, Passage, Patient-Derived Xenograft
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Glycosylated Collagen Interaction with Cells Through DDRs and Integrin
Emma Burris, Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer
Center
Shike Wang, Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer
Center
Hou-Fu Guo, College of Medicine, University of Kentucky
Jonathan M Kurie, Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer
Center
Background: Discoidin domain receptors (DDR1 and DDR2) and Integrin Beta receptors bind to collagen
in the extracellular matrix (ECM) to function as pathways for cells to communicate and adhere to the
surrounding cells and environment. In cancers when DDRs and Integrin beta are dysregulated or
mutated, cell proliferation and migration increases. Collagen inside the ECM is post translationally
modified by an enzyme called Galactosylhydroxylysyl Glucosyltransferase (GGT) which glycosylates
Collagen. It has been found that there are higher levels of glycosylated collagen in cancer tissue
compared to normal tissues. In this experiment, we focused on adhesion of DDRs and Integrin Beta to
collagen when collagen was deglycosylated and glycosylated to determine if these receptors were
collagen glycosylated dependent.
Methods: We created 344SQ cells containing knocked down DDR1, DDR2 and Integrin Beta receptors
through viral transfection. We then used collagen 4 to conduct adhesion experiments. In our experiment,
the control group was left untreated (without PGGHG), and the experimental group was treated with
PGGHG which deglycosylated the collagen.
Results: To ensure our knock down efficiency in our cells worked, we ran a western blot and determined
that the receptors in our cells were knocked down. From this experiment, we saw no significance in
collagen 4 adhesion ability of the 344SQ cells when the cells were knocked down with DDR1, DDR2 or
Integrin beta. We did see significance (**) in adhesion with our control cells that contained our receptors.
Conclusion: Our experimental results show that the receptors we are studying interact with glycosylated
collagen, however, it appears that our results dismiss the idea that collagen glycosylation does not affect
the DDRs and integrin beta receptors binding ability. This ultimately opposes our hypothesis that these
receptors are dependent on glycosylated collagen to adhere. Our goal now is to determine if any
receptors in the 344SQ cell line are collagen glycosylated dependent for adhesion. We also want to
research more about the DDRs and Integrin Beta receptors to better understand how they work and if
they are dependent on other variables to adhere effectively.
Keywords: Glycosylated, Collagen, Receptors, Adhesion
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Developing an IF panel to examine Cyclin and CDK interactions in a Pancreatic Adenocarcinoma
Patient Derived Xenograph
Nathalie Garza, Partnership for Careers in Cancer Science and Medicine, University of Texas MD
Anderson Cancer Center
Ethan Marszalek, Summer Internship, TRACTION, University of Texas MD Anderson Cancer Center
Alyssa Machado, Summer Internship, TRACTION, University of Texas MD Anderson Cancer Center
Brooke Meyers, TRACTION, University of Texas MD Anderson Cancer Center,
Annette Machado, TRACTION, University of Texas MD Anderson Cancer Center
Background: Cyclins coordinate cell division by binding to their associated cdks and maintaining genomic
integrity by tightly controlling these processes. In cancer, cellular proliferation becomes dysregulated,
implicating both cyclins and cdks. Complexes of therapeutic interest are Cyclin E1 (CCNE1) and CDK2,
which complexes during late G1/S phase, and Cyclin A2 (CCNA2) and CDK1/2, which are essential for Sphase progression. Inhibition of specific complexes is thought to be a therapeutic tool to cancer patients
due to their role in cell proliferation and regulating cell cycle checkpoints and response signals. To
evaluate the co-expression of CDK1&2 and their Cyclin counterparts, a multiplex panel was developed
and tested on a Pancreatic ductal adenocarcinoma (PDAC) model.
Methods: Antibody validation was performed by creating positive and negative controls using siRNA
knockdown of the gene of interest. Briefly, HCT116 cells were seeded at optimal density and transfected
with 50nM of siRNA targeting gene using DharmaFect reagents. Cyclin A2 protein was induced by
treating cells with aphidicolin at 10uM for 16hrs, 30uM for 4 hours, and released for 4 hours. Cells were
collected 72 hours later for knock down validation. Cytoblocks were generated and then used for antibody
validation in multiple staining protocols such as IHC (immunohistochemistry), Opal IF, and Opal Multiplex
panel. The optimized multiplex panel was used to stain a PDAC PDX model. Slides were imaged using
Vectra Polaris and co-expression analyzed using Indica Halo software.
Results: Western blots showed successful CCNA2 knockdown. In HCT116 cells, optimized conditions
and overexpression of treated cells were observed. Cytoblocks of these transfected and treated cells
showed appropriate IHC staining patterns with NTC (wild-type) showing low basal expression, siCCNA2
KD lacking expression and treated cell showing overexpression. Multiplex panel of Cyclin CDKs was
developed. The expression and co-expression of Cyclins A2, E1 and CDK1 &2 in a PDAC PDX model
was analyzed. Analysis showed that CDK levels were high (45% CDK1 vs 60% CDK2) and more Cyclin
E1 expression. Further subcellular analysis discovered CDK1 was mostly located in the cytoplasm along
with Cyclin A2, while CDK2 and Cyclin E1 was mostly nuclear.
Conclusion: Targeting certain entities regulating the cell cycle could be a valuable therapeutic tool used in
cancer cell growth prevention and research. Multiplex immunostaining can elucidate cdk complexes and
could be utilized to understand mechanism of response as well as inform on biomarkers for CDK
inhibitors.
Keywords: Cell cycle, Cyclin-CDK complexes, PDAC/PDX model, Multiplex IF Panel
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Barriers to Cervical Cancer Screening for Hispanic/Latinx Women in the Harris Health Safety Net
System
Domenica Gomez, Epidemiology and Faculty Diversity, Equity and Inclusion, University of Texas MD
Anderson Cancer Center
Susan L. Parker, Outreach and Health Disparities, Baylor College of Medicine
Trisha L. Amboree, Epidemiology and Population Health, Baylor College of Medicine
Jane R. Montealegre, Outreach and Health Disparities, Baylor College of Medicine
Elizabeth Y. Chiao, Epidemiology, University of Texas MD Anderson Cancer Center
Background: Cervical cancer screening in the U.S. involves Pap smears and testing for Human
Papillomavirus (HPV), yet Harris County is in the worst 25% of US counties for cervical cancer incidence.
Previous studies have found that Latina women have the highest risk for cervical cancer incidence but are
the least likely to seek screening (Gauss et al., 2013), so the PRESTIS (Prospective Evaluation of SelfTesting to Increase Screening) Trial sends HPV self-sampling kits to eligible and randomized Harris
Health patients. This study investigates whether primary language, English or Spanish, and birthplace
affect cervical cancer screening barriers for Latinx women in the Harris Health system and what solutions
can be implemented to overcome these.
Methods: After PRESTIS mailed self-testing kits, 143 telephone surveys were conducted in English or
Spanish to inquire about experiences with the kit and their healthcare in general. We assessed five
common screening barriers: discomfort, embarrassment, uncomfortable with a male provider, difficulty
getting appointments, and fear of finding out they have cancer. We utilized chi square statistical tests to
evaluate differences between participant groups and constructed cross tabulations for analysis; SAS
Version 9.4 was used for the analyses. We compared barriers to participant’s primary language, whether
they were born in the United States or elsewhere, and to birthplaces: Mexico or Central and South
America.
Results: Among the 143 Hispanic women, 64.2% of Spanish speakers agreed that pap tests are
embarrassing compared to 39.1% of English speakers (P = 0.03). Likewise, 70.0% of Spanish speakers
stated that they would feel uncomfortable with a male provider administering the pap test compared to
47.8% of English speakers (P = 0.05). Birthplace did not have significant effects on their answers for any
of the barriers.
Conclusion: A language barrier could have caused the significant differences in responses for
embarrassment and discomfort with male providers, indicating why more Spanish speakers agreed with
these two reasons than English speakers. Further understanding of the mechanisms causing differences
in cervical cancer screening by primary language should be prioritized. Because birthplace did not affect
participant’s responses, Latinx women may experience similar barriers to pap testing; analogous steps
can be taken to address these issues. Educational programs must be developed for Spanish medical
translators to help ease patient apprehensions about screening.
Keywords: Cervical Cancer, Screening Barriers, Hispanic Women, HPV
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Targeted Combination Therapy Improves Erdafitinib Efficacy in Urothelial Cancer
Omotola Ogundipe, Department of Pharmaceutical Sciences, Howard University
Mohamad Koleilat, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Lawrence Kwong, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Background: Fibroblast growth factor receptor (FGFR)-3 aberrations occur frequently in urothelial cancer.
These aberrations lead to oncogenic signaling through the MAPK and PI3K pathways, but also confer
sensitivity to FGFR inhibitors. Erdafitinib (Erda) is a pan-FGFR inhibitor that is only currently approved for
targeted therapy in advanced urothelial cancer. The efficacy of erdafitinib is short-lived as patients
develop resistance within six months of treatment emphasizing the need for effective combinatorial
approaches to further enhance outcomes in this disease subtype. The overall goal of the project is to
identify modifiers of erdafitinib sensitivity in FGFR3-mutated urothelial cancer and improve erdafitinib
response rate using combinational approaches. Our previous genome-scale knockout CRISPR/Cas9
screen identified CCNC/CDK8, IGF-1R/MAPK, PTPN11/SHP2 inhibitors as synthetic lethality candidates
with erdafitinib. The objective of this study is to validate synergism between erdafitinib and Sel120 (a
CDK8 inhibitor) or SHP099 (a SHP2 inhibitor) in an erdafitinib-sensitive cancer cell line.
Methods: UC14 (FGFR3 S249C) cells were seeded in a 12-well plate at a density of 12000 cells/well.
After 24h, the cells were treated with DMSO, Erda 1uM, Sel120 1uM, SHP099 10uM, Erda 1uM
+Sel1201uM, and Erda1uM +SHP2i 10uM. Each treatment condition was duplicated. After 1 week, the
cells were fixed with cold methanol and stained with propidium iodide supplemented with RNAse A for
capturing in an Incucyte machine. Growth inhibition by each treatment was calculated. Synergism for
Erda + Sel120/SHP099 was measured by dividing the growth inhibition value of combination by that
obtained for each single agent. A value < 0.7 was considered synergistic. Lysates from drug-treated
UC14 cells at 2h, 8h and 24h were blotted for pAKT, total AKT, pERK, total ERK, and GAPDH
expression. Also, RNA sequencing data previously obtained for Erda- and Sel120- treated UC14 cells
were analyzed for gene enrichment using GSEA4.2.3 software. The molecular signature database
selected was C6 collection: oncogenic signature gene set, and p<0.05 was set as the threshold for
screening significantly enriched pathways.
Results: Growth inhibition by Erda+SHP099 / Sel120 > Erda >>> SHP2i > Sel120 > DMSO, and the coinhibition of CCNC/CDK8 or SHP2 shows a synergistic effect with erdafitinib. GSEA also reveals that
Erda (1uM) as a single agent does not significantly suppress FGFR signaling (p-values = 0.06 and 0.14,
respectively, for Erda+Sel120 normalized by Sel120 and Erda alone). Sel120 does not synergize with
Erda due to combined suppression of the MAPK pathway. Its addition to Erda did not further suppress
phosphorylated ERK or AKT. When Erda+Sel120 was normalized by Erda, keratin filament genes were
up-regulated (ES=0.80; nominal p-val=0.00; FDR q-val=0.07) while Hippo signaling was down-regulated
(ES= -0.68; p-val=0.00; FDR q-val=0.33).
Conclusion: The study shows that Sel120 synergizes with erdafitinib possibly via hippo signaling pathway
down-regulation. A future study that involves a drug assay for Erda/Sel120 following genetic knock-out of
keratin filament genes and over-expression of hippo signaling genes in UC14 cells will provide valuable
insights on the mechanism by which synergism occurs.
Keywords: Erdafitinib, Synergism, Urothelial cancer, Sel120
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APR-246 induces ferroptosis and overcomes cisplatin resistance in ovarian cancer.
Ana Hernandez, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Codi Mai, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Shady Tantawy, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Zahid Siddik, Experimental Therapeutics, University of Texas MD Anderson Cancer Center,
Varsha Gandhi, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Background: Ovarian cancer is the fifth deadliest cancer in women and is predicted to cause nearly
13,000 deaths in the United States in 2022. Ninety-six percent of high-grade serious ovarian cancers
express mutations in p53 which is associated with more aggressive disease while 15-30% of patients
develop resistance to platinating agents. APR-246, a thiol reactive compound, has been used in several
clinical trials for solid tumor malignancies (NCT 04383938) due to its ability to restore mutant p53
function. Recently, it was shown that it also targets Thioredoxin-1 and GSH deficiency, thus inducing
oxidative stress. Here we report that APR-246 targets ovarian cancer cell line A2780 for ferroptosis, an
iron dependent cell death, independently of p53 status and can overcome cell resistance to cisplatin
therapy.
Methods: We used isogenic A2780 cell lines (WT and p53 knockout) to test for the role of p53 as well as
A2780 Parental and Cisplatin-resistant cell lines to test APR-246’s ability to overcome cisplatin
resistance. Cell viability was assessed using double negative Annexin-PI by flowcytometry. Assessment
of cellular ROS was accomplished using CellROX Deep Red Reagent and lipid peroxidation was detected
using C11-Bodipy by flowcytometry. GSH concentration was assessed using a 96-well plate luminometer.
Cells were plated and attached overnight prior to drug incubation according to experimental setup and
subsequent extraction with 0.25% trypsin.
Results: APR-246 induced apoptosis independently of the p53 status. APR-246 also induced GSH
deficiency associated with increased cellular ROS and lipid peroxidation. The use of antioxidants (e.g.,
GSH/catalase) or anti-lipid peroxidation (liproxstatin/ferrostatin) rescued cell death, indicating a possible
role for ferroptosis. Interestingly, APR-246 synergistically augmented cell death when combined with
cisplatin (causing a 75% decrease in IC50) and overcame resistance to cisplatin in A2780 cisplatinresistant cell line.
Conclusion: Ultimately, the GSH deficiency induced by APR-246 is associated with ferroptosis in the
ovarian cancer cell line A2780 as evidenced by increased lipid peroxidation and oxidative stress, which is
rescued by ferroptosis inhibitors and antioxidants, respectively. Catalase, specifically, can rescue
ferroptosis by mitigating the oxidative stress necessary for lipid peroxidation which is induced by APR246. The combined effect of APR-246 and cisplatin on cell death in the A2780 parental cell line is
synergistic while overcoming cisplatin resistance in the resistant cell line.
Keywords: Ovarian cancer, APR-246, glutathione deficiency, ferroptosis, cisplatin resistance
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Abstract Number: 91

Role of Wilms' Tumor 1 in Sex Development
Jasmine L. Terrell, Biology, Howard University
Jace A. Aloway, Genetics, University of Texas MD Anderson Cancer Center
Cristy Ruteshouser, Genetics, University of Texas MD Anderson Cancer Center
Vicki Huff, Genetics, University of Texas MD Anderson Cancer Center,
Richard R. Behringer, Genetics, University of Texas MD Anderson Cancer Center
Background: During the development of male and female embryos, both individuals develop two pairs of
epithelial ducts (the Wolffian and Müllerian ducts). The Wolffian duct differentiates into the male-specific
sex organs, the epididymis, seminal vesicles, and vas deferens. The Müllerian duct differentiates into the
female-specific sex organs, the uterus, oviduct, cervix, and upper portion of the vagina. In males, the
Müllerian duct will be eliminated by the presence of anti-Müllerian hormone (AMH) which is produced in
the testis, and the Wolffian duct will differentiate into the male reproductive tract. AMH is able to signal to
its receptor, AMHR2, which is found in the Müllerian duct mesenchyme. Mutations in Amhr2 can lead to
persistent Müllerian duct syndrome in which males have both male and female reproductive tracts.
Previous data shows that Wilms’ Tumor 1 or WT1 is coexpressed with Amhr2 in the MD mesenchyme
prior to and during regression. Our goal is to answer the question “Is the expression of Wt1 in the
Müllerian duct mesenchyme necessary for the regression of the Müllerian duct?”.
Methods: We use a tissue-specific CRE recombinase to interrupt Wt1 signaling in the MD mesenchyme to
prevent expression of Amhr2 prior to regression of the Müllerian duct in male mice. If WT1 is a required
activator of Amhr2, this should result in a male mouse with a retained uterus. Furthermore, we use
histology, microscopy, and fluorescent imaging to analyze our data.
Results: Based on our histology data, when compared to the control uterus and vas deferens, the Wt1
knockout mouse has both the vas deferens and uterus positioned next to each other. Fluorescent imaging
reveals the presence of Wt1 in the uterus of both the female and male reproductive tracts.
This data supports our hypothesis that the Wt1 knockout mice will have both male and female
reproductive tracts. Future directions include using qPCR to confirm normal AMH levels in the testes, and
decreased Amhr2 levels in the Müllerian duct mesenchyme after the knockout of Wt1.
Keywords: Sex development, anti-Müllerian hormone, sex differentiation
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GeoMx digital spatial profiling (DSP) as an important tool to study immune landscape of tumors
Natalia Alaniz, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Sharia Hernandez, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Wei Lu, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Khaja Khan, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center,
Larisa V Kostousov, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Sean W Barnes, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Mei Jiang, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Ignacio I Wistuba, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Luisa M Solis, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Mario L Marques-Piubelli, Translational Molecular Pathology, University of Texas MD Anderson Cancer
Center
Background: Immunoprofiling has become highly significant in order to understand in depth the immune
microenvironment of tumors and their spatial relationships. NanoString GeoMx DSP is a new high-plex
technology that allows the assessment of multiple proteins or RNA in a single slide, promoting the
identification of targetable biomarkers in both tumor and microenvironment. We aim to describe the
standard technical overview of the protein panel of this assay in normal tonsil tissue.
Methods: We used a 4μm FFPE section of a reactive tonsil to run a Human Immuno-Oncology Protein
Panel (24 antibodies) in GeoMx DSP assay. In the first day, we perform the tissue and reagents
preparation, followed by washing, staining, scanning, and region of interest (ROI) selection in the second
day. Indexing oligos were released by the Sequential UV light exposure of each ROI were and quantified
on NanoString's nCounter system. The data was exported and analyzed. Heat maps and box plots were
used to visualize the different levels of protein expression.
Results: A total of 9 regions of interest were selected, passed by quality control, and analyzed. After the
normalization using the signal background ratio, fifteen biomarkers showed median counts higher than
one. Among them, we analyzed the different distribution in tonsil compartments of Pancytokeratin, CD3,
CD4, CD20, CD45, CD68, Granzyme B, and Ki-67. The germinal center areas were characterized by the
high expression of CD20 and Ki-67, while the interfollicular areas showed a high concentration of T-cell
markers, such as CD3, CD4, and Granzyme B. The macrophage marker CD68 had a slightly higher
concentration in germinal centers and there was no difference between the concentrations of the panimmune marker CD45 between germinal center and interfollicular areas.
Conclusion: An adequate protein distribution pattern for typically expressed markers were seen in
different compartments of a normal tonsil. GeoMx DSP is a robust and promising high-plex technology for
the study of spatial protein immune landscape and can represent a great tool for translational cancer
research.
Keywords: immunoprofiling; DSP GeoMx; protein; tumor microenvironment
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Characterizing Novel Kras/p53 Derived NSCLC Cell Lines
Quincyn Perry, Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer
Center
Jared Fradette, Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer
Center
Don L. Gibbons, Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer
Center
Background: Lung Cancer metastasizes by way of epithelial to mesenchymal transition (EMT). Lung
cancer can exhibit a range of epithelial and mesenchymal characteristics. Epithelial cells have polarity
and tight cell junctions. Mesenchymal cells lack polarity and are more invasive. The lab has previously
derived a panel of cell lines from the genetically engineered mouse KrasG12D/+; p53R172H∆G/+(KP∆G):
393P and 344SQ. These cell lines were thoroughly characterized, and it was found that 393P is relatively
epithelial and 344SQ is relatively mesenchymal (Don Gibbons, 2009). More recently, the lab has derived
a new panel of cell lines from KrasG12D/+; p53R172H/R172H(KPMUT) mice: 7064P, 7362P, and 7578P.
This project aims to characterize the novel cell lines on a scale of epithelial to mesenchymal using the
known 393P and 344SQ cell lines as standards.
Methods: Brightfield images taken with a microscope to show the morphology at 10x and 20x. qPCR of
known epithelial and mesenchymal markers was performed, data was normalized, and relative
expression plotted with significance being determined by Student’s t-test in PrismGraphPad. Western blot
of epithelial and mesenchymal markers was performed, and images were taken on the BioRad Chemidoc
using chemiluminescence. Migration assay of the five cell lines was performed by first seeding cells in
triplicate into transwell chambers with serum-free media, and the chambers were placed in wells with
complete FBS media. The cells were allowed to migrate for 16 hours. After which, the cells were fixed and
stained in crystal violet for 24 hours. Five fields were captured per chamber and cells quantified using
ImageJ.
Results: Morphologically, 393P and 7578P form tight clusters, while 344SQ, 7064P, and 7362P do not.
Moreover, 344SQ, 7064P, and 7362P exhibit protrusions indicative of a mesenchymal nature. At the
transcription level the data was inconclusive for the markers looked at; the cell lines showed both over
and under expression for epithelial and mesenchymal markers. Functionally, we see different results at
the protein level, but cells still seem to have contradictory pathways. Looking at the migration images, all
of the cell lines have the capability to mount a migration.
Conclusion: The data suggests that the novel cell lines are more mesenchymal than 393P and more
epithelial than 344SQ. The novel cell lines still lay within the two extremes of the control.
Keywords: NSCLC, Kras, p53, EMT
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The two faces of CD73 in tumor-infiltrating lymphocytes expanded from liposarcoma
Rebeca Rodriguez, Biochemistry, Wellesley College
Jacqueline Oliva Ramirez, TMP-IL, Translational Molecular Pathology, University of Texas MD Anderson
Cancer Center
Carlos Ramos, TMP-IL, Translational Molecular Pathology, University of Texas MD Anderson Cancer
Center
Younghee Lee, TMP-IL, Translational Molecular Pathology, University of Texas MD Anderson Cancer
Center,
Katarzyna Tomczak, TMP-IL, Translational Molecular Pathology, University of Texas MD Anderson
Cancer Center
Davis Ingram, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center
John Livingston, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center
Joseph Ludwig, Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center
Neeta Somaiah, Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer
Center
Cara Haymaker, TMP-IL, Translational Molecular Pathology, University of Texas MD Anderson Cancer
Center
Background: Adoptive cell transfer using tumor-infiltrating lymphocytes (TIL) has shown clinical benefits in
metastatic melanoma as well as other solid tumor types [1]. Liposarcoma is a soft tissue sarcoma with
less than 40% TIL expansion success rate without selection methods and a 60% success rate with
selection based on at least 300 events of CD3+ T cells detected in the fresh tumor sample using flow
cytometry. Previous studies in renal cancer carcinoma indicated that presence of CD73 is correlated with
poor patient prognosis and immunosuppression in the tumor microenvironment (TME) [3]. We
hypothesized that higher expression of adenosine pathway-associated markers, such as CD73, would
result in a paucity of immune infiltration including TIL, and therefore influence TIL expansion success.
Methods: TIL expansion was attempted using the ‘TIL 3.0 MDACC method’ from a total of 18 surgically
resected liposarcoma cases [3]. Briefly, five 1-3 mm3 pieces were plated in a G-rex with media containing
OKT3 (anti-CD3), agonistic anti-41BB, and IL-2. Every 3-4 days, media with IL-2 was refreshed. After 21
days, the cells are harvested and counted. Expanding (E) was defined as 40 x 106 TIL expanded based
upon thresholds needed for clinical REP and treatment. Phenotypic analyses of the TIL populations prior
to expansion were performed using flow cytometry. Statistical analysis was performed in GraphPad Prism
(two means t-test Mann-Whitney).
Results: We first observed no significant differences of total immune infiltrate or lymphocyte subtype
(CD45+, CD3+, CD8+, and CD4+) populations by percentage between expanded (E) and non-expanded
(NE) liposarcoma TIL. Interestingly, CD8+ cells showed significantly higher CD73 expression (p=0.0441)
in the expanded TIL group. No other lymphocyte subtype showed this higher expression of CD73.
Additionally, there was no significant difference in CD73 expression on tumoral cells (CD45-) across
groups. Expanded TIL also had significantly higher Lag3 (p=0.0443) expression in CD4+ cells but not in
CD8+ cells. All the other explored molecules, including PD-1 and 41BB, showed no significant
differences.
Conclusion: Immune cell subtype populations by percent do not affect TIL expansion. Conversely to
previous studies, we demonstrated that expression of CD73 in the TME or on tumoral cells (CD45-) may
not affect the expansion of TIL in liposarcoma and potentially promotes CD8+ T cell proliferation
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indicating that CD73 is not completely an immunosuppressive molecule. Lastly, higher Lag3 in CD4+ in
the expanded samples indicates that Lag3 is not behaving as a marker of T cell exhaustion as seen in
previous studies [4]
Keywords: Tumor Infiltrating Lymphocytes, Immunology, Liposarcoma, CD73, Cell Proliferation
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Abstract Number: 96

Evaluation of newly generated LRP1 antibodies in different cell types: THP1 cancer cell line,
human and mouse immune cells
Scott Semelsberger, Hematopoietic Biology and Malignancy, Indiana University of Pennsylvania
Olga Sizova, Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center
Dan Li, Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center
Qing Ma, Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center,
Lisa St. John, Hematopoietic Biology and Malignancy,
Gheath Al-Atrash, Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer
Center
Jeffrey Molldrem, Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer
Center
Background: Increased knowledge surrounding the biology of T-cell activation and proliferation has
enabled immunotherapy to combat various deadly diseases, such as cancer. Revealing the key
molecules that play vital roles in T-cell proliferation is imperative for the development of new anti-cancer
treatments and therapeutics. Dr. Molldrem’s lab is focusing on ubiquitously expressed molecule - Low
Density Lipoprotein-related protein 1 (LRP1), that has been only recently identified as a novel modulator
of T-cell proliferation. In the lab’s previous findings, LRP1 has been shown to play a direct role in T-cell
proliferation as neutrophil mediated inhibition of PBMCs (human peripheral blood mononuclear cells) was
partially rescued via commercially available anti human LRP1 antibody. To further study the function of
LRP1 in T-cell biology, the lab created a knockout LRP1 T-cell mouse model, where LRP1 is deleted
specifically in T-cells only. To validate this model, as well as study the LRP1’s role in mouse T-cells in
wild-type mice a reliable LRP1 antibody is required. However, there are zero commercially available
LRP1-targeting antibodies that bind well to both human and mouse. There is a critical need in producing
of an effective blocking antibody to study the potential functions of LRP1 in T-cell biology both in vitro and
in vivo.
Methods: Our lab generated six different antibody clones against human LRP1. The goal of the project is
to test each clone’s ability to bind to both mouse and human immune cells utilizing Flow Cytometry
method.
Results: Preliminary data shows there is significant binding in human monocytes compared with T-cells.
On the other hand, flow cytometry revealed strong binding in mouse T-cells, monocytes, and neutrophils.
Specifically, clones 1F7-1, 2A7-1, and 19D4-1 showed consistent binding in THP1 human monocytic
cancer cell line, human healthy donor -derived monocytes, and mouse splenocytes.
Conclusion: An effective blocking antibody is needed to study the potential functions of LRP1 in T-cell
biology in vitro and in vivo. In this experiment, three newly generated LRP1 antibodies showed significant
binding in both human and mouse immune cells. The next steps of this project include determining which
antibody has the strongest binding affinity to mouse and human LRP1, directly conjugate the antibody
with fluorochrome to exclude using a secondary antibody, activate human T-cells to increase LRP1
surface expression and examine binding, and to validate LRP1 KO mouse T-cells model (negative
control) with the chosen LRP1 antibody clones.
Keywords: Cancer Immunology, LRP1, Antibody, Flow Cytometry
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p0071-catenin may modulate dendrite morphology in a phospho-dependent manner
Emily Irikannu, Genetics, University of Texas MD Anderson Cancer Center
Maxsam Donta, Genetics, University of Texas MD Anderson Cancer Center
Yogesh Srivastava, Genetics, University of Texas MD Anderson Cancer Center
Pierre McCrea, Genetics, University of Texas MD Anderson Cancer Center,
Background: Dendrite morphology is crucial for healthy neuron function, and abnormal morphology is
associated with many diseases. Delta-catenin modulates dendrite morphology in a phospho-dependent
manner. Phosphorylated -catenin binds to Pdlim5, promoting dendritic branching, while unphosphorylated
-catenin binds to Magi1, promoting dendritic elongation. p0071-catenin is in the same subfamily as δcatenin, and they share a similar PDZ-binding motif to bind Magi1 and Pdlim5. Thus, we hypothesize that
p0071-catenin will bind Magi1 and Pdlim5 in a phosphor-dependent manner to modulate dendrite
morphology like δ-catenin.
Methods: The ability of p0071-catenin to bind Magi1 and Pdlim5 was assessed via coimmunoprecipitation experiments in HEK 293 cells, then imaged via western blot. Morphological effects of
p0071-catenin phosphorylation were assessed by transfecting phospho-mimetic and phospho-null
mutants into primary rat hippocampal neurons. Dendrite length and branching were quantified dendrite
morphology via Imaris.
Results: p0071-catenin was found to bind Magi1 and Pdlim5 via co-immunoprecipitation. Overexpressing
phospho-mimetic and phospho-null p0071-catenin in neurons increased dendritic length, and
overexpressing phospho-mimetic p0071-catenin in neurons increased dendritic branching.
Conclusion: While changing the phosphorylation state of p0071-catenin affects dendritic branching as
expected, phosphorylated p0071-catenin was not expected to increase dendritic length. This could be
caused by other potential binding partners interacting with p0071-catenin while phosphorylated, which
would differentiate it from delta-catenin. Future studies will include co-immunoprecipitations and
relocalization assays to determine if p0071-catenin binds Magi1 and Pdlim5 in a phospho-dependent
manner.
Keywords: neurons, dendrite morphology, catenin
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Pancreatic Cancer: Looking at the Immunosuppressive Nature of PC (Pancreatic Cancer) in
Relation to CD-8+ T Cell Expression and PD-L1 Expression Levels in Murine Tissue Models
Sarai Garcia, Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center
Background: Pancreatic cancer has rapidly become one of the deadliest cancers worldwide. With overall
survival rates and disease-free survival rates improving only minimally over the past 40 years,
researchers have turned to cancer immunotherapy for answers. One of the key defining features of
pancreatic cancer is it's tumor microenvironment (TME) which is notorious for having a prominent
desmoplastic microenvironment exceedingly high in T cells. When analyzing immunotherapies developed
against pancreatic cancer a key factor that persistently limits therapeutic success is the lack of T cells in
tumor cell regions, a profile termed “immune-excluded”
Methods: In this study I analyze the link between T cell expression in the TME on PC (pancreatic cancer)
positive (Kras;ERT2) and negative (ERT2) mice models via IHC (immunohistochemistry) staining of the
CD-8 surface marker.
Results: Findings from this study indicate through IHC that there is a noticeable difference in CD-8 counts
in PC positive and PC negative murine models. PC positive models reported to have an average of
21.190 ± 5.367 CD-8 stains and PC negative models having an average of 8.184 ± 4.602 CD-8 stains at a
90% confidence interval and an average of 21.190 ± 6.367 CD-8 stains and 8.184 ± 5.483 CD-8 stains at
a 95% confidence interval. Despite higher levels of CD-8 in the cancerous mice models, tumor cellinherent resistance mechanisms in cancer positive models impeded proper T cell infiltration and therefore
lead to a subpar immune response leading to the advancement of the cancer.
Conclusion: After having compared CD-8 expression in PC positive and negative models, I looked further
into another study by the National Cheng Kung University in Taiwan comparing CD-8 stains and PD-L1
levels to further understand the role of CD-8 expression in relation to PD-L1 with regards to OS (overall
survival) and DFS (disease free survival). The National Cheng Kung University in Taiwan established that
low CD-8 cell infiltration and high PD-L1 expression significantly stratified patient survival. Applied to the
case of pancreatic cancer in such a dense desmoplastic TME, T cell expression does not indicate that the
body is lacking a proper immune response but that factors in the TME prevent proper infiltration of
immune cells into tumor growth regions.
Keywords: Pancreatic Cancer, CD-8 Expression, PD-L1 Expression, Tumor Microenvironment, Cancer
Immunotherapies
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Investigating the Relationship between CBP and CARM1 Within CBP Knock Out RL Human
Lymphoma Cells
Amaya Craft, Epigenetics and Molecular Biology, University of Texas MD Anderson Cancer Center
Background: Human lymphoma cells have an acute mutation in the CBP protein and the CARM1 gene
affects lymphoma cells as well. CARM stands for Coactivator Arginine Methyltransferase, which means
CARM1 increases gene expression through methylation. It has been noted from previous studies that the
lowered gene expression of CARM1 shows a decreased methylation of lymphoma cells, which also slows
their growth. CARM1 can methylate CBP, leading to the growth of Non-Hodgkin Lymphoma cells. There
have been few studies behind the relationship between CARM1 and CBP, but not in depth.
Methods: CBP and CARM1’s relationship is being investigated within this experiment. Given two forms of
cells, RL WT and CARM1 RL KO cells. These cells are being created through the vector lentiCRISPRv2.
First the plasmid DNA is mixed with the DNA of E. Coli, this is done to ensure the growth of the vector as
E. Coli replicate quickly. After a colony has formed, it will be inoculated and grown. Four colonies are
separated, and four different oligos (Guide RNA’s) are created through the addgene software. After the
CARM1 guide RNA is created the plasmid DNA is purified through an agarose gel extraction, removing
the filler. The oligo is placed inside the plasmid, using T4 PNK and Ligation Buffer. The oligo is then
annealed inside the plasmid through a heat shock and PCR. The vector is then placed into COS-1 cells.
COS-1 cells are monkey kidney cells with the specific SV40 antigen. This antigen is crucial for growing
lentiviral particles, as it binds to the receptor which then releases viral particles into the media. The
lentivirus can then be harvested from the media. The virus is incubated with puromycin along two types of
cells, RL CBP KO cells and RL WT cells. This vector gives the option of creating a gRNA that will target
the exact sequence of CARM1 and lower its gene expression in both genes. The second version of cells
is RL CBP KO cells, meaning they have no expression of the protein CBP. The lentiCRISPRv2
mechanism is very useful, as it can delete genes/proteins that are being investigated.
Results: The oligo successfully placed inside the plasmid DNA and the RL cells and have DNA
sequencing of the CARM1 gene and gRNA scaffold being placed correctly. The RL human lymphoma
cells have finished the puromycin selection, with the remaining cells containing the puromycin resistance
gene.
Conclusion: The cells are soon to be tested using the T7E1 Assay and single cell colony paired with
western blot. The T7E1 assay is important, as it will find the strands of DNA that did not perfectly match
and will cleave the strands. It will also amplify these specific strands using PCR for further observation.
The single cell colony is imperative, as it will have four colonies from each oligo from a single cell. The
cells will be examined through western blot to test for gene expression of CBP and CARM1.
Keywords: oligo, CBP, CARM1, KO, methylation
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Investigating the Effectiveness of Nanopore Technology and Hi-C Analysis in Detecting Structural
Variations in Human Soft-Tissue Sarcoma Samples
Kristy Mendoza Rangel, Neurosurgery, Barnard College of Columbia University
Kadir Akdemir, Neurosurgery, University of Texas MD Anderson Cancer Center
Background: Structural variations (SVs) are the most disruptive mutation type in human tumors, affecting
the largest fraction of the cancer genomes. Currently, detecting SVs in cancer genomes is challenging
due to technical limitations and complexity of SVs. In this study, we evaluated two cutting-edge genomic
techniques for SV detection in human soft-tissue sarcoma samples. Our first method is Oxford Nanopore
technology which relies on a single strand of DNA to pass through a small protein channel (a nanopore)
that is embedded in an electrically resistant membrane. As the strand of DNA passes through the pore,
each base causes a characteristic current disruption which is then decoded using basecalling algorithms
to determine the DNA sequence. Our second method to examine genomic rearrangements is Hi-C, a
chromosome conformation capture method. Hi-C involves cross-linking DNA within cells to create a
snapshot of which genomic regions physically interact with each other. Hi-C has been identified as an
intuitive method for recognizing structural variations due to the large insert size and the detection of
spatial proximity near breakpoints.
Methods: To investigate structural variation calls identified by Hi-C (using HiCBreakFinder algorithm)
and Nanopore (using Sniffles algorithm) in human tumor samples, we used a data visualization tool,
Juicebox. We looked at Hi-C contact maps for osteosarcoma and 2 different liposarcoma tumor samples.
We analyzed the efficiency of Hi-C and Nanopore and their ability to identify structural variations in cancer
cells by comparing the SV call annotations to the Hi-C contact maps. We noted patterns observed about
where Hi-C and Nanopore would identify structural variations and conclude their efficiency by estimating
the amount of calls in a locus compared to the rearrangements seen in the Hi-C contact maps.
Results: In general, Nanopore was proved to be better at identifying SVs inside TADs and in
interchromosomal areas. Interchromosomal interactions are an indication of a rearrangement and a
problem present in the chromatin organization of that cell. Hi-C did better at identifying SVs in
intrachromosomal areas compared to Nanopore. Neither technologies were able to identify all of the
genomic rearrangements.
Conclusion: Our study revealed that detecting SVs with a single method might have certain limitations.
Therefore, we conclude that a combination of orthogonal methods is needed for precise SV detections in
human tumor samples.
Keywords: Hi-C, Nanopore sequencing, Structural variations
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Identifying Differences in Spatial Transcriptomics Between Subtypes of Pancreatic Ductal
Adenocarcinoma
Daniela Tovar, Radiation Oncology, University of Texas MD Anderson Cancer Center
Galia Jacobson, Radiation Oncology, University of Texas MD Anderson Cancer Center
Marta Sans Escofet, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Vittorio Branchi, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center,
Paola A. Guerrero, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Deyali Chatterjee, Pathology, University of Texas MD Anderson Cancer Center
Huamin Wang, Pathology, University of Texas MD Anderson Cancer Center
Anirban Maitra, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Eugene J. Koay, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer, ranking fourth in cancerrelated deaths in the US. Tumors are frequently heterogeneous and have differing clinical outcomes,
indicating further characterization of tumors into distinct biological subtypes would enable the
development of more personalized and effective therapies. The delta method of CT image analysis is
used to visually categorize tumors as high delta and low delta before treatment. High delta tumors are
more conspicuous on CT, and patients with high delta tumors have earlier distant metastasis and shorter
overall survival compared with patients with tumors classified as low delta, which are less conspicuous on
CT. PDAC transcriptomic classification is used to categorize tumors as classical, which are frequently
resectable, and basal-like, associated with poorer clinical outcome. This project aimed to find the spatial
transcriptomic (ST) differences between high and low delta tumors.
We identified 20 PDAC tumor samples, ten classified as high delta and ten as low delta. Each sample
was sectioned and placed on a Visium slide. The slides were hematoxylin- and eosin-stained and viewed
on a light microscope before undergoing hybridization, ligation, and barcoding using the 10X ST protocol.
The library construction of each sample was prepared, then sequenced and analyzed to investigate
genetic differences.
Results: Preliminary results using one high delta and one low delta found differences in the types of
genes expressed and the average expression of basal-like and classical gene markers. Ten genetic
clusters were identified in both the high and low delta samples. Three of these clusters were found in both
samples and the remaining seven were predominantly seen in either one of the samples. No cluster
assessed contained predominantly the cancer areas. Analysis of these clusters indicated correlation to its
respective morphology and cell composition
Conclusion: The preliminary data indicate differences in the transcriptional profiles of high and low delta
tumors. Data analyses are ongoing and will be validated.
Keywords: pancreatic cancer, spatial transcriptomics, computer tomography, transcriptional profile
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Effects of Education, Income, Gender, and Age on Intention to Get the COVID-19 Vaccine
Arnelle Pender, Health Disparities Research, Meharry Medical College
Nga Nguyen, Biostatistics, University of Texas MD Anderson Cancer Center
Alba Calzada, Health Disparities Research, University of Texas MD Anderson Cancer Center
Belen Villanueva, Health Disparities Research, University of Texas MD Anderson Cancer Center,
Lorna McNeill, Health Disparities Research, University of Texas MD Anderson Cancer Center
Background: Blacks are more likely to be adversely affected by COVID-19.1 Studies have shown that
those with higher education and income and those that are older are more accepting of the COVID-19
vaccine.2,3 This study looks at the association between education, income, gender, and age with
intention to get vaccinated against COVID-19 among Black adults. The hypothesis is that Blacks with
higher education, income, and age will report greater intention to get vaccinated against COVID-19 than
Blacks with lower education, income, and age.
Methods: This study used data from the CEAL study, which stands for Community Engagement Alliance
Against COVID-19 Disparities. CEAL included a web-based pre- and post-survey to explore COVID-19
vaccine hesitancy among Blacks and Hispanics in the local community.4 The pre-survey included selfreported demographics.4 Subjects were recruited from the community with the help of an existing
community advisory board.4 The subjects in this study were Black, aged 18 or older, and did not receive
any COVID-19 vaccine. There were 1064 subjects in this study.4 The primary outcome is intention to
receive a COVID-19 vaccine within the next 30 days.4 Frequencies and descriptive statistics were used
to describe participant characteristics. Unadjusted models were performed for each predictor to access
their relationship with the outcome in univariate logistic regression analyses. Finally, multiple logistic
regression was used to include all significant predictors in the model.
Results: Those with a bachelor’s degree or higher were more than three times as likely to report intention
to get vaccinated in the next 30 days than those with less than a bachelor’s degree. Those who were at
least 30 years old were two times more likely to say they intended to get vaccinated in the next 30 days
than those who were younger than 30. Lastly, those who made at least $50,000 annually were one and a
half times more likely to have intentions to get vaccinated in the next 30 days than those who made less
than that. Gender was not significantly associated with intention to get vaccinated in the next 30 days.
Conclusion: Blacks with higher age, income, and education display greater intention to get vaccinated
against COVID-19 in the next 30 days than those of younger age and with lower income and education.
To continue to make progress towards herd immunity against COVID-19, it is important that public health
officials, healthcare workers, and policy makers remain aware of this disparity amongst Blacks.
Keywords: COVID-19, vaccine, education, age
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Abstract 102-A
Understanding the effect of stress hormones on ovarian cancer cells
Paytience Smith, Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center
Shivanand Pudakalakatti, Cancer Systems Imaging, The University of Texas MD Anderson Cancer
Center
Pahul Hanjra, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson
Cancer Center
Anil Sood, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson
Cancer Center
Pratip Bhattacharya, Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center
Background: Ovarian cancer is one of the leading cancers in women and the fifth highest cause of cancer
related death in women. Understanding the underlined mechanisms of poor prognosis in ovarian cancer
patients will directly aid in developing better treatments. Recently, it has been found that ovarian cancer
patients with poor prognosis’ have shown elevated stress hormones. So, in this summer, I worked on to
understand the metabolic changes occur in ovarian cancer cells when they are treated with stress
inducing hormones employing NMR spectroscopy-based metabolomics.
Methods: HeyA8 is a high grade ovarian serous adenocarcinoma human cell lines and used in this study.
Metabolites were extracted from these cancer cells using a 2:1 methanol-water solvent. The mixture of
cancer cells and ceramic breads were subjected to three cycles of mechanical homogenization and
freeze- thawing process to extract metabolites. This is followed by centrifugation, rotary evaporation, and
lyophilization to remove the solvent. The samples are prepared for nuclear magnetic resonance (NMR)
spectroscopy by dissolving the sample in 2 H2 O containing the reference compound 4,4-dimethyl- 4silapentane-1-sulfonic acid-d6 (DSS). The data was acquired on a Bruker NMRspectrometer operating
500 MHz 1 H resonance equipped with a cryogenically cooled triple resonance (1 H, 1 3 C, 1 5 N) prodigy
BBO probe. Identification of metabolite peaks was done through Chenomx and the Human
Metabolomic Database (HMDB); finally, the peaks were integrated in Topspin and normalized to the
reference compound (DSS). All 1-Dproton NMRspectra were normalized to the cell count before analysis.
Results: The significant difference in metabolites glutamate, guanosine, and uridine was observed
between control and cortisol treated ovarian cancer cells.
Conclusion: NMRspectrometry-based metabolomics was able to establish the difference in metabolism of
control and cortisol treated ovarian cancer cells. Initial results showed difference in glutamate, guanosine,
and uridine levels in cortisol treated cells compared to controls. However, the obtained results need to be
validated with analysis of a greater number of samples.
Keywords: NMR, metabolites, ovarian
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Abstract 102-B
Project Self: Addressing Barriers to Recruiting Hispanic/Latinx Women in Houston Area Housing
Site
Jaqueline Almanza, Health Disparities Research, The University of Texas MD Anderson Cancer Center
Surendranath Shastri, Health Disparities Research, The University of Texas MD Anderson Cancer Center
Loren Bryant, Health Disparities Research, The University of Texas MD Anderson Cancer Center
Edna Paredes, Health Disparities Research, The University of Texas MD Anderson Cancer Center
Background: The objective of this Project Self it to examine the feasibility of conducting an education
intervention trial regarding cervical cancer screening among women of Hispanic and African American
origin living in public housing units in Houston, Texas. Potential participants recruited from Irvinton and
Fulton Village, with Fulton Village having more Hispanic/Latinx resident population. Dr.Shastri and the
Project Self research team worked with the Community Scientist Program to help improve Project Self’s
study design and recruitment materials. It is difficult to attract enough participants for research projects in
general, recruiting non-white Hispanics to participate can be especially tough. Potential Hispanic/Latinx
participants might distrust the research process; fear discrimination, loss of confidentiality, or other harms;
or lack information about the research process and its value—and as a result they may be reluctant or
completely unwilling to participate.
Methods:
•
•
•

Literature Review on recruiting Hispanic/Latinx Women on community-based participatory
research studies/clinical trials.
In depth Interview with the Houston Housing Authority (HHA) Coordinator to learn more about
Fulton Village resident engagement.
Self Observations on how Project Self study staff addresses barriers to recruiting Hispanic/ Latinx
women.

Results:
•
•
•
•
•

Based on our recruitment experiences, we have seen both a high and low number of attendance
at the participating housing sites.
Out of the 34 interested forms completed, 7 forms were from Hispanic/Latinx potential
participants; Fulton Village residents.
HHA Interview
“We must come up with creative ways to engage residents and have them attend events at the
community center... In the past, we’ve had many events at the Community Center where very few
residents attended...”
“Compared to Irvinton Village, Fulton Village has more Hispanic/Latinx residents whose preferred
language is Spanish. Recruitment materials need to be in Spanish...”

Conclusion:
There are several viable strategies for addressing barriers to recruiting Hispanic/Latinx populations:
•
•
•

Collaborate, build and maintain relationships with the targeted community and community
members.
Suggestions from research staff: have study staff that can relate to your targeted population,
based off race/ethnicity and preferred language (Bilingual; Spanish)
Literature Review
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•
•
•

“People from non-White racial groups and other underserved populations, including Latinos, are
frequently reluctant to participate in research...”
A Personal Touch: The Most Important Strategy for Recruiting Latino Research Participants
“Developing relationships with recruits expressed shared Hispanic cultural values of personalismo
(preference for warm relationships that convey care and acceptance of the patient and [their]
circumstances)...”

A Personal Touch: The Most Important Strategy for Recruiting Latino Research Participants
Keywords: Recruitment, Hispanic/Latinx, Women
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102-C
Effects of ZIC1 Silencing in Malignant Peripheral Nerve Sheath Tumors
Jordan Pemberton, Surgical Oncology, The University of Texas MD Anderson Cancer Center
Angela Bhalla, Surgical Oncology, The University of Texas MD Anderson Cancer Center
Sharon Landers, Surgical Oncology, The University of Texas MD Anderson Cancer Center
Veena Kochar, Surgical Oncology, The University of Texas MD Anderson Cancer Center
Keila Torres, Surgical Oncology, The University of Texas MD Anderson Cancer Center
Background: Cancer, broadly defined as the uncontrolled and unregulated growth of abnormal cells in the
body, is the second leading cause of death in America. Within the field of cancer, sarcomas are a cancer
classification that derive from cells within connective tissue. The malignant peripheral nerve sheath tumor
(MPNST) is a specific type of sarcoma pathology thought to arise from the Schwann Cells of the
peripheral nervous system. Currently, there are no effective therapeutic targets for MPNSTs, as they are
notorious for their resistance to chemo and radiotherapeutic strategies. A novel field of research has
positively correlated the upregulation of ZIC1 with polycomb repressive complex (PRC2) mutation status
in MPNSTs. Interestingly, the upregulation of ZIC1 in these cell lines is thought to contribute to a
reversion of MPNSTs to a neural crest (NC) phenotype, an early stage in CNS (Central Nervous System)
neurogenesis where ZIC1 is transcriptionally active. Given the observed phenotypic and epigenomic
differences in PRC2 mutated MPNST cell lines, and the prevalence of PRC2 mutation in MPNSTs (7080%), our lab has identified ZIC1 as an experimental therapeutic target in this sarcoma subtype
Methods: We have utilized the CRISPR-dCas9KRAB system to target identified ZIC1 enhancers to obtain
knockdown of gene expression. However, western blotting of enhancer silenced cell lines indicated no
change of ZIC1 expression. Clonogenicity plating showed no difference of clonal formation in enhancer
silenced cell lines, which aligns with the results of our western blots. To quantify any potential difference
in proliferation within our cell lines, we utilized an MTS assay, which confirmed that there was no
significant difference in proliferative rates between our lines.
Results: Currently, our project suggests that the transcriptional accessibility of currently identified ZIC1
enhancers may not be essential for basal levels of ZIC1 expression, and as such, an ineffective target for
ZIC1 silencing.
Conclusion: Future studies should identify and investigate alternative enhancers of interest in relation to
ZIC1 expression. ZIC1 knockout may be utilized to observe the qualitative effects of this gene in PRC2
mutated MPNST cell lines. Alternatively, it may prove prudent to investigate alternative genes associated
with the NC phenotype, such as WNT3, FZD3, BMP7, and SOX9, which are also aberrantly expressed in
PRC2 mutant MPNST tumors.
Keywords: silencing, MPNST, ZIC1, CRISPR-dcas9KRAB, therapeutic target
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Radiation Oncology Medical Student Summer Research Program
Abstract Number: 103

A preliminary study of potential variations in toxicities from RT in early stage breast Cancer
patients treated pre and post-COVID with attention to ultra-hypofractionation
Revathi Gnanasekaran MBA, Radiation Oncology, Foster School of Medicine, Texas Tech at El Paso.
Melissa Mitchell MD, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: Background: During the weeks and months after COVID, when healthcare resources were
scarce, then recently published UK-FAST-forward data and the 26 Gy in 5 fraction regimen became a
frequent option for early stage patients. This regimen balanced tumor control that is non-inferior to
hypofractionation with decreased time in the hospital at a time when resources were short due to the
COVID pandemic. While the weeklong FAST-forward (ultra-hypofractionation) has rapidly been adopted
in countries like UK and SWEDEN, in USA the 3 weeklong FAST regimen (hypofractionation) remains the
most frequent standard of care as adjuvant therapy after primary surgery for early breast cancer.
Hesitation to utilize the FAST-forward regimen more frequently includes the short follow-up (5 years), as
well as concerns regarding toxicity. The increased utilization of ultrahypofractionation for early stage
breast cancer at MDACC during COVID was recently published, however, this is a preliminary report on
differences seen in toxicity. Additionally, there have been anecdotal increases in toxicity overall for breast
radiation patients in the COVID era. This summer, we did a preliminary study on the adverse effects of
ultra-hypofractionation versus hypofractionation in the pre and post the COVID era to further understand
the impact of fractionation schedule and COVID exposure on breast radiation toxicity
Methods: Background: During the weeks and months after COVID, when healthcare resources were
scarce, then recently published UK-FAST-forward data and the 26 Gy in 5 fraction regimen became a
frequent option for early stage patients. This regimen balanced tumor control that is non-inferior to
hypofractionation with decreased time in the hospital at a time when resources were short due to the
COVID pandemic. While the weeklong FAST-forward (ultra-hypofractionation) has rapidly been adopted
in countries like UK and SWEDEN, in USA the 3 weeklong FAST regimen (hypofractionation) remains the
most frequent standard of care as adjuvant therapy after primary surgery for early breast cancer.
Hesitation to utilize the FAST-forward regimen more frequently includes the short follow-up (5 years), as
well as concerns regarding toxicity. The increased utilization of ultrahypofractionation for early stage
breast cancer at MDACC during COVID was recently published, however, this is a preliminary report on
differences seen in toxicity. Additionally, there have been anecdotal increases in toxicity overall for breast
radiation patients in the COVID era. This summer, we did a preliminary study on the adverse effects of
ultra-hypofractionation versus hypofractionation in the pre and post the COVID era to further understand
the impact of fractionation schedule and COVID exposure on breast radiation toxicity Oncora was used
to identify patients with early stage breast cancer treated with lumpectomy and radiation over the
designated time in the IRB approved protocol Patient and tumor characteristics, as well as dosimetric
data were gathered from the EPIC EMR. We used RedCap to record and verify the data. Statistical
analysis was performed in SPSS
Results: Adverse effects were reduced in ultra-hypfractionation with p<0.05. The Adverse effects studied
using Fischer Exact test with p<0.05 were breast shrinkage, breast discoloration, breast edema, and
breast pain at 6 months in addition to breast pain and dermatitis at the end of the treatment.
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Conclusion: In our preliminary study of 300 records out of about 1000 patient records available Ultrahypofractionation RT has a statistically significant (p < 0.05) reduction of adverse effects in early stage
breast cancer patients.
Keywords: Ultra-hypofractionation, Hypofractionation, Radiation, Adverse, Effect
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Abstract Number: 104

A preliminary study of potential variations in toxicities from RT in early stage breast Cancer
patients treated pre and post-COVID with attention to ultra-hypofractionation
Revathi Gnanasekaran, Radiation Oncology, Foster School of Medicine Texas Tech El Paso
Background: During the weeks and months after COVID, when healthcare resources were scarce, then
recently published UK-FAST-forward data and the 26 Gy in 5 fraction regimen became a frequent option
for early stage patients. This regimen balanced tumor control that is non-inferior to hypofractionation with
decreased time in the hospital at a time when resources were short due to the COVID pandemic. While
the weeklong FAST-forward (ultra-hypofractionation) has rapidly been adopted in countries like UK and
SWEDEN, in USA the 3 weeklong FAST regimen (hypofractionation) remains the most frequent standard
of care as adjuvant therapy after primary surgery for early breast cancer. Hesitation to utilize the FASTforward regimen more frequently includes the short follow-up (5 years), as well as concerns regarding
toxicity. The increased utilization of ultrahypofractionation for early stage breast cancer at MDACC during
COVID was recently published, however, this is a preliminary report on differences seen in toxicity.
Additionally, there have been anecdotal increases in toxicity overall for breast radiation patients in the
COVID era. This summer, we did a preliminary study on the adverse effects of ultra-hypofractionation
versus hypofractionation in the pre and post the COVID era to further understand the impact of
fractionation schedule and COVID exposure on breast radiation toxicity
Methods: We sought to assess the impact of COVID and implementation of ultrahypofractionation on
acute and 6 month toxicity radiation therapy in patients undergoing treatment for early stage breast
cancer. We reviewed 299 charts from patients treated from January 2019 date to September 2021 date
treated with whole breast radiation with or without treatment to the low axilla. We excluded patients
receiving treatment to the partial breast and patients receiving comprehensive nodal radiation.
Demographic and treatment characteristics were extracted from the electronic medical record. We
extracted the following characteristics: age, race, histology, T and N stage, modality, dermatitis, edema,
fibrosis, breast shrinkage, breast discoloration, breast pain, ECOG, chemotherapy, hormone therapy,
smoking history, cardiovascular diseases, COVID exposure, and COVID immunizations. We tabulated
baseline patient and pathologic characteristics for all patients stratified by time and fractionation,
hypofractionation prior to the pandemic, hypofractionation during the pandemic and ultrahypofractionation
during the pandemic. 57 patients received up to 10 fractions of whole breast radiation, 243 patients
received 11-28 fractions of radiation. 17 patients tested covid positive prior to radiation. 36 patients
tested positive following radiation. 36 patients received COVID vaccination.
Results: Adverse effects were reduced in ultra-hypfractionation with p<0.05. The Adverse effects studied
using Fischer Exact test with p<0.05 were breast shrinkage, breast discoloration, breast edema, and
breast pain at 6 months in addition to breast pain and dermatitis at the end of the treatment.
Conclusion: In our preliminary study of 300 records out of about 1000 patient records available Ultrahypofractionation RT has a statistically significant (p < 0.05) reduction of adverse effects in early stage
breast cancer patients.
Keywords: Ultra-hypofractionation, Hypofractionation, Radiation, Adverse, Effect
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Abstract Number: 105

Diagnostic performance of multiparametric MRI in radio-recurrent prostate cancer using the
Prostate Imaging for Recurrence Reporting (PI-RR) and histopathological correlation
Charles Shi, Abdominal Imaging, University of Texas MD Anderson Cancer Center
Background: Prostate MRI for Local Recurrence Reporting (PI-RR): International Consensus-based
Guidelines on Multiparametric MRI (mpMRI) for Prostate Cancer Recurrence after Radiation Therapy
were introduced recently. The purpose of our study was to assess their diagnostic performance using
salvage prostatectomy-based histopathology as a reference standard.
Methods: This is a retrospective study of 52 consecutive patients with biochemical recurrence after
external beam radiotherapy (EBRT). All patients underwent mpMRI between 2010 and 2020 followed by
salvage prostatectomy for locally recurrent prostate cancer. Eight radiologists assessed the presence or
absence of recurrent prostate cancer using PI-RR Guidelines after a dedicated training session.
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and AUC of
mpMRI per hemi-gland were calculated for each reader, and consensus read. A consensus read was
considered positive if at least three independent readers agreed on a score. Inter-reader variability was
assessed using Light’s Kappa coefficient. p values of <0.05 were considered statistically significant.
Results: The median age of the patients was 66 years (range, 46-77). The mean PSA at the time of
mpMRI was 4.1 ng/ml (range, 0.31-48). In 52 patients, histological findings were positive for recurrent
disease in 92 hemi-glands and negative in 12 hemi-glands. Of those, 40 patients had the disease in
bilateral hemi-gland, seven patients in left hemi-gland, and five in right hemi-gland. Sensitivity, specificity,
PPV, NPV, and AUC of consensus read was 73.9%, 91.7%, 98.6%, 31.4% and 0.83 respectively. Interreader agreement was moderate (Light’s Kappa = 0.59; P = 0.99).
Conclusion: Our study suggests that PI-RR International Consensus-based Guidelines have an overall
good diagnostic performance for diagnosing recurrent prostate cancer in the setting of BCR following
EBRT. Radiologists of varying experience demonstrated moderate agreement in detecting recurrence.
Keywords: MRI, Prostate, radiotherapy, recurrence
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Summer Imaging Research Program
Abstract Number: 106

Development of a “Universal” Phantom for Standardization of Chemical Exchange Saturation
Transfer (CEST) MRI
Alexander Quach, Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer
Center, Houston, TX USA
Erin P. Snoddy, Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer
Center, Houston, TX USA
Emily M. Thompson, Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer
Center, Houston, TX USA
Jingfei Ma, Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center,
Houston, TX USA,
Mark D. Pagel, Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer
Center, Houston, TX USA
Background: Chemical Exchange Saturation Transfer (CEST) MRI is an emerging molecular imaging
method for improving cancer diagnoses. While a variety of image acquisition and analysis methods have
been developed over the past twenty years, a standard phantom is needed to compare and standardize
these various methods. Ideally, this standard phantom should contain a variety of materials and chemical
agents that can exhibit a CEST effect to test the ranges of CEST image contrast that can be generated.
CEST effect depends on temperature, necessitating accurate and precise control of the temperature of
the standard phantom. Thus, our objective was to develop a “universal” standard phantom for CEST MRI
at 3T and 7T magnetic field strength that consists of multiple materials that could exhibit CEST effect over
a wide range of saturation frequencies while maintaining longitudinal stability and a steady temperature of
37.0 C during acquisition.
Methods: Base phantoms were obtained through purchase of a Diffusion Phantom from CaliberMRI and
an Enhanced Multi Sample 120 Phantom from Gold Standard Phantom. Construction was achieved
through removing the interior materials of these base phantoms, constructing a custom plate that could
enhance the number of samples fitted, and filling with PureTemp37 (a liquid crystal that undergoes slow
exothermic crystallization). Multiple samples of contrast, exogenous and endogenous agents were
created with varying pH, R1 time, and concentrations. An MR spectrum was taken to verify temperature
and homogeneity of sphere while the phantom was scanned in a 3T MRI to create B0, B1, T1 and T2
maps, as well as a CEST spectra of the samples.
Results: When measured over the course of six hours, the temperature of the isocenter, periphery and
midpoint of the phantom stayed constant. Additionally, an MR spectrum was able to be successfully
obtained. B0, B1, T1 and T2 maps were measured with both B0 and B1 showing homogeneity. The
CEST spectra collected showed good CEST signal and that they were dependent on pH and T1
relaxation time.
Conclusion: Overall we were able to successfully design a physical phantom to capture the CEST effect
and test the process of scanning the phantom. Further tests will be needed to ensure optimal parameters
are created to best accomplish our goal of creating a “universal” phantom. Additionally, more work will be
needed to validate the temporal stability of the phantom and determine optimal agents.
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Keywords: Chemical Exchange Saturation Transfer (CEST), MRI Phantom, CEST effect
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Abstract Number: 107
Measuring the Effect of Myo-inositol Trispyrophosphate on Tumor Hypoxia with Multispectral
Optoacoustic Tomography
Ashley Shin, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, University of
Texas Health Science Center at Houston McGovern Medical School
Caroline Robins, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Texas
Tech University
Renee Chin, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Mark Pagel, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center,
Background: The hypoxic nature of solid tumors creates an environment that promotes tumor growth and
development. Various factors contribute to the hypoxic tumor microenvironment leading to decreased T
cell extravasation and increased T cell apoptosis. Because hypoxia hinders T cell trafficking and function
in the tumor environment, the tumors are resistant to T cell-based cancer immunotherapies, leading to
poor prognoses. Myo-inositol trispyrophosphate (ITPP) will be used to target hypoxia. ITPP increases
oxygen unloading from hemoglobin, thus increasing %sO2. Multispectral Optoacoustic Tomography
(MSOT) will be used to test if ITPP increased oxygenation within the tumor environment. MSOT provides
a non-invasive way to measure tumor hypoxia to determine response to cancer therapies. MSOT
measures deoxyhemoglobin and oxyhemoglobin at distinct wavelengths. The purpose of this study was to
determine if ITPP improves oxygenation within the tumor environment through MSOT imaging to assess
the potential of ITPP to improve response to immunotherapy.
Procedure: 3 days pre-implantation, 10 mice, 6 weeks of age, were shaved. 4T1 mammary epithelial
tumor cells were implanted through a subcutaneous injection into the mammary fat pad. 9 days postimplantation, when the tumors were around 4 to 5 millimeters in diameter, baseline MSOT imaging was
performed. 10 days post-implantation, 5 mice received ITPP injection while the other 5 mice received
phosphate buffered saline (PBS) control injection. 3 hours post-injection, MSOT imaging was performed.
Methods: Each mouse was anesthetized and given 21% medical grade air when put into the MSOT
machine. The scan was run after the mouse equilibrated in the 37 °C water tank within the MSOT
machine. MSOT emits light at different wavelengths (700, 730, 760, 800, 850, and 875 nm). The light is
absorbed by oxyhemoglobin and deoxyhemoglobin, which undergoes thermoelastic expansion, also
known as the optoacoustic effect. The thermoelastic expansion results in ultrasound waves. Images are
created from ultrasound waves. After the images are obtained, spectral unmixing of the tumor image
separates the oxyhemoglobin and deoxyhemoglobin absorption. %sO2 (%sO2 = (HbO2)/(Hb+HbO2)) is
calculated, and the overall oxygenation of the tissue is obtained. The oxygenation levels from the
baseline MSOT scan and post-ITPP injection scan are obtained and compared to determine if ITPP
improved oxygenation. The process will be repeated with a PBS control injection instead of an ITPP
injection to compare results.
Results: Through MSOT imaging analysis, we expect to see that ITPP improved oxygenation in tumors
while PBS control did not.
Conclusion: We anticipate that there will be increased %sO2 in the tumor microenvironment after ITPP
injection. If the ITPP injection improves oxygenation in tumors, future studies will investigate the effect of
ITPP on tumor size and immunogenicity. We expect to see that ITPP reduces tumor size and increases
immunogenicity. Additionally, MSOT imaging is currently being tested within the clinical setting on human
patients to assess hypoxia in tumors and predict response to therapy.
Keywords: Tumor hypoxia, ITPP, MSOT, Immuno-oncology, Checkpoint blockade
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Abstract Number: 108

Irreversible Electroporation (IRE): Preclinical Assessment
Matthew Chang, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Qizhen Cao, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
David Eisenbarth, Cancer Biology, University of Texas MD Anderson Cancer Center
Chun Li, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center,
Background: Irreversible electroporation (IRE) causes irreversible permeabilization of the cell membrane
via short, high-voltage electrical pulses. This technique offers a promising treatment modality for local
ablation of pancreatic ductal adenocarcinoma (PDAC). Our goal was to assess effects of IRE in vitro
against various cell types present in the tumor microenvironment and in vivo in a preclinical liver
metastasis model of PDAC.
Methods: To test the effect of IRE on cell proliferation, murine KRAS* PDAC cells, murine RAW264.7
macrophages, and murine bone marrow derived macrophages (BMDM) were treated with IRE at 300 V or
400 V (20 pulses, 0.1 ms long, 1 second between pulses). Cell proliferation 24 hours after treatment was
assessed with the MTS assay. Furtherly, the transwell migration assay was used to assess if IRE treated
KRAS* tumor cells affected macrophage migration. Immunofluorescence (IF) staining showed the density
of CD169+ macrophages on KRAS* tumor tissues from non-treated and IRE treated mice. Finally, PH252
cells (a variant of KRAS* PDAC cells) were inoculated into the spleen of mice to develop a liver
metastasis model of PDAC. Tumor growth was monitored by T2-weighted MRI. Statistical significance
was determined by one-way ANOVA with p≤0.05 considered statistically significant.
Results: IRE treatment decreased cell proliferation for all types of cells. KRAS* cells were more sensitive
to IRE treatment than both types of macrophages (RAW264.7 and BMDM). Increased IRE voltages were
associated with increased cell death. IRE (400V)-treated KRAS* cells significantly increased macrophage
migration compared to untreated KRAS* cells (p<0.001). In vivo model: IF staining of IRE-treated tumors
revealed higher density of infiltrating CD169+ macrophages infiltration in IRE-treated tumors compared to
non-treated tumors (p<0.001). Finally, MRI showed that injection of PH252 PDAC tumors into the spleen
successfully metastasized to the liver, and the burden of liver metastasis (number of nodules and average
size) was a function of time and number of tumor cells injected intrasplenically.
Conclusion: IRE potently decreased cell proliferation of tumor cells more than macrophages. IRE treated
KRAS* tumor cells promoted macrophage migration. This was confirmed with in vivo experiments, which
showed increased tumor infiltration of CD169+ macrophages 24h after IRE treatment. Because CD169+
macrophages play an important role in antigen presentation, further studies on the effect of IRE on
presentation of tumor associated antigens are warranted.
Keywords: Irreversible Electroporation (IRE), Pancreatic Ductal Adenocarcinoma (PDAC), Macrophage,
Liver Metastasis
Summer Imaging Research Program

133

Abstract Number: 109

Correlation of Brain Dual Energy CT and Single Energy CT With Percent Hematocrit and
Hemoglobin
Satvik Vasireddy, Department of Imaging Physics, Divison of Diagnostic Imaging, University of Texas MD
Anderson Cancer Center
Megan C. Jacobsen, Department of Imaging Physics, Divison of Diagnostic Imaging, University of Texas
MD Anderson Cancer Center
Dawid Schellingerhout, Department of Neuroradiology, Division of Diagnostic Imaging, University of
Texas MD Anderson Cancer Center
Rick R. Layman, Department of Imaging Physics, Divison of Diagnostic Imaging, University of Texas MD
Anderson Cancer Center,
Background: In CT imaging, certain materials can be made up of different elemental compositions but
may possess the same CT numbers (Hounsfield Units, or HU). In order to differentiate these materials
effectively, dual energy CT (DECT) has emerged as a viable solution. DECT uses a second energy to
obtain attenuation measurements, which decomposes a mixture into its individual components and allows
subsequent differentiation of the materials. DECT utilizes virtual monoenergetic images, which simulates
images acquired with one precise energy from a range of 40-140 keV. This is beneficial as it allows one
to optimize for maximum signal-to-noise ratio (SNR). A prior study investigated the relationship between
SECT HU and percent hematocrit in the superior sagittal sinus (SSS). The results showed a statistically
significant correlation between the two variables (r=0.5). In our study, we sought to determine if this
correlation improves using DECT.
Methods: Brain CT was acquired using a routine SECT protocol along with a fast kVp-switching DECT
protocol for hemorrhage and calcification differentiation (Discovery 750HD, General Electric Healthcare,
Waukesha, WI). The patient population (n=102) was selected from a prospective clinical trial of DECT for
hemorrhagic brain lesions. Patients were excluded for incomplete scans, incorrect scanning protocol, or
misaligned SECT and DECT. Identical regions of interest (ROI) were placed within the SSS (AW Server,
Version 3.2, General Electric Healthcare). Mean and standard deviation measurements were measured
for DECT monoenergetic images (40-140 keV) and SECT. Complete blood count (CBC) measurements
were evaluated if they occurred within 30 days of CT. SECT and DECT at 50, 65, 70, and 110 keV were
correlated with percent hematocrit and hemoglobin.
Results: A total of 83 patients were analyzed in this cohort. SNR in the SSS peaked at 65-70 keV. The
correlation of SECT HU to percent hematocrit was r=0.49, which was nearly identical to the literature
value of r=0.5, thus validating our methods of ROI measurements. The correlation increases as energy
increases, with both the 70 and 110 keV conditions (r=0.57 and r=0.64, respectively) exceeding the SECT
and literature values. The same trend is seen for DECT HU correlations with hemoglobin, with both the 70
and 110 keV conditions (r=0.57 and r=0.65, respectively) exceeding the SECT correlation.
Conclusion: Overall, DECT via monoenergetic images shows promising potential for opportunistic
neuroimaging applications. The results of this study may suggest future applications in detecting venous
sinus thrombosis in the brain.
Keywords: Dual-energy CT, quantitative imaging, opportunistic imaging, hemoconcentration
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Pol θ Protein Levels and Half-life in Lung Cancer Cells
Ava C. Conyer, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Mélanie K. Prodhomme, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson
Cancer Center
Richard D. Wood, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Background: Lung cancer continues to be a major cause of death worldwide. Recently, lung cancer has
been identified to display an over-expression of the DNA polymerase theta (around 83% of lung tumors).
DNA polymerase theta (Pol θ, coding by POLQ gene) is a main factor in the DNA double strand break
repair pathway called theta mediated end-joining (TMEJ). The TMEJ pathway is an error prone pathway
but essential to repair double strand break damage. Consequently, when Pol θ is over-expressed, the
activity of this pathway increases which may result in an increase in mutation levels and resistance to
treatment. Lack of suitable antibodies and purified protein has hampered quantification of the expression
of Pol θ in human cells.
Methods: The first objective of my project was to determine the amount of Pol θ in lung cancer cells. To
determine the amount of Pol θ, I compared Pol θ protein levels of lung cell lines to purified full-length Pol
θ by immunoblot. The second aspect of this project is to determine the half-life of Pol θ protein. The Pol θ
protein half-life is studied after blocking the protein production with cycloheximide treatment. The kinetic
of cycloheximide treatment is analyzed by immunoblotting.
Results: The amount of Pol θ depends greatly on the cell line and the cancer being studied. However, in
over-expressed Pol θ lung cancer cell lines, the average number of Pol θ molecules per cell appears to
be in the order of 5.7E4 molecules. The mean half-life of Pol θ appears to be 21 hours. For the half-life of
POLθ, we were able to observe two stages of degradation. First there was an increase in Pol θ protein
levels followed by a decrease in Pol θ protein levels. This suggests that a factor involved in the
degradation of Pol θ has a short half-life, but further experiments are needed to get more precise results.
Conclusion: My project will support our understanding of the threshold where Pol θ can have an activity in
cancer cells. This research measured, for the first time, the level of Pol θ in human cancer cell lines; as
well as the half-life of Pol θ. This sets the stage for future studies to analyze the mechanism of the
degradation of Pol θ. Knowing precisely the protein levels of Pol θ, as well as its half-life, is essential to
better understanding how Pol θ may be inhibited in the fight against cancer.
Keywords: Pol θ, TMEJ, DNA Repair, Lung Cancer
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Abstract Number: 111

Therapeutic potential of PRMT1 as a critical survival dependency target in multiple myeloma
Farid Shahid, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Tabish Hussain, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Sharad Awasthi, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Su Zhe, Biomedical Engineering, The University of Texas at Austin
S. Stephen Yi, Biomedical Engineering, The University of Texas at Austin
Nidhi Sahni, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center,
C Marcelo Aldaz, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Background: Multiple myeloma (MM) is a cancer of antibody-producing plasma B-cells and is the second
most prevalent hematological malignancy worldwide. Intrinsic and acquired drug resistance impacts the
therapeutic management of the disease and contributes significantly to treatment failure. This highlights a
critical unmet need to identify novel vulnerability genes as therapeutic targets.
Methods: We recently identified Protein arginine N-methyltransferase 1 (PRMT1) as a top hit (p=0.0003,
FDR=0.01) in a CRISPR/Cas9 based screen of 2000 sgRNAs targeting 200 DNA damage repair pathway
related genes (i.e. 10 sgRNAs/gene) as a potential therapeutic vulnerability and survival dependency in
MM cells. PRMT1 is a major Type I PRMT enzyme which catalyzes the asymmetric transfer of up to two
methyl groups to arginine residues and regulates key cellular processes by modulating gene transcription
and/ or protein functions via post-translational modification. PRMT1 dysregulation or overexpression has
been observed in multiple solid and hematopoietic malignancies, and its overexpression is associated
with cancer chemoresistance. Based on analysis of expression data from the Cancer Cell Line
Encyclopedia (CCLE), PRMT1 appears significantly overexpressed in MM cell lines.
Results: We tested the recently developed Type I PRMTi GSK3368715 on a panel of MM cell lines and
observed a dose dependent decrease in MM cells survival with IC50s within a range of 20 nM to 3 µM for
MM lines NCI-H929, MOLP8, KMS11, and U266. A decrease in the level of asymmetric dimethylation of
arginine (ADMA) and accumulation of arginine monomethylation (MMA) was observed in PRMTi treated
MM cells. In cell cycle analysis, we observed accumulation of cells in G0/G1 phase and simultaneous
reduction of cells in S phase at 72 hours posttreatment. Further, the limiting dilution assay using different
concentrations of PRMTi showed dose dependent reduction in cell proliferation.
Conclusion: Taken together, our preliminary data demonstrates that MM1 cells have a critical survival
dependency on PRMT1 and shows the therapeutic potential of PRMT1 inhibition.
Keywords: Multiple myeloma, CRISPR/Cas9 screen, PRMT1, GSK3368715
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The Function of Arp5 in INO80 Nucleosome Remodeling Complex Histone Exchange Activity
Karissa Beauchemin, Epigenetics and Molecular Carcinogenesis, Texas A&M University
Yuan Zhong, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Blaine Bartholomew, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson
Cancer Center
Background: The INO80 nucleosome remodeling complex is responsible for genomic repair, recovery,
and replication. It has been shown to repair double strand breaks and stabilize stalled or colliding
replication forks by evicting RNAPII and preventing transcriptional machinery from collapsing the fork.
Arguably the most important role of INO80 is its histone-exchange activity. INO80 evicts H2AZ histones
and replaces them with H2A histones to stabilize the genome and facilitate progression of the cell cycle.
In these experiments, we used the W303a strain of saccharomyces cerevisiae to screen for Arp5 mutants
in the acidic patch and DNA binding domain that restrict growth when under different forms of stress.
Methods: Using PCR, the Arp5 gene in each mutant strain was tagged with an FRB-KanMX6 cassette.
Rapamycin was then used in spot assays to anchor the Arp5 gene out of the nucleus, and phenotypes
were observed for multiple mutants. For FACS analysis, cells were grown with or without HU, and twentyminute timepoints were recorded. RNase A and Proteinase K were used to digest the RNA and proteins
before the cells were stained with Sytox Green. The samples were then analyzed in a flow cytometer.
Results: The phenotypes observed from the spot assays show P7 as the only mutant that is sensitive in
low-phosphate conditions. This suggests that the ARP5Δ1 region may be involved in H2AZ and H2A
dimer exchange. The P2 DBD mutant has a severe defect when combined with P7, a hydrophobic
residue mutant, suggesting these residues have another function in Arp5 other than DNA binding in the
INO80 complex. Due to the synergistic defect seen in the R2RNR strain, it is possible that the arginine
anchor for the H2A acidic patch is among the R2 and RNR mutants. The P6 mutant showed sensitivity on
both the DMSO and rapamycin plates which suggests that the mutant is dominant. The endogenous Arp5
is being affected while still in the nucleus.
Conclusion: The point mutations tested in this set of spot assays show that Arp5 acidic patch interaction
could be the key to discovering how INO80 distinguishes H2AZ from H2A histones and carries out
histone exchange.
Keywords: INO80, Arp5, H2AZ, nucleosome remodeling
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Abstract Number: 113

MS-275 to modulate NK cell response against Osteosarcoma. Implication of the chemokines
CXCL9/CXCL10
Uchechi Asika, The Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center
Ariana Rupp Anjier, The Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center
Yuanzheng Yang, The Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center
Pradeep Shrestha, The Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center,
Anchit Bhagat, The Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center
Nancy Gordon, The Children’s Cancer Hospital, University of Texas MD Anderson Cancer Center
Background: Osteosarcoma (OS) is the most common primary malignant bone tumor in children and
adolescents. It metastasizes almost exclusively to the lungs. Survival has remained stagnant for the last
30 years. Natural Killer (NK) cell therapy has shown benefit in the treatment of OS. However, the
therapeutic effect of NK cells has been limited due to the inability of NK cells to penetrate to the tumor
and this is in part attributed to the harsh immunosuppressive tumor microenvironment. MS-275, a histone
deacetylase inhibitor, has preliminarily shown to enhance NK cell therapeutic efficacy against OS using
an in vivo OS mouse model. However, it is unknown whether this effect is due in part to the ability of MS275 to modulate the expression and/or release of the chemokines, CXCL9 and CXCL10, known to
increase NK cell trafficking. Therefore, we aimed to determine whether pretreatment of NK cells with MS275 influences the expression/release of these chemokines, hence contributing to the enhanced
therapeutic efficacy seen in vivo.
Methods: Expression of CXCL9/CXCL10 on OS cells co-cultured with MS-275 treated and untreated NK
cells was determined using immunocytochemistry and flow cytometry. Soluble CXCL9/10 was assessed
using a chemokine array, and migration of MS-275 treated and untreated NK cells to OS cells was
assessed using a transwell migration assay.
Results: Although exposure of NK cells to OS17 OS cells increases CXCL9/10 expression, epigenetic
modulation of NK cells by MS-275 does not provide an additional increase on chemokine (CXCL9 &
CXCL10) release and/or expression by OS tumor cells. Additionally, the migratory capacity of NK cells
was not enhanced by pretreatment of NK cells with MS-275 (p= 0.6461).
Conclusion: Our preliminary results indicate that exposure of OS cells to NK cells increases CXCL9/10
expression which will then contribute to migration and cytolysis of tumor cells. However, pre-treatment of
NK cells with MS-275 does not trigger additional chemokine release/expression suggesting that these
chemokines might not participate in the enhanced therapeutic efficacy of MS-275NK cells seen in vivo.
Further studies are needed to validate these findings.
Keywords: Histone Deacetylase inhibitor (HDAC), MS-275, Entinostat, osteosarcoma, chemokines
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Abstract Number: 114

Targeting Arginine Methylation Reader SND1 in Acute Myeloid Leukemia
Ananya Kodali, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Guozhen Gao, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Margarida Santos, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Background: Arginine methylation is an epigenetic hallmark of acute myeloid leukemia (AML).
Staphylococcal nuclease and Tudor-domain containing 1 (SND1) is an arginine methylation reader that
binds to symmetric di-methylarginine marks deposited by protein arginine methyltransferase 5 (PRMT5).
Previous studies have shown that PRMT5 has an important role in AML development, and inhibiting
PRMT5 reduces cancer cell growth in cell lines and mouse models of leukemia. We hypothesize that
SND1 is similarly important to AML development and that its inhibition should also affect cancer cell
morphology and growth.
Methods: We created stable and inducible SND1 knockdown lines for the MLL-ENL and NIH-3T3 cell
lines. Western blot was used to assess the SND1 knockdown for each shRNA construct. Samples that
showed SND1 knockdown were analyzed using Giemsa staining to determine changes in cancer cells
(blasts).
Results: Two shRNAs in the pLKO.1 vector showed stable knockdown of SND1 in the NIH-3T3 and MLLENL cell lines. One shRNA in the pGIPZ vector showed knockdown in the NIH-3T3 cell lines but not in
the MLL-ENL cell line. Giemsa staining showed terminal differentiation of blast cells in the two successful
SND1 knockdown lines. For the inducible system, cell lines containing the successful shRNAs in the
pTRIPZ inducible vector are currently being optimized for efficient growth so that SND1 knockdown
efficiency and changes in cell morphology can be assessed.
Conclusion: SND1 has potential as a promising target for AML treatment. Stable knockdown of SND1 in a
leukemia cell line disrupts the morphology of cancer cells. However, a successful inducible knockdown
must be tested in a mouse model to verify this hypothesis.
Keywords: acute myeloid leukemia (AML), arginine methylation, protein arginine methyltransferase 5
(PRMT5), Staphylococcal nuclease and Tudor-domain containing 1 (SND1)
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Abstract Number: 115

Analyzing the Dynamics of MHV68 Uracil-DNA-Glycosylase in vitro and in vivo
Ishar Varma, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Somnath Paul, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Joshua B Plummer, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson
Cancer Center
Kevin McBride, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Background: Epstein Barr virus and Kaposi sarcoma are both human gamma herpes viruses that target B
cell germinal centers in lymphoid tissues. Each of these viruses are defined by lifelong infections and
oncogenic properties. Part of its ability to infect for life is the lytic and latent phases that they undergo.
The lytic phase of these viruses is defined by mass replication, while the latent phase, in which the
infection spends much of the time, is composed of little to no replication except for sporadic lytic
outbursts. Recently, a closely related KSHV homolog was found in rodents called murine herpes virus 68
(MHV68) which makes it an acceptable model for studying the dynamics of these related viruses in mice.
MHV68 expresses its own distinct Uracil-DNA-Glycosylase (vUNG/ORF46) that helps prevent
misincorporation of uracil into its DNA. Previous research implicated that vUNG is essential for the virus
to establish latency in germinal centers (1), but the interactome and dynamics of expression for this
critical gene is still not clear.
Methods: Study have determined that the lytic phase for MHV68 peaks at 14-16 days post infection in
vivo (2). We utilized a plethora of experimental approaches to determine the detectable timeline for
ORF46 expression. in vitro, we infected the virus in vivo, We infected mice intranasally under anesthesia
as well as intraperitoneally at 100k PFU per mouse. These preliminary data will help future work on
understanding the interactome and dynamics of vUNG/ORF46 during different phases of infection for
these classes of viruses.
Results: in vitro, 3T12 fibroblast cells are YFP+ 12 hours post infection, and C1/Alexa647+ 24 hours post
infection with peak lytic replication occurring at 48 hours. ORF46+ expression occurs at 8 days post
infection in CD19+ cells in vivo with peak expression of not only MHV68+ germinal centers, but with
CD19+ cells as well.
Conclusion: ORF46 expression occurs at an early stage (lytic phase) post infection in vitro. In vivo data
suggests significant presence of ORF46 expression in CD19+ B cells at day 14, which is considered peak
of lytic phase (3). ORF46 is important for maintaining the viral genome and may interact with other factors
of the host machinery to assist in highly efficient viral replication. Further replicates are needed to confirm
these results.
Keywords: Gamma herpesvirus, ORF46, oncogenic virus, MHV68, Uracil-DNA-Glycosylase
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Abstract Number: 116

Evaluation of a Nuclear Receptor-Binding SET Domain 2 (NSD2) Inhibitor for the Treatment of
Leukemia & Brain Tumors
Katie Impelman, Pediatrics Research, Epigenetics and Molecular Carcinogenesis, University of Texas MD
Anderson Cancer Center
Lea Stitzlein, Pediatrics Research, Epigenetics and Molecular Carcinogenesis, University of Texas MD
Anderson Cancer Center
Virginia Giuliani, Translational Research to Advance Therapeutics and Innovation in Oncology
(TRACTION), Institute for Applied Cancer Science (IACS), University of Texas MD Anderson Cancer
Center
Joya Chandra, Pediatrics Research, Epigenetics and Molecular Carcinogenesis, University of Texas MD
Anderson Cancer Center
Background: Leukemia and brain tumors are the two most common pediatric cancers. Genome wide
sequencing of these cancers has revealed mutations in epigenetic regulations that are unique to pediatric
cancers, including mutations in the histone writer NSD2. NSD2 catalyzes the di-methylation of histone 3
lysine 36 (H3K36). An activating p.E1099K mutation was identified in acute lymphoblastic leukemia (ALL)
and is associated with relapse. However, the role of NSD2 in other leukemias, such as acute myeloid
leukemia (AML), has not been fully explored. Testing a NSD2 inhibitor on AML cell lines would reveal
more about NSD2’s role in AML. In addition, the brain tumor diffuse intrinsic pontine glioma (DIPG)
harbors a mutation in histone 3 lysine 27 (H3K27) that limits methylation of H3K27 and promotes
methylation of its antagonist H3K36, which is partially accomplished by NSD2. One study showed that
knock down of NSD2 reduced tumor size of mice xenografted with DIPG, suggesting that a NSD2
inhibitor may be an effective treatment for these patients. However, the toxicity of a NSD2 inhibitor on
normal brain cells, such as normal human astrocytes, has yet to be evaluated.
Methods: To determine the effect of the NSD2 inhibitor IACS-17596 on MOLM13 (human AML) cell
proliferation and viability, 83x10⁴ cells per well were plated and then treated with 0.1 µM - 10 µM IACS17596 the following day. Cell densities and viability percentages were then collected using a Beckman
Coulter Vi-Cell Counter for eight days. In addition, alamar blue assays were performed to measure the
effect of IACS-17596 on both MOLM13 and NHA cell viability. NHA cells (5x10⁴) and MOLM13 cells
(20x10⁴) were plated and then treated with up to 50 µM of IACS-17596 the following day. Alamar blue
was added to the MOLM13s one day later and to the NHAs four days later, and then fluorescence was
measured 16-18 hours later using the CLARIOstar microplate reader.
Results: During the few days following drug treatment, MOLM13 proliferation was slowed but viability was
not affected. However, higher concentrations like 5 µM or 10 µM did eventually cause a decrease in
viability, but this may have been due to non-specific effects of the drug. On the other hand, NHA cell
viability was un-affected by concentrations of up to 20 µM.
Conclusion: This compound demonstrates anti-proliferative effects on the MOLM13 cell line and is nontoxic on NHAs at low concentrations, encouraging future testing on leukemias and brain tumors, such as
DIPG.
Keywords: Epigenetics, NSD2, MOLM13, NHA
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Abstract Number: 117

Probing the interaction of E2F1 & SART3, a novel arginine methyl reader
Amanda Trevino, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Swarnalatha Manickavinayaham, Epigenetics and Molecular Carcinogenesis, University of Texas MD
Anderson Cancer Center
Mark T. Bedford, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
David G. Johnson, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Background: Canonical functions of E2F1 (E2 promoter binding factor) are involved in transcription of
genes and regulation of many cellular processes. Its involvement with RB (Retinoblastoma) can either
promote or repress genes important for cell cycle progression depending on the activity of RB. In
response to DNA damage E2F1 promotes DNA repair through its essential post-translational
modifications including phosphorylation and acetylation. Reports on E2F1 methylation suggests that it
also undergoes symmetric and asymmetric dimethylation at different arginine residues (SDMA and
ADMA) during normal proliferation and genotoxic conditions. We are currently exploring the potential
SDMA and ADMA sites of E2F1, their readers, and their biological functions. Recent work from our group
found that SART3 (Squamous cell carcinoma antigen recognized by T-cells 3), is a new class of readers
of SDMA. Here we study the interaction between SART3 and E2F1.
Methods: Our experiments used GFP-Trap immunoprecipitation (IP) assay in cells overexpressing EGFPfused SART3 wild type (WT) or aromatic residue mutants. Then we treated the WT cells with PRMT5
inhibitor (PRMT5i) to know if the interaction is dependent on methylation.
Results: Our preliminary data suggests that SART3 interacts with E2F1. Data also suggests this
interaction requires both aromatic residues of SART3 and symmetric arginine dimethylation of E2F1.
Conclusion: SART3 is likely a novel reader of methylated E2F1.
Keywords: Arginine methylation, E2F1, SART3
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Abstract Number: 118

Examining p53 binding to the promoter of ZNF365
Laasya Achanta, Epigenetics and Molecular Oncology, The University of Texas MD Anderson Cancer
Center
Jie Yang, Epigenetics and Molecular Oncology, The University of Texas MD Anderson Cancer Center
Xiaodong Cheng, Epigenetics and Molecular Oncology, The University of Texas MD Anderson Cancer
Center
Background: P53 is a tumor suppressor protein responsible for triggering various cell fates including cell
cycle arrest and apoptosis. P53 has been known to bind to the promoter site of ZFP365, a mouse variant
of the human ZNF365. Mutations in ZNF365 are associated with BRCA1 and BRCA2 mutations. The first
aim of this experiment is to determine if p53 binds to the ZNF365 promoter, to then determine if p53 can
be used to control expression of ZNF365. In many cancers, the gene encoding p53 is frequently
mutated in some areas (hotspot mutations). The second aim is to understand how these hotspot
mutations arise and why they are not fixed effectively by DNA repair mechanisms.
Methods: Nickel chromatography, ion-exchange chromatography, and size-exchange chromatography
were primarily used to purify p53 DNA binding domain (p53DBD) and p53 core and tetramerization
domain (p53CT) constructs. The protein-DNA interactions were measured by two methods: fluorescence
polarization (FP) and electrophoretic mobility shift assay (EMSA).
Results: 9.64 mg/mL of p53DBD was purified (MW: ~25kDa). 0.341 mg/mL of p53CT was purified (MW:
~32kDa). The data shows that p53CT binds stronger than p53DBD to the p21 promoter at 200mM NaCl
(pH = 7.5). Additionally, increasing ionic strength decreases the binding affinity of p53CT to p21. At a
200mM NaCl concentration (pH = 7.5), p53CT binds weakly to the ZNF365 promoter site, and p53CT
binds weakly to coding regions of p53DNA and p53 T:G mismatch.
Conclusion: The singular base pair differences within the target sites of ZNF365 in comparison to those of
p21 may be responsible for the weak binding of p53CT to the ZNF365 promoter. Additionally, the weak
binding of p53CT to the coding region of p53 DNA and to the coding region of the p53 T:G mismatch may
be explained by the 5 base pairs between the two target sites, compared to the 6 base pair difference
between the p21 target sites.
Keywords: p53CT, p53DBD, ZNF365, p53DNA
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Abstract Number: 119

USP22 regulates EZH2 expression levels and binds its promoter
Daniela Becerril, Epigenetics and Molecular Carcinogenesis, Wellesley College
Kashmira Ghatge, Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics University
of Texas MD Anderson Cancer Center
Sharon Y.R. Dent, Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics University
of Texas MD Anderson Cancer Center
Evangelia Koutelou, Epigenetics and Molecular Carcinogenesis, Center for Cancer Epigenetics University
of Texas MD Anderson Cancer Center
Background: USP22 (Ubiquitin specific peptidase 22), a histone deubiquitinating component of the SAGA
complex, is one of the 11 “death-from-cancer” genes that is overly expressed in several aggressive
cancer types. Our detailed analysis of the embryonic lethality observed in the Usp22 null mouse model
we generated highlighted a critical role for Usp22 in the vasculature of the developing placenta. Usp22
null endothelial cells induced from mouse embryonic stem cells were unable to migrate and form vessels,
possibly due to a defect in terminal differentiation. Endothelial cell differentiation and integrity has been
linked to a functional enzymatic component of the Polycomb Repressive Complex 2 (PRC2), EZH2, a
gene that provides instructions for repressive histone methylation. Since Usp22 expression is positively
correlated with expression of members of the Polycomb group complex, we hypothesize that the levels of
Ezh2 are affected in Usp22 null cells.
Methods: To investigate if the levels of Ezh2 are affected in Usp22 null cells, we used two main data
components: RT-qPCR and ChIP-seq. We looked for amplification of the levels of Ezh2 in Usp22 null
embryonic stem cells, which also consisted of testing other PRC2 complex subunits such as SUZ12,
EED, BMI-1, and more. We aimed to identify the binding sites of Usp22 to map global binding sites of
Usp22 in endothelial cells.
Results: We observed a significant reduction of both transcripts analyzed by RT-qPCR and EZH2 protein
levels in the mutant endothelial cells, but no difference in the expression levels of EZH2 in Usp22 null
mouse embryonic stem cells. We were unable to successfully perform a genome-wide USP22 occupancy
analysis in endothelial cells (by ChIP-seq), however we were able to analyze the genome-wide
recruitment of USP22 in mouse embryonic fibroblasts that express an overexpressed USP22 allele. We
observed binding of USP22 protein to the promoter of EZH2, as well as the promoters of SUZ12 and
EED, the obligatory binding partners of EZH2 in PRC2 complex.
Conclusion: Our results provide insights into an important role of USP22 in the regulation of EZH2
highlighting a potential functional interaction between the two proteins in the development of the
vasculature.
Keywords: USP22, EZH2, PCR2.2 Complex, Embryonic Stem Cells.
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Abstract Number: 121

Investigating Glucose Uptake Prognostic Effects On Pan-Cancer TCGA by METAFLUX
Kyle Tsai, Department of Bioinformatics and Computational Biology, Princeton University
Yuefan Huang, Department of Bioinformatics and Computational Biology, University of Texas MD
Anderson Cancer Center
Ken Chen, Department of Bioinformatics and Computational Biology, University of Texas MD Anderson
Cancer Center
Background: One major hallmark of cancer is deregulation of cellular metabolism. Higher uptake of
glucose into cancer cells has been associated with more aggressive tumors. PET scans have been
leveraged to infer changes in glucose metabolism, but pan-cancer glucose uptake studies for large
cohorts are still lacking. To derive metabolic fluxes, we developed METAFlux, which relies on three steps:
calculating the metabolic reaction activity score (MRAS), flux balance analysis (FBA), and optimization of
biomass reaction. Using METAFlux, the objective of this specific study is to analyze 1) The association of
predicted glucose uptake with clinical outcomes and 2) if these effects are homogenous across different
types of cancer.
Methods: Using gene expression data from The Cancer Genome Atlas, METAFlux calculated the MRAS
using a specified set of gene-protein reaction rules and the Human-GEM, which contains information for
13082 metabolic reactions, 8378 metabolites, and enzyme relationships. METAFlux then sets reaction
and medium constraints for FBA analysis and runs quadratic programming using the OSQP package to
minimize the sum of squared fluxes. We believe cells will minimize the total amount of enzymes to reach
optimal growth. We then extracted glucose uptake data from the computed flux, sorting it into “High” and
“Low” groups. Using the TCGABiolinks package, we analyzed the survival rates of both high and low
glucose groups for every type of cancer.
Results: Thirty one different cancers were analyzed, showing whether glucose uptake levels had a
significant effect on patient prognosis. Twenty-five showed an insignificant difference between high and
low glucose uptake levels. In mesothelioma, lung adenocarcinoma, adrenocortical, and thyroid carcinoma
cancers, survival for patients with lower glucose uptake was significantly higher. Meanwhile, in the brain
lower grade glioma and thymoma cancers, analysis showed an opposite result, in that higher glucose
uptake levels were associated with significantly higher survival.
Conclusion: Four different types of cancers are consistent with previous notions that higher glucose
uptake is associated with more aggressive cancers and worse prognosis. However, two cancers
contradict this and show that higher glucose uptake levels are significantly better. With the remaining
cancers showing insignificant differences, the effect of glucose uptake on survival is non-homogenous
among cancers. During the calculations, the mean was used as the benchmark for determining high
versus low glucose uptake. Further studies with different benchmarks (median, top quartile, etc.) would
be insightful. Using METAFlux, we have identified six different cancers of interest to analyze further.
Keywords: METAFlux, Pan-Cancer, Glucose uptake, Metabolic reprogramming, TCGA
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Abstract Number: 122

KMT2D Loss Promotes Head and Neck Squamous Cell Carcinoma Through modulation of Immune
Microenvironment
Amanda Chiaha, Genomic Medicine, University of Texas MD Anderson Cancer Center
Margarita Divenko, Genomic Medicine, University of Texas MD Anderson Cancer Center
S. Carson Callahan, Genomic Medicine, University of Texas MD Anderson Cancer Center
Emre Arslan, Genomic Medicine, University of Texas MD Anderson Cancer Center,
Kunal Rai, Genomic Medicine, University of Texas MD Anderson Cancer Center
Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common type of cancer
in the world. Epigenetic factors have been acknowledged as the gatekeepers of crucial homeostatic
events in the normally functioning cells. Thus, aberrations in the epigenetic machinery are known to
contribute to tumorigenesis in various cancer settings. Here we focus on KMT2D protein, a major
mammalian histone 3 lysine mono methyltransferase. It has been shown to act as tumor suppressor in
various cancer models. This study investigates KMT2D as a tumor suppressor factor in HNSCC and
discusses its role in regulating tumor-intrinsic antigen presentation machinery.
Methods: Clinically relevant data was acquired from publicly available TCGA dataset and processed for
further analysis. Non-targeted (NT) and Knockdown (KD) KMT2D HN30 HNSCC cell lines were
generated and subjected to RNAseq and Western blotting analysis to assess the terms associated with
antigen processing and presentation machinery. In vivo experiments were conducted on C57BL/6J mice
utilizing NT and KD KMT2D MOC1 DOX-inducible cell lines to orthotopically implement tumors into
tongues.
Results: The analysis of TCGA datasets revealed that KMT2D mutations were observed in 17% of
HNSCC cases. KMT2D mutations were correlated with lower recurrence-free rate survival after two years.
KMT2D knockdown cell lines had decreased mRNA levels of immune-associated factors, such as
interferon regulatory factors (IRFs) and groups of cytokines and chemokines. In addition, the protein and
mRNA levels of two antigen-processing machinery members, TAP2 and ERAP1, were reduced in KMT2D
KD HN30 cell lines. The data collected from our syngeneic mouse model demonstrated a higher tumor
burden in the KMT2D-deficient group.
Conclusion: These findings show that KMT2D is a major epigenetic factor controlling HNSCC onset and
give opportunities to explore novel treatment plans with immunomodulatory approaches for patients
harboring KMT2D loss-of-function mutations.
Keywords: KMT2D, HNSCC, antigen processing and presentation machinery, TAP2, ERAP1
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Abstract Number: 123

Prediction of Liver Regeneration Post-Radiotherapy Using Machine Learning and Deep Learning
Models
Yining Zha, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
Aashish C. Gupta, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
Guillaume Cazoulat, Department of Imaging Physics, The University of Texas MD Anderson Cancer
Center
Brian Sandeep De, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Iwan Paolucci, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Molly McCulloch, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
Mais M. Al Taie, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
Sireesha Yedururi, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
Eugene Jon Koay, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Kristy K. Brock, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center
Background: Risk of hepatic failure due to limited functional liver volume after radiotherapy (RT) can be
minimized when there is an accurate prediction and incorporation of RT induced liver hypertrophy during
RT treatment planning. However, current models lack the response prediction at the segment level.
Therefore, we aimed to identify the predictors responsible for segmental hypertrophy and developed
machine-learning (ML) and deep-learning (DL) models to predict liver segment hypertrophy.
Methods: Computed tomography scans of 105 patients treated for liver cancer at MD Anderson Cancer
Center were obtained. 122 features including clinical and dosimetric parameters were collected.
Volumetric change in liver segments 1, 2, 3, 4, 5-8, and 2-3 were estimated at three-month follow-up and
were binarized into hypertrophy and non-hypertrophy outcomes. Univariate analysis (UA) was performed
to remove non-significant variables (p>0.2). For categorical variables, Chi-squared or Fisher’s exact tests
were used according to expected frequency size. Simple Logistic Regression was used for numerical
variables. Pearson Correlation (ρ>|0.75|) was used to eliminate collinearity among variables. The
resulting dataset were held for ML training. Multivariable analysis (MA) was performed by multiple logistic
regression with backward feature selection to identify relationships among variables. ML models using
Lasso Regression (LR) and Random Forest (RF) (10-fold cross validation, TR=81, T=24) were separately
trained for hypertrophy prediction of each segment. Data were resampled using upsampling,
downsampling, and Random Over-Sampling Examples (ROSE) for segments with imbalance ratio>2.
Further, a single-layered feedforward neural network (10-fold cross validation, TR=80, T=25) with ROSE
was trained on all variables. Accuracy, receiver operating curve (ROC), area under the curve (AUC),
sensitivity, specificity were evaluated for each model.
Results: MA demonstrated that tumor in segment 5-8 was protective factor and percent volume receiving
dose <15Gy in segment 1 was risk factor for segment 1 hypertrophy. Tumor in segment 5-8 was risk
factor for segment 3 hypertrophy. Tumor in segment 4 was protective factor for segment 4 hypertrophy.
Portal vein thrombosis was protective factor for segment 5-8 hypertrophy. Overall, LR with ROSE and RF
with upsampling showed the highest test accuracies and AUC for all segments. RF showed 100% train
accuracy while LR with ROSE showed 73% average train accuracy. DL showed superior performance
than ML for segment 1.
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Conclusion: Tumor locations and dosimetric variables were significant protective/risk factors for MA and
important predictors of liver hypertrophy in all ML and DL models. Overall, ML models showed superior
results than DL models.
Keywords: Liver Regeneration, Radiotherapy, Prediction, Machine Learning, Deep Learning
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Targeting Polo-Like Kinase 4 (PLK4) Triggers Polyploidy and Apoptosis in TP53-mutant Acute
Myeloid Leukemia and Results in Improved Survival
Akhil Marupudi, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Edward Ayoub, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Yuki Nishida, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Wencke Walter, Bioinformatics, Munich Leukemia Laboratory,
Torsten Haferlach, Cytomorphology, Munich Leukemia Laboratory
Michael Andreeff, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Background: TP53 mutations in acute myeloid leukemia (AML) are associated with complex karyotype
and a high risk of relapse. While novel treatment regimens, including the combination of the BCL2
inhibitor venetoclax (VEN) and hypomethylating agents (HMA), have emerged as partially effective
treatments and resulted in higher remission rates in patients with TP53-mutant AML, clearance of the
mutant TP53 clone is rarely achieved and the majority of patients relapse. The mechanisms responsible
for relapse in TP53-mutant AML remain unclear and investigating novel mechanisms is critical to
developing more effective therapies.
Methods: In order to investigate defective signaling pathways in TP53-mut AML, we have analyzed two
clinically annotated (karyotype, survival, complete blood counts, and previous treatments) RNAsequencing datasets: MDACC AML Moonshot dataset included 19 TP53-mutant and 25 TP53-wt
samples, and the Munich Leukemia Laboratory (MLL) included 72 TP53-mutant and 654 TP53-wt
samples. For in vitro experiments, we have utilized TP53-mut CRISPR-generated MOLM13 cells. For in
vivo models, we have transplanted TP53-mut MOLM13 AML cells into NSG mice (n=58: untreated n=28,
treated n=30), and treated with CFI-400945 (oral gavage 7.5 mg/kg, 5 times/week) for 3 weeks.
Results: Using the Moonshot dataset, we identified Polo-like kinase 4 (PLK4), a key regulator of centriole
biogenesis, as a potential target highly expressed in TP53-mutant AML samples (>2 log2-fold change, p=
0.0009). We validated our finding utilizing MLL dataset and confirmed that TP53-mutant AML samples
consistently showed PLK4 upregulation (p= 0.0003). Additionally, PLK4 protein levels were significantly
higher in TP53-mutant AML MOLM13 cells when compared with TP53-wt AML MOLM13 cells.
Experimentally, we found that PLK4 inhibition for 72 hours using 25nM CFI-400945 in TP53-mutant AML
MOLM13 cells triggers polyploidy ~2-fold higher than in TP53-wt AML MOLM13 cells (p< 0.0001).
Furthermore, our data suggested that polyploidy is not reversible after drug removal and resulted in
increased levels of apoptotic cell death in TP53-mutant AML MOLM13 cells. To translate our findings to in
vivo models, we showed that PLK4 inhibition in mice transplanted with MOLM13 cells have improved
overall survival compared to untreated mice (20.7%, 25%, and 37.5% overall survival increase for TP53wt TP53-mut, and TP53-ko respectively).
Conclusion: Our data suggest that TP53-mutant AML expresses higher levels of PLK4 compared to
TP53-wt AML and targeting PLK4 triggers polyploidy and apoptosis in TP53-mutant AML. We show that
PLK4i-induced apoptosis translates to improved survival using in vivo models. TWT-202 is an ongoing
clinical trial testing the efficacy of PLK4i in AML.
Keywords: AML, PLK4, p53, Apoptosis, Polyploidy
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Role of ASH1L in Prostate Cancer Metastasis
Anna DeBruine, Physics and Chemistry, Milwaukee School of Engineering
Chenling Meng, Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center
Di Zhao, Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: ASH1L is a histone lysine methyltransferase that catalyzes the dimethylation of histone H3
at lysine 36 (H3K36). ASH1L regulates gene expression in leukemia and plays a role in acute leukemia
progression and poor prognosis. The overexpression of ASH1L was also found in breast, liver, and
thyroid cancer and has been linked with increased cell cancer growth and disease aggression. However,
the activity of ASH1L has not been explored in prostate cancer (PCa) metastasis.
Methods: Data for bioinformatics analysis was gained from The Cancer Genome Atlas primary PCa and
SU2C metastatic PCa patient samples. Cell migration and 3D invasion assays were performed using
control and ASH1L knockout (KO) PC3M cells. Analysis of invasion assay was conducted with NIH
ImageJ software. Real-time PCR (qPCR) was performed using SYBR Green reagent (Applied
Biosystems) in control and ASH1L overexpressed LNCaP cells. Immunofluorescence (IF) was performed
in bone sections of DX1-derived syngeneic bone metastasis model (intratibial injection) and detected
using a VectraPolaris scanner (PerkinElmer). Western blots were performed to determine expression of
ASH1L, methylations of H3, and EMT transcription factors.
Results: Multi-omics analysis of human PCa samples showed ASH1L gene amplification and gain are
more frequent in metastatic PCa than in primary tumors. Patients with ASH1L amplification exhibited
much shorter overall survival than those with ASH1L diploid, indicating a role in metastasis. In addition,
migration assays and 3D invasion assays were performed with PC3M control and ASH1L KO cells.
Migration assays showed significantly lower migration capacity of ASH1L KO cells. Invasion assays
revealed that ASH1L KO cells have little to no invasion activity, whereas control cells have 7 times longer
invasion lengths and 35 times larger areas than KO cells. Furthermore, we found that ASH1L
overexpression led to increased expression of SNAI1 and SNAI2, both are involved in the epithelialmesenchymal transition (EMT) process. Genes in the matrix metalloproteinases (MMPs) family (involved
in metastasis) were also upregulated upon ASH1L overexpression, implicating ASH1L’s role in mediating
cell migration.
Conclusion: The histone lysine methyltransferase ASH1L gene is frequently amplified in metastatic PCa,
and high expression levels of ASH1L are associated with worse patient survival. Our study uncovered
that ASH1L induced cell migration and invasion, partially due to the upregulation of pro-metastatic genes,
such as MMPs and EMT-related transcription factors. Collectively, these results suggest that ASH1L
plays a metastasis-promoting role in PCa and thus could be a therapeutic target for metastatic PCa.
Keywords: Histone methyltransferase, epithelial-mesenchymal transition, metastasis, ASH1L, prostate
cancer
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Synthesis of Block Copolymers to Deliver Ortho-Carborane for Proton Capture Therapy
Bao Le, Cancer Systems Imaging Department, University of Texas MD Anderson Cancer Center
Guodong Zhang, Cancer Systems Imaging Department, University of Texas MD Anderson Cancer Center
Prof. Chun Li, Cancer Systems Imaging Department, University of Texas MD Anderson Cancer Center
Background: In the last several decades, conventional drug delivery has been intensively researched
utilizing different delivery vehicles, such as nanoparticles, polymers, and conjugated antibodies. However,
medication leakage in the internal organs remains one of the field's greatest obstacles. Utilizing the
unique features of protons, irradiation treatments such as proton therapy could deliver precise treatment
to the intended target. However, the current proton therapy strength could be further improved to
eliminate the tumor effectively. We propose delivering ortho–carborane to the tumor via polymer micelles
to augment proton therapy.
Methods: In order to encapsulate the boron compound, multiple block copolymers are being synthesized
to create polymer micelles of varying sizes. This work illustrates the synthesis of various sizes of
poly(PEGMA)n–b–poly[HEMA–g–(ε–caprolactone)7]m in order to assess their stability and capacity to
encapsulate and release ortho-carborane. The boron cargo will be harmless to all cells and can only be
activated to eradicate cells via proton capture therapy, allowing for precision targeting and safety to other
internal organs.
Results: Poly(PEGMA)n–b–poly[HEMA–g–(ε–caprolactone)7]m in different sizes were successfully
synthesized. Also, they are capable of self-assembling to form nanoparticles in water. In addition, the
dynamic light scattering results demonstrates that the concentration of the polymer does not affect the
size of the nanoparticles.
Conclusion: The block copolymers have been confirmed to be a viable delivery vehicle for orthocarbornane. Further studies are currently under investigation for the optimal block copolymers
configuration that could maximize the ortho-carborane loading capacity and its release profile at the tumor
site.
Keywords: Polymer micelles, Proton capture therapy, Drug delivery
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Evaluating the Reproducibility of Gene Regulatory Networks Construction Using Biological
Replicates
Taylor Carpenter, Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD
Anderson Cancer Center
Daniel Osorio, Livestrong Cancer Institutes, Dell Medical School
Stephen Yi, Livestrong Cancer Institutes, Dell Medical School
Nidhi Sahni, Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson
Cancer Center,
Background: This study aimed to determine whether the single-cell gene regulatory networks generated
by SCORPION, a tool developed in Yi's lab at UT Austin, could be replicated using two samples from
different parts of the same polyp. Using single-cell RNA-seq, the expression of the genes in each sample
was characterized, and this information was used to construct independent gene regulatory networks with
SCORPION. Our working hypothesis was that SCORPION would be able to accurately and consistently
reconstruct the gene regulatory network from multiple biological samples and replicates. Ultimately, this is
significant for future population-based studies because it facilitates the linking of transcription factors to
the target gene they affect in the design of pharmacological agents.
Methods: For this experiment, two publicly accessible single-cell RNA-seq datasets from the same donor
were downloaded from the GEO database. We combined the data using Harmony and labeled the
various cell types on a UMAP low-dimensional representation with canonical markers. We selected Tcells from both samples for the construction of gene regulatory networks. To assess the reproducibility of
the gene regulatory networks, a correlation analysis was performed on the weights of the edges. R was
utilized for all analyses.
Results: The GSM6061664 (9591 cells) and GSM6061665 (2243 cells) samples were downloaded and
loaded into R. After passing quality control, 11834 cells were retained and incorporated using Harmony
into a UMAP low-dimensional representation. We identified 18 cell types in the samples, which
corresponds to the number reported by the dataset's authors. We chose CD3D T-cells in order to
construct gene regulatory networks accounting for the interaction of 622 transcription factors and 15,493
genes. The weights of the edges (9,636,646 in total) between the gene regulation networks of the two
samples were then compared. We found that their Pearson's correlation coefficient was 0.913 and their pvalue was 2.2e-16.
Conclusion: This positive and statistically significant result provides evidence that the gene regulation
networks of the different sections of the polyp were very similar, suggesting that SCORPION will be able
to construct gene regulation networks that are very similar regardless of where the sample is taken,
ensuring that the gene regulation networks can be reproduced using biological replicates.
Keywords: Colorectal Cancer, Gene Regulatory Networks, Single-Cell RNA-seq, SCORPION Program
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Distinguishing between Noncancerous Neural Stem Cells and Neural Tumor Stem Cells
Joelly Cortes, Neuroscience Life Sciences, Yale College
DiAngelo Gonzalez, Department of Genetics, The University of Texas MD Anderson Cancer Center
Sam McLeod, Department of Genetics, The University of Texas MD Anderson Cancer Center
Sadhan Majumder, Department of Genetics, The University of Texas MD Anderson Cancer Center,
Background: Glioblastomas are exceedingly aggressive brain tumors. Inside glioblastomas, cancer stem
cells with the potential to advance tumor resistance, development, and recurrence have been detected.
While noncancerous stem cells are the building blocks of all organs and tissues, cancerous cells with
stem-like qualities have posed a considerable challenge in tumor eradication. SOX2 is a stem cell
marker expressed in noncancerous neural stem cells, while β-III tubulin and synapsin are differentiation
markers. We hypothesize that GSCs express abnormal levels of stem cell markers and differentiation
markers when compared to NSCs. To test this hypothesis, the expression levels of synapsin, SOX2, and
β-III tubulin were analyzed in GSCs and NSCs.
Methods: GSCs were obtained by dissociating a tumor sample removed through a patient receptive
surgery, selecting single tumor cells, and then culturing the sample. NSCs were derived by removing part
of the frontal cortex of mice embryos on the 12th day of development and then culturing until the sample
contained both NSCs and neurons. A western blot was conducted and the protein expression levels in
each cell type for synapsin, SOX2, and β-III tubulin were quantified using actin as a control.
Results: The western blot results show a more than 10-fold decrease in SOX2 protein expression in
GSCs versus NSCs. Additionally, GSCs showed an 8-fold reduction in the protein expression of β-III
tubulin compared to the NSCs, and GSCs had more than an 88-fold decrease in the synapsin protein
expression when contrasted with the NSCs.
Conclusion: In accordance with our hypothesis, our findings show that GSCs express abnormal levels of
stem cell markers and differentiation markers when compared to NSCs. Given that β-III tubulin and
synapsin markers are present when early and late differentiation have transpired, one would expect these
expression levels for GSCs to be low since cancer cells do not differentiate appropriately. Finally,
considering that SOX2 is an NSC marker, it is logical for SOX2 expression to be almost nonexistent in
GSCs. The fact that the GSCs had low β-III tubulin and SOX2 expression levels and a negligible level of
synapsin suggests that the GSC line utilized possesses markers of both stemness and differentiation and
displays abnormal differentiation properties. Further investigation is needed to investigate the
mechanisms that make the expression levels of these stem cell markers and differentiation markers
different in cancer stem cells versus noncancerous stem cells.
Keywords: stem cells, glioblastoma, SOX2, synapsin, β-III tubulin
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Targeting AXL with a Highly Stable Modified Aptamer in Medulloblastoma Cell Lines
Joseph Jansen, Human Nutrition, The University of Alabama
Suna Karadeniz-Saygili, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Cristian Rodriguez-Aguayo, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Gabriel Lopez-Berestein, Experimental Therapeutics, University of Texas MD Anderson Cancer Center,
Paola Amero, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Background: Medulloblastomas are the most common types of pediatric brain tumors and start in the
cerebellum. They represent approximately 20% of pediatric brain tumors, with an average age of
diagnosis between 5 and 9 years old. Surgery followed by radiation, and chemotherapy is the standard
treatment, however, it can be ineffective due to the location of the tumor and the age of the patient. Thus,
patients would benefit from non-toxic, targeted therapeutics. One approach is to use aptamers, synthetic,
single-stranded RNA or DNA oligonucleotides that selectively bind their target proteins with high affinity.
Aptamers are considered chemical antibodies that are non-immunogenic and easily penetrate the tumor
site due to their small size. A promising target for aptamer-induced inhibition is AXL, a receptor tyrosine
kinase overexpressed in many types of cancers and associated with poor patient survival. The main
ligand of AXL is Gas6, and the AXL/Gas6 signaling pathway has been shown to enhance proliferation,
invasion, metastasis, and drug resistance. Inhibiting AXL activation may therefore provide a therapeutic
effect, and we have reported that the highly stable and modified GLB-A04 aptamer inhibits phosphor-AXL
in vitro in Gas6-stimulated medulloblastoma cell line.
Methods: We examined AXL expression and its effect on survival in brain tumor patients using expression
and survival databases. To determine whether GLB-A04 can reduce the expression of the active form of
AXL, we treated Daoy cell line with GLB-A04 and Gas6. We also performed Annexin V and Western blot
to determine the effect of GLB-A04 in apoptosis.
Results: Here, we find that AXL is highly expressed in medulloblastoma cell lines and brain tumors, and
high expression is associated with lower patient survival. Interestingly, we find no difference in cell
viability after 72 hours treatment with concentrations of 1.6 µM of GLB-A04 compared with scramble
aptamer used as negative control. Additionally, we find no difference in the expression of Caspase 9,
Cleaved caspase 9, Caspase 8, and Cleaved PARP.
Conclusion: Lower survival in patients expressing high levels of AXL makes it a potentially viable
therapeutic target in the treatment of brain cancer. Additionally, the enhanced stability of the GLB-A04
aptamer and strong binding to AXL have been shown to inhibit phospho-AXL in vitro. Here, although we
find no difference in cell viability or apoptotic protein expression, experiments need to be repeated with
higher concentrations of aptamer and longer treatment times.
Keywords: Aptamers, AXL, targeting therapy, Medulloblastoma
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Probing Spatial Myeloid Heterogeneity in Glioblastoma
Derek L. Chien, School of Arts and Sciences, University of Rochester
Mohammad Fayyad Zaman, Cancer Biology, The University of Texas MD Anderson Cancer Center
UTHealth Graduate School of Biomedical Sciences
Fatma Betul Aksoy Yasar, Cancer Biology, The University of Texas MD Anderson Cancer Center
Daniel B. Zamler, Cancer Biology, The University of Texas MD Anderson Cancer Center,
Ailiang Zeng, Cancer Biology, The University of Texas MD Anderson Cancer Center
Jian Hu, Cancer Biology, The University of Texas MD Anderson Cancer Center
Background: Conventional adaptive immunotherapy is ineffective against glioblastoma multiforme (GBM)
due to factors like T cell exhaustion. Modulating pro-tumor brain myeloid cell activity would present a
viable alternative. Due to ethical considerations, murine models are better suited than human samples for
investigating myeloid heterogeneity in whole brain tissue. Our immunocompetent GBM model—
QkL/L;PtenL/L;Trp53L/L (QPP)—more faithfully reproduces the immune environment of human GBM than
does GL261, the most common preclinical GBM model. Thus, we leveraged QPP to study myeloid
composition across tumorigenic brains. We probed cell morphology, distinguished resident microglia from
circulation-derived macrophages (CDMs), and examined for pro- or anti-phagocytic markers.
Methods: We generated QPP7 GBM from Nestin-CreERT2;QPP mouse injected with tamoxifen at P7. To
generate syngeneic QPP7 GBM, cells from QPP7 cell line were implanted intracranially into B6 Cx3cr1CreERT2;mTmG mice. Brains were harvested from moribund mice, fixed in 4% paraformaldehyde,
embedded in paraffin, and sectioned at 5 μm via microtome for immunofluorescence. Sections were
stained/co-stained with 1:250 primary antibody dilution and 1:1000 secondary antibody dilution (488/594
nm) and imaged via widefield microscopy.
Results: Iba1 staining revealed four morphotypes with undiscovered functions. Ramified Iba1+ cells,
abundant in non-tumor tissue, have long processes characteristic of homeostatic microglia. Hyperramified and rod Iba1+ cells, found mostly at the tumor border, strongly express Iba1 and have fewer
processes. Activated Iba1+ cells, found increasingly towards the tumor core, lack processes and could be
resident microglia or CDMs. We co-stained for microglial marker TMEM119 but found a lack of TMEM119
expression in all Iba1+ cells, indicating TMEM119’s downregulation in glioma conditions. Iba1+ CD45high
cells, or likely CDMs, were found increasingly towards the tumor core. Tumor cells largely expressed
CD47, indicating phagocytic suppression. Arg1, marking inflammation suppression and tissue healing,
was expressed by mostly tumor associated Iba1+ cells. Co-staining spontaneous QPP tumor sections for
Iba1 and GFP, a reporter signal for Qki-null tumor cells, we discovered phagocytic uptake only in some
border regions. It remains unclear when phagocytosis occurred and if uptake and/or endolysosomal
activity were diminished.
Conclusion: Microglia play some role in defending against or promoting gliomagenesis. Localized or
morphotype-dependent microglial gene signatures can be investigated via fluorescence-activated cell
sorting and single-cell RNA sequencing. In glioma conditions, there are phagocytic suppression and high
CDM trafficking into the tumor. Both can be probed further via secretomics, lineage tracing, in vivo
tracking, and time course studies. Multiplex immunofluorescence and confocal microscopy would allow
stronger visualization of tumor-burdened brains.
Keywords: GBM, microglia, CDM, phagocytosis, Iba1.
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Identifying Biomarkers to Select Patients with Borderline Resectable and Locally Advanced
Pancreatic Ductal Adenocarcinoma (BRPC, LAPC) for Radiotherapy (RT)
Grace Waterman, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Galia Jacobson, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Connor Thunshelle, Radiation Oncology, The University of Texas MD Anderson Cancer Center
Eugene Koay, Radiation Oncology, The University of Texas MD Anderson Cancer Center,
Background: BRPC and LAPC have poor prognosis in which surgery is the only curative treatment. RT
has a controversial role for BRPC and LAPC, with negative and positive data in recent years. There is an
unmet need to identify biomarkers to select subpopulations of patients for RT. Prior results indicated that
CA19-9 response and lymphopenia grade associate with outcomes after RT. Here, we investigated these
variables and other clinical factors to identify biomarkers that may aid the decision to use RT for BRPC
and LAPC.
Methods: We conducted a retrospective study to analyze patients who received chemo followed by RT for
BRPC or LAPC between 2015 and 2020. CA19-9 normalizers were defined by the minimum CA19-9
value between the start of chemo and 6 months post-chemo that was < 40 U/mL. Patients were identified
as having a lymphopenia grade >2 if their ALC fell below 0.5 K/uL during RT. Associations between
variables were tested using Log-rank and Wilcoxon survival analyses. Variables with a p-value less than
0.2 in univariate analyses were then used in a multivariate Cox Proportional Hazard test.
Results: 233 patients were found (108 F, 125 M, median age 67 [30-86]) who received RT for BRPC or
LAPC. Median OS for all patients from date of RT was 12.4 months (range, 0.5-65.8 months). CA19-9
normalization was associated with OS, as median OS from date of RT for CA19-9 normalizers and nonnormalizers were 19.3 months and 11.5 months, respectively (p = 0.015). When analyzing patients who
were non-normalizers, patients who received surgery had a mean OS of 25.4 months vs. 8.84 months for
those who didn’t (p =.0001). For patients with a lymphopenia grade >2, patients with BRPC had a median
OS of 23.4 months compared to LAPC with 11.6 months (p = 0.003). Type of radiation was also found to
be associated with overall survival, with Stereotactic Body Radiation Therapy having the highest median
OS of 22.7 months and Intensity-Modulated Radiation Therapy having the lowest median OS of 10.1
months (p =0.019). Associated variables were ran in a Cox Proportional Hazard test in which CA19-9
normalization (p=.00012), radiation type (p=.0032), and surgery vs. no surgery (p=.0001) were statistically
significant.
Conclusion: Variables associated with higher OS in analyses could be used as potential biomarkers to
select patients for RT. Additional prospective trials are needed to evaluate the ability of these factors to
personalize treatment and solidify stable biomarkers.
Keywords: Pancreatic Ductal Adenocarcinoma, Radiotherapy, Biomarkers, CA19-9, Lymphopenia
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Abstract Number: 132

Cell Differentiation: The Case of Turning THP-1 Cells into M1 Macrophages
Kyle E. Bledsoe, Biochemistry and Molecular Biology, Bryn Mawr College
Maria-Ancuta Jurj, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
George A. Calin, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
Background: The Calin lab focuses on the role of miRNAs, small non-coding RNAs that regulate gene
expression, in cancer. THP-1 is a cell line of monocytes, a type of white blood cell, from an acute myeloid
leukemia patient. The goal of this project is to differentiate monocytes into M1 macrophages, a type of
macrophage that inhibits tumor growth, and characterize the macrophages based on the markers and
miRNAs they express.
Methods: THP-1 cells were cultured and differentiated into M0 macrophages with phorbol 12-myristate
13-acetate (PMA). Cells were then activated into M1 macrophages using lipopolysaccharide (LPS) at
concentrations of 1, 10, and 20 ug/mL for 6 and 24 hours. An MTS assay was done to test the cell
viability after treating with LPS. Total RNA was extracted from treated and control cells and the
concentration was analyzed using Nanodrop spectrophotometer. Total RNA was reverse transcribed into
cDNA and RT-qPCR was used to analyze the expression level of differentiation markers (IL 1β, IL 12α,
and IFN γ) and miRNAs (miRNA 125A, miRNA 146A, and miRNA 155) associated with LPS induced M1
macrophages.
Results: After differentiating with PMA into M0 macrophages, the cells attached after 2 hours and
changed morphology after 72 hours. The MTS Assay showed that cell viability does not significantly
decrease by treating cells with LPS. For the specific genes used to characterize macrophages, only the
10 ug/mL LPS for 6 hours and 1 ug/mL for 6 hours treatments showed at least two out of three significant
increases in gene expression level. The other treatments showed only one significant increase, no
significant changes, or all significant decreases in gene expression level. For the miRNAs associated
with M1 macrophages, only the 20 ug/mL LPS for 24 hours treatment showed at least two out of three
significant increases in miRNA expression level. The other treatments showed either no significant
changes or at least one significant decrease in miRNA expression level.
Conclusion: I concluded that the cells differentiated into M0 macrophages. The MTS assay shows that
LPS does not affect cell viability. For the macrophage genes, I concluded that the 10 ug/mL for 6 hours
and 1 ug/mL for 24 hours treatments worked best. This means that the activation into M1 macrophages is
both time and dose dependent. The miRNA expression is also time and dose dependent as only the 20
ug/mL LPS for 24 hours showed increased expression level of the miRNAs.
Keywords: Macrophages, Differentiation, THP-1, miRNA
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The Role of Exosomal miR-181c-3p Within the Ovarian Tumor Microenvironment
Anam Rawoof, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson
Cancer Center
Chi Lam Au Yeung, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD
Anderson Cancer Center
Rita Siu Fee Cheng, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD
Anderson Cancer Center
Sammy Ferri-Borgogno, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD
Anderson Cancer Center,
Samuel C. Mok, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD
Anderson Cancer Center
Background: Background: Annually, 21,000 women are diagnosed with epithelial ovarian cancer (EOC) in
America. Most of them are short term survivors (STS) who live for less than two years after the initial
therapies, including debulking surgery and chemotherapy, and few are long-term survivors (LTS),
surviving over seven years after treatment. Recent studies showed that cells in the tumor
microenvironment (TME) could communicate through exchange of exosomal microRNAs (miRs) to
modulate the TME and ultimately affect patients’ survival. Previous miR sequencing analysis on formalinfixed paraffin-embedded (FFPE) tumor tissue samples from LTS and STS of high-grade serous ovarian
cancer (HGSC) patients resulted in a signature of 50 miRs that were expressed significantly higher in LTS
than STS. To identify exosomal miRs that could be transferred from ovarian cancer cells to modulate the
TME, another miR sequencing analysis was performed on exosomes isolated from nine HGSC cell lines.
It was found that miR-181c-3p was the only miR that present in exosomes out of those 50 miRs. Target
prediction algorithms indicate that leukemia inhibitory factor (LIF) is a potential gene target of miR-181c3p. Based on these findings, we hypothesize that miR-181c-3p can be transferred from ovarian cancer
cells to various cell types within the TME to suppress LIF expression and increase CD8+ CTL activation
and trafficking.
Methods: First, the expression of miR-181c-3p in FFPE tumor samples from LTS and STS was visualized
using miRNAscope assay (Advanced Cell Diagnostics, Inc.). Next, correlation analysis was performed
between miR-181c-3p expression and the intratumoral CD8+ CTL number in patient tumor samples.
Lastly, the LIF mRNA and protein levels were evaluated in HGSC PEO1 and PEA1 cell lines transfected
with control or miR-181c-3p inhibitor using qRT-PCR and Western Blot analyses, respectively.
Results: Tissue staining confirmed that miR-181c-3p is more prevalent in LTS than STS. Correlation
analysis for miR-181c-3p expression and intratumoral CD8+ CTL count indicates a positive correlation.
Significantly higher LIF mRNA and protein expressions resulted in cells transfected with miR-181c-3p
inhibitor.
Conclusion: These results suggest that miR-181c-3p may increase CD8+ CTL activation and trafficking.
QRT-PCR and Western blot analyses indicate that miR-181c-3p downregulates LIF expression.
Keywords: exosomal microRNA, ovarian cancer, miR-181c-3p, T-cells, leukemia inhibitory factor
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Generating Artificial Antigen Presenting Cells for Adoptive T-Cell Therapy
Jose Elias Martinez, Hematopoietic Biology & Malignancy, Division of Cancer Medicine, University of
Texas at Rio Grande Valley
Pappanaicken R. Kumar, PhD., Hematopoietic Biology & Malignancy, Division of Cancer Medicine,
University of Texas MD Anderson Cancer Center
Sachet A. Shukla, PhD., MS., Hematopoietic Biology & Malignancy, Division of Cancer Medicine,
University of Texas MD Anderson Cancer Center
Background: The transformation for cancers are commonly as a result of a series of hereditary and
somatic DNA mutations that change healthy cells into cancerous ones. Therapeutic cancer vaccines have
the potential to activate and strengthen the patients immune system against cancerous cells. For
instance, the vaccination of patients with tumors can induce strong antigen specific anti-tumor T-cell
responses that lead to cancer clearance. Reason development in the next generation sequencing of the
human genome project paved the pathway to identify an alter gene/mutated genes. Using bioinformatics
analysis, now it is possible to predict mutated peptides that can activate the immune system. The Major
Histocompatibility complex (MHC) proteins, or the human Human Leukocyte Antigens (HLA) systems in
humans, place an important role in presenting these mutated peptides to the immune system. We
propose to develop a cell based tool for validating HLA binding patterns of the predicted neoantigens. We
develop artificial presenting cells (APC's) by expressing HLA subtypes into HLA negative cell line K562.
This will provide an opportunity to study: 1) Peptide and HLA specific interaction and 2) Specific T-cell
interaction with cancer peptide.
Methods: With the use of bacteria transformation we are able to amplify our gene of interest using E. coli.
The High Speed Plasmid Maxiprep Kit, provides us with a simple and fast silica membrane-based method
to isolate high quality plasmid DNA from large recombinant E. coli culture. The ultrafast purification
protocol, based on the remarkable selectivity of patented QIAGEN resin, allows the isolation of ultrapure,
supercoiled plasmid DNA with high yields.
Results: After amplification and purifying HLA samples, HLA's were purified an Elution buffer. Elution
buffer is used to wash away unwanted components from the solution, this is used to purify the final
products. Using lower Elution volumes then the recommended 1000-1500 uL for the PureYield Maxiprep
led to higher DNA concentrations, but lower overall yield. This can be beneficial when higher DNA
concentration are preferred over higher yields for downstream applications such as transfection.
Conclusion: The data obtained suggested that high concentration of plasmid DNA were obtained. Almost
all HLA samples resulted in a high concentration of plasmid DNA, which can be followed by transfection
of K562 cells.
Keywords: Human Leukocyte Antigen (HLA), Antigen Presenting Cells (APC), peptides
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Impermissibility of Social Harm: Impersonal Harm, Social Values, and Genetic Enhancement
John Le, Integrated Ethics, University of Texas MD Anderson Cancer Center
With the advent of CRISPR/Cas9 technology and the usage of preimplantation genetic diagnosis, the
prospect to proactively prevent certain gene mutation-based disorders has become a real possibility.
However, with therapeutic applications for genetic editing, also comes the ability for human beings to
enhance their health beyond what was once thought capable, using genetic enhancement. One principle
which seems to be critical to discussions of genetic enhancement is the theory of impersonal harm, which
is harm done not to any individual, but rather to possible people through a set of decisions. Julian
Savulescu and Guy Kahane argue that the principle of procreative beneficence can circumvent
impersonal harm, and as such, would be an ideal principle by which to guide ethical genetic
enhancement.
I will argue that the theory of impersonal harm has the capacity to fit a social aspect, and that because of
this, the principle of procreative beneficence fails to be an ethical guideline. In replacement, I will further
contend that the principle for the prevention of harm is able to account for social impersonal harm, and
thus would be a better guideline for the ethical implementation of genetic enhancement. I will do this in a
threefold manner: first, I will present and explain the concept of impersonal harm and show why it is a
critical component of procreative genetic enhancement. From there, I will then recount Michael Sandel’s
social values argument, showing how these values are compatible with a notion of impersonal harm such
that one must avoid altering these values in order to ethically implement genetic enhancement. Finally, I
will present Savulescu and Kahane’s argument for procreative beneficence and assert that due to the
social implications of impersonal harm, that procreative beneficence cannot provide ethical guidance for
enhancement, whereas an opposing principle, the principle of the prevention of harm, can prevent this
impersonal-social harm.
Impersonal harm states that one can harm a potential world through a decision which creates a worse off
world, so the absence of certain social values such as accepting the unknown would create a worse off
world. Due to this, it seems that procreative beneficence selecting on a basis of :advantage" leads to a
society in which certain traits are discriminated against in a eugenic fashion, whereas the principle of
prevention of harm, which selects on a basis of "least suffering" would allow for diversity in traits,
sustaining social values.
Refer to "results" section above
Keywords: Procreative Beneficence, Prevention of Harm, Impersonal Harm, Genetic Enhancement
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Investigation of Phosphate Pro-Drug led Inhibition of ENO2 in ENO1-Deleted Cells
Ben Finkenbine, Cancer System Imaging, University of Texas MD Anderson Cancer Center
Md Nassir Uddin, Cancer System Imaging, University of Texas MD Anderson Cancer Center
Brian Grindel, Cancer System Imaging, University of Texas MD Anderson Cancer Center
Steven Millward, Cancer System Imaging, University of Texas MD Anderson Cancer Center,
Background: Previous research has shown that by inhibiting the glycolic gene, ENO2, in ENO1-deleted
tumor cells such as Glioblastoma results in the destruction of these cells. The most effective drug at
targeting these cells is HEX, however it is unable to pass the cell membrane. Various side groups have
been attached to HEX creating new compounds such as POMHEX in the hopes that they will solve this
issue. Although POMHEX can pass the membrane, its large polar side chains cause it to be unstable in
aqueous environments. The most promising compound is IBuVCY27, its cyclic benzyl sidechain makes it
stable in aqueous environments while still being able to pass the cell membrane. With a few altercations,
there may be a more effective form of IBuVCY27, which is the goal of this study.
Methods: By reacting 2-Hydroxy-5-methyl benzyl alcohol, 2-Hydroxy-5-methoxy benzyl alcohol, and 3,5Di-tert-butyl-2-hydroxy benzyl alcohol with the shared intermediate of IBuVCY27, three new compounds,
Drug 1, Drug 2, and Drug 3, were created. These new drugs, along with IBuVCY27 and HEX, were each
tested in vitro on 96 well plates against non-ENO1 D423 cells and control groups of ENO1 D423 cells.
Results: The three drugs were properly created and confirmed using proton NMR. The results of the tests
were quantified vs the normalized response of the drugs effect on ENO1 D423 control cells. IBuVCY27,
Drug 1, and Drug 2 appear to be the best preforming and shared with very similar results.
Conclusion: Since there are no definite conclusions that can be drawn, further testing to compare the
stability and effectiveness in vivo on mice is needed to differentiate these three drugs. If one of them turns
out to be successful, this could lead to a new form of treatment for these types of cancers.
Keywords: HEX, ENO1, ENO2, IBuVCY27, Pro-Drug
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Clinical Implementation of DIGEST as an Evidence-Based Practice Tool to Grade Pharyngeal
Dysphagia in Oncology: An Implementation Evaluation
Ella Aldridge, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Sheila Buoy, MPH, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Katherine Hutcheson, PhD, Head and Neck Surgery, Radiation Oncology, University of Texas MD
Anderson Cancer Center
Background: Pharyngeal dysphagia is a swallowing disorder commonly experienced in cancer patients as
a result of tumor burden and radiation and/or surgery treatments. Pharyngeal dysphagia is characterized
by swallowing difficulties involved in the transit of a bolus from the mouth to the esophagus that is
visualized with the modified barium swallow study (MBS). This x-ray examination is performed by speech
language pathologists (SLP) to visualize a patients’ swallowing anatomy, physiology, and function. The
DIGEST tool was designed to provide a reproducible method to grade results of the MBS in alignment
with toxicity grading benchmarks of the Common Terminology Criteria for Adverse Events (CTCAE). One
of the main goals of DIGEST was to allow scoring of swallowing severity in real-time clinical practice. The
aim of this study was to evaluate the reporting rate of DIGEST in a comprehensive cancer center as a
marker of feasibility of this tool in the clinical setting. Clinical implementation might improve
interprofessional communication and increase dysphagic evidence-based practice (EBP).
Methods: An implementation evaluation was conducted in accordance with the STARI framework. All
consecutive MBS conducted at MD Anderson Cancer Center between 2016-2021 were retrospectively
reviewed. Flowsheet data and chart abstraction from the EPIC electronic health record (EHR) was
conducted to identify presence of DIGEST grading in the MBS notes and to locate sources of
missingness.
Results: Among 13,670 MBS conducted in 7,847 unique patients in the six-year period, 73% of MBS were
conducted in males with a median age of 64 years, 62% among patients with head and neck cancer. The
majority (90%) of MBS were conducted in outpatient encounters while 10% were conducted during
inpatient admissions. DIGEST grades were reported in 93% of MBS records in the EHR (12,721/13,670
MBS, 95% CI: 1808.0-2426.0) with similar reporting rates over each study year. The most common
reason for not reporting a DIGEST grade was due to the patient having a total laryngectomy (TL)
(79.9%,758/949), followed by leak/fistula (8.3%, 79/949), and MBS with severe bolus deviation (5.1%,
48/949).
Conclusion: : DIGEST is shown as a feasible EBP tool to grade pharyngeal swallowing function during an
MBS in diverse oncology populations. Further research should be conducted to investigate the accuracy
and effectiveness of DIGEST in a clinical environment. Most importantly, working to educate health
professionals on the benefits of DIGEST implementation should be a top priority to improve patient’s plan
of care.
Keywords: Dysphagia, head and neck cancer, measurement, feasibility
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CCR7 Immune Cell Receptor Expression in Inflammatory Breast Cancer
Alison Lawrence, Radiation Oncology, University of Texas MD Anderson Cancer Center
Wintana Balema, Radiation Oncology, University of Texas MD Anderson Cancer Center, GSBS The
University of Texas Health Science, The Morgan Welch IBC Clinic and Research Program
Savitri Krishnamurthy, Pathology, University of Texas MD Anderson Cancer Center
Natalie Fowlkes, Veterinary Medicine and Surgery, University of Texas MD Anderson Cancer Center,
Richard Larson, Radiaton Oncology, University of Texas MD Anderson Cancer Center, The Morgan
Welch IBC Clinic and Research Program
Megan M. Rodriguez, Radiation Oncology, University of Texas MD Anderson Cancer Center
Naoto T. Ueno, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, GSBS The
University of Texas Health Science, The Morgan Welch IBC Clinic and Research Program
Wendy A. Woodward, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, GSBS
The University of Texas Health Science, The Morgan Welch IBC Clinic and Research Program
Background: Inflammatory breast cancer (IBC) is a rare form of breast cancer that is characterized by
invasion of tumor emboli into lymphatic vessels. CCR7 is an immune cell receptor involved in immune cell
movement into lymphatics that is upregulated in IBC. Our objective was to investigate the prevalence of
CCR7 in estrogen receptor (ER) positive and negative IBC tissues to understand its role in IBC
proliferation and potential novel therapies.
Methods: A human tissue microarray (TMA) of 36 primary breast tissue biopsies from IBC patients
underwent immunohistochemical staining for CCR7. The TMA was converted to an e-slide and analyzed
for CCR7 positivity using Aperio ImageScope software. Positivity percentage values reflected total CCR7
presence in both tumor and stroma. An expert pathologist reviewed the TMA to differentiate between
positive tumor and stroma. Samples containing tumor (24 out of 36) were evaluated for CCR7 positivity,
staining pattern, percent tumor stained, and intensity. Results were interpreted alongside ER status.
Results: All samples expressed CCR7 positivity in either stromal or tumor cells (Median positivity = 44%).
Of the 24 samples containing tumor, 23 (96%) had CCR7-positive tumor. 65% of positive samples had
complete membranous pattern, 91% had 3+ intensity, and 61 had 100% tumor stain. Of the CCR7positive samples with known ER data, 9 were ER positive and 8 were ER negative.
Conclusion: Since CCR7 was highly expressed in 96% of tumor-containing samples across ER+ and ERsubtypes, it can be investigated as a target for future personalized IBC treatments. Because all samples
lacking tumors still exhibited stromal CCR7 positivity, the effect of stromal CCR7 on IBC development is
an additional point of future investigation. Further analysis includes obtaining ER and HER2 data for
samples of unknown status to further assess the relationship between CCR7 expression and various
receptors implicated in IBC. Additional studies might include patients for whom we have medical images,
as CCR7 may be involved in differences in IBC clinical presentation.
Keywords: IBC, CCR7, estrogen receptors
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An examination of patients’ and providers’ communication about de-escalating testing for
prostate cancer.
Chi Vu, Health Services Research, University of Texas MD Anderson Cancer Center
Dr. Lisa M. Lowenstein, Health Services Research, University of Texas MD Anderson Cancer Center
Background: De-escalating surveillance testing by dropping biopsies or spacing out testing for prostate
cancer progression will personalize care and optimize treatment outcomes. However, the lack of
communication and educational information about prostate cancer diminishes the quality of cancer care,
which could result in overtreatment and over-testing for low-risk prostate cancer patients.
Methods: This was a cross-sectional study recruiting patients from the MD Anderson Cancer Center and
clinicians in the U.S. Eligible patients were men with localized prostate cancer, on active surveillance for
at least 1 year, ≥65 years of age, had no evidence of disease progression, and spoke English. Eligible
clinicians were ≥18 years of age, spoke English, and worked with patients with prostate cancer. Afterconsent patients and clinicians completed a survey about clinicians’ approaches and patients’
understanding of what is involved in low-risk prostate cancer. Means, medians, proportions, and ranges
for the survey items were calculated. Stata was used for analysis.
Results: 36 patients (Age range: 65-82 years, = 71.36, SD = 5.13; African American (AA): 5.56%, White:
94.44%) were recruited from the MD Anderson Cancer Center. 26 clinicians (10 female; age range: 27-64
years, = 44.65, SD = 9.61; years of practice range [1.5,30], SD= 9.31; Black or AA: 11.54%, Asian:
19.23%, White: 69.23%) were recruited in the U.S. Patients and clinicians agreed on effective
communication about the fact that patients had low-risk prostate cancer and they were unlikely to die from
it. Most clinicians (84.62%) communicated that those patients would have testing for their prostate
cancer, and 56% of clinicians told patients their prostate cancer did not need any treatment at this time.
However, patients still had an unclear picture of what the future may hold for their treatment. Some
clinicians never (7.69%) or rarely (34.62%) handed out educational materials to patients, which shows the
inconsistency in informative communications about prostate cancer between clinicians and patients.
Conclusion: Patients need to get educational materials about prostate cancer at the time of their
diagnosis or before de-escalating surveillance testing. Communication interventions help patients decide
when de-escalating surveillance testing is appropriate, which supports patients to make well-informed
decisions and provides them with better healthcare services that align with their values.
Keywords: prostate cancer, cancer communication, de-escalation, shared decision-making, patientprovider communication.
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Investigating a Potential Relationship Between Distinct Cancer-Associated Lactobacillus iners
and Chemoradiotherapy Resistance in Cervical Cancer Patients
Grace I. DeAlessandro, Radiation Oncology, University of Texas MD Anderson Cancer Center; Baylor
University Honors College
David Lo, Radiation Oncology, University of Texas MD Anderson Cancer Center
Lauren E. Colbert, M.D., MSCR, Radiation Oncology, University of Texas MD Anderson Cancer Center
Background: Chemoradiotherapy (CRT) is the combined efficacious administration of chemotherapy and
chemoradiation as an antineoplastic approach. However, instances of poor clinical response to treatment,
diminished recurrence-free survival rates, and incurable relapse in cervical cancer patients are alarming,
prompting the investigation of potential markers of CRT resistance. Lactobacillus iners do not exhibit
protective capabilities in the cervical microbiome as this species cannot maintain intravaginal acidity and
contributes to the onset and progression of infectious conditions. Previous research suggests that tumor
microbiomes predominated by Lactobacillus iners are significantly associated with poor patient outcomes,
unfeasible recoveries, and dysfunctional immune responses. There is an insufficient amount of
understood and certified molecular markers to pinpoint patients who will respond poorly to treatment. To
remedy this, the tumor microbiome in cervical cancer patients serves as a manifestation of the radiosensitivity of cervical cancer cells, which can be thoroughly examined to detect how these cells will react
to CRT interventions.
Methods: The cervical cancer cell line, HeLa cells, were co-cultured with supernatants from the ATCC
55195 L. iners strain, L. iners derived from the cervical swabs of patient 366, and L. iners isolated from
the cervical swabs of patient 370. These treatment groups were evaluated and compared to negative
controls of NYC III and MEM 1X mediums. Cisplatin chemotherapy was administered at doses of 0.5 –
1.0 μg/mL concurrent with 1.5 – 3.0 Gy of chemoradiation. Clonogenic cell survival assays were
conducted through crystal violet staining in conjunction with Cell Titer-Glo Luminescent cell viability
assays.
Results: It is expected that there will be a strong association between tumors subjugated by Lactobacillus
iners and poor clinical response to CRT, which is emblematic of curtailed recurrence-free survival rates
and an impaired quality of life in cervical cancer patients. Numerous procedures were performed prior to
the supernatant experiment in order to ascertain baseline control groups while establishing validated
responses of cervical cancer cells to chemoradiotherapy before co-culturing the cells with Lactobacillus
iners.
Conclusion: This detrimental in-vitro effect of Lactobacillus iners’ supernatants on cervical cancer cells
must be further scrutinized to substantiate it as a novel marker in the tumor microbiome that predicts poor
clinical responses to chemoradiotherapy modalities. The Colbert Laboratory has discerned that the
pathotype of cancer-associated Lactobacillus iners promote in-vitro resistance of cervical cancer cells
while modifying the local tumor immunologic microenvironment. Bearing this in mind, future objectives to
enhance the curative properties of CRT must include the generation of low-risk, focused interventions that
transform the cervical microbiome while mitigating the dominance of L. iners through the proposed
employment of bacteriocins, lytic phages, or probiotics.
Keywords: Lactobacillus iners, Chemoradiotherapy, Cervical Cancer, Microbiome
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STING Activation Combined with cMET Inhibition and ICB Therapy Promotes Anti-Tumor Effect in
DEN Mouse Model
Sherwin Newton, Immunology, The University of Texas MD Anderson Cancer Center
Ricardo de Azevedo, Immunology, The University of Texas MD Anderson Cancer Center
Michael Curran, Immunology, The University of Texas MD Anderson Cancer Center

Background: Hepatocellular Carcinoma (HCC) accounts for 90% of all liver cancers. Surgical
resection, radiotherapy, liver transplantation, and Immune Checkpoint Blockade (ICB) are viable
options; however, patient prognoses remain poor.
Targeting aberrant Mesenchymal-to-Epithelial Transition (MET) is a possible clinical treatment.
Unfortunately, inhibition of MET upregulates PD-L1 (Programmed Cell Death Ligand)
expression which triggers immunosuppression. STING agonists, yet another therapeutic,
promote tumor-specific T-cell responses by stimulating Interferon-⍺ (IFN⍺) production.
The purpose of our experiment was to investigate the efficacy of a Triad Therapy joining cMET
inhibition, ⍺PD-1, and STING agonists. We hypothesized that the immunosuppressive effect of
cMET inhibition would be counteracted through combination therapy with ⍺PD-1 and increase
tumor-infiltration of lymphocytes.

Methods: To establish that cMET inhibition upregulates PD-L1 expression, we plated 4 6-well
plates (2.5 X 105 cells/well) for each of 3 human cell lines (SNU-449, C3A, PLC/PRF/5) and 1
mouse cell line (HCA-1). Each of three different cMET inhibitors were given to each cell line at
10 µM and 1 µM, and PD-L1 expression was measured through flow cytometry. Capmatinib was
chosen for our in-vivo experiment due to lowest levels of PD-L1 expression.
The in vivo experiment began with implanting chunk tumors subcutaneously in the right flanks of
40 HCC-resistant DEN mice randomized into 8 groups. Once tumor burden exceeded 50mm3,
the 10-day treatment cycle began. Capmatinib (10 mg/kg) was delivered daily via gavage. The
α-PD-1 antibody (250 µg per mice) was delivered intraperitoneally every other day, and the
STING agonist (10 µg/mice) was administered intratumorally thrice. Ultimately, mice were
euthanized, and their tumors were abstracted and analyzed using flow cytometry for tumorinfiltrating lymphocytes.
Results: We found that Triad Therapy led to statistically significant antitumor effects in the mice.
Primarily, relative to other treatment combinations, Triad Therapy increased the tumor-infiltration
of CD4+ lymphocytes. The triple-therapy combination also enhanced CD8+ Teff and NK cells
infiltration of the tumor microenvironment (TME). Additionally, Triad Therapy decreased the
presence of CD4+FoxP3+ Treg cells in the TME which suppress the activated immune response.
Conclusion: The goal of our study was to explore the potential for combination therapy to
increase lymphocyte infiltration of the tumor microenvironment. Our results confirm that
combining cMET inhibition, STING agonist, and anti-PD-L1 therapies is a promising avenue for
further research. Our study was limited by the number of mice in our in vivo experiment; still
provides basis for future experiments that are scaled proportionately to include more samples.
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Manipulation of Abro1 Localization in U2OS Cells
Sophia Lopez, Genetics, University of Texas MD Anderson Cancer Center and Baylor University
Shichang Liu, Genetics, University of Texas MD Anderson Cancer Center
Bin Wang, Genetics, University of Texas MD Anderson Cancer Center
Background: When a DNA replication fork stalls, it can lead to replication stress. Defects in stalled fork
protection in the replication stress response leads to genomic instability. Abro1 has been found to be a
key factor in protecting the integrity of stalled replication forks. Abro1 is present in both the cytoplasm and
nucleus of the cells. The functional importance of the localization of Abro1 is not clear. To further study its
localization, we generated two mutants of Abro1 with either a Nuclear Localization Signal (NLS) or
Nuclear Export Signal (NES), which only localizes the Abro1 to either the nucleus or cytoplasm.
Methods: Abro1-NLS and Abro1-NES were generated on pENTR-Abro1 by mutagenesis PCR to
generate the mutant genes. The PCR products were transfected to E. Coli, which was then spread on
Luria Broth (LB) plates and screened. Individual clones were picked and sequence verified. The products
were then transferred from pENTR vectors to destination vectors to generate HA-Abro1, HA-Abro1-NLS,
and HA-Abro1-NES. These recombination products were then transfected to E. Coli and individual clones
with accurate recombination were identified. The plasmids were then extracted and used for transient
expression in U2OS cells for 48 hours. A western blot was performed to verify expression.
Immunofluorescence was performed and images were taken by a Confocal microscope.
Results: Western blot results indicated that the Abro1-NLS and Abro1-NES mutants were successfully
generated with the correct localization signals. The immunofluorescence results showed that the NLS
signal successfully localized Abro1 inside of the nucleus and the NES signal successfully localized Abro1
in the cytosol, outside of the nucleus.
Conclusion: The successful generation of the two Abro1 mutants is an important first step in the
understanding of Abro1. In the future, these mutants could be used for further testing of the different
functions of Abro1 based on its localization and how these functions interact. Thus, with a deeper
understanding of Abro1, we can have an increased understanding of genome stability which can have
implications for tumor suppression.
Keywords: Abro1, Stalled Replication Fork Stability
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Ki67 Quantitation in Breast Cancer: A Comparative Analysis of Four Counting Methodologies
Mary Mersereau, Department of Pathology, University of Texas MD Anderson Cancer Center
Hui Chen MD, PhD, Department of Pathology, University of Texas MD Anderson Cancer Center
Constance Albarracin, Department of Pathology, University of Texas MD Anderson Cancer Center
Background: Ki67, an important tumor marker in breast cancer, is associated with cell proliferation. Ki67
is suggested to be of clinical value in determining whether adjuvant chemotherapy is necessary in ER
positive/HER2 negative breast cancer patients. While immunohistochemical stains are commonly used to
assess Ki67, quantitation is limited by lack of standard scoring methods. Most laboratories visually or
digitally quantify Ki67 in the entire tumor. Another method is quantifying Ki67 in “hotspots” with the
highest nuclear labeling. Recently, the International Ki67 Working Group (IKWG) proposed quantifying
areas of varying Ki67 positivity. Currently, no single method has gained universal acceptance as a
reliable method for Ki67 quantitation. Therefore, the goal of this study was to identify a reliable method of
Ki67 quantitation by comparing four methodologies: Visual Total Count (TC), Digital Total Count (TC),
Hotspot Count and IKWG Unweighted (IKWG-U).
Methods: Ki67 immunohistochemical stains of 100 cases of HER2 negative/ER positive breast cancers
were scored and categorized into low (<17%), moderate (17-35%) and high Ki67 (>35%). Visual TC
method, the method used in our institution, was the consensus score for Ki67 staining in the entire
invasive tumor and served as the standard. Digital TC method quantified Ki67 in the entire tumor by
digital analysis (Image J). IKWG-U method quantified Ki67 in four areas of different staining densities.
Hotspot Count quantified Ki67 in representative areas with the highest Ki67 labelling. The time required
for each method was noted.
Results: In comparison to Visual TC, the Digital TC and IKWG-U methods each altered Ki67 categories in
3 of 100 cases. Hotspot Count altered Ki67 categories in 16 of 100 cases. The scores from each method
were compared to Visual TC using a scatter plot and linear regression, yielding R2 values of 0.9756,
0.9776, and 0.8678 for Digital TC, IKWG-U and Hotspot Count respectively. Average Time required for
Visual TC was < 2 mins, Digital TC was 28 mins, IKWG-U was 10 mins and Hotspot Count was 6 mins.
Conclusion: This study demonstrated high correlation amongst Visual TC, Digital TC and IKWG-U
methods for Ki67 evaluation. While these methods yielded comparable results, Visual TC required the
least amount of time and can be easily utilized in a clinical setting. These results validate the use of
Visual TC as a viable and effective method to quantify Ki67 in our clinical work. Further studies to
establish clinical relevance of these quantitation methods and their impact on clinical management is
necessary.
Keywords: Ki67, breast, pathology, quantitation
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Role of Antimicrobial Peptide, SAA3, in inducible protection by Pam2-ODN in mouse lung
epithelial cells
Lijo Andrews, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center
Shreya Bhattacharya, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center
Scott E. Evans, Pulmonary Medicine, The University of Texas MD Anderson Cancer Center
Background: Pneumonia is an invasive disease that results in the inflammation of the alveolar sacs in the
lungs, causing fluid retention. The retention of fluid results in the impairment of breathing and can cause
sepsis, often leading to death. The disease is most commonly seen in those with a weakened immune
system, such as those undergoing chemotherapy treatment. Previous studies have indicated that the
epithelial cells of the lungs can be stimulated to provide protection against these pneumonias. This
stimulation was induced by treatment consisting of the combination of two TLR agonists. These agonists,
TLR 2/6 and TLR9 work in synergy by recognizing the motifs Pam2CSK (Pam2) and oligonucleotide
(ODN) M362, respectively, triggering a signaling cascade which modulates the immune response after
pathogenic infection. Combined, the TLR’s are recognized as Pam2-ODN. Previous microarray analyses
have indicated upregulated genes coding for antimicrobial peptides (AMPs) after the addition of PAM2ODN treatment. One of them, Serum amyloid A (SAA), is an AMP that is known to modulate inflammatory
feedback responses. A murine isoform of the protein, SAA3, produces similar responses in epithelial
cells. This response renders the protein as a biomarker for infection, allowing us to use it as a
measurement tool following the administration of treatment. As such, this study aimed to validate the
microarray analysis by performing qRT-PCR ran at various time points to better understand the gene
expression level over time.
Methods: This study consisted of various timed trials ran in five phases: cell culture, addition of
treatment, RNA extraction, cDNA conversion, and qRT-PCR analysis. Once the cells reached full
confluence, treatments were added according to their designated time frame. Once the time was
complete, cells were then lysed and RNA was extracted using a spin column. Gene expression of SAA3
was measured by qRT-PCR relative to housekeeping gene 18s. The data were analyzed using the
GraphPad software.
Results: Data showed increased levels of SAA3 production in treatment group, at the 2 and 4 hour time
frames.
Conclusion: The results show that SAA3 is expressed significantly at 2 hours and 4 hours due to Pam2ODN treatment. Pam2-ODN induces a protective response through AMPs such as SAA3, especially at
these time frames in the MLE15 cell line. Further studies involving in-vitro infection model must be
performed to assess the protectiveness of SAA3 and other AMPs induced by Pam2-ODN to gain more
insight into the mechanism of action behind this protection.
Keywords: Antimicrobial Peptide, lung epithelium, synergy, inducible protection
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Using the Persuasive Design Model to Refine a Novel Stimuli-Responsive Polymeric Sensor in
Head and Neck Cancer Patients
Dylan J. Leupi, Behavioral Science, University of Texas MD Anderson Cancer Center
Tarek Rafeedi, Nanoengineering, University of California San Diego
Laura L. Becerra, Electrical & Computer Engineering, University of California San Diego
Ehab Hanna, Radiation Oncology, University of Texas MD Anderson Cancer Center,
Susan Peterson, Behavioral Science, University of Texas MD Anderson Cancer Center
Darren Lipomi, Nanoengineering, University of California San Diego
Adam S. Garden, Head and Neck Surgery, University of Texas MD Anderson Cancer Center
Eileen H. Shinn, Behavioral Science, University of Texas MD Anderson Cancer Center
Background: We conducted two user-centered tests with head and neck survivors to evaluate long-term
usability of a novel sensor to detect developing dysphagia after radiation. Radiation-associated dysphagia
is permanent and occurs in 40% of laryngeal/pharyngeal cancer patients treated with curative radiation.
We prototyped a stretchable neck-worn epidermal dual-layer strain/sEMG sensor that measures
swallowing muscle activity to aid in the earlier detection of dysphagia development. Ideally, home-based
monitoring with the sensor during the 1-2 year post-radiation treatment period would detect developing
dysphagia in time to initiate preventive interventions. However, most U.S. patients abandon wearable
health technologies within a few months, lessening their clinical impact. To sustain patient engagement,
user-centered testing is needed but often neglected in the development of these technologies. To
evaluate the sensor’s long-term usability, we used the persuasive design model to test four parameters of
technology: ease of use, user feedback, credibility and social support.
Methods: Two studies were conducted to gauge patient preferences. First, we asked 138
pharyngeal/laryngeal cancer survivors who were 2-5 years post-radiation: a) their understanding of the
sensor’s rationale, b) willingness to wear the sensor for 1 year post-radiation and c) design preferences.
Second, we conducted swallowing tests with 27 laryngeal/pharyngeal cancer patients while wearing the
sensor prototype and repeated the questions from Study 1.
Results: Study 1: N=138 survivors answered questions about future trial participation in a 9-month long
sensor study: 83.5% (n=116) of the participants indicated willingness to participate. Of those unwilling to
participate (16.5%, n=23), 9 months was perceived as too long of a trial period (86.4%, n=19). Study 2:
After swallowing tests with the sensor, 77.8% (n=21) indicated willingness to participate, citing support for
the preventive rationale of the epidermal sensor as the main reason for participation (100%, n=21). Those
unwilling to participate (22.2%, n=6) also indicated 9 months too long of a trial period (83.3%, n=5).
Patients communicated that sensor application was the main barrier to sustained use while conveying the
need for instant haptic feedback. Participants also expressed that sending sensor data to doctors would
be a more efficient way of monitoring dysphagia development.
Conclusion: In the framework of the persuasive design model, these results indicate strong support for
further development of the sensor’s ease of use, user feedback and credibility. Survivors are willing to
use home-based technologies to support adherence to preventive strategies, but this willingness is
dependent on the sensor being compatible with their lifestyle and post-treatment radiation side effects.
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Targeting DNA damage repair pathways in diffuse intrinsic pontine gliomas
Alejandra Rodríguez, Department of Pediatrics, University of Notre Dame
Sandeep Singh, Department of Pediatrics, University of Texas MD Anderson Cancer Center
Shinji Maegawa, Department of Pediatrics, University of Texas MD Anderson Cancer Center
Jyo Swaminathan, Department of Pediatrics, University of Texas MD Anderson Cancer Center,
Vidya Gopalakrishnan, Department of Pediatrics, University of Texas MD Anderson Cancer Center
Background: Diffuse intrinsic pontine gliomas (DIPGs) are a uniformly fatal class of highly aggressive
pediatric brainstem tumors. In the absence of effective treatments and more than 250 failed clinical trials,
prognosis remains exceptionally poor at a median survival of 9-11 months post-diagnosis. Data from our
lab has shown that DNA damage machinery genes, downstream of BRAC1 and PARP1, are upregulated
in DIPG tumors. Their expression positively correlated with that of the oncogene, REST. Objectives: To
explore the therapeutic potential of targeting BRAC1 and PARP1 signaling using drugs that can target
PARP and RAD51 proteins. We hypothesize that REST elevation in DIPGs induces DNA double stranded
breaks and these cells are dependent on repair for their survival. Therefore, blocking this repair
machinery will induce cellular stress and cell death.
Methods: DIPG cell lines (3 parental and 3 isogenic REST overexpressing) were exposed to the PARP
inhibitor - Talazoparib and the RAD51 inhibitor – Berberine at various concentrations for 5 days. Drug
sensitivity was evaluated by determining cell viability using an MTT assay. Flow cytometry was used to
conduct cell cycle analysis.
Results: Talazoparib increased cell death significantly in multiple cell lines at various concentrations. Flow
cytometry revealed a G2/M-phase cell cycle arrest at a concentration of 1600nM Talazoparib. Berberine
showed a small decrease in cell growth in DIPG cells but induced G1 arrest at a drug concentration of
2000nM. Cell lines with high-REST expression demonstrated greater sensitivity to both drugs. Phase
contrast imaging revealed a decline in neurosphere formation following drug treatment.
Conclusion: PARP and RAD51 show promise as potential therapeutic targets for DIPG. High-REST
expression further sensitizes tumors to drug treatment. Decrease in neurosphere formation suggests a
decline in the stem/progenitor cancer cell population.
Keywords: Diffuse intrinsic pontine glioma, DNA damage repair, cytotoxicity, cell-cycle arrest, REST
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Combined inhibition of IRS-1 and HDAC blocks uveal melanoma cell survival and induces
apoptosis.
Joshua Abebe, Melanoma Medical Oncology, University of Notre Dame
Chandrani Chattopadhyay, Melanoma Medical Oncology, University of Texas MD Anderson Cancer
Center
Background: Uveal Melanoma (UM) is a rare subtype of melanoma of the uveal tract of the eye. The
primary tumor is treatable, but poor prognosis comes from metastatic disease to the liver. There is an
urgent need to develop new therapies as only one FDA approved therapy exists. IRS-1 (insulin receptor
substrate-1) inhibition partially blocked UM cell survival and cell migration. Single agent therapies in
melanoma lack effectiveness in the long run. To develop a combination therapy, a high throughput
combination drug screen with IRS-1 inhibition was performed and showed a possible synergistic effect
with the histone deacetylase (HDAC) inhibitor, Belinostat (Bel), in UM cell killing activity. To validate these
findings, I performed combination treatments with NT157 (IRS-1 inhibitor) and Belinostat on UM cell lines
to determine their combined effect on UM cell survival and the mechanism of such.
Methods: We used UM cell lines: MM28, MP38, 92.1, MP41, MP65, MEL202, and MEL20-06-039 with
representative genotypes. NT157 and Belinostat were purchased from SelleckChem. We assayed UM
cell survival using MTT assays and a clonogenic colony formation assay. Routine western blots were
used for the molecular analysis of protein markers.
Results: High Throughput Drug Screen (HTS) for novel combination therapy strategies for UM: Our initial
combination HTS allowed us to predict a synergistic relationship between IRS-1 and HDAC inhibition.
Over 2000 approved drugs were tested for UM cell killing activity and filtered down to 31 candidates for a
combination screen. From this Belinostat was chosen as it showed a good synergy score with NT157 in
combination. UM cell survival is efficiently blocked with combined treatment of Belinostat and NT157:
Combination treatment with NT157 and Belinostat substantially improved inhibition of UM cell survival
over individual single agent treatments from our MTT assays, which we confirmed using clonogenic
colony formation assays with UM cells. Apoptosis was induced in UM cells treated with NT 157 and
Belinostat in combination: Western blots indicated that single agent treatments targeted respective
pathways and combination treatments induced apoptosis (increased PARP breakdown) in UM cells.
Conclusion:
•
•
•
•
•

IRS-1 inhibition partially blocked UM cell survival and migration.
Unbiased high throughput drug screen indicated synergy between IRS-1 and HDAC inhibition.
This was validated in in vitro assays in the current study with nanomolar doses of each targeting
agent.
Dual targeting of IRS-1 and the HDAC pathways improved UM cell killing over single agent
treatments.
Apoptosis was extensively induced in UM cells with combination treatments.
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Specificity of the S9.6 Antibody in the Detection of R-loops and RNaseH1
Ivonne Arguelles, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center
Ruidong Chen, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center
Guang Peng, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center
Background: Previous studies involving the specificity of the S9.6 antibody in the detection of R-loops rely
primarily on immunodetection which specifically binds DNA-RNA hybrids. Regulation of these R-loops via
RNaseH1, a protein that cleaves R-loops, is necessary to maintain genomic stability. Studies
investigating the underlying molecular basis and mechanisms of the specificity of the S9.6 antibody in the
detection of R-loops and the RNaseH1 protein are still not completely understood, especially not in
cholangiocarcinoma. To better understand these underlying mechanisms, a study would need to be
conducted that establishes that R-loops can accurately be detected using immunofluorescent analysis
using the S9.6 antibody and that it is specific to RNaseH1 in SSP25 cells.
Methods: We conducted an immunofluorescence microscopic analysis using the S9.6 antibody and DAPI
to image DNA signals for R-loops and stain nuclei of the SSP25 cell line with different shPTEN samples
and ATR inhibitors. Using CalFectin, we transfected RNaseH1 DNA into 293T cells. We then ran a
western blot to test the RNaseH1 WT and its mutants (WKKD and D210N) to test the specificity of
RNaseH1 and its expression with respect to the S9.6 antibody. The last step in the methods section
would have been transfecting RNaseH1 DNA into the SSP25 cell line, running an identical western blot,
and then another immunofluorescence analysis.
Results: Immunofluorescent analysis shows that the S9.6 antibody can accurately detect S9.6 signals.
The analysis also shows that there was a decrease in S9.6 signal intensity in the ATRi BAY1895344 with
both PTEN knockdown samples. Immunofluorescent analysis also showed that there is an increase in
S9.6 signaling intensity in both shPTEN samples. Western blot analysis shows the expression of
RNaseH1 in all RNaseH1 samples except for the one containing the GFP plasmid. RNaseH1 diminished
the expression of GFP in PeGFP-RNaseH1. V5 resulted in the overexpression of RNaseH1.
Conclusion: Immunofluorescent analysis revealed the S9.6 antibody’s ability to accurately detect S9.6
signals and stain nuclei. Immunofluorescent analysis also showed that ATRi BAY1895344 decreases the
nuclear intensity of the S9.6 signal in shPTEN and that shPTEN generally increases the nuclear intensity
of the S9.6 signal. The western blot showed the expression of RnaseH1 was detected in all RnaseH1
mutants and in the WT except for the one containing the GFP plasmid. Future studies will need to test the
expression of RNaseH1 in SP225 cells and the detection of R-loops.
Keywords: S9.6, RNaseH1, R-loops, Cholangiocarcinoma, ATRi
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Bismuth Nanoparticle and Dipyridamole-loaded Electrospun Polymeric Scaffold as Radiopaque
Bioresorbable Drug-Eluting Vascular Graft
Sarah Honegger, Biological Sciences, University of Notre Dame
Erin San Valentin, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Marvin Barnardino, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Jossana Damasco, Interventional Radiology, The University of Texas MD Anderson Cancer Center,
Karem Court, Nanomedicine, Methodist Research Hospital
Biana Godin, Nanomedicine, The University of Texas MD Anderson Cancer Center
Steven Y. Huang, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Marites P. Melancon, Interventional Radiology, The University of Texas MD Anderson Cancer Center
Background: Arteriovenous grafts are used as an interventional access point for patients on dialysis.
However, upon failure, graft placement can lead to neointimal hyperplasia (NIH). Anti-platelet and
vasodilator drugs such as dipyridamole (DPA) mitigate NIH and long-term patency post graft placement.
In addition, nanoparticles allow for visualization and long-term monitoring of these absorbable medical
devices. This study aims to develop a bismuth nanoparticle (BiNP) and DPA-loaded scaffold made of
polycaprolactone (PCL) and polyethylene glycol (PEG). These scaffolds were tested for their efficacy as
novel bioresorbable, radiopaque, drug-eluting vascular grafts.
Methods: BiNPs were synthesized via the thermal decomposition method and its size was determined by
transmission electron microscopy (TEM). Solutions of PCL (80,000kDa), PEG (8,000kDa), BiNP, and
DPA were electrospun into 3cm scaffolds, and physiochemical properties were characterized. Scaffolds
were monitored over 6 weeks in terms of drug (UV-vis absorption) and nanoparticle (elemental analysis)
released, tensile strength (MTESTQuattro universal testing system), and radiopacity (Bruker microcomputed tomography). Immortalized human vascular endothelial cells (EC-RF24) and vascular smooth
muscle cells (MOVAS) were used to determine the scaffolds cytotoxicity using alamarBlue assay. Grafts
were surgically implanted in rats to begin in vivo imaging and efficacy studies.
Results: BiNPs size was 3.44 nm ± 0.59 nm as determined by TEM. Morphology and physiochemical
properties of the scaffolds varied. Fiber diameter increased with the addition of BiNP and DPA (PCLPEG-BiNP-DPA: 2.53±0.64 µm vs. PCL-PEG: 1.56±0.59 µm). Mechanical strength decreased with the
addition of BiNP (PCL-PEG: 6.28±2.77 MPa vs. PCL-PEG-BiNP: 2.12±0.42 MPa). DPA-loaded grafts
released ~50% of the drug over 7 days (PCL-PEG-DPA: 49.62%±0.7% vs PCL-PEG-BiNP-DPA:
45.85%±3.7%), which increased to ~60% release over six weeks (PCL-PEG-DPA: 60.50%±2.5% vs PCLPEG-BiNP-DPA: 55.90%±4.9%). BiNP-loaded grafts released between 1-2% of the nanoparticle in the
first week, which correlated with the quantification of radiopacity in Hounsfield units (HU, PCL-PEG-BiNPDPA: 1001.2±111.8 HU at week 0 vs. PCL-PEG: -880.4±13.6 HU). EC-RF24 and MOVAS remained
viable in the presence of BiNP and DPA treated media. The presence of DPA in grafts increased blood
lysis by about 2% (PCL-PEG-DPA: 1.86%±1.1% vs PCL-PEG-BiNP-DPA: 2.54%±0.5%).
Conclusion: Trilayer scaffolds made of PCL and PEG and loaded with both DPA and BiNP demonstrated
increased radiopacity with no detrimental effects on epithelial or vascular smooth muscle cells, and an
effective release of dipyridamole over time. These results confer its advantage for serial non-invasive
imaging over time to assess degree of polymer resorption and potential for in vivo NIH inhibition.
Keywords: Bismuth, radiopacity, medical device
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UBA1 Depletion Sensitizes Ovarian, Breast, and Colorectal Cancer Cell Lines to Olaparib PARP
inhibitor
Jayden Fagbola, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Sharad Awasthi, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer
Center
Nidhi Sahni, Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center
Background: Protein poly ADP-ribosylation (PARylation) is a post translational modification which is
catalyzed by poly (ADP-ribose) polymerases (PARPs). This post translational modification regulates
several biological processes such as DNA damage response, apoptosis, chromatin remodeling, mitosis
and transcriptional regulation. Specifically, the catalytic activity of PARP proteins is important for single
stranded break repair (base excision repair). Depletion or inhibition of PARP catalytic activity converts
ssDNA lesions to DNA double stranded breaks which are repaired by homologous recombination repair
(HR). In recent years, PARP inhibitors have been established as a proficient strategy to treat HR deficient
cancers. But it is less efficient to treat homologous recombination efficient and RAS mutant tumors. Here
we have attempted to identify candidates whose loss of function can make homologous recombination
efficient and RAS mutant tumors more sensitive to PARP inhibitors.
Methods: We performed genome wide CRISPR KO screens in ovarian and breast cancer cell lines to
identify target genes whose loss can make cells more sensitive to PARP inhibitor treatment. Further, we
validated the CRISPR KO screen findings by using cell proliferation and clonogenic potential of the
cancerous cells.
Results: We analyzed the screen by using MaGeCK and DrugZ pipelines. We identified several key
components of the DNA damage repair pathway such as BRCA1, BRCA2, RAD50, FANCD2 and FEN1.
In addition to these known players in the DNA damage repair pathway we found UBA1 (a major
ubiquitination activation enzyme) as a top depleted gene. To investigate the effect of UBA1 depletion on
Olaparib sensitivity, We Knockdown UBA1 in ovarian, breast and colorectal cancer cell lines using
siRNAs targeting UBA1. We confirmed the UBA1 knockdown efficiency at protein level by using western
blot. We found UBA1 depletion results in a significant increase in Olaparib sensitivity, compared to the
control siRNA treatment in all tested cell lines. We also observed a very strong reduction in colony
forming potential in UBA1 depleted cells treated with different doses of Olaparib in comparison to control
siRNA cells treated with different doses of Olaparib. Together, these findings indicate that the UBA1
depletion sensitizes ovarian, breast and colorectal cancer cells to Olaparib treatment.
Conclusion: We Identified UBA1 as top depleted gene in our genome wide CRISPR KO screens which
suggests that UBA1 loss of function sensitizes the ovarian and colorectal cancer cells to PARPi.
Validation experiments with siUBA1 further confirms our genome wide CRISPR KO screen findings.
Keywords: Olaparib PARP inhibitor treatment, UBA1, genome-wide CRISPR knockout
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Biomechanical Processes of the Mullerian Duct During Sex Development of Mice
Ariah Richards, Genetics, University of Texas MD Anderson Cancer Center
Diana Machado, Genetics, University of Texas MD Anderson Cancer Center
Rachel Mullen, Genetics, University of Texas MD Anderson Cancer Center
Richard Behringer, Genetics, University of Texas MD Anderson Cancer Center,
Background: Amniotes, regardless of sex, develop bipotential gonads, Mullerian Ducts (MD), and Wolffian
Ducts (WD). In mice the MD is fully formed by embryonic day 13.5 (E13.5). The MD is the precursor to
the female reproductive system and will develop into the oviduct, uterus, cervix, and upper vagina. The
WD is the precursor to the male reproductive system and will develop into the epididymis, vas deferens,
and seminal vesicles. In males, the bipotential gonads develop as testes and release anti-Mullerian
hormone (AMH) which will eliminate the MD. Additionally, the testes release testosterone which stabilizes
the WD. Without AMH or testosterone in females, the MD will remain and the WD will passively degrade.
Methods: To visualize these processes in the mouse reproductive tracts three methods were used: X-gal
staining of Lim1-LacZ (a marker of MD and WD epithelial cells) mice, Ex Vivo Organ Culture and Whole
Mount immunofluorescence. Reproductive tracts from Lim1-LacZ positive mice were dissected, stained
with X-gal, and cleared with BABB to visualize the MD and WD. The Ex Vivo Organ Culture used a glass
bottom disk with a filter and growth medium to support the tissue. The reproductive tracts were imaged on
the dissecting and spinning disk microscopes. Whole mounts were stained with Keratin 8 and Cleaved
Caspase 3, mounted on slides, and imaged on the confocal microscope.
Results: The X- gal staining showed that fusion of the MD occurs in males and females at E14.5, and
there is regression in the MD of males at E14.5. Ex Vivo Organ Cultures showed fusion at E14.5 and the
elimination of the MD in males by E18.5. The Whole Mounts showed apoptosis in throughout the MD in
males starting at E.14.5.
Conclusion: Fusion is a process that begins at E14.5. After E14.5 in males, the MD begins to regress in
three stages before it is eliminated: thinning, breaking, and contracting. Apoptosis is seen in the MD of
male mice starting at E14.5 and helps to aid the process of regression. Observed cellular behaviors and
movements of the MD, observed by static and time-lapse imaging, during MD fusion and regression also
suggest biomechanical processes are involved.
Keywords: Sex, Biomechanics, Sex Differentiation, Mullerian Duct, Microscopy
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Inhibition of toll-like receptor 4 and STAT3 changes cell proportions in livers affected by
nonalcoholic steatohepatitis.
Srilalitha Jyosyula, Molecular and Cellular Oncology - Beretta Lab, University of Texas MD Anderson
Cancer Center
Jessica Sanchez, Molecular and Cellular Oncology - Beretta Lab, University of Texas MD Anderson
Cancer Center
Suet-Ying Kwan, Molecular and Cellular Oncology - Beretta Lab, University of Texas MD Anderson
Cancer Center
Laura Beretta, Molecular and Cellular Oncology - Beretta Lab, University of Texas MD Anderson Cancer
Center,
Background: TAK-242 is an inhibitor of Toll-like receptor 4 (TLR4), which is a known driver of
hepatocellular carcinoma (HCC) development in non-alcoholic steatohepatitis (NASH)-associated HCC,
as identified in the HepPten- mouse model by the Beretta lab. Signal Transducer and Activator of
Transcription 3 (STAT3) is known to contribute to liver fibrosis and HCC in mice as also shown by the
Beretta lab. This experiment was designed to determine whether TAK-242 and TTI-101, an inhibitor of
STAT3, change the liver cell proportions to prevent HCC.
Methods: CIBERSORTx was used to generate a cell deconvolution analysis using a landscape adult liver
mouse matrix from Nanostring and RNA sequencing data from both the HepPten- NASH mouse livers
treated by the STAT3 inhibitor and treated by the TAK-242 inhibitor. To correlate this data’s results in
human livers, another cell deconvolution analysis was run on data collected by The Cancer Genome
Atlas from 371 HCC tumors and paired normal adjacent samples using the landscape adult liver mouse
matrix, a SafeTME matrix, and an adult immune census matrix.
Results: Siglech-high dendritic cells showed a statistically significant decrease when both TLR4
(p=0.0138) and STAT3 (p=0.0004) were inhibited. Endothelial cells (p=0.0107) and mt-nd4-high
hepatocytes(p=0.0163) showed a statistically decrease in cell proportions when TLR4 (was inhibited and
a decreasing trend when STAT3 was inhibited. Spp1-high epithelial cells (p=0.0163), Kupffer
cells(p=0.0003), and pericentral hepatocytes (p=0.0005) showed a significant decrease in cell proportions
when STAT3 was inhibited, and a decreasing trend when TLR4 was inhibited in epithelial and Kupffer
cells, while pericentral hepatocytes showed an increasing trend when TLR4 was inhibited. J Chain-high B
cells (p=0.0424), epithelial cells(p=0.0402), and periportal hepatocytes (p<0.0001) showed a statistically
significant increase in cell proportions when STAT3 was inhibited. Both periportal hepatocytes and B cells
(J Chain high) showed an increasing trend in cell proportions when TLR4 was inhibited, while epithelial
cells showed no change in cell proportion. From the cell proportions in comparison with the 50 normal
adjacent liver samples, the primary tumors saw significantly more hematopoietic stem cells (p=0.0041),
protumor B cells (p=0.0323), myeloid dendritic cells (p=0.0461), endothelial cells (p=0.0002), fibroblasts
(p=0.0308), gamma delta T cells (p=0.0393), and hepatocytes (p=0.0153). There was also a statistically
significant decrease in megakaryocytes (p<0.001), naïve B cells (p=0.0198), natural killer cells
(p=0.0020), and cholangiocytes (p=0.0008).
Conclusion: The role of STAT3 and TLR4 in the prevention of HCC through the alteration of cell
proportions is a promising avenue to investigate in NASH-affected livers.
Keywords: hepatocellular carcinoma, cell deconvolution, cell proportions
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Combined Drug Efficacy in Preclinical Models of Colorectal Cancer
Ayushi Mohanty, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Seong-Woo Bae, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Cong-Dat Pham, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center
Henry C. Manning, Cancer Systems Imaging, University of Texas MD Anderson Cancer Center,
Background: Colorectal cancer is the third most commonly diagnosed cancer and the second leading
cause of cancer death in men and women combined in the U.S. Albeit not widely represented in terms of
cancer awareness, about 150,000 Americans are diagnosed with this disease and more than 50,000 die
annually. Patients suffer from a change in bowel habits, diarrhea, constipation, discomfort in the abdomen
among many other symptoms. Several treatment plans are available including but not limited to surgery,
radiation therapy, chemotherapy, as well as targeted therapy. In this study, we sought to optimize
targeted therapy more specifically in terms of a combination drug therapy. We hypothesize that
combination drug treatment using blockades against cancer proliferation-inducing targets will lead to
greater efficacy compared to single-drug therapy. The treatment focuses on inhibiting EGFR, a receptor
prominent in cancer cells and promotes their growth, through panitumumab as well as blocking the amino
acid transporter, ASCT2, utilized by cancer cells for rapid reproduction, using V-9302 and its variants, the
CDP series.
Methods: As a preliminary characterization of the colorectal cancer cell lines utilized in the study, a BCA
protein assay was conducted to quantitate protein concentration of each sample extracted. Using the
results from the protein assays, a Western Blot was conducted to detect proteins related to EGFR and
ASCT2 in the samples. The antibodies used were Phospho-EGF Receptor, EGF Receptor, ASCT2, AntiGAPDH antibody, Anti-rabbit IgG HRP-linked Antibody. From there, the effects of panitumumab and V9302 on viability of the cancer cells were observed through single-drug therapy at several dose ranges
(0.01 - 1000 g/mL for Panitumumab & 0.001 - 100 M for V-9302) with a 48 hour incubation. Finally, to
determine the efficacy of the combined treatment another cell viability assay was conducted using
panitumumab and either V-9302, CDP3, or CDP7.
Results: In our Western Blot, of the five cell lines used (DiFi, Caco2, SNUC4, HT29, SW48) it was
observed that the relative concentration of EGFR was particularly high in DiFi, and the concentration of
ASCT2 was relatively high in HT29 and SW48. From our single-drug therapy using panitumumab, we
were able to observe a sizeable decrease in viability in DiFi and showed minimal death in the other cell
lines. In treatment using V-9302, DiFi was also much more sensitive compared to the other four cell lines
in the study. The combined treatment showed a substantial decrease in viability when compared to the
single-drug therapy and ranged between 92% to 98% cancer cell death.
Conclusion: These studies provide confirmation that a combined drug treatment lead to not only greater
cancer cell death when compared to single-drug treatment, but also to a significant and reliable degree. In
the future expanding through further trials as well as a bioinformatics analysis to characterize the cell
lines used. Comprehending the relationship between Western Blot results and sensitivity to drug
treatment can also be extremely beneficial. The results of this study prompt us to look further into
combination therapy and its implication as an important form of anti-cancer treatment for patients who
suffer from colorectal cancer.
Keywords: Colorectal Cancer, Combined Drug Therapy, Panitumumab, V-9302
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Arthritis-irAE: Underlying mechanisms and Therapeutic targets
Maria Puche, Immunology, Houston Baptist University
Roza Nurieva, Immunology, University of Texas MD Anderson Cancer Center
Kim Sang, Immunology, University of Texas MD Anderson Cancer Center
William Padron, Immunology, University of Texas MD Anderson Cancer Center,
Naimah Turner, Immunology, University of Texas MD Anderson Cancer Center
Background: Immune-checkpoint inhibitors (ICIs) have been widely used to treat various cancers by
rejuvenating T cell responses to attack tumors. ICIs have been associated with immune-related adverse
events (irAEs) that have the ability to affect nearly any organ in the body. This study focuses on arthritisirAE which can significantly impact a patient’s quality of life by causing joint discomfort and inflammation.
In most cases, arthritis is treated with steroids, however, studies have shown that steroids can
significantly abrogate antitumor immunity induced by ICI therapy. Recently, by analyzing synovial fluid
from patients with arthritis-irAE, we demonstrated that treatment of patients with combined ICIs (CTLA-4
and PD-1 inhibitors) results in steroid-resistant inflammatory arthritis with enhanced T helper (Th)-17 cell
signatures (Nat. Com. (2022)). However, to date, further knowledge of arthritis-irAE pathophysiology is
limited due to the lack of a preclinical murine model.
Methods: C57BL/6 mice were immunized with Chicken Collagen Type II emulsified with Complete
Freund’s Adjuvant (CII/CFA) then injected with either PBS, PD-1 inhibitor, or combined ICIs. In some
experiments, mice injected with combined ICIs were treated with antibodies targeting Th-17 related
cytokines. At the endpoint of each experiment, we harvested spleen, synovium and bone from euthanized
mice to perform flow cytometry (synovium and spleen) and histology (bone) analyses.
Results: Similar to humans, combined ICI therapy induced more severe arthritis in mice with enhanced
Th17 cell signatures compared to PD-1 inhibitor monotherapy. Of note, treatment of arthritis-irAE mice
with agents targeting Th17-related cytokines results in improvement in arthritis severity.
Conclusion: We created a pre-clinical murine model of arthritis-irAE that mimics the clinical setting. Like
humans, we observed enhanced Th17 cell signatures in arthritis-irAE induced by combined ICIs in vivo.
Implying that blocking of Th17 cell-related factors may have an essential role in improving the clinical
outcomes of patients suffering from arthritis-irAE.
Keywords: Immune-checkpoint inhibitors, immune-related adverse events, inflammatory arthritis, Th17
cells
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The Role of Ndufs4 and Slc2a1 on D4M-UV2 Melanoma Tumor Metabolism and Growth
Kate-Yeonjae Jeong, Dept. of Melanoma Medical Oncology, Dept. of Translational Molecular Pathology,
The University of Texas MD Anderson Cancer Center
Renato A. Guerrieri, BS, Dept. of Melanoma Medical Oncology, Dept. of Translational Molecular
Pathology, Immunology Graduate Program, The University of Texas MD Anderson Cancer Center
Michael A. Davies, MD, PhD, Dept. of Melanoma Medical Oncology, Dept. of Translational Molecular
Pathology, Dept. of Systems Biology, The University of Texas MD Anderson Cancer Center
Background: Brain metastases are a common and devastating complication of melanoma, which is the
most aggressive form of skin cancer. We recently showed that oxidative phosphorylation (OXPHOS) is
elevated in melanoma brain metastases (MBMs). Additional studies suggest that aberrant tumor
metabolism may suppress immune responses in cancer. However, the role of increased OXPHOS in
MBMs on the immune microenvironment is unclear. We hypothesize that elevated tumor OXPHOS
negatively impacts the tumor-immune microenvironment in MBMs.
Methods: In order to test this hypothesis, we generated D4M-UV2 murine melanoma cells in which we
inhibited OXPHOS by knocking out (KO) Ndufs4 using CRISPR technology. As a comparator, we also
generated D4M-UV2 cells with KO of Slc2a1 to inhibit glycolysis. Metabolic effects of each gene KO were
analyzed using the Seahorse MitoStress Test on cells growing in vitro. The oxygen consumption rate
(OCR) was measured to assess OXPHOS and extracellular acidification rate (ECAR) to assess
glycolysis. The Cell Titer Blue assay was performed to determine the effects of each gene KO on cell
growth. Measurement of the cytokines secreted by each cell line is ongoing using the MSD Cytokine
Array platform.
Results: KO of NDUFS4 resulted in 44.6% reduction of basal OCR compared to wildtype (WT) D4M-UV2
(p<0.0001), whereas SLC2A1 KO did not significantly affect OCR. KO of SLC2A1 resulted in a 69.8%
reduction in ECAR compared to the WT D4M-UV2 (p<0.0001), while NDUFS4 KO had a 20.6% inhibitory
effect (p = 0.0439). Neither NDUFS4 KO nor SLC2A1 KO significantly inhibited in vitro cell growth after 24
hours compared to WT D4M-UV2 cells. Samples have been collected and submitted for cytokine array
analysis; results are pending at this time.
Conclusion: Our results demonstrate that KO of NDUFS4 or SLC2A1 result in predominant inhibition of
OXPHOS or glycolysis, respectively, in D4M-UV2 melanoma cells. KO of NDUFS4 or SLC2A1 did not
impact the proliferation of D4M-UV2 cells in vitro. Together, these results demonstrate that KO of
NDUFS4 and SLC2A1 effectively model inhibition of tumor OXPHOS and glycolysis, respectively, without
eliminating cell viability. In the future, we plan to use these models to evaluate the effects of OXPHOS
and glycolysis inhibition in vivo, including on the anti-tumor immune response in MBMs. These
experiments will help determine if there is a rationale to develop combinatorial treatment strategies
targeting tumor metabolism and immunotherapy for MBMs.
Keywords: Melanoma, Tumor Metabolism, Immunotherapy, Melanoma Brain Metastases,
Immunosuppression
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Fibronectin and FAK signaling regulate ARHI-induced autophagy
Kirsten Hamilton, Experimental Therapeutics, Houston Baptist University
Jing Guo, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Janice Santiago-O'Farrill, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Zhen Lu, Experimental Therapeutics, University of Texas MD Anderson Cancer Center,
Robert Bast Jr, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Background: Autophagy or “self-eating” is a process that degrades cellular proteins and impaired
organelles, providing energy amongst times of nutritional detriment or in the appearance of stress. Our
lab has reported that the tumor suppressor gene ARHI (Aplasia Ras Homolog Member 1), also known as
DIRAS3, is decreased in over 60% of ovarian cancers and induces autophagy in ovarian cancer cells.
The perseverance of DIRAS3-induced autophagy hinders ovarian cancer cell growth in ovarian cancer
cells in vitro, however DIRAS3-induced autophagy sustains dormancy in vivo. Here, we explored whether
Fibronectin (FN), an extracellular matrix, can rescue ovarian cancer cells from cell death that is induced
by DIRAS3 in culture.
Methods: Cell viability of ovarian cancer cells with or without DIRAS3 expression were accessed using
SRB assay. Autophagy markers (LC3 and LC3II) were evaluated with Western blot analysis in the ovarian
cancer cells with or without DIRAS3 expression. Signaling pathways required for DIRAS3-induced
autophagic cell death were explored with Reverse Phase Protein Array (RPPA) and Western blot
analysis.
Results: We have showed that DIRAS3-induced autophagy was inhibited by FN in two human ovarian
cancer cell lines (SKOv3 and OVCAR8). Re-expression of DIRAS3 decreased the phosphorylation of
FAK and AKT that could be reversed by addition of FN. Treatment of ovarian cancer cells with defactinib,
a FAK inhibitor, decrease their growth and colony formation
Conclusion: Overall, we conclude Fibronectin reduces DIRAS3/autophagy induced cell death through
activation of FAK signaling pathway. FAK inhibitor partially blocks FN-mediated signaling and inhibits
tumor cell growth in ovarian cancer cells
Keywords: Ovarian Cancer, Autophagy, Integrin, FAK, Fibronectin
UPWARDS Summer Program

184

Abstract Number: 157

Fibronectin and FAK signaling regulate ARHI-induced autophagy
Kirsten Hamilton, Experimental Therapeutics, Houston Baptist University
Jing Guo, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Janice Santiago-O'Farrill, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Zhen Lu, Experimental Therapeutics, University of Texas MD Anderson Cancer Center,
Robert Bast Jr, Experimental Therapeutics, University of Texas MD Anderson Cancer Center
Background: Autophagy or “self-eating” is a process that degrades cellular proteins and impaired
organelles, providing energy amongst times of nutritional detriment or in the appearance of stress. Our
lab has reported that the tumor suppressor gene ARHI (Aplasia Ras Homolog Member 1), also known as
DIRAS3, is decreased in over 60% of ovarian cancers and induces autophagy in ovarian cancer cells.
The perseverance of DIRAS3-induced autophagy hinders ovarian cancer cell growth in ovarian cancer
cells in vitro. Nonetheless, in vivo DIRAS3-induced autophagy sustains dormancy. Here, we explored
how Fibronectin (FN), an extracellular matrix, to a certain extent, can rescue ovarian cancer cells from cell
death that is induced by DIRAS3 in culture
Methods: Autophagy was induced by re-expression of DIRAS3 and conversion of LC3/LC3II was
evaluated with Western blot analysis. Signaling pathways required for DIRAS3-induced autophagic cell
death were explored with Reverse Phase Protein Array (RPPA) and Western blot analysis. Growth
inhibition was evaluated by using SRB assay
Results: We showed that DIRAS3-induced autophagy was inhibited by FN in two human ovarian cancer
cell lines (SKOv3 and OVCAR8). Re-expression of DIRAS3 decreased the phosphorylation of FAK and
AKT. Further analysis revealed that addition of FN decreased the inhibitory effect of DIRAS3 on FAK and
AKT. Treatment with defactinib, inhibited the growth of ovarian cancer cells and decreased their ability to
form colonies.
Conclusion: Overall, we conclude from our data that certain factors in the tumor microenvironment, like
fibronectin, can rescue ovarian cancer cells from DIRAS3-induced cell death and contribute to their
survival.
Keywords: Autophagy, Fibronectin, integrin, FAK, ovarian cancer
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